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Escherichia	   coli	   is	   normally	   found	   in	   the	   intestinal	   microbiota	   of	   most	   mammals	   and	   is	  
regarded	  as	  a	  commensal	  bacterium.	  However,	  several	  strains	  have	  evolved	  as	  pathogens	  
through	  the	  acquisition	  of	  pathogenicity	  islands.	  E.	  coli	  O157:H7	  is	  a	  commensal	  bacterium	  
for	  cattle,	  but	  can	  be	  transmitted	  to	  humans	  where	  it	  acts	  as	  a	  pathogen.	  In	  humans,	  E.	  coli	  
O157:H7	   infections	   cause	   bloody	   diarrhoea,	   haemorrhagic	   colitis	   and	   in	   some	   cases	  
haemolytic	  uremic	  syndrome	  (HUS),	  which	  can	   lead	  to	  death.	  Treatment	  of	  this	  bacterial	  
infection	  is	  rather	  complicated	  as	  traditional	  antibiotics	  have	  demonstrated	  to	  worsen	  the	  
clinical	   symptoms	   and	   the	   outcome	   of	   the	   infection.	   Therefore,	   the	   discovery	   of	   new	  
treatments	  for	  this	  infection	  is	  of	  great	  relevance.	  
Anti-­‐virulence	   (AV)	   compounds	   are	   one	   of	   the	   most	   promising	   classes	   of	   drugs	   for	   the	  
treatment	   of	   E.	   coli	  O157:H7	   infections,	   as	   they	   selectively	   target	   key	   virulence	   factors.	  
This	   approach	   selectively	   decreases	   the	   ability	   of	   the	   pathogen	   to	   cause	   disease	   rather	  
than	   its	   ability	   to	   survive,	   thus	   reducing	   the	   chances	   for	   the	  development	   of	   resistance.	  
The	   type	   three	  secretion	  system	  (T3SS)	   is	  a	  key	  virulence	   factor	   for	  E.	  coli	  O157:H7	  as	   it	  
enables	  the	  tight	  attachment	  of	  the	  bacterium	  to	  the	  host	  cell	  and	  the	  secretion	  of	  effector	  
proteins	   to	   initiate	   the	   colonisation	   process.	   The	   T3SS	   is	   a	   very	   attractive	   target	   for	   the	  
development	  of	  selective	  AV	  compounds	  for	  E.	  coli	  O157:H7.	  
Salicylidene	  acylhydrazides	  (SA)	  are	  the	  most	  well-­‐studied	  class	  of	  AV	  compounds	  targeting	  
the	  T3SS	   in	  several	  Gram-­‐negative	  bacteria.	  ME0055	  was	  found	  to	  be	  one	  of	  the	  best	  SA	  
compounds	   against	   the	   T3SS	   in	   E.	   coli	   O157:H7,	   but	   it	   is	   considered	   as	   a	   promiscuous	  
binder	   since	   its	   effects	  derived	   from	  a	  modulation	  of	   several	  metabolic	  pathways	   rather	  
than	  a	  direct	   interaction	  with	   the	  T3SS.	  However,	  ME0055	  provides	  an	  excellent	  starting	  
point	   for	   chemical	   optimisation	   and	   the	   generation	   of	   more	   stable	   and	   potent	   T3SS	  
inhibitors.	  
The	  aim	  of	   this	  work	  was	   to	  chemically	  modify	   the	  ME0055	  scaffold	   in	  order	   to	  create	  a	  
small	  focused	  library	  of	  new	  anti-­‐virulence	  compounds.	  Three	  new	  active	  scaffolds	  based	  
on	  the	  SA	  compound’s	  core	  were	  found	  to	  be	  active	  against	  E.	  coli	  O157:H7	  T3SS.	  Further	  
biological	  studies	  also	  revealed	  the	  main	  protein	  target	  of	  this	  new	  class	  of	  anti-­‐virulence	  
compounds,	   enabling	   future	   investigations	   in	   the	   pursuit	   of	   new	   and	   more	   potent	  
molecules	  against	  the	  T3SS.	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LB	   Luria-­‐Bertani	  broth	  
LEE	   Locus	  of	  enterocyte	  effacement	  
Ler	   LEE-­‐encoded	  regulator	  
LogP	   Partition	  coefficient	  
Lys	   Lysine	  
MEM	   Minimum	  essential	  media	  
mg	   Milligram(s)	  
MHz	   Megahertz	  
min	   Minute(s)	  
mL	   Millilitre(s)	  
mM	   Millimolar	  
MNEC	   Meningitis	  associated	  Escherichia	  coli	  
m.p.	   Melting	  point	  
mRNA	   Messenger	  ribonucleic	  acid	  
MST	   Microscale	  thermophoresis	  
MW	   Molecular	  weight	  
NADH	   Nicotinamide	  adenine	  dinucleotide	  
NHS	   N-­‐Hydroxysuccinimide	  
Nle	   Non-­‐LEE	  encoded	  effector(s)	  
nm	   Nanometer	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nM	   Nanomolar	  
NSAID	   Non-­‐steroidal	  anti-­‐inflammatory	  drug	  
NMR	   Nuclear	  magnetic	  resonance	  
OD600	   Optical	  density	  at	  600	  nm	  
ORF	   Open	  reading	  frame	  
PAI	   Pathogenicity	  island	  
PARP	   Poly	  ADP	  ribose	  polymerase	  
PBS	   Phosphate	  buffered	  saline	  
PCR	   Polymerase	  chain	  reaction	  
RAJ	   Rectal-­‐anal	  junction	  
rpm	   Revolutions	  per	  minute	  
rt	   Room	  temperature	  
SA	   Salicylidene	  acylhydrazide	  
SAR	   Structure-­‐activity	  relationship	  
SDS-­‐PAGE	   Sodium	  dodecyl	  sulphate-­‐polyacrilamide	  gel	  electrophoresis	  
S/N	   Supernatant	  
SPR	   Surface	  plasmon	  resonance	  
Stx	   Shiga	  toxin	  
T3SS	   Type	  three	  secretion	  system	  
TAE	   Tris-­‐acetate	  EDTA	  
TEA	   Triethylamine	  
TEM	   Transmission	  electron	  microscopy	  
THF	   Tetrahydrofuran	  
THP	   1,4,5,6-­‐Tetrahydro	  pyridazine	  
Tir	   Translocated	  intimin	  receptor	  
TLC	   Thin	  layer	  chromatography	  
Tpx	   Thiol	  peroxidase	  
TZP	   [1,2,4]-­‐Triazolo[4,3-­‐b]pyridazine	  
UK	   United	  Kingdom	  
UPEC	   Uropathogenic	  Escherichia	  coli	  
USA	   United	  States	  of	  America	  
UTI	   Urinary	  tract	  infection	  
v/v	   Volume	  per	  volume	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W/C	   Whole	  cell	  lysate	  
WrbA	   Tryptophan	  repressor	  binding	  protein	  
WT	   Wild	  type	  
μL	   Microlitre(s)	  
μM	   Micromolar	  
μm	   Micron(s)	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1	  Escherichia	  coli	  O157:H7	  
Escherichia	  coli	  (E.	  coli)	   is	  a	  rod-­‐shaped	  Gram-­‐negative	  bacterium	  belonging	  to	  the	  genus	  
of	  the	  Enterobacteriacee.	  This	  bacterium	  is	  one	  the	  best-­‐studied	  prokaryotic	  organisms	  in	  
research	   laboratories	   due	   to	   its	   fast	   growth	   and	   easy	   genetic	   manipulation.	   E.	   coli	   is	  
considered	  a	  commensal	  bacterium	  and	  is	  found	  in	  the	  gastro-­‐intestinal	  tract	  (GI	  tract)	  of	  
warm-­‐blooded	  animals,	  especially	  ruminants.	  In	  humans,	  E.	  coli	  can	  be	  found	  as	  part	  of	  the	  
commensal	  microbiota	  in	  the	  mucosal	  surface	  of	  the	  colon.	  Under	  normal	  circumstances,	  
this	   bacterium	   lives	   in	   a	   beneficial	   symbiotic	   relationship	   with	   its	   host.	   However,	   the	  
acquisition	  of	  virulence	  factors	  generated	  pathogenic	  strains	  of	  E.	  coli,	  which	  mainly	  cause	  
diarrhoeal	   disease,	   urinary	   tract	   infections	   (UTIs)	   and	   meningitis.	   Virulence	   factors	   are	  
transferred	  between	  strains	  by	  horizontal	  gene	   transfer	   (HGT)	  or	  mobile	  gene	  elements;	  
therefore,	  several	  pathogenic	  serotypes	  of	  E.	  coli	  employ	  homologous	  virulence	  systems	  1–
3.	  A	  total	  of	  5	  diarrhoeagenic	  groups	  of	  E.	  coli	  has	  been	  identified:	  enteroaggregative	  E.	  coli	  
(EAEC),	  enterohaemorrhagic	  E.	  coli	  (EHEC),	  enteropathogenic	  E.	  coli	  (EPEC),	  enteroinvasive	  
E.	  coli	  (EIEC)	  and	  enterotoxigenic	  E.	  coli	  (ETEC)	  4.	  Urinary	  tract	  infections	  are	  mainly	  caused	  
by	   strains	   belonging	   to	   the	   uropathogenic	   E.	   coli	   (UPEC)	   family	   5,6,	   while	   meningitis	  
associated	  E.	  coli	  (MNEC)	  pathotypes	  are	  responsible	  for	  meningitis	  7.	  
E.	  coli	  O157:H7	  belongs	  to	  the	  enterohaemorrhagic	  E.	  coli	  (EHEC)	  group	  and,	  according	  to	  
the	  World	  Health	  Organisation,	   is	  considered	  the	  most	  dangerous	  serotype	  of	  this	   family	  
(Organisation,	  2011).	  The	  first	  outbreak	  of	  this	  bacterium	  was	  reported	  in	  1982	  and	  traced	  
to	   the	   contamination	   of	   hamburger	  meat	   10.	   It	   is	   known	   that	   E.	   coli	   O157:H7	   colonises	  
cattle	   asymptomatically	   in	   the	   rectal-­‐anal	   junction	   (RAJ),	   facilitating	   the	   bacterium’s	  
shedding	   in	   the	   faeces	   11–13.	   Thus,	   infection	   in	   humans	   typically	   arise	   via	   the	   faecal-­‐oral	  
route	   from	   the	   consumption	   of	   contaminated	   meat	   and	   vegetables.	   Once	   the	   food	   is	  
contaminated,	   the	   infective	   dose	   required	   to	   colonise	   a	   healthy	   individual	   is	   very	   low	  
(estimated	  to	  be	  50-­‐100	  colony-­‐forming	  unit	  (CFUs))	  14.	  Symptoms	  associated	  with	  E.	  coli	  
O157:H7	   infections	  are	   typically	  haemorrhagic	  colitis	   leading	  to	  bloody	  diarrhoea,	  severe	  
abdominal	   cramps	   and	   haemolytic	   uremic	   syndrome	   (HUS),	   which	   is	   characterised	   by	   a	  
combination	   of	   acute	   renal	   failure,	   thrombocytopenia	   and	  microangyopathic	   haemolytic	  
anemia	  10,15.	  HUS	  onset	   is	  associated	  with	  the	  production	  of	  Shiga	  toxin	  (Stx),	  a	  cytotoxin	  
capable	   of	   damaging	   both	   intestinal	   and	   renal	   tissue	   16.	   It	   is	   thought	   that	   the	   ability	   to	  
produce	  Stx	  has	  been	  acquired	  by	  the	  enteropathogenic	  E.	  coli	  (EPEC)	  strain	  O55	  through	  a	  
Stx-­‐encoding	  lambdoid-­‐like	  bacteriophage,	  which	  lead	  to	  the	  generation	  of	  the	  EHEC	  strain	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E.	  coli	  O157:H7	  3.	  It	  has	  also	  been	  demonstrated	  that	  traditional	  antibiotic	  treatments	  of	  E.	  
coli	   O157:H7	   infections	   resulted	   in	   an	   increase	   of	   diseases	   severity,	   promoting	   an	  
enhanced	  release	  of	  Stx,	  which	  leads	  to	  HUS	  17.	  Selective	  treatments,	  such	  as	  anti-­‐virulence	  
(AV)	   compounds,	   might	   be	   the	   ideal	   solution	   for	   eradicating	   the	   infection	   without	   the	  
release	  of	  the	  toxin,	  thus	  avoiding	  its	  harsh	  symptoms.	  
	  
2	  E.	  coli	  O157:H7	  virulence	  factors	  
2.1	  Type	  three	  secretion	  system	  (T3SS)	  
One	  of	  the	  main	  E.	  coli	  O157:H7	  virulence	  factors	  is	  the	  type	  three	  secretion	  system	  (T3SS).	  
The	   T3SS	   is	   a	   needle-­‐like	   multi-­‐protein	   complex	   that	   spans	   outside	   the	   bacterium	   and	  
hijacks	   the	  host	   cell	  membrane.	   This	   injection	   system	   translocates	  effector	  proteins	   into	  
the	   host	   cytoplasm	   to	   create	   a	   niche	   to	   allow	   bacterial	   colonisation	   18.	   The	   T3SS	   is	   also	  
required	   for	   the	   intimate	   attachment	   of	   the	   bacterium	   to	   epithelial	   cells,	   which	   causes	  
attaching	  and	  effacing	  (A/E)	  lesions,	  a	  characteristic	  trait	  of	  EHEC	  and	  EPEC	  infections	  19,20.	  
The	   formation	   of	   these	   lesions	   is	   a	   complex	   process	   and	   it	   is	   initiated	   by	   specific	  
translocated	   effector	   proteins	   which	   trigger	   actin	   and	   cytoskeleton	   rearrangements,	  
resulting	  in	  the	  formation	  of	  “pedestal”	  structure	  and	  intimate	  bacterial	  attachment	  to	  the	  




The	   T3SS	   apparatus	   comprises	   three	   main	   structural	   components:	   the	   basal	   body,	   the	  
needle	  filament	  and	  the	  translocon	  (Fig.	  1).	  The	  basal	  body	  stretches	  between	  the	  bacterial	  
inner	  and	  outer	  membrane	  and	  functions	  as	  an	  export	  apparatus	  for	  other	  T3SS	  proteins.	  
EscJ	   is	   a	   “neck-­‐like”	  protein	   that	  protrudes	   into	   the	  periplasmic	   space	   and	   consequently	  
oligomerises	   in	  a	  24-­‐mer	   ring.	   It	   is	   thought	   that	   the	  correct	  assembly	  of	   this	  key	  protein	  
initiates	  the	  recruitment	  of	  other	  basal	  body	  proteins,	  namely	  EscT,	  R,	  S	  and	  V,	  to	  form	  the	  
inner	  membrane	  complex	  23.	  EscU	  is	  another	  component	  of	  this	  complex	  and	  is	  supposed	  
to	  partially	   regulate	   the	  export	  of	  virulence	  proteins	   24.	  EscN	   is	  an	  ATPase	  and	  energises	  
the	  whole	  export	  mechanism	  of	  T3SS	  components	  and	  effector	  proteins.	  EscN	  sits	  onto	  the	  
cytosolic	   side	  of	   the	  basal	   body	  anchoring	   itself	   to	  EscL	   and	   EscQ	   25.	   SepL	  and	  SepD	  are	  
other	   proteins	   that	   sit	   outside	   the	   export	   apparatus	   and	   function	   as	   “gatekeepers”,	  
enabling	  the	  injection	  of	  effector	  proteins	  only	  when	  the	  needle-­‐like	  structure	  is	  complete	  
26,27.	  EscC	  is	  an	  oligomeric	  protein	  formed	  by	  20	  subunits	  that	  lies	  on	  the	  outer	  membrane	  
and	  closely	  interacts	  with	  EscJ.	  EscC	  N-­‐terminal	  domain	  is	  positioned	  into	  the	  periplasmic	  
space	   and	   bound	   to	   EscJ,	   while	   the	   C-­‐terminal	   domain	   is	   protruding	   into	   the	   outer	  
membrane	  28.	  
Fig.	  1:	  EHEC	  T3SS:	  Schematic	   representation	  of	   the	  EHEC	  T3SS.	  The	  basal	  
body	   spans	   between	   the	   inner	   and	   outer	   membrane,	   while	   the	   needle	  
filament	   and	   the	   translocon	   function	   as	   a	   conduit	   to	   the	   host	   cell.	   Figure	  
adapted	  from	  199.	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The	   initial	  portion	  of	  the	  needle	  filament	   is	   formed	  by	  EspF,	  an	  outer	  membrane	  protein	  
which	   interacts	  with	  both	  EscC	  and	  EscJ.	  EspF	  acts	  as	  a	  platform	  for	   the	  assembly	  of	   the	  
needle-­‐like	   structure	   by	   EspA.	   EspA	   is	   secreted	   through	   the	   export	   apparatus	   and	  
polymerises	  in	  a	  helical	  arrangement	  with	  5	  to	  6	  subunits	  per	  turn	  29.	  EspA	  interacts	  with	  a	  
selective	   chaperone	   CesA	   to	   prevent	   premature	   polymerisation	  within	   the	   cytoplasm	   23.	  
Once	  the	  needle	  structure	  has	  reached	  the	  desired	  length	  (normally	  up	  to	  600	  nm),	  2	  pore-­‐
forming	  proteins,	   EspD	  and	  EspB,	   are	   secreted	   to	  generate	   the	   translocon	  pore	   into	   the	  
host	  cell	  membrane	  with	  a	  4:1	  EspD:EspB	  ratio	  30.	  EspD,	  a	  39	  kDa	  protein,	   is	  another	  key	  
protein	  of	  the	  T3SS,	  which	   is	  secreted	  through	  the	  needle	  and	  inserted	   into	  the	  host	  cell	  
membrane	  31,32.	  Once	  the	  translocon	  pore	  is	  formed,	  EspA	  can	  anchor	  to	  EspD	  to	  complete	  
the	  correct	  assembly	  of	  the	  T3SS	  and	  to	  initiate	  the	  translocation	  of	  effector	  proteins	  into	  
the	  host	  cytoplasm	  32–34.	   It	  has	  been	  demonstrated	  that	  an	  absence	  or	  malfunctioning	  of	  
this	  pore-­‐forming	  protein	  blocks	   the	  correct	  assembly	  of	   the	  T3SS	  and,	   therefore,	  E.	   coli	  
O157:H7	   colonisation	   31,32,34.	   Despite	   the	  well-­‐known	   role,	   EspD	   structure	   is	   still	   unclear	  
due	  to	   its	  complex	  biological	  properties.	   It	  has	  been	  predicted	  that	  this	  virulence	  protein	  
contains	   2	   coiled-­‐coil	   domains	   for	   host	   cell	   membrane	   anchoring	   and	   homo-­‐
oligomerisation,	   2	   transmembrane	   domains	   for	   host	   cell	   membrane	   insertion	   and	   two	  
amphipatic	  regions	  thought	  to	  be	   involved	   in	  the	  secretion	  process	  of	  the	  protein	  and	   in	  
chaperone	   recognition	   31,32,34.	   To	   date,	   no	   crystallographic	   data	   are	   available	   for	   this	  
membrane	  protein.	  
The	  overall	  structure	  of	  the	  T3SS	  is	  also	  well-­‐conserved	  in	  more	  than	  25	  species	  of	  Gram-­‐
negative	  bacteria	  such	  as	  Salmonella	  sp.,	  Yersinia	  sp.,	  S.	  flexneri,	  C.	  rodentium,	  Chlamydia	  
sp.	   and	  P.	  Aeruginosa	   35.	   The	  protein	   nomenclature	  differs	   between	   species,	   as	   listed	   in	  
Table	  1.	  The	  T3SS	  in	  the	  mouse	  pathogen	  Citrobacter	  rodentium	  is	  especially	  important	  for	  
in	   vivo	   model	   of	   EHEC	   infection,	   since	   EHEC	   cannot	   infect	   mice	   36,37.	   Bioluminescence	  
imaging	  (BLI)	  was	  utilised	  by	  Wiles	  et	  al.	  to	  generate	  a	  bioluminescent	  C.	  rodentium	  strain	  
for	   colonisation	   imaging	   in	   live	   animals	   as	   a	   reproducible	   in	   vivo	   model	   to	   evaluate	  
potential	  T3SS	  inhibitors	  36.	  This	  homology	  between	  different	  pathogens	  makes	  the	  T3SS	  a	  
very	   attractive	   target	   for	   the	   development	   of	   potential	   broad	   spectrum	   compounds	  
focused	   on	   the	   inhibition	   of	   this	   virulence	   weapon.	   A	   detailed	   list	   of	   T3SS	   inhibitors	   is	  





E.	  coli	   C.	  rodentium	   Yersinia	   Salmonella	  
EscC	   EscC	   YscC	   InvG	  
EscD	   EscD	   YscD	   PrgH	  
EscJ	   EscJ	   YscJ	   PrgK	  
EscN	   EscN	   YscN	   InvC	  
EscR	   EscR	   YscR	   SpaP	  
EscS	   EscS	   YscS	   SpaQ	  
EscT	   EscT	   YscT	   SpaR	  
EscU	   EscU	   YscU	   SpaS	  
EscV	   EscV	   YscV	   InvA	  
EspA	   EspA	   LcrV	   SipD	  
EspB	   EspB	   YopV	   SipC	  
EspD	   EspD	   YopB	   SipB	  
EspF	   EspF	   YscF	   PrgI	  
	  
Table	  1:	  Nomenclature	  of	  homologous	  T3SS	  proteins	  in	  E.	  coli,	  C.	  rodentium,	  Yersinia	  sp.	  and	  Salmonella	  sp.:	  The	  T3SS	  
proteins	  nomenclature	  for	  different	  Gram-­‐negative	  bacteria	  is	  listed	  in	  the	  table	  above.	  	  
	  
2.2	  Locus	  of	  enterocyte	  effacement	  (LEE)	  
The	   T3SS	   is	   encoded	   in	   the	   locus	  of	   enterocyte	   effacement	   (LEE),	   a	   pathogenicity	   island	  
(PAI)	   containing	  41	  genes	   arranged	   in	  5	  polycistronic	  operons,	   namely	  LEE1,	  LEE2,	  LEE3,	  
LEE4	  and	  LEE5	  38,39.	  LEE1,	  LEE2	  and	  LEE3	  primarily	  encode	  genes	  for	  the	  production	  of	  the	  
T3SS	  basal	  body	  proteins,	  esc	  and	  sep	  proteins	  40,	  while	  LEE4	  is	  responsible	  for	  the	  proteins	  
of	  the	  needle	  structure	  (EspF	  and	  EspA)	  and	  the	  translocon	  (EspD	  and	  EspB)	  31,33,41,42	  (Fig.	  













































































































































































































Expression	  of	   this	  pathogenicity	   island	   is	  mainly	   regulated	  by	   the	  master	   regulator	   (Ler),	  
encoded	   in	   the	   first	   operon	   (LEE1)	   44	   (Fig.	   3).	   Ler	   is	   a	   transcriptional	   activator	   and	   its	  
function	  is	  to	  release	  the	  H-­‐NS	  repressor	  to	  allow	  LEE2-­‐5	  transcription	  45,46.	  The	  expression	  
of	  Ler	  is	  also	  regulated	  by	  several	  factors	  within	  the	  bacterium.	  
	  
	  
The	   Global	   Regulator	   of	   the	   LEE	   Activator	   (GrlA)	   and	   its	   opposing	   Repressor	   (GrlR)	   are	  
other	  regulatory	  elements	  encoded	  in	  the	  LEE	  which	  interact	  with	  Ler.	  While	  GrlA	  activates	  
Ler	  and	  consequently	  the	  expression	  of	  the	  T3SS,	  GrlR	  functions	  as	  a	  repressor	  for	  the	  LEE	  
transcription	   37,47.	  QseA,	   instead,	   is	   a	   direct	   activator	   of	   Ler	   encoded	  outside	   the	   LEE	   48.	  
QseE	   and	   QseC	   are	   2	   sensor	   kinase	   receptors	   sensitive	   to	   the	   outer	   and	   endogenous	  
stimuli	  (i.e.	  sulphates,	  phosphates,	  adrenaline	  and	  EHEC	  Autoinducer	  (AI)),	  which	  indirectly	  
regulate	  Ler	   through	  phosphorylation	  of	  QseF	  and	  KdpE	  respectively	   48,49.	  Other	  external	  
regulators	  of	  the	  whole	  LEE	  pathogenicity	  island	  are	  EtrA	  and	  EivF,	  which	  repress	  the	  LEE	  
transcription,	  and	  the	  RNA	  chaperone	  Hfq,	  known	  to	  bind	  to	  ler	  mRNA	  in	  order	  to	  block	  its	  
transcription	   through	   the	   ribosome	  50,51.	  Environmental	   factors,	   such	  as	  media	  nutrients,	  
are	  also	  key	  regulators	  of	  the	  LEE	  and	  Ler.	  For	  example,	  it	  has	  been	  observed	  that	  0.4%	  of	  
glucose	  in	  EHEC	  growth	  media	  reduced	  ler	  expression,	  whereas	  0.1%	  of	  glucose	  activated	  
the	   ler	   transcription	  due	   to	   the	  gluconeogenesis-­‐like	   conditions	   49.	  MEM-­‐HEPES	  media	   is	  
also	  known	  to	  greatly	  increase	  the	  LEE	  expression	  during	  growth	  and	  it	  is,	  therefore,	  used	  
Fig.	  3:	  Regulation	  of	   the	  LEE	  pathogenicity	   island:	  Schematic	   representation	  of	   the	  LEE	  regulation.	  Regulators	   are	  
shown	  by	  colour	  coded	  rectangle	  and	  arrows.	  Normal	  arrows	  represent	  positive	  regulation	  and	  blunt	  arrows	  specify	  
negative	  regulation.	  Dashed	  arrows	  indicate	  expression	  of	  a	  regulatory	  protein	  from	  the	  LEE.	  The	  LEE	  operons	  (LEE1-­‐




as	  a	  T3SS-­‐inducing	  media	  for	  in	  vitro	  experiments	  20,35.	  However,	  the	  mechanism	  of	  this	  up-­‐
regulation	   is	   still	   unclear.	   Furthermore,	   the	   LEE	   expression	   is	   also	   regulated	   by	   the	  
expression	  of	  other	  EHEC	  virulence	  factors	  such	  as	  the	  flagella	  47.	  
The	   complex	   and	   multi-­‐layered	   regulation	   of	   this	   pathogenicity	   island	   highlights	   the	  
relevant	   role	   of	   the	   T3SS	   for	   EHEC	   colonisation.	   T3SS	   is	   an	   essential	   and	   energetically	  
“expensive”	   virulence	   weapon	   for	   the	   bacterium’s	   infection	   and,	   therefore,	   it	   must	   be	  
expressed	  only	  in	  favourable	  environmental	  and	  endogenous	  conditions.	  
	  
2.3	  Effector	  proteins	  
The	  LEE	  pathogenicity	  island	  also	  encodes	  7	  effector	  proteins	  (Tir,	  Map,	  EspF,	  EspZ,	  EspG,	  
EspB	   and	   EspH)	   that	   are	   translocated	   into	   the	   host	   cell	   as	   well	   as	   intimin,	   which	   is	  
expressed	   on	   the	   bacterium’s	   outer	   membrane.	   Tir	   is	   one	   of	   the	   first	   effectors	   to	   be	  
transported	   into	  the	  host	  after	  the	  T3SS	  assembly.	  Once	  translocated,	  Tir	   is	   inserted	   into	  
the	   outer	   membrane	   and	   binds	   to	   the	   bacterial	   intimin	   with	   its	   extracellular	   domain,	  
providing	   an	   intimate	   attachment	   between	   the	   bacterium	   and	   the	   host	   cell	   52.	   Tir	  
intracellular	   domain	   phosphorylates	   the	   host	   cell	   protein	   N-­‐WASP,	   which	   then	   recruits	  
actin	  related	  proteins	  2	  and	  3	  (Arp2/3),	  causing	  nucleation	  of	  actin	  filaments.	  This	  process	  
promotes	   the	   pedestal-­‐like	   rearrangements	   of	   the	   host,	   forming	   the	   characteristic	   A/E	  
lesions	  53.	  Other	  effector	  proteins	  act	  on	  the	  host	  cell	  cytoskeleton	  (i.e.	  EspB	  and	  EspF)	  and	  
on	  the	  disruption	  of	  mitochondrial	  functions	  (i.e.	  Map	  and	  EspF)	  54–56.	  More	  than	  60	  non-­‐
LEE	   encoded	   effectors	   (NLEs)	   have	   been	   identified	   and	   studied,	   but	   they	   will	   not	   be	  
discussed	  further	  here	  (for	  a	  recent	  and	  detailed	  review	  refer	  to	  57).	  
	  
2.4	  Shiga	  toxin	  
Shiga	  toxin	  (Stx)	  is	  another	  relevant	  E.	  coli	  O157:H7	  virulence	  factor	  and	  belongs	  to	  the	  AB5	  
toxin	  family,	  where	  the	  catalytic	  subunit	  A	  is	  non-­‐covalently	  bound	  to	  a	  pentamer	  formed	  
by	  subunit	  B	  58.	  The	  subunit	  A	  possesses	  N-­‐glycosidase	  activity	  that	  cleaves	  an	  adenosine	  
residue	   from	   the	   28S	   ribosomal	   RNA	   of	   the	   60S	   ribosomal	   subunit,	   leading	   to	   protein	  
synthesis	  inhibition	  and	  then	  to	  apoptosis	  59.	  It	  has	  been	  demonstrated	  that	  the	  subunit	  B	  
has	   specific	   affinity	   for	   the	   globotriaosylceramide	   receptor	   (Gb3)	   on	   the	   surface	   of	  
eukaryotic	  cells	  such	  as	  intestinal	  and	  renal	  epithelial	  cells.	  Once	  the	  subunit	  B	  is	  bound	  to	  




mentioned	  before	  (Paragraph	  1),	  E.	  coli	  O157:H7	  has	  the	  ability	  of	  producing	  Shiga	  toxin	  3.	  
The	   manifestation	   of	   its	   release	   is	   the	   selective	   apoptosis	   of	   the	   intestinal	   and	   renal	  
epithelial	  cells,	  which	  leads	  to	  bloody	  diarrhoea	  and	  HUS	  4.	  Stx	  is	  a	  relevant	  EHEC	  virulence	  
weapon	  and	  has	  been	  extensively	  studied,	  but	  it	  will	  not	  be	  discussed	  any	  further	  here	  (for	  
detailed	  reviews	  refer	  to	  4,61,62).	  
	  
3	  Therapies	  for	  EHEC	  infection	  
Treatment	   of	   EHEC	   infections,	   especially	   E.	   coli	   O157:H7,	   with	   antibiotics	   is	   not	  
recommended	  due	  to	  the	  increase	  of	  Stx	  release	  and,	  therefore,	  enhanced	  disease	  severity	  
from	  cell	   lysis	   63–65.	   In	  addition,	  antibiotics	   induce	   the	  bacterial	   general	   stress	   responses,	  
which	  lead	  to	  up-­‐regulation	  of	  Shiga	  toxin	  expression	  and	  to	  the	  development	  of	  resistance	  
48.	  Currently,	  EHEC	  infection	  therapies	  are	  only	  supportive	  and	  a	  rehydration	  therapy	  is	  the	  
most	  relevant	  treatment	  for	  children	  and	  elderly	  with	  diarrhoea.	  There	  are	  many	  areas	  of	  
ongoing	  research	  targeting	  the	  reduction	  of	  EHEC	  infections	  and,	  thus,	  limiting	  the	  effects	  
of	   the	   Stx	   release.	   For	   example,	   SYNSORB	   Pk	   (SYNSORB,	   Canada)	   is	   a	   competitive	  
antagonist	  of	  Stx	  for	  the	  Gb3	  receptor.	  The	  higher	  affinity	  of	  this	  drug	  displaces	  the	  toxin	  
from	  the	  receptor,	  thus,	  reducing	  tissue	  damage.	  Unfortunately,	  SYNSORB	  Pk	  was	  found	  to	  
be	  almost	  inactive	  during	  human	  clinical	  trials	  due	  to	  the	  poor	  uptake	  in	  the	  bloodstream	  
66,67.	   Another	   alternative	   is	   the	   development	   of	   a	   vaccine	   to	   reduce	   EHEC	   infection.	  
Investigation	  for	  the	  use	  of	  an	  inactive	  form	  of	  the	  Stx	  antigen	  have	  been	  performed	  and	  
showed	   promising	   results	   of	   protection	   in	  mouse	  models	   68.	   Other	   studies,	   instead,	   are	  
focused	   to	   reduce	   the	   carriage	   of	   EHEC	   in	   cattle,	   therefore	   decreasing	   the	   possibility	   of	  
food	   contamination	   69.	   Aiming	   to	   other	   EHEC	   virulence	   weapons,	   such	   as	   the	   bacterial	  
adhesion,	   biofilm	   formation,	   intercellular	   signalling	   or	   the	   T3SS,	   is	   another	   alternative	  
treatment.	   The	   use	   of	   anti-­‐virulence	   (AV)	   compounds	   that	   selectively	   target	   virulence	  
without	   inducing	   any	   stress	   or	   SOS	   responses	   is	   a	   promising	   area	   of	   research.	   This	   is	  








4	  Anti-­‐virulence	  compounds	  
As	  mentioned	  previously	  (Paragraph	  3),	  E.	  coli	  O157:H7	  infections	  are	  difficult	  to	  treat	  with	  
traditional	  antibiotics	  therapies	  due	  to	  the	  Shiga	  toxin	  release.	  Anti-­‐virulence	  compounds	  
(AV)	   are	   one	   of	   the	   most	   promising	   class	   of	   drugs	   for	   an	   alternative	   EHEC	   infection	  
treatment.	  The	  selectivity	  of	  AV	   results	   in	   less	  evolutionary	  pressure	  and	  SOS	   responses,	  
which	  consequently	  lead	  to	  reduced	  possibilities	  for	  bacteria	  to	  develop	  resistance	  and	  to	  
release	   Shiga	   toxin.	  Due	   to	   the	   limited	  options	   in	   EHEC	   treatments,	   the	   investigation	  on	  
specific	  AV	  compounds	   for	  EHEC	  virulence	  weapons	   is	  essential	   for	   fighting	  this	  bacterial	  
infection.	  
	  
4.1	  Quorum	  sensing	  inhibitors	  
The	   quorum	   sensing	   system	   is	   the	   essential	   cell-­‐to-­‐cell	   communication	   apparatus	   that	  
controls	   various	   biological	   processes	   in	   both	   Gram-­‐positive	   and	  Gram-­‐negative	   bacteria.	  
This	  system	  recognises	  specific	  signalling	  molecules	  secreted	  by	  growing	  bacteria	  and	  then	  
regulates	   relevant	   cell	   pathways,	   including	   bioluminescence,	   toxin	   release,	   biofilm	  
formation	   and	   virulence	   gene	   expression.	   Therefore,	   blocking	   the	   quorum	   sensing	   can	  
result	  in	  the	  inhibition	  of	  bacterial	  virulence	  weapons,	  making	  it	  a	  plausible	  target	  for	  anti-­‐
virulence	  compounds.	  
Fig.	  4:	  QseC	  signalling	  pathway	  (left)	  and	  the	  chemical	  structure	  of	  LED209	  (right):	  Schematic	  representation	  of	   the	  
QseC	  signalling	  pathway	  is	  shown	  on	  the	  left.	  Phosphorylation	   is	  represented	  by	  the	  P	  in	  the	  yellow	  rectangles.	  Red	  





The	  main	  quorum	  sensing	  receptor	   in	  E.	  coli	  O157:H7	  is	  the	  histidine	  kinase	  QseC	  70	  (Fig.	  
4).	   QseC	   is	   a	   highly	   conserved	   membrane	   protein	   which	   auto-­‐phosphorylates	   in	   the	  
presence	  of	  epinephrine,	  norepinephrine	  and	  the	  endogenous	  aromatic	  autoinducer	  (AI-­‐3)	  
70–72.	   Once	   phosphorylated,	   QseC	   activates	   3	   transcription	   factors	   through	  
phosphorylation,	  namely	  QseB,	  QseF	  and	  KdpE.	  QseB	   is	   involved	   in	   the	  activation	  of	   the	  
flagellar	  and	  motility	  systems,	  binding	  to	  the	  master	  regulator	   flhDC	   48,73.	  QseF	  and	  KdpE	  
are	   directly	   involved	   in	   the	   up-­‐regulation	   of	   the	   T3SS	   expression,	   interacting	   with	   the	  
master	   regulator	   Ler.	   In	   addition,	  QseF	   is	   also	   responsible	   for	   the	   initiation	   of	   the	   Shiga	  
toxin	  production	  48,74,75.	   It	  has	  already	  been	  demonstrated	  that	  generation	  of	  a	  qseC	  null	  
mutant	  (ΔqseC)	  leads	  to	  attenuated	  expression	  of	  the	  T3SS	  system	  in	  EHEC,	  Salmonella	  sp.	  
and	   Francisella	   sp.	   70,76.	   Therefore,	   inhibitors	   of	   the	  QseC	   receptor	   can	   selectively	   block	  
virulence	  genes	  transcription	  without	  affecting	  essential	  cell	  pathways.	  
In	   2008,	   Rasko	   et	   al.	   identified	   through	   a	   high-­‐throughput	   screening	   the	   promising	  
molecule	   LED209	   as	   QseC	   inhibitor	   for	   its	   potency	   and	   low	   toxicity.	   LED209,	   a	   phenyl-­‐
thiourea	  derivative,	  demonstrated	  to	  have	  a	  selective	  affinity	  for	  the	  bacterial	  receptor	  and	  
to	   antagonise	   epinephrine,	   norepinephrine	   and	   AI-­‐3	   at	   5	   pM,	   acting	   as	   a	   competitive	  
antagonist	   for	   the	   active	   substrates.	   Consequently,	   the	   inhibition	   of	   the	   QseC	   signalling	  
resulted	  in	  down-­‐regulation	  of	  the	  expression	  of	  both	  T3SS	  proteins	  EspA	  and	  EspB	  and	  the	  
attenuation	   of	   A/E	   lesions.	   Furthermore,	   LED209	   did	   not	   affect	   bacterial	   growth	   nor	  
induced	  SOS	  responses.	  The	  compound	  also	  displayed	  activity	  against	  QseC	  in	  other	  Gram-­‐
negative	   bacteria	   such	   as	   S.typhimurium	   and	   Francisella	   sp.,	   due	   to	   the	   well-­‐conserved	  
homology	   of	   the	   receptor	   in	   various	   Gram-­‐negative	   bacteria	   74.	   Positive	   results	   were	  
obtained	   in	   EHEC	   infection	   mouse	   models,	   while	   rabbit	   models	   did	   not	   show	   any	  
prevention	   of	   intestinal	   colonisation	   due	   to	   rapid	   GI	   tract	   absorption.	   Despite	   LED209	  
encouraging	  effects	  in	  reducing	  bacterial	  virulence	  weapons,	  its	  mode	  of	  action	  falls	  at	  the	  
edge	  of	  what	  can	  be	  considered	  an	  anti-­‐virulence	  compound	  since	  QseC	  indirectly	  controls	  
the	   expression	   of	   the	   T3SS	   and	   Shiga	   toxin.	   Nonetheless,	   LED209	   is	   a	   promising	   lead	  
compound	  which	   can	  be	   chemically	  optimised	  and	  used	   in	   combination	  with	  other	   anti-­‐
virulence	  compounds	  to	  block	  virulence	  weapons.	  
	  	  




4.2	  Adhesin	  inhibitors	  
The	  preliminary	  binding	  of	  the	  bacteria	  to	  the	  host	  cell	  is	  mediated	  by	  hair-­‐like	  organelles	  
called	  pili	  or	  fimbriae,	  which	  initiate	  the	  bacterial	  adhesion.	  The	  biogenesis	  of	  these	  fibers	  
is	  characterised	  by	  a	  complex	  and	  well-­‐studied	  chaperone-­‐usher	  pathway	  and,	  therefore,	  
inhibition	   of	   the	   pili’s	   biosynthesis	   can	   lead	   specifically	   to	   a	   less	   effective	   bacterial	  
colonisation	  77,78.	  
	  
P	   pili	   and	   type	   I	   pili	   are	   the	   most	   well-­‐characterised	   types	   of	   fibers	   produced	   by	  
Uropathogenic	   E.	   coli	   (UPEC),	   responsible	   for	   urinary	   tract	   infections.	   P	   pili	   contain	   the	  
adhesin	   PapG	   selective	   for	   renal	   epithelial	   cells,	   while	   type	   I	   pili	   contain	   FimH	   adhesin,	  
responsible	  for	  E.	  coli	  invasion	  into	  the	  bladder	  epithelium	  79–82.	  As	  just	  mentioned	  above,	  
the	   biosynthesis	   of	   the	   pili	   involves	   a	   chaperone-­‐usher	   pathway,	   where	   mechanistically	  
cognate	   periplasmic	   chaperones	   are	   essential	   for	   the	   correct	   assembly,	   stabilisation	   and	  
elongation	  of	   the	   fibers	   77	   (Fig.	   5).	   PapD	  and	  FimC	  are	   specific	   chaperones	   for	  P	  pili	   and	  
type	  I	  pili	  respectively	  and	  they	  catalyse	  the	  folding	  of	  every	  pilus	  subunit	  in	  the	  periplasm	  
83,84.	   The	   binding	   between	   the	   pilus	   subunit	   and	   the	   chaperone	   is	   characterised	   by	   a	  
process	   called	   donor-­‐strand	   complementation,	   where	   the	   subunit	   anchors	   to	   the	  
chaperone	  G1-­‐β-­‐strand	   through	  an	   ion	  pair	   formation	   in	  a	   cleft	   containing	   two	   residues:	  
Arg8	  and	  Lys112	  85–88.	  Once	  the	  pilus	  subunit-­‐chaperone	  complex	   is	   formed	   is	  selectively	  
recognised	   by	   the	   outer	   membrane	   usher,	   responsible	   for	   the	   pilus	   assembly	   89,90.	   The	  
Fig.	  5:	  Pilus	  biogenesis	  (left)	  and	  the	  chemical	  structure	  of	  the	  tyrosine	  derivative	  1	  and	  pyridinone	  2	  (right):	  Schematic	  
representation	   of	   the	  pilus	   biogenesis	   through	   the	   chaperone-­‐usher	  pathway	   is	   shown	  on	   the	   left.	   The	   usher	   and	   the	  
chaperone	   are	   indicated	   in	   red	   and	  blue	   respectively,	  while	   the	  pilus	   subunit	   is	   coloured	   in	   yellow.	  Both	  donor-­‐strand	  
complementation	  and	  exchange	  are	  highlighted	  by	  black	  arrows.	  Figure	  adapted	  from	  184.	  The	  chemical	  structure	  of	  the	  




subunit-­‐chaperone	  complex	  binds	  to	  a	  hydrophobic	  patch	  on	  the	  N-­‐terminal	  portion	  of	  the	  
usher	  and	  releases	  the	  pilus	  subunit	  inside	  its	  cavity	  91,92.	  
	  
	  
Through	   a	   process	   called	   donor-­‐strand	   exchange,	   the	   pilus	   subunit	   unravels	   from	   the	  
chaperone	   G1-­‐β-­‐strand	   and	   binds	   to	   the	   N-­‐terminal	   portion	   of	   a	   second	   pilus	   subunit	  
within	  the	  usher’s	  cavity	  88,93–95.	  This	  process	   is	   then	  reiterated	  several	   times	  to	  elongate	  
the	  pilus	  outside	  the	  bacterial	  membrane.	  
In	  2001,	  Kilhberg	  et	  al.	  designed	  and	  synthesised	   two	  classes	  of	  molecules	   to	   inhibit	   the	  
pilus	  subunit-­‐chaperone	  complex	  based	  on	  the	  anchoring	  of	  the	  pilus	  subunit	  into	  the	  Arg-­‐
Lys	  cleft	  96,97	   (Fig.	  5).	  A	  tyrosine	  derivative	  1	  and	  a	  pyridinone	  2	  were	  found	  to	  be	  strong	  
binders	   of	   both	   chaperones	   PapD	   and	   FimC	   and,	   after	   further	   biological	   evaluation,	  
pyridinone	   2	   was	   subjected	   to	   chemical	   modifications	   to	   improve	   its	   solubility	   (Fig.	   6).	  
Morpholine	  installation	  onto	  position	  C6	  yielded	  a	  potent	  compound	  (3)	  against	  the	  P	  pili	  
and	   type	   I	   pili	   formation	  with	   enhanced	   solubility	   properties.	   In	   addition,	  Almqvist	  et	   al.	  
also	   crystallised	   the	   new	   pyridinone	   3	   with	   the	   pilus	   subunit-­‐chaperone-­‐usher	   complex,	  
revealing	   that	   the	  molecule	   binds	   between	   the	   usher	   and	   the	   chaperone	   instead	   of	   the	  
Arg-­‐Lys	   cleft,	   thus	   blocking	   the	   correct	   pilus	   subunit	   release	   98.	   The	   crystal	   structure	  
obtained	  also	  disclosed	  the	  relevance	  of	  the	  carbonyl	  group	  in	  C7	  and	  the	  carboxylic	  acid	  in	  
C3,	   both	   interacting	   with	   the	   usher	   through	   hydrogen	   bonding.	   Further	   chemical	  
modifications	  in	  C2	  provided	  a	  very	  potent	  derivative	  (4)	  against	  the	  pili	  biogenesis	  in	  vitro	  
and	   in	  UPEC	  mouse	  model	   infections,	   thanks	   to	   the	  position	  and	   stereochemistry	  of	   the	  
new	  phenyl	  ring	  99,100.	  All	  the	  compounds	  demonstrated	  to	  be	  highly	  efficient	  against	  E.	  coli	  
infections	  only	  when	   the	  bacteria	  were	   treated	  before	   the	   infection.	  However,	   this	  does	  
not	  represent	  a	  real-­‐life	  scenario,	  where	  the	  infection	  is	  established	  and	  then	  treated.	  
	  
Fig.	  6:	  SAR	  studies	  on	  the	  pyridinone	  2:	  Scheme	  of	  the	  structural	  changes	  on	  the	  lead	  compound	  2.	  Installation	  
of	  a	  morpholine	  moiety	  in	  C6	  produced	  a	  more	  hydrophilic	  analogue	  3,	  which	  yielded	  the	  crystal	  structure	  of	  
the	  pyridinone	  bound	  to	  the	  pilus	  subunit-­‐chaperone-­‐usher	  complex.	  From	  the	  crystal	  structure,	  it	  was	  possible	  





4.3	  T3SS	  inhibitors	  
As	   discussed	   before	   in	   Paragraph	   2.1,	   the	   T3SS	   is	   a	   needle-­‐like	   complex	   that	   protrudes	  
from	   the	   prokaryotic	   cells	   and	   allows	   the	   bacterium	   to	   hijack	   the	   host	   cell,	   facilitating	  
colonisation.	   It	   has	   been	   previously	   demonstrated	   that	   the	   T3SS	   is	   essential	   for	   the	  
virulence	  of	  many	  pathogens	  101,	  indeed	  deletion	  of	  EspA	  prevent	  EHEC	  colonisation	  of	  the	  
bovine	  host	  12.	  The	  fact	  that	  this	  system	  is	  well-­‐conserved	  amongst	  Gram-­‐negative	  bacteria	  
makes	  it	  a	  very	  promising	  target	  to	  selectively	  block	  virulence	  in	  different	  bacteria,	  leading	  
to	  a	  potential	  broad-­‐spectrum	  anti-­‐virulence	  compounds	  concept.	  For	  these	  reasons,	   the	  
T3SS	  has	  been	  widely	  studied	  and	  many	  research	  groups	  have	  focused	  their	  efforts	  on	  the	  
discovery	  and	  understanding	  of	  selective	  T3SS	  inhibitors.	  




4.3.1	  Natural	  products	  
Name	   Chemical	  Structure	   Effective	  against	   Reference	  
Caminoside	  B	  
	  

















Yersinia	  T3SS	   107	  
	  
Table	  2:	  List	  of	  active	  natural	  products	  against	  T3SS:	  The	  chemical	  structure	  of	  bioactive	  natural	  product	  against	  T3SS	  is	  
listed	  above.	  The	  species	  and	  the	  T3SS	  targeted	  by	  the	  different	  molecules	  is	  also	  listed.	  	  
	  
The	   first	   T3SS	   inhibitor	  was	   reported	   by	   Linington	   et	   al.	   in	   2002	   after	   screening	   various	  
extracts	  from	  the	  marine	  sponge	  Caminus	  sphaeroconia	  against	  the	  virulence	  protein	  EspB.	  
Caminoside	  B,	  a	  carbohydrate	  derivative	  formed	  by	  a	  6-­‐deoxytalose	  ring,	  a	  quinovose	  ring	  




bacterial	   growth.	  Unfortunately,	   due	   to	   the	   complex	   synthesis,	   its	  mode	  of	   action	   is	   still	  
unknown	  102,108	  (Table	  2).	  
Another	   natural	   product	   of	   interest	   is	   Aurodox,	   a	   complex	   compound	   produced	   by	  
Streptomyces	  goldiniensis.	   Initially,	  Aurodox	  was	  described	  as	  an	  anti-­‐bacterial	  compound	  
against	  Gram-­‐positive	  bacteria	  due	  to	  its	  affinity	  to	  the	  elongation	  factor	  Tu	  109.	  It	  has	  been	  
recently	  shown	  by	  Kimura	  et	  al.	  that	  Aurodox	  inhibited	  EPEC	  T3SS-­‐mediated	  haemolysis	  at	  
1.5	   μM	   by	   down-­‐regulating	   T3SS	   proteins	   such	   as	   EspB,	   EspF	   and	   Map,	   with	   no	   anti-­‐
bacterial	  effect.	  Mouse	  models	  of	  C.	  rodentium	  infections	  demonstrated	  that	  Aurodox	  had	  
the	   ability	   to	   protect	   the	  mice	   from	  an	  otherwise	   lethal	   dose	  of	   bacteria	   104.	  Despite	   its	  
known	  anti-­‐bacterial	  target,	  the	  mode	  of	  action	  of	  the	  Aurodox	  anti-­‐virulence	  effect	  is	  still	  
unclear.	  However,	   the	  selective	  decrease	   in	  production	  of	  T3SS	  proteins	  might	   indicate	  a	  
potential	  interaction	  with	  LEE-­‐related	  transcriptional	  regulators.	  
Guadinomines	  are	  unusual	  natural	  products	  produced	  by	  Streptomyces	  K01-­‐509	  and	  were	  
found	   to	   be	   active	   against	   the	   T3SS	   in	   EPEC	   by	   Iwatsuki	   et	   al..	   Guadinomines	   A	   and	   B	  
displayed	   a	   high	   activity	   in	   inhibiting	   EPEC-­‐induced	   haemolysis	   in	   a	   dose-­‐dependent	  
manner,	  with	   an	   IC50	   of	   0.01	  μM.	   Further	   SAR	   studies	   revealed	   that	   the	  diamine	  moiety	  
and	   the	   valine	   subunit	   on	   the	   right-­‐hand	   of	   the	   molecule	   are	   essential	   for	   the	   anti-­‐
virulence	  effect	  of	  these	  compounds	  105.	  Guadinomines	  are	  very	  promising	   lead	  scaffolds	  
against	   the	   T3SS	   due	   to	   their	   high	   potency;	   however,	   their	   mode	   of	   action	   and	   their	  
efficacy	  in	  vivo	  have	  yet	  to	  be	  confirmed.	  
Recently,	   Elofsson	   et	   al.	   isolated	   the	   natural	   product	   (-­‐)-­‐hopeaphenol,	   a	   resveratrol	  
tetramer	  which	  was	  found	  to	  be	  active	  against	  Y.	  pseudotuberculosis	  T3SS	  protein	  YopD.	  It	  
has	   been	   demonstrated	   that	   this	   complex	  molecule	   inhibited	   secretion	   of	   Yops	   proteins	  
without	   affecting	   their	   transcription	  and	   it	   has	  been	  postulated	   that	  hopeaphenol	  might	  
bind	  irreversibly	  to	  its	  still	  unknown	  protein	  target.	  Furthermore,	  this	  molecule	  was	  found	  
to	   have	   a	   similar	   activity	   against	   P.	   aeruginosa	   and	   C.	   trachomatis	   blocking	   the	   secrete	  
effector	   ExoS	   in	   the	   first	   pathogen	   and	   interfering	   with	   the	   cell	   entry	   and	   intracellular	  
growth	  with	   the	   second	  one	   106.	   Even	   in	   this	   case,	   the	   cellular	   target	   of	   hopeaphenol	   is	  
unknown.	  However,	   it	   has	   been	   speculated	   that	   the	   compound,	   considering	   its	   size	   and	  
the	  amount	  of	  polar	  groups,	  might	  act	  on	  the	  outer	  membrane	  of	  the	  bacterial	  cell.	  
The	  marine	  natural	  products	  piericidin	  A1	  and	  its	  derivative	  Mer-­‐A	  2026B	  were	  also	  found	  
to	   be	   active	   against	   Y.	   pseudotuberculosis	   T3SS,	   inhibiting	   Yops	   proteins	   secretion	   and	  




detected	   for	   these	   new	   compounds	   that	   selectively	   blocked	   the	   T3SS	   107.	   Interestingly,	  
both	  molecules	   contain	   a	   γ-­‐pyridone	   ring,	   an	   extremely	   rare	   feature	   in	   nature	   that	   also	  
belongs	   to	   Aurodox.	   It	   is	   easy	   to	   speculate	   a	   potential	   common	  protein	   target	   between	  
these	  two	  classes	  of	  natural	  products,	  but	  direct	  evidences	  are	  yet	  to	  be	  confirmed.	  
	  
4.3.2	  Other	  synthetic	  T3SS	  inhibitors	  
High-­‐throughput	   screenings	   of	   synthetic	   libraries	   have	   also	   been	   employed	   as	   a	   fast	  
method	  to	  identify	  new	  non-­‐natural	  compounds	  against	  the	  T3SS	  (Fig.	  7).	  In	  2008,	  Goguen	  
et	  al.	  screened	  a	   library	  of	  more	  than	  70’000	  compounds	  against	  Y.	  pestis	  by	  means	  of	  a	  
monitored	  growth	  assay	  where	   the	  expression	  of	   the	  T3SS	   resulted	   in	  growth	   inhibition.	  
From	  this	  method,	  4	  putative	  T3SS	  inhibitors	  of	  different	  chemical	  nature	  were	  identified	  
and	  selected	  for	  further	  evaluation.	  Biological	  tests	  revealed	  that	  the	  candidates	  also	  had	  
different	   effects	   on	   the	   virulence	   effectors	   YopM	   and	   YopH	   and	   the	   structural	   protein	  
YopD,	   which	   forms	   the	   terminal	   pore	   of	   the	   T3SS	   in	   Y.	   pestis.	   The	   best	   potency	   was	  
displayed	   by	   compound	   5,	   a	   4,4’-­‐thiobis-­‐(3-­‐methylphenol),	   which	   proved	   to	   be	   active	  
against	  all	  3	  virulence	  proteins	  in	  low	  micromolar	  range	  and	  to	  protect	  HeLa	  cells	  from	  the	  
pathogen	   infection.	   However,	   the	   compound	   demonstrated	   to	   be	   toxic	   for	   mammalian	  
cells,	  suggesting	  that	  further	  chemical	  modifications	  may	  be	  required	  110.	  
	  
An	   important	   class	   of	   synthetic	   compounds	   active	   against	   the	   T3SS	   is	   the	   2-­‐imino-­‐5-­‐
arylidene	   thiazolidinones.	   The	   lead	   compound	   (6)	   of	   this	   class	   was	   identified	   through	   a	  
high-­‐throughput	   screening	   against	   S.	   typhimurium	   using	   a	   reporter	   fusion	   assay	   of	   the	  
Fig.	   7:	   Chemical	   structure	   of	   known	   non-­‐natural	   T3SS	   inhibitors:	   The	   structure	   of	   the	   4,4’-­‐thiobis-­‐(3-­‐methylphenol)	  
derivative	   (5)	   identified	  by	  Goguen	  et	  al	   is	   shown	  on	  the	   left.	  The	  structure	  of	   the	   lead	  compound	  2-­‐imino-­‐5-­‐arylidene	  
thiazolidinone	  6	  is	  depicted	  on	  the	  right.	  SAR	  studies	  allowed	  to	  yield	  the	  amino	  acidic	  derivative	  7,	  which	  demonstrated	  




secreted	   effector	   SipA	   expression.	   Thiazolidinone	   6	  was	   found	   to	   be	   active	   against	   SipA	  
without	  affecting	  bacterial	  growth	  or	  motility.	  In	  addition,	  the	  candidate	  exhibited	  activity	  
against	   the	   T3SS	   of	   P.	   syringae,	   F.	   novicida	   and	   F.	   tularensis,	   demonstrating	   a	   broad	  
spectrum	  activity.	  In	  vivo	  studies	  proved	  that	  compound	  6	  protected	  eukaryoitic	  cells	  from	  
S.	   typhimurium	   and	   P.	   syringae	   respectively	   in	   a	   macrophage	   tissue	   experiment	   and	   in	  
tobacco	  plant	  model,	  while	  showing	  no	  toxic	  effect	  on	  macrophages.	  These	  findings	  drove	  
the	   authors	   to	   conclude	   that	   thiazolidinone	   6	   might	   be	   targeting	   a	   common	   and	   well-­‐
preserved	   structural	   component	   of	   the	   T3SS,	   but	   no	   evidence	   of	   this	   has	   yet	   been	  
demonstrated	   111.	   To	   investigate	   the	   structure-­‐activity	   relationship	   (SAR)	  of	   this	   scaffold,	  
Kline	  et	  al.	  designed	  and	  synthesised	  different	   structural	  derivatives	   in	  order	   to	  evaluate	  
the	  thiazolidinone	  core.	  Both	  3-­‐phenylimido	  and	  5-­‐phenylidene	  features	  were	  found	  to	  be	  
essential	   for	  activity	  against	  SipA	  expression,	  while	   the	  N2	  position	  showed	  to	  be	  almost	  
irrelevant	   for	   the	  activity.	  Especially	   the	  position	  C5	   (5-­‐phenylidene)	  demonstrated	   to	  be	  
the	   interactive	   site	   of	   the	   molecule,	   since	   even	   small	   modifications	   on	   this	   substituent	  
caused	  drastic	   reductions	   in	   activity.	   Position	  N2	  was	   then	   targeted	   for	   further	   chemical	  
changes	  in	  order	  to	  achieve	  a	  better	  solubility	  profile.	  For	  these	  reason,	  a	  polar	  chain	  that	  
vaguely	   recall	   an	  arginine	  motif	  was	   installed	   in	  N2	   to	  yield	  compound	  7.	  This	  derivative	  
was	   directly	   compared	   with	   6	   and	   resulted	   to	   be	   a	   better	   T3SS	   inhibitor	   than	   the	   lead	  
compound	   112.	   Given	   the	   ease	   of	   synthesis	   and	   the	   broad	   spectrum	   activity,	   the	  
thiazolidinone	  class	  are	  a	  promising	  group	  of	  T3SS	  inhibitors.	  
	  
4.3.3	  Salicylidene	  acylhydrazide	  (SA)	  
Salicylidene	  acylhydrazides	   (SA)	  are	  the	  most	  studied	  T3SS	   inhibitors	  due	  to	  their	  activity	  
on	  different	  pathogens	  and	  their	  ease	  of	  synthesis	   (Table	  3).	  The	   first	  SA	  compound	  was	  
discovered	   in	   2003	   by	   Kauppi	   et	   al.	   by	   means	   of	   a	   high-­‐throughput	   screening	   with	   a	  
yopE:luciferase	  reporter	  assay	  against	  Y.	  pseudotuberculosis.	  In	  this	  screening	  method,	  the	  
luciferase	   intensity	   was	   proportional	   to	   the	   yopE	   expression;	   therefore,	   a	   reduction	   of	  
luciferase	  intensity	  represented	  activity	  against	  yopE	  transcription.	  A	  total	  of	  4	  candidates	  
were	  selected	  from	  the	  screening	  and	  the	  SA	  compound	  INP0007	  demonstrated	  to	  be	  the	  
best	  compound,	  inhibiting	  the	  secretion	  of	  other	  T3SS	  proteins,	  such	  as	  YopD	  and	  YopH,	  in	  
a	   dose-­‐dependent	   manner	   and	   with	   an	   IC50	   of	   less	   than	   50	   μM.	   Due	   to	   the	   similarity	  




against	  motility	   and	   INP0007	   resulted	   to	   be	   the	   only	  molecule	   to	   inhibit	   the	   pathogen’s	  
motility	  as	  well	  113.	  This	  indicates	  that	  the	  SA	  compound	  may	  bind	  to	  a	  common	  regulator	  
or	  structural	  components	  of	  these	  two	  systems.	  
After	   these	   findings,	   several	   research	   groups	   also	   tested	   similar	   SA	   compounds	   against	  
various	  T3SS-­‐harbouring	  Gram-­‐negative	  bacteria.	  Wolf	  et	  al.	  employed	  INP0007	  and	  other	  
SA	   compounds	   identified	   by	   Kauppi	  et	   al.	   against	   the	   obligate	   intracellular	   bacterium	  C.	  
trachomatis.	   The	  biological	   evaluation	   showed	   that	   the	   compounds	   significantly	   affected	  
the	  pathogen’s	  infective	  cycle,	  disrupting	  differentiation	  and	  multiplication	  in	  mammalian	  
cells	   114,115.	   At	   the	   time	   of	   the	   study	   little	   was	   known	   about	   the	   role	   of	   the	   T3SS	   in	   C.	  
trachomatis	  and,	  therefore,	  the	  use	  of	  these	  compounds	  revealed	  relevant	  insights	  of	  the	  
regulation	  of	  the	  T3SS	  in	  Chlamydia.	  
SA	   compounds	   were	   also	   found	   active	   against	   S.	   enterica	   serovar	   typhimurium,	   where	  
INP0007	   and	   INP0403	   displayed	   inhibition	   of	   the	   SPI-­‐1	   T3SS	   at	   10	   and	   100	   μM	  without	  
affecting	  the	  bacterial	  growth.	  Furthermore,	  both	  SA	  compounds	  demonstrated	  to	  protect	  
HeLa	   cells	   from	   infection	   at	   up	   to	   60%	   and	   to	   reduce	   inflammation	   levels	   in	   a	   bovine	  
intestinal	  ligated	  loop	  model,	  highlighting	  the	  ability	  of	  this	  compounds	  to	  reduce	  virulence	  
in	   vivo	   116.	   In	   the	   same	  year,	  Negrea	  et	  al.	  used	  other	  SA	  compounds	   (INP0400-­‐0406)	   to	  
confirm	   their	   activity	   against	   SPI-­‐1	   and	   also	   SPI-­‐2	   in	   S.	   typhimurium.	   The	   compounds	  
inhibited	   intracellular	   replication	   and	   two	   of	   them	   reduced	   the	  motility	   by	   affecting	   the	  

















Name	   Structure	   Effective	  against	   Reference	  
INP0007	  
	  





Salmonella	  T3SS,	  EHEC	  T3SS	   117,118	  
INP0400	  
	  
Salmonella	  T3SS,	  S.	  flexneri	  T3SS	   117,119	  
INP0401	  
	  
Salmonella	  T3SS	   117	  
INP0402	  
	  
Salmonella	  T3SS,	  S.	  flexneri	  T3SS	   117,119	  
INP0403	  
	  
Salmonella	  T3SS,	  EHEC	  T3SS	   117,118	  
INP0404	  
	  
Salmonella	  T3SS	   117	  
INP0405	  
	  
Salmonella	  T3SS	   117	  
INP0406	  
	  
Salmonella	  T3SS	   117	  
ME0055	  
	  
EHEC	  T3SS	   118	  
	  
Table	  3:	  List	  of	  the	  SA	  compounds	  active	  against	  T3SS:	  The	  chemical	  structure	  of	  active	  SA	  compounds	  against	  T3SS	  is	  
listed	  above.	  The	  species	  and	  the	  T3SS	  targeted	  by	  the	  different	  molecules	  is	  also	  listed,	  highlighting	  the	  broad	  spectrum	  





The	   same	   group	   of	   SA	   compounds	   was	   also	   evaluated	   against	   the	   invasive	   intracellular	  
pathogen	  S.	  flexneri	  by	  Veenendaal	  et	  al..	  All	  SA	  compounds	  resulted	  to	  be	  active	  against	  
Ipa	   T3SS	   and	   INP0400	   showed	   the	   best	   activity	   profile	   of	   the	   group.	   In	   addition,	   the	  
compounds	  demonstrated	   to	   reduce	  cell	   invasion	   in	  HeLa	  cells	  and	   induced	  macrophage	  
apoptosis	  as	  well	  119.	  
In	  2009,	  Tree	  et	  al.	  tested	  4	  SA	  compounds	  against	  EHEC	  (E.	  coli	  O157:H7	  TUV	  93-­‐0	  strain)	  
and	  ME0055	  was	  found	  to	  be	  the	  best	  T3SS	  inhibitor,	  blocking	  transcription	  and	  secretion	  
of	  the	  virulence	  proteins	  EspD	  and	  Tir	  at	  20	  μM.	  This	  SA	  compound	  also	  showed	  protection	  
of	  HeLa	  cells	  from	  the	  characteristic	  A/E	  lesions,	  typically	  associated	  with	  EHEC	  infections.	  
However,	  ME0055	  was	  found	  to	  also	  have	  anti-­‐bacterial	  effects	  with	  concentrations	  higher	  
than	  20	  μM	  118.	  
Despite	   the	   promising	   activity,	   the	   SA	   compounds	   chemical	   structure	   includes	   an	   imine	  
bond	  prone	  to	  hydrolysis	  in	  acidic	  media.	  However,	  this	  limitation	  makes	  these	  molecules	  a	  
more	  than	  optimal	  lead	  compound	  to	  build	  more	  stable	  and	  more	  potent	  inhibitors	  based	  
on	   the	   SA	   scaffold.	   In	   2010,	   Elofsson	   et	   al.	   conducted	   a	   scaffold	   hopping	   study	   for	   the	  
modification	   of	   the	   acylhydrazone	   core.	   A	   2-­‐(2-­‐aminopyrimidine)-­‐2,2-­‐difluoroethanol	   (8)	  
and	   a	   [4-­‐(2-­‐hydroxylphenyl)thiazol-­‐2-­‐yl]methanone	   (9)	   core	   were	   identified	   from	   the	  
structural	  study	  and	  used	  to	  replace	  the	  weak	   imine	  bond	  of	   the	  SA	  compounds	   (Fig.	  8).	  
These	  new	  heterocycles	  were	  designed	  in	  order	  to	  retain	  the	  intracellular	  hydrogen	  bond	  
between	  the	  ortho-­‐positioned	  hydroxyl	  group	  and	  the	  nitrogen	  of	  the	  hydrazone	  moiety.	  
Two	   new	   series	   of	  molecules	   based	   on	   these	   heterocycles	  were	   synthesised	   and	   tested	  
against	   the	   T3SS	   in	   Yersinia.	   Unfortunately,	   the	   new	   derivatives	   did	   not	   show	   any	  
significant	   activity	   against	   the	  T3SS	   to	  pursue	   further	  biological	   investigations	   120,121.	   The	  
promiscuity	   of	   the	   SA	   compounds	   makes	   their	   structural	   optimisation	   and	   biological	  
evaluation	   very	   challenging,	   since	   only	   whole-­‐cell	   based	   assays	   are	   available	   and,	  
therefore,	  many	  factors	  can	  influence	  the	  derivatives’	  activity.	  
Fig.	  8:	  Scaffold	  hopping	  based	  on	  the	  SA	  compounds	  core:	  Scheme	  representing	  the	  two	  heterocycle	  cores	  8	  and	  9	  





To	   conclude,	   SA	   compounds	   are	   a	   well-­‐studied	   class	   of	   T3SS	   inhibitors	   with	   a	   broad	  
spectrum	   activity.	   In	   different	   cases,	   the	   compounds	   also	   showed	   to	   affect	   the	   flagellar	  
system	  together	  with	  the	  T3SS	  113,117;	  however,	  this	  effect	  between	  species	  resulted	  to	  be	  
inconsistent.	  Although	  SA	  compounds	  have	  been	  described	  as	  T3SS	  inhibitors,	  their	  mode	  
of	   action	   is	   still	   unclear	   and	   is	   yet	   to	   be	   elucidated.	   Nonetheless,	   this	   class	   of	   T3SS	  
inhibitors	   is	   ideal	   for	   further	   chemical	   optimisation	   that	   could	   lead	   to	   more	   stable	   and	  
more	  potent	  derivatives	  and	  to	  clarify	  their	  mechanism	  of	  action.	  
	  
4.3.4	  Mode	  of	  action	  of	  SA	  compounds	  
Three	  different	  hypotheses	  have	  been	  suggested	  regarding	  the	  mode	  of	  action	  of	  the	  SA	  
compound.	   Slepenkin	   et	   al.	   have	   proposed	   and	   studied	   the	   possibility	   that	   the	   SA	  
molecules	  could	  chelate	   iron	  and	  thus	  disrupt	   the	  cellular	   iron	  stores.	  The	  study	  showed	  
how	  addition	  of	  iron	  salts	  to	  HeLa	  cells	  infected	  with	  C.	  trachomatis	  reversed	  the	  effect	  of	  
the	  SA	  compound.	  In	  addition,	  this	  effect	  was	  only	  observed	  with	  iron	  and	  not	  with	  other	  
divalent	  metal	   ions,	   suggesting	   a	   selective	   affinity	   of	   the	   acylhydrazone	  moiety	  with	   the	  
Fe2+	   ions.	   However,	   this	   study	   has	   to	   be	   considered	   inconclusive	   since	   the	   inactive	   SA	  
compound	   against	   C.	   trachomatis	   T3SS	   chelated	   iron	   as	   well	   as	   the	   active	   ones	   122.	   An	  
analogous	  study	  on	  Salmonella	  by	  Layton	  et	  al.	  demonstrated	  that	  the	  addition	  of	  iron	  salts	  
only	  partially	  reversed	  the	  SA	  compound’s	  effect.	  Transcriptomic	  analysis	  revealed	  an	  up-­‐
regulation	  of	  the	  genes	   involved	   in	  the	   iron	  regulation;	  however,	  the	  addition	  of	   iron	  did	  
not	   fully	   reverse	   the	   inhibitory	   effect	   of	   the	   SA	   compounds	   123.	   Another	   transcriptomic	  
analysis	   performed	   on	   EHEC	   treated	   with	   the	   SA	   compounds	   and	   additional	   iron	   salts	  
displayed	   a	   significant	   down-­‐regulation	  of	   T3SS-­‐related	   genes;	   thus,	   suggesting	   that	   iron	  
did	  not	  reverse	  the	  SA	  compound’s	  activity	  118.	  To	  sum	  up,	   it	   is	  still	  unclear	  how	  iron	  can	  
influence	  the	  SA	  compound’s	  effects	  on	  the	  T3SS	  in	  certain	  bacteria.	  Further	  studies	  have	  
to	  be	  performed	  in	  order	  to	  elucidate	  this	  peculiar	  interaction.	  
Veenendaal	  et	  al.,	  instead,	  have	  proposed	  that	  the	  SA	  compound	  might	  bind	  to	  a	  structural	  
component	  of	  the	  T3SS.	  Since	  the	  compounds	  were	  found	  to	  also	  affect	  motility	  in	  Shigella	  
and	   Yersinia,	   the	   target	   may	   be	   a	   homologous	   component	   between	   the	   T3SS	   and	   the	  
flagellar	  system.	  In	  the	  study,	  it	  was	  also	  observed	  that	  the	  needle	  of	  the	  T3SS	  of	  S.	  flexneri	  




with	  the	  T3SS	  assembly	  119.	  A	  recent	  study	  aimed	  to	  clarify	  this	  mode	  of	  action	  hypothesis	  
by	   using	   strains	   lacking	   different	   flagellar	   component	   in	   Salmonella.	   Unfortunately,	   the	  
study	  was	  unable	   to	  detect	   the	   interaction	  between	  the	  SA	  compound	  and	  the	  potential	  
flagellar	  component,	  excluding	  the	  possibility	  of	  a	  direct	  binding	  to	  the	  T3SS	  apparatus.	  It	  is	  
likely	  that,	  in	  this	  case,	  the	  SA	  compound	  interact	  with	  other	  intracellular	  targets	  and	  then	  
indirectly	  inhibit	  the	  T3SS	  assembly	  124.	  
The	   last	   mode	   of	   action	   hypothesis	   is	   that	   the	   SA	   compound	  may	   somehow	   affect	   the	  
regulation	   of	   the	   T3SS.	   To	   identify	   the	   target	   proteins,	   Wang	   et	   al.	   designed	   and	  
synthesised	   an	   Affi-­‐Gel	   and	   biotin	   labelled	   version	   of	   the	   SA	   compounds	   ME0052	   and	  
ME0055	   for	   an	   affinity	   pull-­‐down	   experiment	   against	   EHEC	   cell	   lysate.	   Once	   the	  
immobilised	  labelled	  molecule	  was	  incubated	  with	  the	  whole	  cell	  lysate	  solution,	  unspecific	  
bound	   proteins	   were	   washed	   off	   and	   high	   concentrations	   of	   the	   SA	   compound	   were	  
employed	  to	  displace	  the	  specific	  bound	  proteins.	  These	  proteins	  were	  then	  analysed	  by	  
SDS-­‐PAGE	   electrophoresis	   and	   tandem	   mass	   spectrometry	   for	   identification.	   From	   this	  
study,	  19	  putative	  target	  proteins	  were	   identified	  125.	  The	  research	  group	  mainly	  focused	  
on	   4	   of	   them,	   namely	   FolX,	   Tpx,	  WrbA	   and	  AdhE	   125–131.	   Subsequent	  work	   validated	   the	  
binding	  of	  ME0055	  with	  Tpx	  and	  WrbA	  through	  chemical	  shift	  NMR	  and	  co-­‐crystallisation	  
techniques,	   but	   the	   most	   significant	   target	   regarding	   the	   control	   of	   EHEC	   virulence	  
weapons	  was	  AdhE.	  Beckham	  et	  al.	  found	  that	  deletion	  of	  the	  AdhE	  gene	  (adhE)	  yielded	  a	  
stark	  pleiotropic	  phenotype	  with	  strong	  T3SS	  down-­‐regulation	  and	  over-­‐expression	  of	  non-­‐
functional	  flagella.	  It	  was	  showed	  that	  the	  suppression	  of	  the	  T3SS	  was	  post-­‐transcriptional	  
and	   triggered	   by	   the	   Ler	   mRNA	   regulator	   Hfq,	   resulting	   in	   a	   less	   virulent	   phenotype.	  
However,	   this	   studies	   highlighted	   the	   complexity	   and	   promiscuity	   of	   the	   SA	   compounds	  
and	  their	  mechanism	  of	  action.	  It	  was	  concluded	  that	  their	  effects	  on	  the	  T3SS	  is	  a	  result	  of	  
the	  modulation	  of	  several	  metabolic	  pathways	  rather	  than	  a	  direct	  control	  of	  the	  virulence	  
factors	  themselves	  132.	  
	  
5	  Aims	  of	  the	  project	  
The	  aim	  of	  this	  project	  was	  to	  build	  a	  library	  of	  EHEC	  T3SS	  inhibitors	  based	  on	  the	  the	  most	  
promising	   SA	   compound,	   ME0055.	   Despite	   the	   promising	   activity	   against	   the	   T3SS	   of	  




was	  prone	  to	  hydrolysis	  in	  acidic	  media	  due	  to	  the	  weak	  imine	  bond.	  In	  addition,	  ME0055	  
mode	   of	   action	   is	   still	   partially	   unclear	   and	   derivatives	   of	   this	   molecule	   could	   better	  
elucidate	   its	   mechanism	   of	   action.	   Therefore,	   ME0055	   represents	   an	   attractive	   lead	  
compound	   for	   chemical	   optimisation.	   Once	   designed	   and	   synthesised	   new	   potential	  
chemical	  scaffolds,	  the	  aim	  was	  to	  screen	  and	  biologically	  evaluate	  the	  series	  against	  EHEC	  
T3SS	  using	  phenotypic	  characterisation	  assays.	  Three	  active	  scaffolds	  were	   identified	  and	  
tested	  against	  EHEC	  T3SS.	  By	  means	  of	  biotin	  labelling,	  it	  was	  possible	  to	  identify	  the	  main	  
protein	   target	   of	   the	   new	   inhibitors,	   enabling	   future	   investigations	   on	   the	   determined	  






	   	  





Hydrazine-­‐containing	   heterocycles	   are	   valuable	   building	   blocks	   for	   drugs.	   It	   has	   been	  
estimated	  that	  50%	  of	  all	  drug	  molecules	  contain	  a	  phenyl	  ring,	  which	  can	  be	  consequently	  
substituted	   with	   different	   nitrogen-­‐containing	   rings.	   The	   replacement	   with	   hydrazine-­‐
containing	   heterocycles	   opens	   a	   variety	   of	   potential	   diaza	   analogues	   (i.e.	   pyrazole,	  
pyridazine,	  phthalazine,	  cinnoline,	  etc),	  presenting	  more	  interaction	  possibilities	  thanks	  to	  
the	  two	  nitrogens	  (hydrogen	  bond	  acceptors),	  lower	  LogP	  values	  and	  improved	  crystalline	  
properties	  133.	  
Many	  commercially	  available	  drugs	  include	  hydrazine-­‐containing	  heterocycles	  such	  as	  the	  
selective	   COX-­‐2	   inhibitor	   Celecoxib	   (10)	   by	   Pfizer,	   which	   is	   used	   for	   acute	   pain,	  
osteoarthritis	  and	  rheumatoid	  arthritis	  (Fig.	  9).	  Other	  inhibitors	  of	  the	  same	  NSAID	  family	  
bear	   a	   3-­‐	   or	   5-­‐pyrazolone	   ring	   as	   pharmacophore.	   Ampyrone	   (11),	  metamizole	   (12)	   and	  
phenazone	  (13)	  are	  all	  used	  as	  pain	  reliever,	  antispasmodic	  and	  fever	  reducer	  with	  effects	  
similar	   to	   paracetamol.	   A	   historic	   example	   of	   a	   pyridazine	   is	   the	   commercially	   available	  
sulphonamide	   antibiotic	   sulphamethoxypyridazine	   (14),	   which	   was	   introduced	   on	   the	  
market	  around	  1950s	  as	  one	  of	  the	  first	  hydrazine-­‐containing	  heterocycle	  drugs	  133.	  
	  
Another	   hydrazine-­‐containing	   heterocycle	   of	   interest	   is	   the	   phthalazinone	   ring,	   which	   is	  
usually	  used	  as	  a	  chromophore	  scaffold	  (i.e	  Luminol	  (15)),	  but	  recently	  has	  gained	  interest	  
as	  a	  drug	  building	  block.	  Olaparib	  (16)	  is	  an	  experimental	  drug	  by	  AstraZeneca	  for	  treating	  
prostate	   cancer,	   which	   binds	   to	   poly	   ADP	   ribose	   polymerase	   (PARP).	   The	   phthalazinone	  
Fig.	  9:	  Chemical	  structures	  of	  relevant	  hydrazine-­‐containing	  heterocycle	  drugs.	  From	  left	  
to	   right:	   Celecoxib	   (10)	   form	   Pfizer,	   ampyrone	   (11),	   metamizole	   (12),	   phenazone	   (13),	  




ring	   is	   one	   of	   the	   key	   elements	   for	   the	   inhibitory	   effect	   and	   replaces	   the	   original	  
nicotinamide	  pharmacophore	  134.	  




7	   1,4,5,6-­‐Tetrahydropyridazine	   (THP)	   and	   1,2-­‐Dihydrophthalazine	  
(DHP)	  Derivatives	  
7.1	  Design	  and	  rationale	  of	  the	  THP	  and	  DHP	  cores	  
Previous	  studies	  in	  our	  group	  were	  focused	  on	  the	  characterisation	  of	  potential	  type	  three	  
secretion	  system	  (T3SS)	  inhibitors	  such	  as	  salicylidene	  acylhydrazide	  (SA)	  118.	  A	  number	  of	  
SA	  compounds	  tested	  against	  E.	  coli	  T3SS	  produced	  positive	  results	  and	  experiments	  were	  
performed	   to	   understand	   their	   mode	   of	   action	   125.	   Amongst	   the	   compounds	   tested,	  
ME0055	  showed	  the	  most	  promising	  effects	  as	  a	  potential	  selective	  inhibitor	  of	  the	  T3SS.	  
However,	  the	  mode	  of	  action	  of	  this	  acylhydrazone	  is	  still	  unclear	  due	  to	  its	  promiscuity	  in	  
binding	  several	  off-­‐target	  proteins,	  which	  makes	  it	  difficult	  to	  establish	  a	  clear	  and	  specific	  
target	   125.	   The	   poor	   solubility	   of	   ME0055	   in	   biological	   media	   has	   also	   hampered	   many	  
binding	  studies	  such	  as	   isothermal	  calorimetric	  experiments	  (ITC),	  enzyme	  kinetics	  assays	  
and	  NMR,	  which	   could	   clarify	   its	  mode	  of	   action	   (unpublished	   data).	   The	   imine	   bond	  of	  
ME0055	  was	  found	  to	  be	  prone	  to	  hydrolysis	   in	  aqueous	  acidic	  media	  through	  electronic	  
ionisation	  mass	  spectrometry	  and	  NMR	  analysis	  (data	  not	  shown).	  Due	  to	  these	  limitations,	  
ME0055	   was	   chosen	   as	   the	   lead	   compound	   to	   build	   a	   small	   focused	   library	   of	   new	  
potential	  anti-­‐virulence	  compounds,	  in	  order	  to	  improve	  the	  stability	  and	  selectivity	  of	  the	  
SA	   compound.	   Furthermore,	   a	   new	   series	   of	   more	   stable	   compounds	   could	   provide	  
essential	   data	   to	   elucidate	   the	   mode	   of	   action	   and	   the	   structure-­‐activity	   relationship	  
around	  the	  SA	  compounds	  core.	  
	  
It	  was	  decided	   to	  modify	   the	  molecule	  by	   including	   the	   imine	  bond	  of	   the	  SA	  scaffold	   in	  
hydrazine-­‐containing	   heterocycles	   (Fig.	   10).	   A	   pyridazine	   and	   a	   phthalazine	   core	   were	  
Fig.	   10:	   Rational	   design	   of	   the	   THP	   and	   DHP	   cores:	   It	   was	   decided	   to	   include	   the	   imine	   motif	   in	   two	   hydrazine-­‐
containing	  heterocycles	  (THP	  and	  DHP),	  in	  order	  to	  stabilise	  the	  chemical	  structure	  of	  the	  SA	  compound	  ME0055.	  The	  
THP	   core	   provided	   a	   stable	   derivative,	   allowing	   to	   also	   explore	   the	   chemical	   space	   around	   the	   central	   core	   of	   the	  
molecule,	   since	   its	   half	   chair	   conformation.	   The	   DHP	   analogue,	   instead,	   offered	   a	   planar	   central	   core	   to	   facilitate	  




chosen	  to	  be	  introduced	  in	  the	  central	  part	  of	  the	  molecule.	  In	  addition,	  retention	  of	  the	  
intra-­‐molecular	   hydrogen	  bond	  between	   the	  ortho-­‐hydroxyl	   group	  and	   the	  nitrogen	  was	  
also	  planned	  to	  mimic	  ME0055	  chemical	  features.	  Two	  different	  hydrazine-­‐containing	  rings	  
were	   selected:	   the	   1,4,5,6-­‐tetrahydro	   pyridazine	   (THP)	   and	   the	   1,2-­‐dihydrophthalazine	  
(DHP).	   The	   THP	   core	   includes	   the	   two	  nitrogen	   in	   a	   six-­‐membered	   ring	  with	   a	   half-­‐chair	  
conformation,	  allowing	  the	  investigation	  of	  the	  chemical	  space	  around	  the	  hydrazine	  core	  
with	  a	  minimum	  of	  steric	  hindrance.	  The	  DHP	  core,	  on	  the	  other	  hand,	  has	  a	  completely	  
planar	  conformation	  and	  the	  ortho-­‐fused	  phenyl	  ring	  gives	  a	  much	  greater	  hindrance	  in	  the	  
central	  core	  of	  the	  molecule	  than	  the	  THP	  scaffold,	  also	  increasing	  the	  lipophilicity	  of	  the	  
compound.	   At	   the	   same	   time,	   this	   fused	   heterocycle	   can	   take	   part	   in	   hypothetical	  
hydrophobic	   interactions	   as	   pi	   stacking	   overlaps.	   All	   the	   substituents	   of	   ME0055	   were	  
retained	  to	  have	  a	  direct	  comparison	  of	  the	  impact	  of	  the	  two	  cores	  on	  the	  activity	  of	  the	  
compounds.	  
	  
7.2	  Synthesis	  of	  the	  THP	  and	  DHP	  derivatives	  
The	   synthesis	   of	   both	  THP	  and	  DHP	  derivatives	   started	   from	   resorcindimethylether	   (17),	  
which	  underwent	  Friedel-­‐Crafts	  acylation	  with	  both	  succinic	  (A)	  and	  phthalic	  anhydride	  (B)	  
to	   afford	   carboxylic	   acids	   intermediates	   18	   and	   19	   (Fig.	   11).	   Pyridazinone	   20	   and	  
phthalazinone	   21	  were	   obtained	   in	   excellent	   yield	   by	   treating	   18	   and	   19	  with	   hydrazine	  
hydrate	   in	   refluxing	   ethanol.	   Lithium	   aluminiumhydride	   reduction	   afforded	   the	  
corresponding	  amines	  22	  and	  23	  135.	  Acylation	  with	  4-­‐nitrobenzoyl	  chloride	  subsequently	  
achieved	  the	  di-­‐methoxyl	  analogues	  RCZ09	  (THP)	  and	  RCZ17	  (DHP)	  in	  moderate	  yield.	  After	  
trying	   different	   de-­‐methylation	   conditions,	   the	   di-­‐hydroxyl	   derivatives	   RCZ10	   (THP)	   and	  





In	   order	   to	   expand	   the	   series,	   it	   was	   decided	   to	   replace	   the	   carbonyl	   function	   with	   a	  
sulphone	  group	   (Fig.	  12).	  Consequently,	   the	   two	  amines,	  22	  and	  23,	  were	   sulphonylated	  
with	  nosyl	  chloride	  and	  then	  de-­‐methylated	  with	  the	  previous	  conditions,	  to	  afford	  RCZ12	  
(THP)	   and	   RCZ20	   (DHP).	   Although	   in	   this	   case	   the	   de-­‐methylation	   step	  was	   found	   to	   be	  
problematic	  and	  provided	  very	  poor	  yield,	  we	  obtained	  enough	  final	  material	  to	  carry	  on	  
with	  biological	  tests.	  
	  
Fig.	  11:	  Synthetic	  route	  for	  THP	  and	  DHP	  derivatives:	  The	  synthesis	  started	  from	  resorcindimethylether	  (17)	  
which	  reacted	  with	  both	  succinic	  (A)	  or	  phthalic	  (B)	  anhydride	  in	  presence	  of	  AlCl3.	  Intermediates	  18	  and	  19	  
were	   converted	   in	   the	   corresponding	   amides	  20	   and	  21	   in	   very	   good	   yield	   upon	  hydrazine	   treatment	   in	  
refluxing	   ethanol.	   LiAlH4	   reduction	   yielded	   amines	   22	   and	  23,	  which	  were	   consequently	   acylated	  with	  4-­‐
nitrobenzoyl	  chloride	  to	  obtain	  the	  di-­‐methoxyl	  THP	  and	  DHP	  derivatives	  RCZ09	  and	  RCZ17.	  Demethylation	  
was	  carried	  out	  with	  BBr3	  in	  DCM	  at	  40	  °C	  to	  finally	  afford	  the	  two	  di-­‐hydroxyl	  analogues	  RCZ10	  and	  RCZ18.	  
	  
Fig.	  12:	  Synthesis	  of	  sulphonyl	  THP	  and	  DHP	  derivatives:	  To	  expand	  our	  series,	  amines	  22	  and	  23	  were	  sulphonylated	  with	  
nosyl	  chloride	  to	  afford	  di-­‐methoxyl	  analogues	  RCZ11	  and	  RCZ19.	  Demethylation	  was	  carried	  out	  with	  the	  same	  protocol	  
used	  previously	  to	  yield	  RCZ12	  and	  RCZ20	  in	  poor	  yields.	  Despite	  the	  inefficient	  de-­‐protection,	  the	  amount	  obtained	  of	  the	  





7.3	  Biological	  evaluation	  of	  the	  THP	  and	  DHP	  derivatives	  
A	   total	   of	   8	   compounds	   (RCZ09-­‐20)	   were	   selected	   to	   be	   tested	   for	   activity	   against	   the	  
expression	  of	  the	  T3SS	  in	  E.	  coli	  O157:H7.	  The	  strain	  TUV	  93-­‐0	  was	  used	  as	  this	   lacks	  the	  
potent	   Shiga	   toxin	   making	   it	   suitable	   for	   work	   in	   category	   II	   containment	   facilities.	  
Together	  with	   the	   di-­‐hydroxyl	   carbonyl	   and	   sulphonyl	   derivatives	   (RCZ10,	   RCZ18,	   RCZ12	  
and	   20),	  we	   also	   included	   all	   4	   di-­‐methoxyl	   compounds	   (RCZ09,	   11,	   17	   and	   19)	   derived	  
from	   our	   synthetic	   route.	   This	   allowed	   us	   to	   investigate	   the	   relevance	   of	   the	   carbonyl	  
(hydrogen	  bond	  acceptor)	  on	  the	  left	  hand	  side	  of	  the	  molecule	  and,	  at	  the	  same	  time,	  the	  
role	  played	  by	  the	  two	  hydroxyl	  groups	  (hydrogen	  bond	  acceptor/donor)	  on	  the	  right	  side.	  
All	  compounds	  were	   firstly	  evaluated	   for	   their	  ability	   to	  affect	  bacterial	  growth	  and	  then	  
screened	  on	  the	  ability	  to	  block	  secretion	  of	  the	  T3SS	  associated	  virulence	  protein	  EspD.	  
	  
7.3.1	  Bacterial	  growth	  
Anti-­‐virulence	   compounds	   are	   specifically	   designed	   to	   disarm	   the	   bacterial	   virulence	  
weapons	   without	   affecting	   essential	   pathways	   such	   as	   bacterial	   growth	   or	   protein	  
synthesis.	  This	  particular	  feature	  is	  essential	  to	  reduce	  the	  evolutionary	  pressure	  and	  SOS	  
responses	  associated	  with	  treatment	  using	  traditional	  antibiotic	  treatments.	  Thus,	  our	  new	  


















Entry	  (50	  µM)	   Structure	   OD600	  after	  5	  h	  
WT	   -­‐	   0.680	  ±	  0.008	  
ME0055**	  
	  
0.507	  ±	  0.021	  
RCZ09	  
	  
0.690	  ±	  0.018	  
RCZ10	  
	  
0.745	  ±	  0.026	  
RCZ11	  
	  
0.724	  ±	  0.029	  
RCZ12	  
	  
0.705	  ±	  0.024	  
RCZ17	  
	  
0.693	  ±	  0.014	  
RCZ18	  
	  
0.708	  ±	  0.011	  
RCZ19*	  
	  
0.760	  ±	  0.066	  
RCZ20	  
	  
0.706	  ±	  0.010	  
	  
Table	  4:	  Bacterial	  growth	  after	  5	  hours	  of	  incubation:	  The	  mean	  OD600	  values	  and	  their	  standard	  deviation	  for	  
each	   sample	   are	   represented	   in	   the	   table	   on	   the	   left.	   Mean	   OD600	   values	   were	   obtained	   through	   linear	  
regression	   analysis	   of	   the	   growth	   curve	   interpolated	   at	   desired	   time	   value	   (5	   h).	   Mean	   OD600	   values	   of	  
treated	  samples	  were	  compared	  to	  the	  control	  sample	  (WT)	  by	  Student’s	  t-­‐test	  for	  statistical	  significance	  (P	  
value	  <	  0.05).	  Significant	  samples	  are	  indicated	  by	  an	  asterisk.	  ME0055	  growth	  inhibition	  resulted	  to	  be	  very	  






The	  8	  compounds	  were	  incubated	  at	  50	  µM	  with	  TUV	  93-­‐0	  strain	  in	  a	  T3SS-­‐inducing	  media	  
and	  the	  bacterial	  concentration	  (OD600)	  was	  calculated	  hourly	  by	  means	  of	  a	  refractometer	  
(Table	  4).	  As	  previously	  observed	   in	  our	  group,	  ME0055	  showed	  a	  significant	  effect	   (1.4-­‐
fold	  reduction)	  on	  the	  rate	  of	  bacterial	  growth	  at	  this	  concentration	  118.	  In	  comparison,	  all	  
the	  derivatives	  did	  not	  show	  any	  substantial	  effect	  on	  the	  growth	  of	  the	  pathogen,	  which	  
was	  deemed	  a	  desirable	  trait	  for	  a	  potential	  anti-­‐virulence	  compound.	  
	  	  	  
7.3.2	  THP	  and	  DHP	  screening	  
The	  amount	  of	  secreted	  virulence	  proteins	  by	  E.	  coli	  O157	  TUV	  93-­‐0	  strain	  was	  investigated	  
by	   western	   blot	   analysis	   as	   a	   screening	   experiment	   for	   our	   small	   series	   of	   ME0055	  
analogues	   (Fig.	   13).	   The	   derivatives	   were	   evaluated	   by	   measuring	   the	   quantity	   of	   the	  
secreted	  virulence	  protein	  EspD,	  essential	  part	  of	   the	   translocon	  pore	  136,	  at	  50	  µM	  as	  a	  
preliminary	   assessment.	  ME0055	   showed	   a	   5-­‐fold	   reduction	   of	   the	   secretion	   of	   EspD	   as	  
previously	  demonstrated	  118.	  
	  
Fig.	  13:	  α-­‐EspD	  Western	  blot	   for	  THP	  and	  DHP	  derivatives	   at	  50	  µM	  (top)	  and	  plotted	  relative	  EspD	   secretion	  
percentage	   graph	   (bottom):	   Western	   blot	   analysis	   were	   carried	   out	   according	   to	   standard	   procedure	   (see	  
Experimental	   Part	   for	   methods	   and	   Ab	   dilutions).	   Blots	   were	   performed	   in	   triplicates	   coming	   from	   three	  
independent	   experiments.	   The	   plotted	   relative	   secretion	   was	   obtained	   evaluating	   X-­‐rays	   film	   pixel	   density	   by	  
means	  of	   ImageJ	   program	   from	   three	   independent	   experiments.	   Untreated	   samples	   (WT)	  were	   considered	   as	  
total	   secretion	   (100%)	   and	   treated	   samples	  were	   normalised	   accordingly.	  Mean	   relative	   secretion	   values	   are	  
represented	   in	   the	   graph.	   Standard	   deviation	   from	   the	   mean	   is	   shown	   by	   error	   bars.	   RCZ12	   and	   RCZ20	  
demonstrated	  to	  be	  the	  best	  compounds	  of	  the	  series,	  decreasing	  by	  four-­‐fold	  EspD	  secretion.	  The	  di-­‐hydroxyl	  
sulphonyl	   activity	  was	   found	   to	   be	   comparable	   to	  ME0055	   and,	   since	   they	   share	   common	   structural	   features,	  




The	   effects	   of	   the	   new	   compounds	   on	   EspD	   secretion	   were	   also	   assessed.	   Carbonyl	   di-­‐
methoxyl	  analogues	  (RCZ09	  and	  RCZ17)	  did	  not	  significantly	  reduce	  EspD	  secretion,	  while	  
the	   sulphonyl	   di-­‐methoxyl	  molecules	   (RCZ11	   and	  RCZ19)	   decreased	   the	   secretion	   of	   the	  
protein	   by	   2-­‐fold	   compared	   to	   the	   uninhibited	   control.	   The	   same	   activity	   pattern	   was	  
detected	   for	   the	   4	   di-­‐hydroxyl	   compounds	   (RCZ10,	   12,	   18	   and	   20)	   with	   the	   sulphonyl	  
derivatives	   having	   a	   better	   inhibition	   profile	   than	   the	   carbonyl.	   RCZ18	   showed	   a	   poor	  
activity	   (1.3-­‐fold	   reduction),	  while	  RCZ10	   lowered	   the	  virulence	  protein	  secretion	  by	  2.5-­‐
fold.	  RCZ12	  and	  RCZ20	  displayed	  a	  significant	  activity	  against	  EspD	  decreasing	   its	  relative	  
secretion	  by	  4-­‐fold	  and	   resulting	   the	  most	  active	   compounds	  of	   the	  entire	   series.	   It	  was	  
interesting	  to	  notice	  that	  the	  inhibition	  by	  the	  4	  di-­‐hydroxyl	  derivatives	  was	  generally	  more	  
marked	  than	  that	  observed	  for	  the	  4	  di-­‐methoxyl	  molecules,	  suggesting	  that	  the	  hydroxyl	  
groups	  may	  be	  contributing	  to	  activity.	  The	  inhibition	  observed	  for	  RCZ12	  and	  RCZ20	  was	  
found	   to	   be	   slightly	  weaker	   than	   the	   inhibition	   by	  ME0055:	   however,	   it	  was	   planned	   to	  
pursue	  further	  biological	  assays	  with	  the	  two	  sulphonyl	  di-­‐hydroxyl	  candidates.	  
	  
7.3.4	  Western	  blot	  analyses	  for	  RCZ12	  and	  RCZ20	  
	  
Fig.	  14:	  α-­‐Tir	  (S/N),	  α-­‐EspD	  (S/N	  and	  W/C)	  and	  α-­‐GroEL	  (W/C)	  Western	  blots	  for	  RCZ12	  and	  RCZ20	  at	  50	  µM:	  Western	  blot	  
analyses	  were	   carried	  out	   according	   to	   standard	  procedure	   (see	   Experimental	   Part	   for	  methods	   and	  Ab	  dilutions).	   Both	  
supernatant	   proteins	   (S/N)	   and	   whole	   cell	   lysate	   solution	   (W/C)	   were	   analysed.	   The	   relative	   secretion	   values	   were	  
obtained	  evaluating	  X-­‐rays	  film	  pixel	  density	  by	  means	  of	  ImageJ	  from	  three	  independent	  experiments.	  Untreated	  samples	  
(WT)	  were	  considered	  as	  total	  secretion/expression	  (100%)	  and	  treated	  samples	  were	  normalised	  accordingly.	  Both	  RCZ12	  
and	  RCZ20	  displayed	  a	  different	  effect	  on	  T3SS	  proteins	  than	  ME0055	  at	  50	  µM.	  Reduction	  of	  EspD	  secretion	  seems	  to	  be	  
a	  selective	  post-­‐transcriptional	  effect,	   since	  equal	  amount	  of	   the	  virulence	  protein	  were	   found	   inside	  the	  cell	  when	  TUV	  
93-­‐0	  was	  treated	  with	  our	  new	  derivatives.	  A	  very	  weak	  effect	  was	  also	  detected	  for	  another	  T3SS	  protein	  (Tir)	  for	  RCZ20,	  




To	  complete	  the	  profile	  of	  the	  T3SS	  proteins	  secretion	  in	  presence	  of	  RCZ12	  and	  RCZ20	  at	  
50	  µM,	  the	  amount	  of	  secreted	  Tir	  (translocated	  intimin	  receptor)	  was	  measured	  through	  
western	  blot	  analysis	   (Fig.	  14).	  As	  previously	  observed,	  ME0055	  completely	   inhibited	   the	  
secretion	  of	  this	  virulence	  protein	  118.	  RCZ12	  and	  RCZ20	  resulted	  in	  a	  very	  weak	  effect	  on	  
Tir	  secretion	  (1.2-­‐fold	  reduction).	  Both	  candidates	  demonstrated	  a	  more	  marked	  effect	  on	  
EspD	  secretion	  than	  Tir.	  To	  further	  understand	  the	  basis	  of	  this	  selectivity,	  the	  intracellular	  
quantity	  of	  EspD	  was	  also	  analysed	  by	  western	  blot.	  A	  total	  reduction	  of	  the	  protein	   into	  
the	   cytosol	   was	   detected	   for	   the	   SA	   compound	   118,	   indicating	   a	   strong	   effect	   at	  
transcriptional	   level	   for	   this	   virulence	   protein.	   Interestingly,	   both	   RCZ12	   and	   RCZ20	  
resulted	   in	   a	   very	   different	   phenotype	   to	   the	   SA	   compound.	   Intracellular	   EspD	   did	   not	  
decrease,	  instead	  resulting	  in	  the	  retention	  of	  the	  protein	  inside	  the	  cell.	  Unlike	  ME0055,	  
which	  reduced	  both	  EspD	  transcription	  and	  secretion,	  the	  two	  derivatives	  only	  appeared	  to	  
interfere	  with	  protein	  secretion.	  As	  previously	  demonstrated,	  ME0055	  activity	  seemed	  to	  
be	  mediated	  by	  down-­‐regulating	   the	  expression	  of	   the	  entire	   locus	   that	  encodes	   for	   the	  
T3SS	  apparatus,	  inhibiting	  both	  EspD	  and	  Tir	  secretion	  118.	  Interestingly,	  RCZ12	  and	  RCZ20	  
mode	   of	   action	   appeared	   to	   be	   focused	   selectively	   on	   EspD	   secretion	   at	   a	   post-­‐
transcriptional	  level,	  without	  significantly	  affecting	  the	  protein’s	  intracellular	  concentration	  
and	  Tir	  secretion.	  GroEL	  concentration	  was	  also	  evaluated	  as	  an	  experimental	  control	  and	  
to	   exclude	   any	   other	   possible	   effect	   on	   bacterial	   housekeeping	   activity	   by	   our	   new	  
molecules.	   As	   previously	   demonstrated,	   ME0055	   did	   not	   affect	   GroEL	   production	   118,	   a	  
trait	  that	  was	  mirrored	  by	  the	  candidate	  compounds.	  
Entry	   CFU/mL	   Standard	  deviation	  
WT	   2.00*1011	   ±3.46*1010	  
RCZ12	   1.97*1011	   ±2.78*1010	  
RCZ20	   1.96*1011	   ±2.91*1010	  
	  
Table	  5:	  Colony	  count	  for	  RCZ12	  and	  RCZ20	  at	  200	  µM:	  Colony	  count	  analysis	  was	  carried	  out	  through	  a	  modified	  version	  
of	  the	  Miles	  and	  Misra	  protocol	  (see	  Experimental	  Part).	  A	  total	  of	  9	  independent	  experiments	  were	  performed	  for	  each	  
entry,	  plating	  a	  dilution	  range	  between	  10-­‐3	  to	  10-­‐10.	  CFU/mL	  mean	  values	  are	  represented	  in	  the	  table	  above	  with	  the	  
corresponding	  standard	  deviation	  values.	  No	  effects	  on	  bacterial	  growth	  were	  observed	  for	  either	  RCZ12	  and	  RCZ20	  at	  
200	  µM.	  
	  
The	   results	   obtained	   by	   these	   analyses	   drove	   us	   to	   propose	   that	   the	   THP	   and	   DHP	  
derivatives	   might	   selectively	   block	   EspD	   secretion	   at	   the	   post-­‐transcriptional	   level.	   To	  




O157	  TUV	  93-­‐0	  was	  treated	  with	  decreasing	  concentrations	  of	  RCZ12	  and	  RCZ20,	   from	  a	  
maximum	   concentration	   of	   200	   µM	   and	   a	   minimum	   concentration	   of	   10	   µM	   (Fig.	   15).	  
Bacterial	  growth	  was	  assessed	  to	  evaluate	  any	  effects	  on	  growth	  rates	  and	  colony	  counts	  
was	  performed	  to	  determine	  any	  detrimental	  effects	  on	  bacterial	  viability	   (Table	  5).	  TUV	  
93-­‐0	  was	   incubated	  with	  200	  µM	  of	   the	  two	  candidates	   for	  6	  hours,	   the	  cultures	  diluted	  
and	   then	  plated	  at	   the	  desired	  dilution	   ranges.	  Colonies	  were	  counted	  and	  processed	   to	  
obtain	  the	  CFU/mL	  unit	  values.	  Neither	  RCZ12	  or	  RCZ20	  affected	  the	  bacterial	  growth	  or	  
survival	  at	  200	  µM,	  the	  highest	  concentration	  of	  the	  compound	  used	  in	  any	  assays.	  EspD	  
secretion	   was	   then	  measured	   with	   decreasing	   concentrations	   of	   the	   two	   candidates	   by	  
western	   blotting.	   Both	   RCZ12	   and	   RCZ20	   interfered	   with	   the	   protein	   secretion	   in	   a	  
concentration-­‐dependent	   manner.	   A	   strong	   inhibition	   of	   EspD	   secretion	   (25-­‐fold	  
reduction)	  was	  detected	  at	  200	  µM	  and	  a	  significant	  5-­‐fold	  reduction	  was	  also	  observed	  at	  
100	  µM.	  Both	  candidates	  showed	  an	  absent	  or	  weak	  1.5-­‐fold	  reduction	  of	  the	  T3SS	  protein	  
secretion	  at	  25	  µM	  and	  10	  µM.	  Intracellular	  amounts	  of	  EspD	  were	  also	  measured	  at	  200	  
µM	   to	   verify	   the	   correct	   transcription	   of	   the	   virulence	   protein	   even	   at	   higher	  
concentrations.	  Retention	  of	  the	  T3SS	  protein	  was	  also	  observed	  in	  this	  case	  for	  both	  our	  
candidates.	  Slightly	  increased	  amounts	  of	  EspD	  were	  detected	  inside	  the	  cells	  treated	  with	  
RCZ12	  and	  RCZ20,	  which	   confirmed	   the	   retention	  of	   the	   virulence	  protein	   in	   absence	  of	  
secretion.	  At	  this	  concentration,	  also	  Tir	  secretion	  was	  inhibited	  and	  a	  α-­‐Tir	  analysis	  on	  the	  
whole	   cell	   lysate	   showed	   reduction	   of	   Tir	   expression.	   GroEL	   immunoblotting	   was	  
performed	  as	  an	  experimental	  control	  and	  to	  assess	  any	  effects	  of	  the	  compounds	  on	  non-­‐
T3SS	   associated	   pathways	   at	   high	   concentrations.	   The	   two	   sulphonyl	   derivatives	   did	   not	  
affect	  GroEL	  expression.	  The	  western	  blot	  results	  demonstrated	  that	  200	  μM	  is	  the	  optimal	  
concentration	  to	  obtain	  a	  total	  inhibition	  of	  EspD	  secretion.	  At	  this	  high	  concentration,	  our	  
new	  compounds	  also	  showed	  to	  block	  Tir	  secretion	  and	  expression	  as	  resulted	  from	  the	  α-­‐
Tir	  analyses	  inside	  and	  outside	  the	  cell.	   It	  can	  be	  postulated	  that	  RCZ12	  and	  RCZ20	  share	  
the	   same	   mechanism	   of	   action,	   which	   primarily	   interfere	   with	   EspD	   secretion	   in	   a	  





	   	  
Fig.	   15:	   α-­‐EspD	  Western	   blot	   for	   RCZ12	   and	   RCZ20	   (200	   µM	   -­‐	   10	   µM)	   (left)	   and	   α-­‐EspD,	   α-­‐Tir	   and	   α-­‐GroEL	  
Western	   blot	   for	   RCZ12	   and	   RCZ20	   at	   200	   µM	   (right):	   Western	   blot	   analyses	   were	   carried	   out	   according	   to	  
standard	  procedure	   (see	  Experimental	  Part	   for	  methods	   and	  Ab	  dilutions).	  Both	  supernatant	   proteins	   (S/N)	  and	  
whole	  cell	  lysate	  solution	  (W/C)	  were	  analysed.	  The	  relative	  secretion	  values	  were	  obtained	  evaluating	  X-­‐rays	  film	  
pixel	  density	  by	  means	  of	  ImageJ	  from	  three	  independent	  experiments.	  Untreated	  samples	  (WT)	  were	  considered	  
as	  total	  secretion	  (100%)	  and	  treated	  samples	  were	  normalised	  accordingly.	  RCZ12	  and	  RCZ20	  demonstrated	  to	  
have	  a	  concentration-­‐dependant	  effect	  on	  EspD	  secretion.	  200	  µM	  was	  considered	  as	  the	  ideal	  concentration	  to	  
have	  an	  almost	   total	   inhibition	  of	   the	  secretion	  without	  affecting	   the	  bacterial	  growth.	  To	  complete	  the	  activity	  
profile	  of	  RCZ12	  and	  RCZ20	  at	  200	  µM,	  α-­‐EspD,	  α-­‐Tir	  and	  α-­‐GroEL	  Western	  blot	  were	  performed.	  Both	  candidates	  
showed	  to	  inhibit	  EspD	  secretion,	  while	  retaining	  the	  virulence	  protein	  inside	  the	  cell,	  as	  suggested	  by	  the	  α–EspD	  
W/C	   Western	   blot	   result.	   Also	   Tir	   secretion	   and	   expression	   resulted	   decreased	   at	   this	   high	   concentration.	  





7.3.5	  T3SS	  genes	  transcription	  
The	  western	   blot	   analyses	   showed	   that	   EspD	   secretion	   is	   affected	   by	   the	   THP	   and	   DHP	  
derivatives,	   but	   also	   that	   Tir	   secretion	   and	   expression	   were	   influenced.	   To	   further	  
investigate	   these	   transcriptional	   effects,	   transcriptomic	   analyses	   were	   carried	   out	   for	  
RCZ20	   at	   50	   μM	   (Fig.	   16).	   This	   concentration	   was	   selected	   as	   it	   provided	   a	   direct	  
comparison	  with	  our	  previous	  study	  into	  the	  effects	  of	  the	  SA	  compounds	  118.	  mRNA	  reads	  
of	   samples	   of	   untreated	   TUV	   93-­‐0	   and	   TUV	   93-­‐0	   treated	   with	   RCZ20	   grown	   in	   T3SS-­‐
inducing	  media	  were	  compared	  and	  analysed	   to	  visualise	  any	  changes	   in	   transcription	   in	  
the	  whole	  E.	  coli	  genome.	  
	  
Fig.	  16:	  RNAseq	  data	   summary	   and	   LEE-­‐related	   genes	  heatmap:	  A)	   Summary	  of	   differentially	   expressed	   genes	   (DEGs)	  
identified	  by	  RNA-­‐seq.	  EHEC	  TUV	  93-­‐0	  was	  cultured	  under	  T3SS-­‐inducing	  conditions	  (MEM-­‐HEPES;	  37	  °C,	  200	  rpm)	  with	  
and	  without	  RCZ20	  supplemented	  at	  50	  μM.	  The	  total	  number	  of	  DEGs	  is	  indicated	  with	  the	  proportion	  of	  up-­‐	  or	  down-­‐
regulated	  genes	  illustrated	  by	  the	  appropriate	  bars.	  A	  gene	  was	  considered	  differentially	  expressed	  if	  it	  exhibited	  a	  fold	  
change	  greater	   than	  1.5	  from	  the	  wild	  type	  (FDR	  P-­‐value	  <	  0.05).	  DEGs	  were	  clustered	  into	  biological	   functional	  groups	  
according	   to	   gene	   ontology	   (GO).	   LEE-­‐associated	   genes	   are	   highlighted	   in	   red.	   B)	   Heatmap	   of	   normalised	   genes	  
expression	   values	  within	   the	   LEE	   island	   specifically	   as	   identified	   by	   RNA-­‐seq.	  Wild	   type	   EHEC	   and	   the	   RCZ20	   treated	  
replicates	  are	   indicated	  on	  the	   left	   and	  the	  structure	  of	   the	  LEE	  operons	   and	   associated	  ORFs	   are	   labelled	  above.	  The	  




A	  specific	  but	  mild	  down-­‐regulation	  effect	   (between	  1.5-­‐	  and	  2-­‐fold	  decrement)	  on	  T3SS	  
genes	  was	  detected	  especially	  in	  LEE1,	  LEE4	  and	  LEE5	  operon	  regions,	  which	  contain	  genes	  
such	   as	   ler,	   tir,	   espD,	   espB,	   eae	   and	   espA,	   while	   no	   particular	   effects	   were	   observed	   in	  
other	  areas	  of	  the	  genome	  44	  (Table	  6).	  These	  findings	  proved	  that	  our	  new	  derivatives	  act	  
also	   at	   a	   transcriptional	   level,	   selectively	   down-­‐regulating	   T3SS	   genes.	   Although	   the	  
influence	  on	   the	   LEE-­‐based	  genes	   is	  mild,	   it	   is	   an	   indication	   that	  both	  RCZ12	  and	  RCZ20	  
display	  also	  activity	  against	  the	  T3SS	  genes	  transcription.	  In	  addition,	  the	  down-­‐regulation	  
provided	   by	   our	   compounds	   is	   specific	   to	   the	   LEE	   region,	   while	   ME0055	   previously	  
demonstrated	  to	  have	  more	  widespread	  transcriptional	  effects,	  affecting	  many	  non	  T3SS-­‐
related	  genes	  118.	  
To	   validate	   the	   RNAseq	   data,	   RCZ12	   and	   RCZ20	   transcriptional	   effects	   were	   evaluated	  
through	   a	   GFP	   reporter	   fusion	   assay	   at	   both	   50	   and	   200	   μM,	  where	   the	   activity	   of	   the	  
promoter	  of	  the	  desired	  gene	  is	  proportional	  to	  GFP	  expression	  (Fig.	  17).	  rpsM	  promoter	  
Fig.	  17:	  rpsM:gfp,	  LEE1:gfp	  and	  tir:gfp	  promoter	  activity	  at	  
OD600	  =	  0.6	  with	  ME0055,	  RCZ12	  and	  RCZ20	  at	  50	  and	  200	  
µM:	  GFP-­‐reporter	  fusion	  assays	  were	  carried	  out	  according	  
to	   standard	   procedure	   (see	   Experimental	   Part	   for	  
methods).	   The	   promoter	   activity	   was	   measured	   for	   every	  
sample	   plotting	   fluorescence	   (RFU)	   against	   OD600.	   The	  
curves	   thus	   obtained	   were	   analysed	   through	   linear	  
regression	  and	  interpolated	  with	  a	  determined	  OD600	  value	  
(0.6).	  Interpolated	  RFU	  mean	  values	  are	  represented	  in	  the	  
graphs	   on	   the	   left.	   Standard	   deviation	   from	   the	   mean	   is	  
shown	   by	   error	   bars.	   RFU	   values	   of	   treated	   samples	  were	  
compared	   to	   the	   control	   sample	   (WT)	   by	   Student’s	   t-­‐test	  
for	   statistical	   significance	   (P	   value	   <	   0.05).	   Significant	  
samples	   are	   indicated	   by	   an	   asterisk,	   very	   significant	  
samples	  by	  two	  asterisks	  and	  extremely	  significant	  samples	  
by	  three	  asterisks.	  RCZ12	  and	  RCZ20	  demonstrated	  to	  have	  
an	  effect	  at	  transcriptional	  level.	  Promoter	  activities	  of	  both	  
LEE1	   and	   tir	   were	   found	   to	   be	   down-­‐regulated	   at	   50	   and	  
200	   µM.	   The	   effect	   detected	   by	   our	   compounds	   was	  
weaker	  and	  more	  selective	  than	  ME0055,	  which	  resulted	  in	  
a	   greater	   down-­‐regulation	   of	   the	   two	   T3SS-­‐related	   genes,	  
but	   also	   influenced	   house-­‐keeping	   genes	   (rpsM)	   as	   shown	  
in	  previous	  studies	  118.	  These	  results	  are	  in	  accordance	  with	  




activity	   (30S	   ribosomal	   subunit)	  was	   firstly	  assessed	  as	  a	  control,	   in	  order	   to	  analyse	  any	  
unwanted	  effect	  by	  the	  candidates	  on	  an	  essential	  housekeeping	  gene	  not	  related	  to	  T3SS.	  
rpsM	   transcription	   was	   found	   to	   be	   significantly	   down-­‐regulated	   in	   the	   presence	   of	  
ME0055	  at	  50	  and	  200	  μM	  118.	  In	  addition,	  the	  SA	  compound	  displayed	  a	  very	  strong	  effect	  
on	  bacterial	  growth	  at	  200	  μM,	  reducing	  by	  more	  than	  2-­‐fold	  the	  growth	  rate.	  
Gene	   Log2	  fold	  change	   P	  value	   Function	  
escN	   -­‐1.5	   6.09E-­‐05	   ATPase	  
map	   -­‐1.54	   9.35E-­‐05	   Secreted	  effector	  protein	  
espD	   -­‐1.55	   1.78E-­‐04	   Translocon	  
espA	   -­‐1.57	   1.05E-­‐04	   Needle	  filament	  
espH	   -­‐1.59	   7.15E-­‐05	   Secreted	  effector	  protein	  
eae	   -­‐1.61	   2.37E-­‐07	   Intimin	  
tir	   -­‐1.62	   6.91E-­‐06	   Translocated	  intimin	  receptor	  
espF	   -­‐1.63	   3.10E-­‐05	   Secreted	  effector	  protein	  
espB	   -­‐1.64	   3.53E-­‐05	   Translocon	  
escC	   -­‐1.64	   7.83E-­‐06	   Secretin	  (T3SS	  basal	  body	  protein)	  
espJ	   -­‐1.66	   2.51E-­‐05	   Secreted	  effector	  protein	  
escF	   -­‐1.66	   3.09E-­‐04	   T3SS	  basal	  body	  protein	  
sepL	   -­‐1.66	   3.12E-­‐07	   Gatekeeper	  protein	  
ler	   -­‐1.69	   1.55E-­‐05	   LEE	  master	  regulator	  
sepQ	   -­‐1.75	   5.05E-­‐06	   T3SS	  basal	  body	  protein	  
espG	   -­‐1.9	   8.39E-­‐06	   Secreted	  effector	  protein	  
escR	   -­‐1.95	   4.94E-­‐05	   Unknown	  
	  
Table	  6:	   Summary	  of	   the	   effects	   of	   RCZ20	  on	   LEE-­‐related	   genes	   expression	   as	   identified	  by	  RNAseq	  experiment:	   The	  
name	  of	  the	  LEE-­‐related	  genes	  expression	  affected	  from	  the	  treatment	  of	  RCZ20	  at	  50	  μM.	  The	  Log2	  fold	  change	  and	  the	  
P	  values	  are	  also	  listed.	  The	  function	  of	  the	  corresponding	  proteins	  is	  specified	  on	  the	  right-­‐hand	  side	  of	  the	  table.	  
	  
Our	  derivatives	  did	  not	  show	  a	  statistically	  significant	  activity	  against	  rpsM	  transcription	  at	  
both	   concentrations.	   LEE1	   transcription	  was	   then	  measured	   as	   this	   encodes	   the	  master	  
regulator	   of	   the	   entire	   T3SS	   and	   is	   key	   to	   activation.	   As	   previously	   shown,	   ME0055	  
significantly	  down-­‐regulated	  by	  2.2	  and	  2.5-­‐fold	  LEE1	  transcription	  at	  50	  µM	  and	  200	  μM	  
respectively	  118.	  A	  noteworthy	  down-­‐regulation	  (1.8	  and	  1.9-­‐fold	  reduction	  at	  200	  μM)	  of	  
the	   promoter	   activity	   was	   also	   detected	   for	   RCZ12	   and	   RCZ20	   in	   a	   concentration-­‐
dependent	  way.	  However,	  the	  transcriptional	  effects	  of	  our	  compounds	  were	  weaker	  than	  
those	  observed	  for	  the	  SA	  compound.	  The	  activity	  of	  the	  tir	  promoter	  was	  also	  measured	  




down-­‐regulation.	  ME0055	  resulted	  in	  a	  very	  strong	  down-­‐regulation	  of	  the	  promoter	  (2.7-­‐
fold	  reduction	  at	  200	  μM),	  as	  previously	  reported	  118.	  Also	  RCZ12	  and	  RCZ20	  influenced	  the	  
promoter	   activity	   of	   this	   gene,	   but	   exhibited	   a	   significantly	   weaker	   activity	   than	   the	   SA	  
compound,	   down-­‐regulating	   tir	   transcription	   by	   1.5-­‐fold.	   The	   results	   obtained	   from	   the	  
GFP-­‐reporter	   fusion	  assays	  were	   in	  accordance	  with	   the	   transcriptomic	  and	  western	  blot	  
data.	  RCZ12	  and	  RCZ20	  showed	  to	  have	  a	  selective	  transcriptional	  effect	  on	  T3SS-­‐related	  
genes,	   as	   shown	   by	   the	   rpsM:gfp	   results,	   where	   no	   influence	   was	   detected	   for	   our	  
compounds	  while	  a	  significant	  activity	  was	  registered	  for	  ME0055.	  Down-­‐regulation	  of	  the	  
promoters	   of	   both	   T3SS-­‐related	   genes	   LEE1	   and	   tir	   was	   also	   observed.	   However,	   the	  
magnitude	   of	   the	   effect	   of	   the	   THP	   and	   DHP	   derivatives	   was	   weaker	   than	   the	   SA	  
compound	   activity.	   This	   confirms	   that	   RCZ12	   and	   RCZ20	   have	   a	   transcriptional	   effect	  
beside	  a	  direct	  activity	  on	  EspD	  secretion.	  RNAseq	  and	  GFP-­‐reporter	  fusion	  assays	  results	  
highlighted	   the	  specific	   transcriptional	  effect,	  even	   though	   it	   resulted	   to	  be	  weaker	   than	  
ME0055	  activity.	  In	  summary,	  these	  data	  demonstrated	  that	  the	  transcriptional	  effects	  of	  
RCZ12	  and	  RCZ20	  are	  largely	  focused	  on	  the	  T3SS-­‐related	  genes,	  while	  the	  SA	  compound	  
has	  a	  broader	  influence	  across	  the	  whole	  E.	  coli	  genome.	  
	  
7.3.6	  Additional	  transcriptional	  evaluation	  
The	  transcriptional	  results	  obtained	  from	  the	  RNAseq	  and	  GFP	  reporter	  fusion	  assays	  drew	  
us	   to	   hypothesise	   a	   potential	   inhibitory	   feedback	   circuit	   due	   to	   the	   reduced	   EspD	  
secretion.	  It	  is	  possible	  that	  the	  intracellular	  retention	  of	  EspD	  caused	  by	  RCZ12	  and	  RCZ20	  
could	   trigger	   inhibitory	   signals	   towards	   the	  expression	  of	  other	  T3SS	  proteins,	   leading	   to	  
the	  down-­‐regulation	  of	  the	  LEE.	  It	  has	  previously	  been	  demonstrated	  in	  C.	  rodentium	  that	  
espD	  null	  mutants	  express	  and	  secrete	  Tir	  and	  other	  T3SS	  proteins	  normally,	   indicating	  a	  
lack	  of	  LEE-­‐encoded	  feedback	  circuits.	  However,	   the	  same	  study	  highlighted	  that	  the	  LEE	  
regulation	  is	  extremely	  species-­‐dependent,	  as	  differences	  in	  T3SS	  proteins	  were	  observed	  
in	  EPEC,	  EHEC	  and	  C.	  rodentium	  37.	  On	  the	  other	  hand,	  the	  THP	  and	  DHP	  derivatives	  may	  
also	  act	  directly	  on	  LEE	  transcription.	  The	  down-­‐regulation	  of	  both	  LEE1	  and	  tir	  is	  especially	  
marked	  when	  the	  compounds	  are	  employed	  in	  high	  concentrations	  (200	  µM),	  thus	  it	  might	  
be	  the	  result	  of	  secondary	  interactions	  within	  the	  cell.	  
To	   investigate	   the	   transcriptional	   effect	   caused	   by	   RCZ12	   and	   RCZ20,	   it	   was	   planned	   to	  




generated	   by	   transforming	   the	   GFP	   reporter	   plasmids	   for	   LEE1	   and	   tir	   in	   EHEC	   ΔespD	  
strain,	   thus	   creating	   ΔespD	   LEE1:gfp	   and	   ΔespD	   tir:gfp.	   The	   new	   ΔespD	   GFP	   reporter	  
strains	  were	  first	  compared	  with	  the	  corresponding	  TUV	  93-­‐0	  GFP	  reporter	  strains	  in	  order	  
to	  highlight	  a	  potential	  down-­‐regulation	  caused	  by	  the	   lack	  of	  the	  virulence	  protein	  EspD	  
(Fig.	  18).	  While	  the	  promoter	  activity	  of	  LEE1	  was	  found	  to	  be	  comparable	  in	  both	  strains,	  
tir	   transcription	   proved	   to	   be	   slightly	   down-­‐regulated	   by	   1.3-­‐fold	   in	   the	   ΔespD	  mutant,	  
suggesting	  a	  mild	  effect	  on	  tir	  expression	  due	  to	  the	  lack	  of	  EspD.	  The	  2	  new	  strains	  were	  
then	  treated	  with	  RCZ12	  and	  RCZ20	  at	  200	  µM	  to	  evaluate	  their	  transcriptional	  effect	  on	  
the	   LEE	   in	   absence	   of	   the	   virulence	   protein	   EspD.	   In	   both	   cases,	   RCZ12	   and	   RCZ20	  
negatively	   influenced	  the	  promoters’	  activity	   in	  the	  ΔespD	  GFP	  strains.	  LEE1	   transcription	  
was	   reduced	  by	  1.5-­‐fold,	  while	   tir	  expression	  was	   inhibited	  by	  2-­‐fold,	  highlighting	  RCZ12	  
and	  RCZ20	  effect	  on	  transcription	  at	  200	  μM.	  
	  
Fig.	  18:	  ΔespD	  LEE1:gfp	  and	  ΔespD	  tir:gfp	  promoter	  activity	  at	  OD600	  =	  0.7	  compared	  with	  their	  TUV	  93-­‐0	  counterpart	  
and	   with	   RCZ12	   and	   RCZ20	   at	   200	   µM:	   GFP-­‐reporter	   fusion	   assays	   analyses	   were	   carried	   out	   according	   to	   standard	  
procedure	   (see	   Experimental	   Part	   for	  methods).	   The	  promoter’s	   activity	  was	   calculated	   at	  OD600	   =	   0.7	   and	  RFU	  mean	  
values	  are	   represented	   in	   the	  graphs	  above.	   Standard	  deviation	   from	   the	  mean	   is	   shown	  by	  error	  bars.	  RFU	  values	  of	  
treated	   samples	  were	   compared	   to	   the	   control	   sample	   (WT)	   by	   Student’s	   t-­‐test	   for	   statistical	   significance.	   Significant	  
samples	   are	   indicated	   by	   an	   asterisk	   (P	   value	   <	   0.05),	   very	   significant	   samples	   by	   two	   asterisks	   (P	   value	   <	   0.01)	   and	  
extremely	   significant	   samples	   by	   three	   asterisks	   (P	   value	   <	   0.005).	   ΔespD	   LEE1:gfp	   was	   firstly	   compared	   with	   TUV	  
LEE1:gfp	   (first	   graph	   from	   the	   left)	   and	   then	   treated	  with	  RCZ12	   and	  RCZ20	   at	   200	  µM	   (second	   graph	   from	   the	   left).	  
ΔespD	  tir:gfp	  was	  firstly	  compared	  with	  TUV	  tir:gfp	  (third	  graph	  from	  the	  left)	  and	  then	  treated	  with	  RCZ12	  and	  RCZ20	  at	  
200	  µM	   (fourth	   graph	   from	   the	   left).	   Both	   the	   THP	   and	  DHP	   compounds	   displayed	   a	   direct	   influence	   on	   LEE1	   and	   tir	  
transcription.	  In	  addition,	  the	  lack	  of	  espD	  in	  ΔespD	  tir:gfp	  also	  down-­‐regulated	  tir	  expression	  compared	  to	  the	  TUV	  93-­‐0	  
expression.	  
	  
The	  results	  obtained	  by	  this	  additional	  GFP	  reporter	  fusion	  assay	  revealed	  that	  EspD	  has	  a	  
mild	  negative	  feedback	  on	  tir	  transcription,	  as	  ΔespD	  tir:gfp	  showed	  a	  reduced	  activity	  of	  




RCZ12	  and	  RCZ20	  at	  200	  μM	  also	  demonstrated	  that	  both	  compounds	  have	  a	  direct	  effect	  
on	  LEE1	  and	  tir	  transcription.	  In	  conclusion,	  it	  is	  clear	  that	  our	  THP	  and	  DHP	  candidates	  act	  
primarily	   on	   EspD	   secretion	   and	   also	   directly	   influence	   the	   transcription	   of	   LEE-­‐related	  
genes.	   However,	   it	   cannot	   be	   excluded	   that	   the	   lack	   or	   the	   incorrect	   secretion	   of	   the	  
virulence	  protein	  EspD	  might	  also	  down-­‐regulate	  tir	  expression.	  	  	  	  	  	  	  	  
	  
7.3.7	  Transmission	  electron	  microscopy	  (TEM)	  experiment	  	  
RCZ12	  and	  RCZ20	  demonstrated	  to	  primarily	  affect	  the	  secretion	  of	  the	  virulence	  protein	  
EspD,	  causing	   its	   intracellular	  accumulation.	   It	  has	  been	  previously	  reported	  that	  the	   lack	  
or	  malfunctioning	  of	  EspD	  result	  in	  the	  production	  of	  aborted	  T3SS	  filaments.	  Kresse	  et	  al.	  
demonstrated	   that	   espD	   null	   mutant	   strains	   displayed	   an	   impaired	   attachment	   to	   HeLa	  
cells.	  Microscopy	   studies	   revealed	   only	   a	   focal	   accumulation	   of	   the	   protein	   EspA	  on	   the	  
bacterium’s	   surface	   instead	   of	   the	   correct	   assembly	   of	   the	   T3SS,	   showing	   significantly	  
smaller	  needle	   formation	   than	   the	  wild	   type	   33.	   It	  was	   then	  decided	   to	  evaluate	   through	  
microscopy	  studies	  the	  formation	  of	  EspA	  filaments	  in	  the	  presence	  of	  our	  compound,	  as	  
both	  RCZ12	  and	  RCZ20	  affected	  EspD	  secretion	  (Fig.	  19).	  Untreated	  E.	  coli	  O157	  TUV	  93-­‐0	  
and	  the	  ΔespD	  strain	  were	  employed	  as	  positive	  and	  negative	  controls	  respectively.	  
Sample	   n°	  EspA	  filaments	  (>500	  nm)	   SD	   N	  
WT	   4.960	   ±	  2.791	   25	  
RCZ12	   1.040	   ±	  1.020	   25	  
RCZ20	   1.720	   ±	  1.646	   25	  
ΔespD	   0.785	   ±	  1.475	   25	  
	  
Table	  7:	  Determination	  of	   the	  number	  of	   EspA	   filaments	   (>500	  nm)	   for	   bacteria	   treated	  with	  RCZ12	   and	  RCZ20:	   The	  
average	  number	  of	  EspA	  filaments	   (>500	  nm)	   for	   the	  TEM	  samples	   is	  shown	   in	  the	  table	  above.	  The	  values	  have	  been	  
calculated	  from	  25	  different	  images	  taken	  from	  5	  independent	  experiments.	  Standard	  deviation	  from	  the	  mean	  value	  is	  
also	  shown	  in	  the	  table.	  
	  
Bacteria	  were	  grown	  in	  a	  T3SS-­‐inducing	  media	  and	  then	  immobilised	  in	  paraformaldehyde.	  
Before	  exposure	  to	  the	  microscope,	   the	  samples	  were	   incubated	  with	  a	  α-­‐EspA	  antibody	  
and	  then	  with	  the	  corresponding	  secondary	  antibody	  conjugate	  with	  gold	  nanoparticle	  for	  
visualisation.	  Untreated	  E.	   coli	   O157	   TUV	   93-­‐0	   produced	   an	   average	   of	   five	   long	   needle	  
formations	   (>500	   nm)	   per	   bacterium,	   while	   ΔespD	   did	   not	   show	   any	   EspA	   filament	  
formations	   as	   expected	   (an	   average	   of	   0.78	   functioning	   needles).	   RCZ12-­‐	   and	   RCZ20-­‐




functioning	  needle	  per	  bacterium),	  as	   the	  bacteria	   revealed	  only	   short	  needle	   structures	  
(<500	  nm)	  and	  accumulation	  of	  EspA	  on	  the	  surface,	  indicating	  an	  aborted	  T3SS	  apparatus.	  	  
The	  count	  of	  EspA	  filaments	   longer	   than	  500	  nm	  revealed	  that	   the	  samples	   treated	  with	  
RCZ12	   and	   RCZ20	   produced	   an	   average	   of	   1	   functioning	   T3SS	   needle	   apparatus,	   a	  
reduction	  of	  5-­‐fold	  compared	  to	  the	  wild	  type	  (Table	  7).	  
	  
7.4	  Conclusions	  
The	   SA	   compound	   ME0055	   was	   used	   as	   a	   starting	   point	   to	   create	   a	   small	   series	   of	  
potentially	   more	   selective	   and	   stable	   T3SS	   inhibitors	   of	   E.	   coli	   O157:H7.	   Two	   different	  
Fig.	   19:	   TEM	   images	   of	   EspA	   filaments	   with	   RCZ12	   and	   RCZ20:	   Bacteria	   were	   grown	   in	   T3SS-­‐inducing	   media	   and	  
immobilised	   in	   paraformaldehyde.	   Before	   exposure	   on	   the	   microscope,	   the	   samples	   were	   incubated	   with	   an	   α-­‐EspA	  
primary	  antibody	  and	  then	  with	  the	  corresponding	  secondary	  antibody	  conjugated	  with	  gold	  nanoparticle.	  The	  black	  dots	  
on	  the	  images	  represents	   the	  gold	  particles,	  which	  specifically	  identify	  EspA.	  RCZ12	  and	  RCZ20	  demonstrated	  to	  reduce	  




cores	   (THP	  and	  DHP)	  were	  designed	  and	   synthesised,	   incorporating	   the	   imine	   feature	   in	  
heterocycles	   and	   retaining	   all	   ME0055	   substituents.	   Synthesis	   started	   with	   a	   common	  
commercially	  available	  starting	  material,	  resorcindimethylether	  (17),	  and	  was	  completed	  in	  
only	  5	  steps.	  A	  total	  of	  8	  derivatives	  was	  synthesised	  and	  evaluated	  against	  the	  T3SS	  of	  E.	  
coli	  TUV	  93-­‐0	  strain.	  In	  addition	  to	  the	  two	  carbonyl	  di-­‐hydroxyl	  inhibitors	  (RCZ10	  and	  18),	  
we	   synthesised	   two	   sulphonyl	   di-­‐hydroxyl	   analogues	   (RCZ12	   and	   20)	   to	   explore	   the	   left	  
hand	  side	  of	  the	  molecule	  and	  we	  also	  included	  all	  4	  di-­‐methoxyl	  compounds	  (RCZ09,	  11,	  
17	  and	  19),	  derived	  from	  our	  synthetic	  route.	  These	  inclusions	  allowed	  examination	  of	  the	  
relevance	   of	   the	   carbonyl	   and	   the	   hydroxyl	   groups.	   A	   preliminary	   biological	   evaluation	  
showed	  that	  all	  our	  molecules	  did	  not	  affect	  bacterial	  growth,	  making	  them	  suitable	  anti-­‐
virulence	   candidates.	   The	   secretion	  of	   T3SS	  protein	  EspD	  by	  western	  blot	  was	  used	  as	  a	  
screening	   assay	   to	   evaluate	   the	   activity	   of	   the	   series.	   The	   two	   sulphonyl	   di-­‐hydroxyl	  
molecules	   (RCZ12	  and	  20)	  demonstrated	   to	  be	   the	  most	  active	  compounds	  of	   the	  series	  
and	  the	  only	  two	  candidates	  to	  have	  a	  comparable	  effect	  to	  the	  lead	  compound	  ME0055,	  
with	  a	  4-­‐fold	  reduction	  of	  EspD	  secretion	  at	  50	  µM.	  Further	  western	  blot	  analyses	  showed	  
that	  RCZ12	  and	  RCZ20	  acted	  in	  a	  mechanism	  somewhat	  distinct	  from	  ME0055,	  since	  their	  
activity	   was	   focused	   more	   on	   EspD	   secretion	   and	   not	   on	   the	   whole	   T3SS	   apparatus.	  
Analysis	  on	  the	  secreted	  T3SS	  proteins	  revealed	  the	  inhibition	  of	  EspD	  and	  a	  weaker	  effect	  
on	  Tir.	  Interestingly,	  the	  virulence	  protein	  was	  retained	  inside	  the	  cell	  as	  shown	  by	  western	  
blot	  of	  the	  whole	  cell	  lysate	  solution.	  This	  EspD	  retention	  into	  the	  cytosol	  indicated	  a	  post-­‐
transcriptional	  effect	  on	  the	  T3SS	  protein	  by	  our	  compounds,	  which	  differs	  from	  ME0055	  
activity.	   Therefore,	   the	   inclusion	  of	   the	   imine	   feature	   into	  a	  heterocycles	  provided	  more	  
stable	   compounds	   with	   a	   different	   activity	   against	   E.	   coli	   O157:H7.	   When	   employed	   in	  
decreasing	   concentrations,	   RCZ12	   and	   RCZ20	   also	   displayed	   a	   concentration-­‐dependent	  
effect	  on	  EspD	  secretion.	  The	  experiment	  also	  highlighted	  a	  total	  inhibition	  of	  the	  secretion	  
at	  200	  µM	  and	  retention	  of	  such	  virulence	  protein	  inside	  the	  bacterial	  cytosol.	  α-­‐Tir	  at	  this	  
high	   concentration	   showed	   also	   inhibition	   of	   Tir	   secretion	   and	   expression,	   suggesting	   a	  
potential	  effect	  on	  transcription	  at	  200	  µM.	  RNAseq	  analysis	  proved	  a	  mild	  and	  selective	  
transcriptional	  effect	  on	  T3SS-­‐related	  genes.	  GFP-­‐reporter	  fusion	  assays	  on	  rpsM,	  LEE1	  and	  
tir	  promoter	  activity	  confirmed	  the	  transcriptional	  activity	  of	  RCZ12	  and	  RCZ20	  at	  both	  50	  
and	  200	  µM.	  However,	  the	  effect	  exhibited	  by	  our	  compounds	  was	  weaker	  than	  ME0055	  
activity.	   In	   addition,	   the	   down-­‐regulation	   was	   limited	   to	   LEE-­‐based	   genes,	   while	   the	   SA	  




118.	   We	   postulated	   that	   the	   primary	   activity	   of	   both	   RCZ12	   and	   RCZ20	   is	   the	   post-­‐
transcriptional	   inhibition	   of	   EspD	   secretion,	   while	   the	   selective	   transcriptional	   down-­‐
regulation	  of	  T3SS	  genes	  was	  considered	  as	  a	  secondary	  activity.	  The	  milder	  effect	  on	  LEE-­‐
based	   genes	   drew	  us	   to	   think	   that	   the	   down-­‐regulation	  might	   be	   a	   consequence	   of	   the	  
EspD	  secretion	  inhibition.	  It	  has	  been	  demonstrated	  that	  espD	  null	  mutant	  strain	  produces	  
the	   virulence	   effector	   Tir	   normally,	   indicating	   a	   lack	   of	   LEE-­‐encoded	   feedback	   inhibitory	  
mechanism	   in	   C.	   rodentium.	   However,	   the	   study	   also	   reveals	   that	   the	   T3SS	   proteins	  
regulation	   is	   highly	   species-­‐dependent,	   as	   discrepancies	   in	   the	   LEE	   transcription	   were	  
shown	  in	  EPEC,	  EHEC	  and	  C.	  rodentium	  37.	  Generation	  of	  ΔespD	  LEE1:gfp	  and	  ΔespD	  tir:gfp	  
strains	   revealed	   that	   the	   THP	   and	   DHP	   derivatives	   acted	   directly	   on	   LEE1	   and	   tir	  
transcription	   as	   a	   secondary	   interaction	   within	   the	   cell.	   It	   is	   easy	   to	   also	   speculate	   a	  
possible	   negative	   feedback	   pathway	   derived	   from	   the	   incorrect	   secretion	   of	   EspD	   to	  
suppress	   the	   T3SS	   proteins	   production,	   but,	   unfortunately,	   we	   did	   not	   explore	   these	  
effects	  any	  further.	  The	  major	  focus	  was	  to	  try	  and	  examine	  the	  mode	  of	  action	  of	  RCZ12	  
and	   RCZ20.	   Transmission	   electron	   microscopy	   experiment	   also	   showed	   that	   our	  
compounds	   blocked	   the	   correct	   formation	   of	   EspA	   filaments;	   a	   consequence	   of	   the	  
inhibition	  of	  the	  secretion	  of	  EspD.	  




8	  Understanding	  RCZ12	  and	  RCZ20	  Mode	  of	  Action	  
8.1	  Introduction	  
RCZ12	  and	  RCZ20	  proved	  to	  be	  active	  against	  T3SS	  protein	  expression	  and	  secretion	   in	  a	  
relatively	  selective	  manner,	  compared	  to	  the	  lead	  compound.	  EspD	  secretion	  was	  inhibited	  
by	   increasing	   concentrations	   of	   the	   two	   candidates	   and	   retention	   of	   this	   protein	   was	  
observed	  into	  the	  pathogen	  cytosol.	  Tir	  was	  found	  to	  be	  inhibited	  at	  a	  transcriptional	  and	  
post-­‐transcriptional	   level	   by	   our	   derivatives	   at	   200	   μM.	   Despite	   both	   molecules	   being	  
derived	   from	  ME0055,	   they	   seemed	   to	  act	  on	  bacterial	   virulence	  weapons	   in	  a	  different	  
and	  more	  selective	  way	  than	  the	  SA	  compound.	  
Previous	   studies	   within	   our	   group	   were	   focused	   to	   discover	   ME0055	   mode	   of	   action	  
through	  different	  affinity	  assays.	  A	  biotinylated	  derivative	  of	  the	  salicylidene	  acylhydrazide	  
was	   employed	   for	   a	   pull-­‐down	   experiment,	   revealing	  more	   than	   16	   putative	   proteins	   as	  
targets	   125.	   Investigation	   of	   these	   possible	   targets	   confirmed	   that	   ME0055	   was	   a	   very	  
promiscuous	   binder	   and	   its	   efficiency	   could	   have	   been	   the	   result	   of	  multiple	  metabolic	  
effects	   within	   the	   pathogen	   125.	   Since	   both	   our	   candidates	   displayed	   a	   more	   selective	  
activity	  than	  the	  lead	  compound,	  it	  was	  decided	  to	  investigate	  the	  mode	  of	  action	  of	  RCZ12	  
and	   RCZ20	   by	   labelling	   the	   two	   compounds	   with	   a	   variety	   of	   affinity	   tags,	   in	   order	   to	  
investigate	  the	  molecular	  mechanism	  of	  action.	  
	  
8.2	  Design	  of	  RCZ12	  and	  RCZ20	  labelled	  version	  
To	   further	   investigate	   the	  mechanism	  of	   action	  of	   the	  new	  derivatives,	   it	  was	   chosen	   to	  
label	   both	   molecules	   with	   specific	   probes	   to	   perform	   affinity	   experiments.	   Due	   to	   the	  
candidates’	  small	  dimensions,	  we	  selected	  just	  two	  potential	  sites	  to	  place	  the	  tag;	  on	  the	  
left-­‐hand	  side	  (Fig.20	  in	  blue)	  or	  on	  the	  right-­‐hand	  side	  (Fig.20	  in	  red)	  phenyl	  rings.	  From	  
our	  previous	  biological	  assays,	  results	  showed	  how	  the	  di-­‐hydroxyl	  derivatives	  displayed	  a	  
better	   activity	   profile	   than	   the	   di-­‐methoxyl	   ones,	   underlining	   the	   relevance	   of	   the	   free	  
hydroxyl	   groups	   for	   activity	   against	   EspD	   secretion.	   In	   addition,	   in	   earlier	   studies	   125,	  
ME0055	   tag	   was	   placed	   on	   the	   left-­‐hand	   side	   phenyl	   ring	   to	   perform	   pull-­‐down	  
experiments.	  Due	  to	  these	  findings,	  it	  was	  opted	  to	  position	  the	  tag	  on	  the	  left-­‐hand	  side	  
and	   to	   reduce	   the	   nitro	   group	   to	   an	   amino	   group	   to	   place	   a	   small	   linker	   between	   the	  





	  8.3	  Alternative	  route	  for	  RCZ12	  and	  RCZ20	  synthesis	  
Our	   initial	   synthesis	   of	   THP	   and	   DHP	   cores	   proved	   to	   be	   problematic	   in	   the	   final	   step	  
especially	   for	   the	   two	   sulphonyl	   derivatives	   RCZ12	   and	   RCZ20.	   BBr3-­‐mediated	   de-­‐
methylation	   at	   40	   °C	   provided	   very	   poor	   yields	   and	   difficult	   separation	   of	   the	   desired	  
product.	  Thus,	  we	  designed	  a	  new	  synthetic	  route	  to	  afford	  our	  two	  analogues	  of	  interest	  
in	  a	  more	  efficient	  way	  for	  our	  labelling	  synthesis.	  
Fig.	  21:	  New	  synthetic	  route	  for	  RCZ12:	  The	  alternative	  route	  for	  RCZ12	  started	  from	  3,6-­‐dichloropyridazine	  (24)	  which	  
underwent	   Friedel-­‐Crafts	   acylation	  with	  resorcinol	   to	   afford	   intermediate	  25.	  The	  two	  hydroxyl	  groups	  were	  protected	  
with	  2-­‐bromo	  propane	  and	  intermediate	  26	  was	  then	  converted	  to	  the	  corresponding	  amide	  27	  in	  presence	  of	  sodium	  
acetate	   in	   refluxing	   acetic	   acid.	   LiAlH4	   reduction	  was	   performed	   following	   the	   previous	   protocol	   to	   obtain	   amine	   28.	  
Sulphonylation	  with	   nosyl	   chloride	   afforded	   the	   protected	   intermediate	   29,	   which	  was	   consequently	   de-­‐protected	   by	  
BBr3	  in	  DCM	  in	  very	  good	  yield.	  RCZ12	  was	  synthesised	  in	  6	  steps	  from	  24.	  
Fig.	  20:	  Design	  of	  RCZ12	  and	  RCZ20	   labelled	  version:	  Due	  to	  RCZ12	  and	  RCZ20	  small	   dimensions,	   only	   the	   left-­‐
hand	  side	  (blue)	  and	  right-­‐hand	  side	  (red)	  phenyl	  rings	  were	  chosen	  as	  plausible	  labelling	  sites.	  Since	  our	  findings	  
suggested	  that	   the	  two	  hydroxyl	  groups	  might	  be	  relevant	  to	  the	  activity	  of	  the	  molecules,	  it	  was	  opted	  to	  place	  
the	   affinity	   tag	   (sphere)	   on	  the	   left-­‐hand	   side	  of	   the	  molecule	  and	  to	  reduce	  the	  nitro	   group	  to	  amino	   group	  to	  





It	  was	   firstly	   planned	   to	   retain	   the	   LiAlH4	   amide	   reduction	   of	   the	   previous	   route	   and	   to	  
avoid	   any	   protecting	   groups.	   Unfortunately,	   this	   approach	   resulted	   in	   an	   unstable	  
substrate	   for	   the	   reduction	   step	   that	   decomposed	   quickly	   and	   forced	   us	   to	   change	  
immediately	   our	   strategy.	   Placement	   of	   other	   non-­‐ether-­‐like	   protecting	   groups	   was	  
attempted,	  but	  they	  all	  demonstrated	  to	  be	  too	  sensitive	  to	  LiAlH4	  (data	  not	  shown).	  It	  was	  
then	  decided	  to	  place	  a	  branched	  ether	  (iso-­‐propyl)	  as	  protection	  of	  the	  hydroxyl	  groups,	  
which	  proved	  to	  be	  sufficiently	  stable	   for	   the	  harsh	  conditions	  of	   the	  reduction	  step	  and	  
was	  found	  to	  be	  easier	  to	  remove	  than	  the	  methyl	  groups.	  
Our	   alternative	   synthesis	   of	   RCZ12	   started	   with	   3,6-­‐dichloropyridazine	   (24),	   which	  
underwent	  Friedel-­‐Crafts	  acylation	  with	  resorcinol	  to	  afford	  the	  desired	  adduct	  25	  137	  (Fig.	  
21).	  The	  two	  hydroxyl	  groups	  were	  protected	  with	  2-­‐bromo	  propane	  and	  intermediate	  26	  
was	   subsequently	   converted	   into	   the	   corresponding	   amide	   27	   137.	   28	   was	   afforded	   in	  
excellent	  yield	  by	  means	  of	  the	  same	  LiAlH4	  reduction	  protocol	  of	  our	  initial	  synthesis	  135.	  
The	  corresponding	  amine	  (28)	  was	  sulphonylated	  according	  to	  our	  previous	  conditions	  and	  
adduct	  29	  was	  de-­‐protected	  with	  BBr3	  at	  room	  temperature	  in	  good	  yield.	  
Fig.	   22:	   New	   synthetic	   route	   for	   RCZ20:	   The	   alternative	   route	   for	   RCZ20	   started	   from	   phthalhydrazide	   (30)	   which	  was	  
converted	  in	  1,4-­‐dichlorophthalazine	  (31)	  upon	  treatment	  with	  refluxing	  POCl3.	  31	  was	  reacted	  with	  resorcinol	  in	  presence	  
of	  AlCl3	  to	  obtain	  intermediate	  32	  in	  very	  good	  yield.	  The	  two	  hydroxyl	  groups	  were	  protected	  with	  2-­‐bromo	  propane	  and	  
intermediate	  33	  was	  converted	  in	  the	  corresponding	  amide	  34	  with	  sodium	  acetate.	  Amine	  35	  was	  achieved	  by	  the	  previous	  
LiAlH4	  reduction	  protocol	  and	  then	  sulphonylated	  with	  nosyl	  chloride	  to	  yield	  the	  protected	  intermediate	  36.	  De-­‐protection	  





RCZ20	  new	   synthesis	  was	   carried	  out	   similarly	   to	   RCZ12	   route	   (Fig.	   22).	   Phthalhydrazide	  
(30)	  was	  stirred	  in	  refluxing	  POCl3	  to	  obtain	  1,4-­‐dichloro	  phthalazine	  (31)	  in	  very	  good	  yield	  
138.	   31	   reacted	   with	   resorcinol	   to	   afford	   intermediate	   32	   137,	   which	   was	   consequently	  
protected	  with	  2-­‐bromo	  propane.	  Adduct	  33	  was	  converted	  into	  the	  corresponding	  amide	  
(34)	   with	   sodium	   acetate	   in	   refluxing	   acetic	   acid	   overnight	   137	   and	   LiAlH4	   reduction	  
afforded	   the	   desired	   amine	   35	   in	   excellent	   yield	   135.	   Sulphonylated	   product	   36	   was	  
generated	  with	  standard	  conditions	  and	  the	  de-­‐protecting	  step	  was	  completed	  by	  a	  milder	  
reagent	  (AlCl3)	  overnight	  to	  obtain	  RCZ20	  in	  very	  good	  yield.	  
Although	   these	   two	  new	  synthetic	   routes	  employed	   respectively	  6	  and	  7	   steps	  against	  5	  
steps	   of	   our	   initial	   synthesis,	   they	   provided	   high	   yielding	   reactions	   with	   easy	   and	   fast	  
purification	   procedures.	   Furthermore,	   the	   last	   de-­‐protecting	   step,	   which	   resulted	  
problematic	   in	   the	   previous	   synthesis	   (yield	   12%	   and	   25%),	   afforded	   our	   final	   products,	  
RCZ12	   and	   RCZ20,	   in	   good	   yield	   (61%	   and	   75%)	   and	   with	   an	   easier	   chromatographic	  
purification.	  We	  were	  also	  able	  to	  replace	  the	  use	  of	  BBr3	  with	  AlCl3	  in	  the	  case	  of	  RCZ20	  
synthesis	  as	  the	  substrate	  was	  protected	  with	  weaker	  protecting	  groups.	  Iso-­‐propyl	  groups	  
demonstrated	  to	  be	  more	  sensitive	  to	  strong	  Lewis	  acid	  than	  methyl	  groups	  thanks	  to	  their	  
ability	   to	   stabilise	   carbocation	   and	   consequently	   to	   lower	   the	   activation	   free	   energies	  
involved	  in	  the	  BBr3-­‐assisted	  de-­‐protection	  mechanism	  139.	  
	  
8.4	  Pull-­‐down	  assay	  
Following	  previous	  works	   in	  our	  research	  group	  on	  the	   identification	  of	  ME0055	  putative	  
targets	   125,	   biotin	   was	   chosen	   as	   the	   first	   tag	   for	   labelling	   RCZ12	   and	   RCZ20	   thereby	  
creating	   the	   compounds	   to	   perform	   a	   pull-­‐down	   assay.	   Since	   biotin	   has	   a	   high	   specific	  
affinity	   for	   the	   protein	   streptavidin,	   the	   biotinylated	   compounds	   were	   attached	   to	  
streptavidin-­‐coated	  magnetic	  beads	  and	   incubated	  with	  a	  whole	  cell	   lysate	   to	  determine	  









8.4.1	  Synthesis	  of	  biotinylated	  RCZ12	  and	  RCZ20	  
Two	  major	  synthons	  were	  created	  to	  generate	  the	  two	  desired	  biotin	  labelled	  adducts	  by	  
means	  of	  a	  Huisgen	  1,3-­‐dipolar	  copper-­‐catalysed	  cycloaddition	  (Fig.23).	  It	  was	  planned	  to	  
install	  the	  azide	  group	  on	  the	  biotin	  synthon,	  while	  the	  alkyne	  feature	  was	  thought	  to	  be	  
inserted	   in	  the	  RCZ	  synthon	  through	  acylation	  with	  an	  acid	  chloride	  after	  the	  nitro	  group	  
reduction.	   In	   order	   to	   avoid	   the	   drastic	   conditions	   of	   the	   de-­‐protection	   of	   the	   two	   iso-­‐
propyl	  groups	   in	   the	   last	   step,	   it	  was	  decided	   to	   start	   from	  RCZ12	  and	  RCZ20	  and	   to	   re-­‐




Fig.	   23:	   Retrosynthetic	   scheme	   of	   Biotin-­‐RCZ12	   and	   Biotin-­‐RCZ20:	   A	   Huisgen	   copper-­‐catalysed	   1,3-­‐dipolar	   cycloaddition	   was	  
chosen	   to	   generate	   the	  two	  biotinylated	   version	  of	  our	  candidates.	  The	  azide	  group	  was	  planned	  to	  be	   installed	  onto	  the	  biotin	  
synthon	  and	  the	  alkyne	  group	  onto	  the	  RCZ	  synthon.	  Reduction	  of	   the	  nitro	  group	  on	   the	  RCZ12	  and	  RCZ20	   scaffold	  could	  then	  





To	   create	   the	  RCZ	   synthons,	   RCZ12	  and	  RCZ20	  were	   firstly	   treated	  with	   allyl	   bromide	   to	  
afford	  intermediates	  37	  and	  38	  in	  excellent	  yields	  (Fig.	  24).	  Nitro	  reduction	  was	  carried	  out	  
in	  mild	   conditions	   in	   the	  presence	  of	   iron	  and	  an	  aqueous	   solution	  of	  NH4Cl	   in	   refluxing	  
ethanol.	   Intermediates	  39	  and	  40,	  thus	  obtained,	  underwent	  acylation	  with	  freshly	  made	  
hex-­‐5-­‐ynoyl	  chloride	  in	  very	  good	  yields	  to	  obtain	  both	  RCZ	  synthons	  in	  just	  3	  steps.	  
	  
The	  biotin	  synthon	  synthesis	  started	  with	  an	  EDC/NHS	  amide	  coupling	  reaction	  to	  create	  
the	   reactive	   biotin-­‐succinimide	   ester	   41	   140	   (Fig.	   25).	   The	   ester	   was	   then	   replaced	   to	  
generate	  the	  desired	  biotin	  synthon	  by	  3-­‐azidopropylamine	  43,	  which	  was	  prepared	  from	  
3-­‐chloropropylamine	  hydrochloride	  42.	  
	  
Huisgen	   copper	   catalysed	   1,3-­‐dipolar	   cycloaddition	   was	   performed	   in	   presence	   of	  
copper(II)sulphate	   and	   sodium	  ascorbate	   in	   a	   3:1	  mixture	  of	   THF	   and	  water	   at	   50	   °C	   141	  
(Fig.	  26).	  The	  protected	  biotin-­‐RCZ12	  and	  biotin-­‐RCZ20	  44	  and	  45,	  thus	  obtained,	  were	  de-­‐	  
Fig.	  24:	  Synthetic	  route	  for	  RCZ12	  and	  RCZ20	  synthons:	  The	  two	  desired	  synthons	  were	  obtained	  starting	  from	  RCZ12	  and	  
RCZ20	   in	  only	  3	  steps.	  After	   the	  allyl	   protection,	   intermediate	  37	   and	  38	  were	  reduced	  to	  the	  corresponding	  aniline	   in	  
order	   to	  be	  acylated	  with	  hex-­‐5-­‐ynoyl	  chloride.	  Hex-­‐5-­‐ynoyl	  chloride	  was	  prepared	  from	  hex-­‐5-­‐yonoic	  acid	  the	  same	  day	  
of	  the	  acylation	  and	  used	  immediately	  (see	  Experimental	  Part).	  
Fig.	  25:	  Synthetic	  route	  for	  Biotin	  Synthons:	  Commercially	  available	  (+)-­‐biotin	  was	  treated	  with	  standard	  EDC/NHS	  
succinimide	  ester	  coupling	  conditions	  140	   to	  afford	  the	  reactive	  NHS	  ester	  41.	  The	  biotin	  synthon	  was	  obtained	  by	  




protected	  with	  tetrakis(triphenylphosphine)	  palladium	  in	  refluxing	  methanol	  in	  good	  yields	  




8.4.2	  Pull-­‐down	  assay	  results	  
Streptavidin-­‐coated	  magnetic	  beads	  were	  employed	  to	  perform	  the	  pull-­‐down	  assay	  with	  
our	   two	   biotinylated	   compounds.	   The	   beads	   were	   first	   incubated	   with	   the	   biotin	  
derivatives	  and	  then	  with	  an	  E.	  coli	  O157	  TUV	  93-­‐0	  whole	  cell	   lysate.	  Following	  extensive	  
washing	  to	  reduce	  low	  affinity	  or	  non	  specifically	  bound	  proteins,	  the	  beads	  were	  boiled	  in	  
SDS	   for	   proteins	   denaturation	   and	   run	   on	   a	   SDS-­‐PAGE	   gel	   for	   separation.	   Visible	   bands	  
were	  removed	  and	  then	  analysed	  by	  tandem	  mass	  spectrometry	  for	  identification.	  
Biotin-­‐RCZ12	  and	  biotin-­‐RCZ20	   showed	   to	  have	  affinity	   for	   similar	   targets	   as	   the	   same	  3	  
protein	  bands	  appeared	  in	  both	  final	  samples	  (Fig.	  27).	  Interestingly,	  the	  most	  visible	  bands	  
in	   the	  assay	   (band	  3	  and	  3’)	   resulted	   to	  be	   the	   virulence	  protein	  EspD	   (MOWSE	   score/#	  
peptides	   matched:	   1266/45	   for	   RCZ12	   and	   1174/40	   for	   RCZ20),	   while	   the	   other	   bands	  
were	  found	  to	  be	  unrelated	  to	  the	  T3SS.	  EspD	  (39	  kDa)	  is	  the	  main	  component	  of	  the	  T3SS	  
translocon	  and	  is	  secreted	  through	  the	  needle-­‐like	  complex	  to	  generate	  the	  terminal	  tip	  of	  
the	  virulence	  apparatus	   into	   the	  host	   cell	  membrane	   31,33,143.	  Once	  EspD	  has	   formed	   the	  
pore,	  all	  the	  virulence	  effectors	  can	  be	  injected	  into	  the	  host	  cell	  to	  start	  the	  colonisation	  
Fig.	   26:	   Huisgen	   1,3-­‐dipolar	   cycloaddition	   and	   synthesis	   of	   biotin-­‐RCZ12	   and	   20:	   Copper(II)sulphate	   and	   ascorbic	   acid	  
were	   used	   to	   catalyse	   the	   cycloaddition	   to	   afford	   intermediate	   44	   and	   45.	   De-­‐protection	   of	   the	   two	   allyl	   groups	   was	  




process.	  It	  is	  also	  involved	  in	  the	  control	  of	  the	  secretion	  of	  other	  T3SS	  proteins	  (EspA	  and	  
EspB)	  and	  the	  consequent	  attaching/effacing	  lesions	  (A/E	  lesions)	  typical	  of	  E.	  coli	  O157:H7	  
infections	  143,144.	  This	  result,	  thus	  obtained,	  is	   in	  accordance	  with	  the	  effects	  observed	  on	  
EspD	  secretion	  in	  the	  western	  blot	  experiment.	  
Bands	  number	  1	  and	  1’	  were	  identified	  as	  2-­‐oxoglutarate	  dehydrogenase	  (MOWSE	  score/#	  
peptides	   matched:	   1716/106	   for	   RCZ12),	   which	   is	   an	   enzyme	   complex	   involved	   in	   the	  
decarboxylation	   of	   2-­‐oxoglutarate	   to	   succinyl	   coenzyme	   A,	   CO2	   and	   NADH	   145,	   but	   not	  
involved	  in	  EspD	  secretion	  or	  T3SS	  assembly.	  Band	  2	  was	  identified	  as	  the	  elongation	  factor	  
Tu	   (Ef-­‐Tu)	   (MOWSE	   score/#	   peptide	  matched:	   745/75	   for	   RCZ12),	   a	   guanine	   nucleotide-­‐
binding	   protein	   (GBP)	   which	   functions	   as	   a	   carrier	   of	   amino	   acyl-­‐tRNA	   to	   the	   ribosome	  
146,147.	  This	  protein	  has	  also	  never	  been	  linked	  to	  the	  regulation	  of	  the	  T3SS.	  Bands	  number	  
4	   and	   4’	   resulted	   as	   the	   30S	   ribosomal	   subunit	   protein	   S10	   (MOWSE	   score/#	   peptide	  
matched:	  235/10	   for	  RCZ12)	  and	   it	  demonstrated	   to	  be	  an	  unspecific	   interacting	  protein	  
bound	  to	  streptavidin	  rather	  than	  our	  biotinylated	  compounds,	  as	  shown	  by	  our	  negative	  
control.	   These	   additional	   results	   were	   all	   treated	   as	   unlikely	   to	   be	   associated	   with	   the	  
mechanism	  of	  action,	  since	  RCZ12	  and	  RCZ20	  might	  just	  have	  a	  slight	  effect	  on	  the	  succinyl	  
coenzyme	   A	   metabolism	   and	   bind	   Ef-­‐Tu,	   but	   neither	   of	   them	   is	   linked	   to	   the	   T3SS	  





From	  the	  two	  SDS	  wash	  lanes,	  RCZ20	  proved	  to	  be	  marginally	  more	  selective	  for	  EspD	  than	  
RCZ12.	  The	  concentration	  of	  the	  off-­‐target	  band	  1’	  was	  less	  evident	  for	  the	  DHP	  derivative	  
and	  the	  off-­‐target	  band	  2	  was	  absent	  from	  its	  SDS	  wash	  lane.	  These	  results	  suggested	  that	  
RCZ20	   might	   have	   fewer	   interactions	   with	   other	   unrelated	   T3SS	   proteins	   than	   RCZ12.	  
Nonetheless,	  both	  molecules	  appeared	  to	  bind	  the	  virulence	  protein	  EspD	  and	  this	  result	  
was	  consistent	  with	  the	  phenotype	  observed	  in	  previous	  assays.	  
	  
8.4.3	  Conclusions	  
A	  selective	  affinity	  for	  the	  virulence	  protein	  EspD	  was	  observed	  for	  both	  our	  biotinylated	  
compounds	   from	  the	  pull-­‐down	  assay	  results.	  Other	  bands	  were	  detected	  and	  proved	  to	  
Fig.	  27:	  SDS-­‐PAGE	  gel	  for	  the	  pull-­‐down	  assay:	  Biotin-­‐RCZ12	  and	  biotin-­‐RCZ20	  pull-­‐down	  assay	  is	  shown	  in	  the	  gel	  above	  
(see	  Experimental	  Part).	  PBS	  washes	  were	  carried	  out	  three	  times	  after	  incubation	  of	  the	  whole	  cell	  lysate	  to	  remove	  the	  
unspecific	  bound	  proteins	  (PBS	  Wash	  lanes	  I,	  II	  and	  III).	  The	  beads	  were	  then	  boiled	  in	  SDS	  and	  run	  through	  an	  SDS-­‐PAGE	  
gel	  with	  constant	  voltage	  to	  separate	  the	  proteins	  (SDS	  wash	  lanes).	  Negative	  control	  was	  performed	  in	  order	  to	  visualise	  
unspecific	  proteins	  interacting	  with	  streptavidin	  (Negative	  control	  lanes).	  Relevant	  protein	  bands	  (1,	  2,	  3,	  3’	  and	  4)	  were	  
excised,	   trypsin	   digested	   and	   analysed	   through	   tandem	  mass	   spectrometry.	   Both	   bands	   3	   and	   3’	   resulted	   to	   be	   the	  
virulence	   protein	   EspD,	   while	   the	   other	   bands	   (1	   and	   2)	   proved	   to	   be	   proteins	   unrelated	   to	   the	   T3SS	   apparatus	   and	  
assembly,	  hence	  considered	  off-­‐targets.	  Bands	  4	  resulted	  as	  30S	  ribosomal	  subunit	  S10	  and	  regarded	  as	  unspecific	  due	  
to	  the	  binding	  in	  the	  negative	  control	  lanes.	  From	  this	  result,	  we	  hypothesised	  that	  EspD	  is	  the	  only	  genuine	  T3SS-­‐related	  




be	  proteins	  bound	  to	  streptavidin	  or	  unrelated	  to	  the	  T3SS,	  which	  were	  considered	  as	  off-­‐
targets	  and	  unlikely	  to	  be	  responsible	  for	  the	  phenotype.	  These	  results,	  together	  with	  the	  
western	  blot	  data,	  drew	  us	   to	  propose	   that	  RCZ12	  and	  RCZ20	  might	  bind	   to	  EspD	   in	   the	  
cytosol	  inducing	  conformational	  changes,	  that	  dramatically	  affect	  its	  proper	  secretion	  and	  
cause	  a	  retention	  of	  the	  protein	  inside	  the	  bacterial	  cell.	  This	  is	  consistent	  with	  the	  western	  
blot	   analyses	   of	   EspD	   expression	   and	   secretion	   in	   presence	   of	   these	   candidates.	   This	  
assumes	  that	  the	  compounds	  have	  to	  be	  taken	  up	  by	  the	  bacterial	  cell	  or	  freely	  cross	  the	  
bacterial	  membrane	  in	  order	  to	  interact	  with	  the	  protein	  in	  its	  intracellular	  conformations.	  
It	   is	   thought	   that	   native	   EspD	   adopts	   a	   chaotic	   configuration	   to	   then	   be	   recognised	   by	  
selective	   chaperones,	   CesD	   and	   CesD2,	   for	   the	   correct	   secretion	   through	   the	   T3SS	  
apparatus	   32,148,149.	   RCZ12	   and	   RCZ20	   could	   then	   interact	   either	   with	   the	   protein	   in	   its	  
“native”	  configuration	  or	  to	  the	  chaperone-­‐EspD	  complex	  to	  enable	  their	  inhibitory	  effect.	  
This	  protein	   target	  and	  all	   the	  consequent	  hypotheses	  have	   to	  be	  validated	  by	  means	  of	  
other	  binding	  techniques	  and	  assays.	  
Attempts	   in	   the	  over-­‐expression	  and	  purification	  of	   EspD	  have	  been	   carried	  out	  without	  
any	   success.	   The	   protein	   proved	   to	   be	   extremely	   difficult	   to	   handle	   and	   purify	   through	  
several	   standard	   and	   non-­‐standard	   protocols	   (data	   not	   shown).	   Chatterjee	   et	   al.	  
successfully	   produced	   the	   first	   recombinant	   purified	   EspD	   (rEspD)	   in	   2015	   34.	   Several	  
batches	  of	   the	  purified	  protein	  were	  kindly	  donated	   from	  this	   research	  group,	  but	   rEspD	  
was	   found	   to	   be	   problematic	   to	   solubilise	   and	   to	   fold	   in	   its	   correct	   intracellular	  
conformation.	  High	  concentration	  of	  urea	  (8	  M)	  and	  detergents	  had	  to	  be	  used	  to	  dissolve	  
the	  protein	   in	  a	   “semi-­‐native”	  configuration,	  which	   resulted	   to	  be	   incompatible	  with	  our	  
compounds	  and/or	  instruments.	  Pull-­‐down	  experiments	  with	  rEspD	  failed	  to	  replicate	  the	  
previous	   results	   as	   the	   recombinant	   protein	   showed	   no	   binding	   to	   our	   biotinylated	  
derivatives	  (See	  Paragraph	  8.7.5,	  Fig.	  31).	  This	  finding	  proved	  that	  EspD	  is	  a	  very	  insoluble	  
and	  sensitive	  membrane	  protein	  that	  probably	  has	  to	  be	  folded	  in	  its	  original	  intracellular	  
conformation	  to	  bind	  to	  the	  two	  candidates.	  
	  
8.5	  Metabolomics	  analysis	  
From	   the	   pull-­‐down	   results,	   it	   was	   postulated	   a	   putative	   interaction	   between	   our	  
derivatives	  and	  EspD	   into	  the	  bacterial	  cytosol.	  RCZ12	  and	  RCZ20	  are	  then	   likely	  to	  cross	  
the	  bacterial	  membrane	  to	  perform	  this	  hypothetical	  binding.	  Metabolomics	  analyses	  were	  




(Table	  8).	  Bacteria	  were	  grown	  in	  M9	  minimal	  medium	  and	  then	  incubated	  with	  RCZ12	  or	  
RCZ20.	   Once	   centrifuged,	   both	   bacterial	   pellets	   and	   supernatant	   solutions	  were	   treated	  
with	   a	   1:1:3	   (CHCl3:H2O:CH3OH)	   solution	   and	   analysed	   by	   hydrophilic	   interaction	   liquid	  
chromatography	  (HILIC)	  to	  highlight	  the	  differences	  in	  concentration	  of	  the	  two	  samples.	  A	  
noteworthy	   cellular	   uptake	  was	   detected	   for	   both	   our	   derivatives	   as	   the	   concentrations	  
found	  inside	  the	  bacterial	  pellets	  were	  higher	  than	  the	  supernatant,	  indicating	  a	  strong	  E.	  
coli	  uptake.	  Both	  molecules	  crossed	  the	  membrane	  and	  the	  final	  concentrations	  inside	  the	  
cells	  were	  found	  to	  be	  three	  fold	  higher	  than	  the	  supernatant.	  These	  results	  assessed	  the	  
cellular	  uptake	  of	  RCZ12	  and	  RCZ20	  inside	  the	  bacterial	  cells	  and	  then	  confirmed	  that	  the	  
interaction	  with	  EspD	  occurs	  inside	  the	  bacterial	  cytosol.	  
Entry	   Experimental	  Blank	   Supernatant	   Bacterial	  pellets	  
RCZ12	   6.7*105	   10.3*106	  ±	  1.7*106	   5.93*109	  ±	  4.48*108	  
RCZ20	   6.6*106	   12.2*106	  ±	  6.16*105	   9.06*109	  ±	  7.54*108	  
	  
Table	   8:	   Metabolomics	   data	   for	   RCZ12	   and	   RCZ20	   cellular	   uptake:	   Average	   intensities	   of	   RCZ12	   and	   RCZ20	   and	  
corresponding	   standard	   deviation	   in	   Supernatant	   and	   Bacterial	   pellets	   samples	   are	   represented	   in	   the	   table	   above.	  
Experimental	   triplicates	  were	   prepared	   and	   analysed	   through	   hydrophilic	   interaction	   liquid	   chromatography	   (HILIC).	   A	  
three	  magnitude	  increase	  of	  the	  compounds’	  concentration	  was	  registered	  for	  the	  Bacterial	  pellets	  samples,	  indicating	  a	  
cellular	  uptake	  of	  both	  drugs	  inside	  the	  bacteria.	  This	  confirms	  that	  the	  compound-­‐EspD	  interaction	  can	  occur	  inside	  the	  
bacterial	  cytosol.	  
	  
8.6	  Surface	  plasmon	  resonance	  (SPR)	  
Both	  biotinylated	  version	  of	  RCZ12	  and	  RCZ20	  proved	   to	  bind	  EspD	   through	  a	  pull-­‐down	  
assay	  using	  a	  whole	  cell	  lysate	  solution	  from	  E.	  coli	  O157	  TUV	  93-­‐0.	  A	  plausible	  interaction	  
between	   our	   compounds	   and	   EspD	   inside	   the	   bacterial	   cell	   could	   occur,	   inhibiting	   the	  
secretion	   of	   this	   virulence	   protein.	   The	   mode	   of	   action	   hypothesised	   is	   supported	   by	  
western	  blot	  and	  metabolomics	  analyses	  previously	  carried	  out.	  
In	  order	  to	  validate	  this	  hypothesis,	  we	  chose	  to	  prove	  the	  binding	  of	  our	  candidates	  with	  
EspD	  by	  means	  of	  a	  surface	  plasmon	  resonance	  experiment	   (SPR).	  SPR	   is	  a	  common	  and	  
sensitive	   technique	   widely	   used	   for	   detecting	   protein-­‐protein,	   DNA-­‐protein	   or	   ligand-­‐
protein	   interactions	   through	   the	  measurement	  of	   the	   refractive	   index	  variations	   induced	  
by	  an	  analyte	  adsorption	  onto	  an	  appropriate	   gold	  or	   silver	   stationary	  phase	   150–152.	   The	  
most	  commonly	  used	  stationary	  phases	  are	  commercially	  available	  gold	  chip	  which	  could	  
be	  employed	  in	  different	  SPR	  assay	  and	  then	  treated	  with	  the	  analyte	  solution	  to	  calculate	  




target	   affinity	   (IC50)	   and	   it	   is	   considered	   one	   of	   the	   key	   tools	   for	   proving	   biochemical	  
interactions	  153.	  
	  
8.6.1	  SPR	  analysis	  with	  biotinylated	  RCZ12	  and	  RCZ20	  
A	  carboxymethylated	  dextran-­‐coated	  gold	  chip	  (BiaCore®	  chip	  CM5)	  was	  used	  to	  validate	  
the	   binding	   between	   our	   candidates	   and	   EspD	   through	   SPR.	   The	   coating	   is	   extremely	  
versatile	  and	  can	  be	  modified	  by	  attaching	  different	  functional	  groups	  on	  the	  gold	  surface.	  
Neutravidin,	  a	  derivative	  of	  streptavidin,	  was	  covalently	  bound	  to	  the	  dextran	  coating	  and	  
the	   chip	  was	   then	   incubated	  with	  one	  of	   the	   two	  biotinylated	   compounds.	   The	   reaction	  
wasn’t	   successful	   as	   expected	   since	   only	   a	   small	   amount	   of	   the	   labelled	  molecules	   was	  
bound	  to	  the	  dextran	  surface.	  The	  chips	  were	  incubated	  with	  a	  whole	  cell	  lysate	  solution	  as	  
planned,	   but,	   unfortunately,	   the	   data	   were	   too	   inaccurate	   due	   to	   the	   instrument	  
background	   noise	   and	   the	   poor	   amount	   of	   biotin-­‐RCZ12	   and	   biotin-­‐RCZ20	   on	   the	   gold	  
surface.	  The	  outcome	  of	  the	  experiment	  was	  considered	  inconclusive.	  
	  
8.6.2	  Synthesis	  of	  amino-­‐labelled	  RCZ12	  and	  RCZ20	  
Following	   the	   initial	   unsuccessful	   strategy,	   the	   biotin	   tag	   was	   replaced	   with	   a	   primary	  
amino	  group	  in	  order	  to	  immobilise	  our	  compounds	  directly	  onto	  the	  gold	  chip.	  
	  
Fig.	   28:	   Synthetic	   route	   for	   amino-­‐labelled	   RCZ12	   and	   RCZ20:	   6-­‐Bromohexanoic	   acid	   was	   reacted	   with	  
sodium	   azide	   in	   DMF	   154	   and	   the	   corresponding	   carboxylic	   acid	   was	   then	   converted	   into	   the	   desired	   6-­‐
azidohexanoyl	  chloride,	  which	  was	  used	  to	  acylate	   intermediate	  39	  and	  40.	  The	  azido	  derivatives	  46	  and	  47,	  
thus	   obtained,	   were	   de-­‐allylated	   with	   tetrakis(triphenylphosphine)palladium	   following	   our	   previous	  
conditions	  142.	  The	  azido	  group	  was	  then	  reduced	  with	  a	  Staudinger	  reaction	  by	  means	  of	  polymer	  supported-­‐




The	   carboxymethylated	   dextran	   could	   be	   treated	   with	   EDC/NHS	   conditions	   to	   create	   a	  
reactive	  succinimide	  ester	  and	  then	  coupled	  with	  the	  two	  amino-­‐labelled	  RCZ	  molecules.	  
Previously	  obtained	  intermediates	  39	  and	  40	  were	  reacted	  with	  6-­‐azidohexanoyl	  chloride	  
154	   to	   afford	   the	   acylated	   adduct	   46	   and	   47	   (Fig.	   28).	  
Tetrakis(triphenylphosphine)palladium-­‐mediated	   de-­‐allylation	   142	   followed	   by	   Staudinger	  
reaction	  with	  polymer	  supported-­‐triphenylphosphine	  and	  water	  were	  performed	  to	  yield	  
the	  two	  desired	  amino-­‐labelled	  RCZ12	  and	  RCZ20	  in	  3	  steps.	  
	  
8.6.3	  SPR	  analysis	  with	  amino-­‐labelled	  RCZ12	  and	  RCZ20	  	  	  
An	   identical	   carboxymethylated	   dextran-­‐coated	   gold	   chip	   was	   used	   for	   this	   second	   SPR	  
experiment.	  EDC/NHS	  conditions	  were	  employed	  to	  generate	  a	  reactive	  succinimide	  ester	  
on	  the	  gold	  chip.	  The	  two	  amino-­‐labelled	  compounds	  reacted	  with	  the	  esters	  and	  bound	  
successfully	  onto	  the	  dextran	  surface.	  Incubation	  of	  a	  whole	  cell	  lysate	  solution	  from	  E.	  coli	  
O157	   TUV	   93-­‐0	   was	   let	   to	   flow	   through	   the	   chip.	   Unfortunately,	   no	   refractive	   index	  
variations	   were	   detected	   by	   the	   instrument,	   meaning	   that	   no	   interaction	   occurred	  
between	   our	   derivatives	   and	   any	   protein	   of	   the	   whole	   cell	   lysate.	   The	   outcome	   of	   this	  
experiment	  was	   probably	   influenced	   by	   the	   different	   dilution	   of	   the	  whole	   cell	   solution	  
used	  for	  the	  pull-­‐down	  assay	  and	  the	  SPR	  analysis.	   In	  the	  pull-­‐down	  assay,	  the	  whole	  cell	  
lysate	  had	  a	  dense	  and	  viscous	  form	  due	  to	  the	  high	  concentration	  of	  proteins,	  membrane	  
remnants	   and	   DNA.	   Since	   the	   SPR	   instrument	   is	   very	   sensitive,	   the	   same	   concentrated	  
whole	  cell	   lysate	  solution	  had	  to	  be	  diluted	  by	  1/1’000	  in	  order	  to	  be	  flowed	  through	  the	  
chip	   channel.	   This	   might	   have	   compromised	   the	   compound-­‐EspD	   interaction,	   since	   our	  
amino-­‐labelled	  compounds	  were	  exposed	   to	   smaller	   concentration	  of	  EspD	   in	   the	  whole	  
cell	  lysate	  solution.	  The	  outcome	  of	  the	  experiment	  was	  deemed	  inconclusive.	  
	  
8.7	  Micro-­‐scale	  thermophoresis	  (MST)	  
Biotinylated	  version	  of	  RCZ12	  and	  RCZ20	  proved	  to	  bind	  to	  the	  virulence	  protein	  EspD	  in	  
the	  pull-­‐down	  assay,	   but	   failed	   in	   validating	   this	   target	   through	   SPR	  experiment.	  Amino-­‐
labelled	  derivatives	  were	  synthesised	  to	  overcome	  binding	  issue	  to	  the	  SPR	  chip,	  but,	  even	  
in	   this	   case,	   the	   binding	   between	  our	   candidates	   and	   EspD	  was	   not	   detected.	  However,	  
concentrated	   whole	   cell	   lysate	   solution	   had	   to	   be	   diluted	   due	   to	   the	   instrument	   safety	  




compounds	  were	   exposed	   to	   a	  much	   smaller	   concentration	   of	   EspD	   than	   the	   pull-­‐down	  
experiment.	  Therefore,	  to	  validate	  the	  binding	  previously	  observed,	   it	  was	  planned	  to	  try	  
micro-­‐scale	  thermophoresis	  (MST).	  
MST	  analysis	  are	  based	  on	  thermophoresis,	  which	  describes	  the	  movement	  of	  molecules	  in	  
a	   temperature	   gradient	   155.	   The	  molecules	  motion	   depends	   on	   a	   plethora	   of	   properties	  
such	   as	   size,	   charge,	   hydration	   shell	   and	   conformation	   155,156.	   MST	   detects	   this	   motion	  
through	  the	  gradient	  by	  attached	  fluorophores	  in	  a	  very	  sensitive	  manner	  and	  can	  evaluate	  
protein-­‐protein	  or	  ligand-­‐protein	  interactions	  (for	  more	  biophysical	  details:	  (Duhr	  &	  Braun,	  
2006a,	   2006b;	   Jerabek-­‐Willemsen,	  Wienken,	   Braun,	   Baaske,	   &	   Duhr,	   2011;	   Seidel	   et	   al.,	  
2013)).	  If	  binding	  is	  observed,	  the	  instrument	  can	  also	  measure	  the	  affinity	  of	  the	  titrated	  
protein	  samples	  from	  the	  differences	  of	  the	  fluorescently	  labelled	  ligand	  movements	  in	  the	  
temperature	  gradient	  156.	  
	  
8.7.1	  Synthesis	  of	  BODIPY-­‐labelled	  RCZ12	  and	  RCZ20	  
Since	  a	   fluorophore	   is	   required	   for	  performing	  MST	  analysis,	   it	  was	   firstly	  planned	  to	   tag	  
RCZ12	   and	   RCZ20	  with	   a	   fluorescent	   tag.	   Previous	   studies	   in	   our	   groups	   highlighted	   the	  
versatility	   and	   the	   ease	   of	   synthesis	   of	   the	   well-­‐known	   fluorescent	   probe	   BODIPY	   161,	   a	  
difluoro-­‐bora-­‐diaza-­‐indacene	  dye	  widely	  used	  in	  biological	  assays	  (for	  reviews:	  162).	  
Once	   the	   compounds	   had	   their	   attached	   fluorophore,	   they	   could	   then	   be	   treated	   with	  
Fig.	  29:	  Synthetic	  route	  for	  BODIPY-­‐labelled	  RCZ12	  and	  RCZ20:	  BODIPY-­‐N3	  was	  obtained	  following	  previous	  protocols	  in	  
our	  lab	  161	  and	  coupled	  with	  both	  RCZ	  synthons	  by	  means	  of	  a	  Huisgen	  1,3-­‐dipolar	  cycloaddition.	  Protected	  intermediates	  
48	   and	   49	   were	   de-­‐allylated	   in	   presence	   of	   tetrakis(triphenylphosphine)palladium	   in	   refluxing	   methanol	   142.	   BODIPY-­‐




titrated	   solution	   of	   whole	   cell	   lysate	   from	   E.	   coli	   O157	   TUV	   93-­‐0	   to	   detect	   their	  
hypothesised	  interaction	  with	  EspD.	  BODIPY-­‐N3	  was	  synthesised	  according	  to	  the	  research	  
group	   protocols	   and	   reacted	   with	   both	   RCZ12	   and	   RCZ20	   synthons	   in	   a	   click	   reaction	  
fashion	   in	   presence	   of	   catalytic	   amount	   of	   copper(I)iodide	   and	   DIPEA	   161	   (Fig.	   29).	  
Protected	   intermediates	   48	   and	   49	   were	   de-­‐allylated	   in	   presence	   of	  
tetrakis(triphenylphosphine)palladium	   following	   our	   previous	   conditions	   142	   to	   afford	  
BODIPY-­‐labelled	  RCZ12	  and	  RCZ20.	  
	  
8.7.2	  MST	  analysis	  with	  BODIPY-­‐labelled	  RCZ12	  and	  RCZ20	  
MST	  experiment	  between	  our	  BODIPY-­‐labelled	  RCZ12	  and	  RCZ20	  and	  a	  whole	  cell	   lysate	  
solution	   from	   E.	   coli	   O157	   TUV	   93-­‐0	   were	   performed	   by	   means	   of	   a	   Nanotemper®	  
Monolith	   NT115.	   The	   concentration	   of	   the	   fluorescent	   ligand	   was	   kept	   constant	   in	   all	  
samples,	  while	  the	  whole	  cell	  solution	  was	  diluted	  with	  decreasing	  concentrations	  in	  order	  
to	   detect	   the	   interaction	   and	   to	   calculate	   its	   possible	   affinity.	   Unfortunately,	   the	   buffer	  
used	   resulted	   to	   be	   incompatible	   with	   our	   2	   BODIPY-­‐labelled	   derivatives,	   which	  
precipitated	   and	   lost	   fluorescence.	   After	   changing	   a	   variety	   of	   buffer	   systems,	   it	   was	  
obvious	   that	   the	   components	   of	   the	   experiments	   were	   mismatched	   and	   especially	   the	  
fluorescent	   probe	   was	   particularly	   sensitive	   to	   the	   aqueous	  media.	   An	   attempt	   to	  MST	  
analysis	  was	  performed,	  but	  the	  fluorescent	  signal	  was	  found	  to	  be	  weak	  and	  not	  sufficient	  
to	  carry	  out	  the	  experiment	  as	  expected.	  
After	  these	  discouraging	  findings,	   it	  was	  planned	  to	   install	   the	  fluorescence	  unit	  on	  EspD	  
and	   to	   treat	   it	  with	   serial	   dilutions	   of	   RCZ12	   and	   RCZ20.	   This	  was	   chosen	   to	   detect	   the	  
movements	   of	   EspD	   when	   in	   presence	   of	   our	   molecules.	   Since	   EspD	   purification	   and	  
solubility	  showed	  to	  be	  problematic,	  the	  decision	  was	  made	  to	  try	  the	  MST	  analysis	  with	  a	  
whole	  cell	  lysate	  solution	  with	  EspD-­‐GFP	  replacing	  the	  wild-­‐type	  virulence	  protein	  EspD.	  
	  
8.7.3	  Generation	  of	  ΔespD	  pRZ001	  strain	  
EspD-­‐GFP	   was	   designed	   and	   created	   to	   overcome	   the	   solubility	   and	   stability	   issues	  
demonstrated	   by	   the	   BODIPY-­‐labelled	   RCZ12	   and	   RCZ20	   during	   our	   first	   MST	   analysis	  
attempt.	   The	   plasmid	   was	   constructed	   using	   pAJR70	   as	   a	   backbone,	   a	   promoter-­‐less	  
plasmid	  containing	  the	  gfp	  gene,	  which	  encodes	  for	  the	  desired	  green	  fluorescent	  protein	  




GenScript®),	  expressed	  in	  a	  DH5-­‐α	  strain	  and	  digested	  to	  extract	  the	  desired	  DNA	  portion.	  
The	   purified	   DNA	   construct	   was	   then	   cloned	   directly	   upstream	   of	   the	   gfp	   gene	   in	   the	  
pAJR70	  backbone.	  Correct	  insertion	  was	  confirmed	  by	  diagnostic	  digestion	  (HindIII)	  and	  the	  
new	  plasmid	  was	  named	  pRZ001.	  The	  purified	  plasmid	  was	  transformed	  into	  ΔespD	  mutant	  
in	  order	  to	  have	  only	  EspD-­‐GFP	  expression	  inside	  the	  bacterial	  cell	  (ΔespD	  pRZ001	  strain).	  
Fluorescence	  was	   assessed	  by	  measuring	   the	   absorbance	  of	   the	  GFP	  probe	   (480	  nm)	   of	  
chemically	   lysed	  ΔespD	  pRZ001	  cells	  grown	   in	  a	  T3SS-­‐inducing	  media	   (Fig.	  30).	  TUV	  93-­‐0	  
and	  EPEC	  ptirGFP	   strains	  were	  used	  as	  negative	   and	  positive	   controls	   respectively.	   RFUs	  
were	  measured	   before	   and	   after	   treatment	  with	   the	   lysis	   buffer	   solution	   to	   display	   the	  
maximum	  intensity	  for	  the	  EspD-­‐GFP	  protein.	  Western	  blot	  analysis	  revealed	  that	  the	  new	  
EspD-­‐GFP	  was	  not	  detectable	  by	  the	  α-­‐EspD	  antibody,	  while	  the	  α-­‐GFP	  antibody	  showed	  a	  
well-­‐marked	   band	   at	   65	   kDa,	   the	   correct	   predicted	   molecular	   weight	   for	   the	   new	  
fluorescent	  protein.	  
	  
8.7.4	  MST	  analysis	  with	  EspD-­‐GFP	  
A	  whole	  cell	  lysate	  solution	  from	  the	  ΔespD	  pRZ001	  strain,	  containing	  EspD-­‐GFP,	  was	  used	  
for	   the	   second	   attempt	   to	   MST	   experiments.	   Cells	   were	   grown	   under	   T3SS-­‐inducing	  
conditions,	  pelleted	  and	  lysed.	  The	  corresponding	  viscous	  solution	  was	  diluted	  by	  1/1’000	  
in	   accordance	   with	   the	   protocols	   recommended	   by	   the	   instrument	   manufacturer	   and	  
Fig.	  30:	  Western	  blot	  results	  for	  α-­‐EspD	  and	  α-­‐GFP	  antibodies	  (left)	  and	  GFP	  intensity	  of	  the	  ΔespD	  pRZ001	  
strain	   (right):	   Western	   blot	   analysis	   were	   carried	   out	   to	   confirm	   the	   expression	   of	   the	   new	   EspD-­‐GFP	  
protein	   (see	   Experimental	   Part	   for	   Ab	   dilution).	   EspD-­‐GFP	   was	   not	   detected	   by	   means	   of	   the	   α-­‐EspD	  
antibody,	  but	  a	  65	  kDa	  protein	  was	  identified	  when	  using	  the	  α-­‐GFP	  antibody,	  indication	  of	  the	  expression	  
of	  EspD-­‐GFP.	  Fluorescence	  intensity	  was	  measured	  through	  absorbance	  at	  480	  nm.	  Lysed	  cells	  from	  ΔespD	  
pRZ001	  showed	  a	  maximum	  intensity	  when	   lysed	  with	  BugBuster	  mix.	  TUV	  93-­‐0	  and	  EPEC	  ptirGFP	  strains	  




aliquoted.	  Decreasing	   concentrations	  of	  both	  RCZ12	  and	  RCZ20	  were	   then	  added	   to	   the	  
fluorescent	   protein	   solution.	   Even	   in	   this	   case,	   the	   two	   candidates	   demonstrated	   to	   be	  
insoluble	   in	   the	  aqueous	  media	  and	  precipitated	  or	   formed	  emulsions	  according	   to	   their	  
concentrations.	   Increasing	   percentages	   of	   DMSO	   were	   added	   in	   order	   to	   solubilise	   the	  
compounds	  to	  a	  maximum	  of	  20%	  on	  the	  total	  volume	  of	  the	  samples.	  MST	  analyses	  were	  
performed,	  but	  no	  indications	  of	  interaction	  were	  detected	  by	  the	  instrument.	  The	  result	  
of	  the	  experiment	  was	  considered	  inconclusive	  due	  to	  the	  high	  DMSO	  percentage.	  
The	  MST	  experiment	  highlighted	  the	  solubility	  issues	  of	  both	  our	  synthetic	  derivatives	  that	  
proved	  to	  be	  incompatible	  with	  most	  of	  the	  biological	  buffers	  used	  for	  such	  analysis.	  Unlike	  
the	   biotinylated	   derivatives,	   which	   easily	   solubilise	   in	   aqueous	   media,	   both	   BODIPY-­‐
labelled	   and	   the	   unlabelled	   RCZ12	   and	   RCZ20	   were	   found	   to	   be	   incompatible	   with	   the	  
whole	   cell	   lysate	   media.	   The	   outcomes	   of	   the	   two	   experiments	   were	   affected	   by	   this	  
incomplete	   solubilisation	   and	   mismatch	   of	   our	   molecules.	   To	   overcome	   this	   problem,	  
increasing	  DMSO	  percentages	  were	  used	  up	  to	  20%	  on	  the	  total	  volume	  of	   the	  samples.	  
The	  clear	  solutions	  were	  tested,	  but	  revealed	  no	  evidence	  of	  binding.	  It	  is	  well-­‐known	  that	  
the	  presence	  of	  DMSO	  affects	  the	  folding,	  behaviour	  and	  binding	  abilities	  of	  the	  proteins	  
164.	  Especially	  at	  high	  concentrations,	  as	  we	  employed,	   results	  could	  be	  tampered	  by	  the	  
DMSO	  effects,	  which	  help	  the	  solubilisation	  of	  the	  compounds	  and,	  at	  the	  same	  time,	  alter	  
the	  properties	  of	  the	  whole	  cell	   lysate	  proteins.	   In	  addition,	   it	   is	  possible	  that	  the	  bulk	  of	  
the	  GFP	  protein	  could	  have	  hindered	  RCZ12	  and	  RCZ20	  binding	  site	  or	  compromised	  the	  
intracellular	   folding	   of	   EspD,	   obstructing	   its	   “native”	   or	   chaperone-­‐bound	   conformation.	  
Indications	  of	  this	  obstruction	  were	  suggested	  by	  the	  western	  blot	  analysis	  performed	  on	  
the	  ΔespD	  pRZ001	  strain,	  where	  EspD-­‐GFP	  was	  not	  recognised	  by	  the	  α-­‐EspD	  antibody,	  but	  
only	   by	   the	   α-­‐GFP.	   Due	   to	   all	   these	   findings,	   the	   results	   obtained	   from	   the	   MST	  
experiments	  had	  to	  be	  considered	  questionable	  and	  inconclusive.	  




8.7.5	  Pull-­‐down	  assay	  with	  EspD-­‐GFP	  
MST	  analysis	  with	  ΔespD	  pRZ001	  whole	  cell	   lysate	  solution	  has	  clearly	  demonstrated	  the	  
unsuitability	  of	  RCZ12	  and	  RCZ20	  in	  many	  different	  biological	  buffers.	  In	  addition,	  the	  GFP	  
unit	   could	  have	  also	  played	  a	  key	   role	   in	   impeding	   the	  binding	  between	   the	  compounds	  
and	  the	  protein.	  	  
	  
	  
To	   confirm	   this	  obstruction,	   a	  pull-­‐down	  assay	  with	  ΔespD	   pRZ001	  whole	   cell	   lysate	  was	  
performed.	  Whole	  cell	   lysate	  solution	  from	  E.	  coli	  O157	  TUV	  93-­‐0	  and	  ΔespD	  strain	  were	  
employed	   as	   positive	   and	   negative	   controls	   respectively	   and	   an	   rEspD	   solution	  was	   also	  
Fig.	  31:	  SDS-­‐PAGE	  gel	  for	  the	  pull-­‐down	  assay	  with	  ΔespD	  pRZ001	  strain:	  Biotin-­‐RCZ12	  and	  biotin-­‐RCZ20	  
pull-­‐down	  assay	  with	   different	   bacterial	   strains	   is	   shown	   in	   the	   gel	   above	   (see	   Experimental	   Section).	  
SDS	  wash	   lanes	   for	   each	  bacterial	   strain	  used	  are	  shown	   in	   the	  gel.	   	  The	  TUV	  93-­‐0	   strain	  was	  used	   as	  
positive	   control	   as	   both	   biotin-­‐RCZ12	   and	   biotin-­‐RCZ20	   bind	   to	   EspD,	   as	   previously	   shown	   (Fig.21,	  
Paragraph	  3.32),	  while	   the	  ΔespD	  strain	  was	  employed	  as	  negative	  control	   for	  EspD.	  EspD-­‐GFP	  (ΔespD	  
pRZ001	  strain)	  wasn’t	  detected	  in	  the	  gel	  when	  incubated	  with	  our	  biotinylated	  compounds.	  The	  result	  
supports	   the	  hypothesis	   that	   the	  GFP	  core	  might	  hinder	  the	  binding	  site	  or	  change	  the	  conformational	  
configuration	  of	  the	  virulence	  protein	  disabling	  the	  interaction	  with	  the	  compounds.	  In	  addition,	  a	  rEspD	  
solution	   was	   also	   incubated	   with	   the	   biotin-­‐labelled	   molecules	   and,	   interestingly,	   no	   binding	   was	  
observed.	   This	   data	   corroborates	   the	   extremely	   difficult	   handling	   and	   the	   issue	   of	   solubilising	   this	  




used	  to	  prove	  the	  binding	  of	  our	  molecules.	  As	  observed	  in	  our	  previous	  pull-­‐down	  assay	  
(Fig.27,	  Paragraph	  8.4.2),	  both	  biotin-­‐RCZ12	  and	  biotin-­‐RCZ20	  bound	  to	  EspD	  (band	  3	  and	  
3’)	   when	   treated	   with	   the	   TUV	   93-­‐0	   cell	   lysate	   and	   showed	   to	   bind	   the	   same	   T3SS	  
unrelated	  protein	  2-­‐oxo-­‐glutarate	  dehydrogenase	  (1	  and	  1’)	  (Fig.	  31).	  Band	  2	  and	  2’	  were	  
detected	  for	  the	  first	  time	  and	  resulted	  to	  be	  the	  virulence	  protein	  EspB	  (MOWSE	  score/#	  
peptide	  matched:	  1154/77	   for	  RCZ12).	  Since	  EspB	  has	  a	  molecular	  weight	  of	  31	  kDa,	  we	  
assumed	  the	  interaction	  with	  our	  biotinylated	  compounds	  occurred	  in	  the	  homodimerised	  
form,	  as	  the	  band	  appeared	  to	  have	  a	  molecular	  weight	  of	  63	  kDa.	  It	   is	  rather	  unusual	  to	  
have	   homodimers	   after	   SDS	   treatment	   and	   thus,	   this	   band	   result	   was	   considered	   not	  
reliable	  and	  unspecific,	  as	  it	  never	  appeared	  again	  in	  the	  SDS	  wash	  lane	  of	  other	  pull-­‐down	  
experiments.	  No	  EspD	  band	  was	  detected	  in	  both	  ΔespD	  and	  ΔespD	  pRZ001	  strains	   lanes	  
when	  the	  whole	  cell	   lysate	  solutions	  were	  incubated	  with	  biotin-­‐RCZ12	  and	  biotin-­‐RCZ20.	  
While	  the	  ΔespD	   result	  was	  expected	  as	  no	  EspD	   is	  produced	  by	  the	  bacteria,	   the	  ΔespD	  
pRZ001	   confirmed	   that	   EspD-­‐GFP	   has	   less	   affinity	   for	   our	   compounds	   as	   the	   GFP	   unit	  
modifies	   the	   conformational	   configuration	   of	   the	   virulence	   protein	   inside	   the	   cell.	   Also	  
rEspD	   showed	   no	   interaction	   when	   incubated	   with	   the	   biotinylated	   compounds,	  
corroborating	   the	   issues	   of	   EspD	   solubility	   and	   partially	   “native”	   configuration	   with	   the	  
buffer	   used,	   which	   affected	   the	   outcome	   of	   the	   experiment.	   In	   addition,	   the	   rEspD	  
displayed	  a	  poor	  level	  of	  purity	  as	  other	  bands	  in	  the	  SDS	  wash	  lane	  were	  detected	  in	  very	  
low	  concentration.	  	  
	  	  
8.8	  Generation	  of	  truncated-­‐EspD-­‐HA	  strains	  
Validating	  EspD	  as	   the	  main	  protein	   target	   for	  RCZ12	  and	  RCZ20	  proved	   to	  be	  a	  difficult	  
task	  due	  to	  issues	  associated	  with	  both	  the	  protein	  and	  the	  solubility	  of	  the	  compounds,	  as	  
observed	  by	  the	  SPR	  and	  MST	  experiments.	  Metabolomics	  data	  verified	  the	  cellular	  uptake	  
of	   our	   compounds	   by	   E.	   coli,	   supporting	   the	   intracellular	   interaction	   between	   the	   two	  
derivatives	   and	   the	   T3SS	   protein	   EspD,	   hypothesised	   from	   the	   pull-­‐down	   assay	   results.	  
Unfortunately,	   the	   other	   binding	   techniques	   used	   failed	   to	   verify	   the	   result	   due	   to	   the	  
aforementioned	  issues.	  To	  overcome	  these	  limitations,	  it	  was	  decided	  to	  generate	  a	  series	  
of	  five	  truncates	  of	  EspD	  to	  then	  observe	  any	  possible	  variation	  or	  loss	  of	  activity	  by	  RCZ12	  
and	   RCZ20.	   As	   mentioned	   before,	   EspD	   is	   a	   key	   virulence	   protein	   for	   the	   EHEC	   T3SS	  
apparatus,	  which	  mediates	  the	  anchoring	  of	  the	  bacterium	  to	  the	  host	  cells	  and	  allows	  the	  




possesses	   2	   coiled-­‐coil	   domains	   for	   host	   cell	   membrane	   anchoring	   and	   homo-­‐
oligomerisation,	   2	   transmembrane	   domains	   for	   insertion	   and	   two	   amphipatic	   regions	  
thought	   to	   be	   involved	   in	   the	   secretion	   process	   of	   the	   protein	   and	   in	   chaperone	  
recognition	   31,32,34.	   It	  was	   decided	   to	   delete	   these	   functional	   regions	   to	   validate	   EspD	   as	  
main	  protein	  target	  of	  our	  derivatives	  and	  then	  to	  evaluate	  the	  inhibition	  of	  the	  secretion	  
through	  western	  blot	  analysis.	  If	  EspD	  is	  the	  main	  protein	  target	  of	  RCZ12	  and	  RCZ20,	  key	  
modifications	   in	   its	  structure	  would	  reverse	  the	  compounds	  effect	  on	  secretion.	  To	  allow	  
immunoblotting	   of	   the	   new	   constructs,	   the	   truncated-­‐EspD	   were	   tagged	   with	   an	   HA	  
sequence	  at	  the	  carboxy-­‐terminus.	  
	  
8.8.1	  Creation	  of	  TUV	  93-­‐0	  EspD-­‐HA	  
A	   new	   strain	   producing	   full	   length	   EspD-­‐HA	   was	   firstly	   created	   as	   a	   starting	   point	   for	  
further	  truncations	  and	  modifications.	  Generation	  of	  this	  strain	  was	  achieved	  by	  means	  of	  
a	  process	  called	  allelic	  exchange,	  which	  it	  was	  optimised	  for	  EHEC	  by	  Emmerson	  et	  al.	  165	  
(for	  more	  details	  refer	  to	  Experimental	  Part,	  Paragraph	  13.2.14).	  This	  ensures	  that	  a	  single	  
chromosomally	  encoded	  copy	  of	  the	  gene	  is	  integrated	  into	  the	  genome,	  overcoming	  the	  
issues	   associated	   with	   plasmid	   based	   expression	   systems	   such	   as	   copy	   number	   and	  
stability.	  
Fig.	  32:	  TUV	  93-­‐0	  EspD-­‐HA	  Western	  blot	  analysis:	  Western	  blot	  analyses	  were	  carried	  
out	   according	   to	   standard	   procedure	   (see	   Experimental	   Part	   for	   methods	   and	   Ab	  
dilutions).	   Both	   supernatant	   proteins	   (S/N)	   and	  whole	   cell	   lysate	   solution	   (W/C)	  were	  
analysed	  in	  repeats	  of	  three	  independent	  experiments.	  As	  expected,	  the	  new	  construct	  
EspD-­‐HA	   was	   recognised	   by	   both	   α-­‐EspD	   and	   α-­‐HA	   antibodies,	   which	   confirmed	   its	  





The	   espD-­‐HA	   gene	   was	   flanked	   between	   the	   3’	   and	   5’	   homologous	   regions	   of	   the	  
endogenous	   gene	   espD	   (purchased	   from	   GenScript®)	   and	   cloned	   into	   a	   temperature	  
sensitive	   exchange	   plasmid	   (pIB307)	   to	   create	   the	   first	   allelic	   exchange	   plasmid	   pIB307-­‐
LEE4-­‐EspD-­‐HA.	   Generation	   of	   the	   second	   allelic	   exchange	   plasmid	   pIB307-­‐LEE4-­‐sacB-­‐kan	  
was	   achieved	   by	  BamH1	   digestion	   of	   pIB307-­‐LEE4-­‐EspD-­‐HA	   and	   subsequent	   insertion	   of	  
the	   sacB-­‐kan	   cassette.	   pIB307-­‐LEE4-­‐sacB-­‐kan	   was	   transformed	   into	   TUV	   93-­‐0	   and	   the	  
strain	   then	   underwent	   allelic	   exchange	   to	   yield	   TUV	   93-­‐0	   ΔespD	   sacB-­‐kan,	   intermediate	  
strain	  where	   the	  endogenous	  gene	  espD	  was	   replaced	  by	   the	  sacB-­‐kan	  cassette	   through	  
homologous	   recombination.	   pIB307-­‐LEE4-­‐EspD-­‐HA	   was	   then	   transformed	   into	   this	  
intermediate	   strain	   and	   a	   second	   allelic	   exchange	  was	   performed	   to	   obtain	   the	   desired	  
TUV	  93-­‐0	  EspD-­‐HA	  strain.	  The	  correct	  insertion	  of	  the	  gene	  was	  confirmed	  by	  PCR	  across	  
the	   new	   espD-­‐HA	   gene	   and	  western	   blot	   with	   both	   α-­‐EspD	   and	   α-­‐HA	   antibodies	   of	   the	  
supernatant	  and	  whole	  cell	   lysate	  (Fig.	  32).	  As	  expected,	  EspD-­‐HA	  was	  correctly	  secreted	  
and	  expressed	  by	  bacteria.	  
	  
8.8.2	  Creation	  of	  truncated-­‐EspD-­‐HA	  strains	  
To	   create	   the	   correct	   exchange	   plasmids	   for	   the	   truncated-­‐EspD-­‐HA	   strains,	   various	  
regions	   of	   the	   espD-­‐HA	   gene	   were	   amplified	   and	   then	   ligated	   together	   through	   a	   DNA	  
assembly	   reaction	   with	   the	   pIB307	   backbone.	   8	   espD-­‐HA	   fragments	   were	   purified	   to	  
assemble	  4	  temperature	  sensitive	  exchange	  plasmids:	  pIB307-­‐LEE4-­‐EspD-­‐HAΔ26-­‐81,	  pIB307-­‐
LEE4-­‐EspD-­‐HAΔ138-­‐171,	   pIB307-­‐LEE4-­‐EspD-­‐HAΔ176-­‐251	   and	   pIB307-­‐LEE4-­‐EspD-­‐HAΔ333-­‐356.	  
Plasmids	  were	   then	   transformed	   into	   the	   intermediate	   TUV	   93-­‐0	   ΔespD	   sacB-­‐kan	   strain	  
and	  subjected	  to	  allelic	  exchange	  treatment	  to	  afford	  the	  corresponding	  4	  truncated-­‐EspD-­‐
HA	  strains	  (Fig.23):	  TUV	  93-­‐0	  EspD-­‐HAΔ26-­‐81,	  where	  the	  two	  predicted	  amphipathic	  regions	  
1	   and	   2	   (Amph1/2)	   adjacent	   to	   the	  N-­‐terminus	  were	   deleted,	   TUV	   93-­‐0	   EspD-­‐HAΔ138-­‐171,	  
where	  the	  coiled-­‐coil	  domain	  1	  (COIL1)	  was	  deleted,	  TUV	  93-­‐0	  EspD-­‐HAΔ176-­‐251,	  where	  the	  
two	  transmembrane	  domains	  1	  and	  2	  (TMD1/2)	  were	  deleted,	  and	  TUV	  93-­‐0	  EspD-­‐HAΔ333-­‐
356,	  where	  the	  coiled-­‐coil	  domain	  2	  (COIL2)	  was	  deleted.	  The	  new	  strains	  were	  confirmed	  
by	  PCR	  across	  the	  new	  genes	  inserted	  and	  western	  blot	  analysis	  with	  α-­‐HA	  antibody	  of	  the	  





All	   the	   new	   strains	   expressed	   and	   secreted	   the	   HA-­‐labelled	   constructs	   beside	   TUV	   93-­‐0	  
EspD-­‐HAΔ26-­‐81,	  which	  did	  not	  express	  or	  secrete	  any	  construct.	  It	  has	  been	  postulated	  that	  
the	   amphipatic	   region	   2	   (Amph2),	   predicted	   to	   be	   located	   between	   amino	   acids	   66-­‐83,	  
functions	  as	  a	  recognition	  site	  for	  EspD	  chaperones	  CesD	  and	  CesD2,	  which	  maintain	  the	  
virulence	  protein	   in	   a	   secretion	   competent	   conformation	   32,148,149.	   Therefore,	   deletion	  of	  
this	  region	  produces	  a	  misfolded	  EspD	  which	  undergoes	  rapid	  degradation,	  since	  it	  cannot	  
be	  secreted	  correctly	  32.	  Evidence	  of	  this	  has	  already	  been	  observed	  by	  Dasanayake	  et	  al.	  
and	  verified	  by	   the	   fact	   that	  our	  new	  strain	  TUV	  93-­‐0	  EspD-­‐HAΔ26-­‐81	  did	  not	  express	  and	  
secrete	  any	  EspD	  construct	  according	  to	  the	  α-­‐HA	  Western	  blot.	  
	  
8.8.3	  Western	  blot	  analysis	  with	  RCZ12	  
Since	   we	   already	   assumed	   that	   our	   derivatives	   share	   the	   same	  mode	   of	   action	   against	  
EHEC	  T3SS,	   it	  was	  decided	  to	  evaluate	  RCZ12	  against	   the	  new	  truncated-­‐EspD-­‐HA	  strains	  
due	  to	  its	  potency	  and	  slightly	  better	  solubility	  in	  biological	  media	  (Fig.	  34).	  The	  compound	  
Fig.	  33:	  Western	  blots	  of	  the	  truncated-­‐EspD-­‐HA	  producing	  strains	  (left)	  and	  cartoon	  showing	  the	  4	  deleted	  functional	  
regions	  of	  EspD	  (right):	  Western	  blot	  analyses	  were	  carried	  out	  according	  to	  standard	  procedure	  (see	  Experimental	  Part	  
for	  methods	  and	  Ab	  dilutions).	  Both	  supernatant	  proteins	  (S/N)	  and	  whole	  cell	   lysate	  solution	  (W/C)	  were	  analysed	  in	  
repeats	  of	   three	   independent	   experiments.	  All	   the	  new	  strains	  demonstrated	  to	  express	  and	  secrete	  their	   truncated-­‐
EspD-­‐HA	   constructs	   beside	   TUV	   93-­‐0	   EspD-­‐HAΔ26-­‐81,	   which	   did	   not	   express	   any	   new	   construct.	   Deletion	   of	   the	  
amphipathic	  region	  2	  (Amph	  2)	  (aa.	  63-­‐88)	  in	  EspD	  resulted	  in	  the	  production	  of	  a	  misfolded	  protein,	  which	  is	  in	  a	  non-­‐
secretive	  competent	  conformation,	  due	  to	  the	   lack	  of	   the	  chaperone	  recognition	  site.	  Therefore,	   our	  new	  strain	  TUV	  
93-­‐0	  EspD-­‐HAΔ26-­‐81	  produced	  a	  construct	  which	  was	  rapidly	  degraded	  by	  the	  cell	  because	  of	  the	  lack	  of	  this	  recognition	  
site.	  Despite	  no	   crystallographic	   data	   available	   for	   EspD,	   it	   has	  been	  predicted	   that	   this	   virulence	   protein	   contains	   2	  
amphipathic	   regions	   (Amph1/2),	   two	   coiled-­‐coil	   domains	   (COIL1	   and	   COIL2)	   and	   two	   transmembrane	   domains	  
(TMD1/2).	   Each	   truncated-­‐EspD-­‐HA	   strains	   produce	   a	   different	   EspD-­‐HA	   construct	   with	   a	   specific	   deletion	   of	   the	  
functional	   regions	   shown	   in	   the	   figure	   above.	   Unfortunately,	   when	   Amph2	   is	   deleted,	   no	   production	   of	   the	   new	  





showed	  total	  inhibition	  of	  EspD	  secretion	  at	  200	  μM	  and	  this	  concentration	  was	  chosen	  for	  
the	  western	   blot	   experiment.	  When	   TUV	   93-­‐0	   EspD-­‐HA	  was	   treated	  with	   RCZ12,	   a	   total	  
inhibition	  of	  EspD-­‐HA	  secretion	  was	  detected,	  indicating	  that	  the	  HA	  tag	  did	  not	  influence	  
the	  compound’s	  activity.	  Retention	  of	   total	   inhibition	  of	   the	  secretion	  was	  also	  observed	  
for	  EspD-­‐HAΔ176-­‐251	  (25-­‐fold	  inhibition)	  and	  EspD-­‐HAΔ333-­‐356	  (15-­‐fold	  inhibition),	  even	  though	  
in	  the	  latter	  case	  a	  slightly	  attenuated	  effect	  was	  registered.	  Secretion	  of	  EspD-­‐HAΔ138-­‐171,	  
instead,	  was	  not	  affected	  by	  RCZ12,	  as	  equal	  amounts	  of	  the	  truncated	  protein	  were	  found	  
in	  the	  untreated	  and	  treated	  samples,	  highlighting	  a	  complete	  loss	  of	  activity.	  
	  
These	  results	  confirmed	  the	  hypothesis	  proposed	  from	  the	  pull-­‐down	  experiment	  in	  which	  
RCZ12	  and	  RCZ20	  bind	  to	  EspD,	  consequently	  blocking	  its	  secretion.	  Various	  modifications	  
of	  the	  virulence	  protein	  structure	  resulted	  in	  both	  retention	  and	  loss	  of	  activity	  by	  RCZ12.	  
When	   the	   two	  TMD1/2	  domains	  or	  COIL2	  were	  deleted,	   inhibition	  of	   the	   corresponding	  
constructs	   by	   our	   derivative	   was	   detected,	   while	   normal	   secretion	   was	   observed	   when	  
COIL1	  was	  absent	   in	  the	  structure.	  The	  fact	  that	  RCZ12	  lost	   its	  effect	  on	  secretion	  with	  a	  
truncated	   version	  of	   EspD,	   confirms	   that	   the	   virulence	  protein	   is	   the	  main	   target	   of	   our	  
Fig.	  34:	  Western	  blot	  analyses	  of	   truncated-­‐EspD-­‐HA	  strains	  with	  and	  without	  RCZ12	  treatment	  at	  200	  µM:	  Western	  
blot	  analyses	  were	  carried	  out	  according	  to	  standard	  procedure	  (see	  Experimental	  Part	  for	  methods	  and	  Ab	  dilutions).	  
Supernatant	  proteins	  (S/N)	  were	  analysed	  in	  repeats	  of	  three	  independent	  experiments	  for	  each	  strain.	  RCZ12	  showed	  
retention	   of	   inhibition	   of	   EspD-­‐HA,	   EspD-­‐HAΔ176-­‐251	   and	   EspD-­‐HAΔ333-­‐356	   at	   200	   µM,	   while	   no	   activity	   was	   detected	  
against	  EspD-­‐HAΔ138-­‐171.	  The	  results	  detected	  from	  this	  assay	  validated	  EspD	  as	  main	  target	  of	  both	  RCZ12	  and	  RCZ20,	  
as	   RCZ12	   lost	   is	   activity	   when	   EspD	   structure	   was	   specifically	   modified.	   A	   complete	   loss	   of	   activity	   was	   registered	  
against	   EspD-­‐HAΔ138-­‐171,	   which	   supports	   the	   pull-­‐down	   assay	   findings	   confirming	   the	   direct	   interaction	   between	   our	  
compounds	  and	  the	  virulence	  protein	  EspD.	  It	  can	  be	  speculated	  that	  RCZ12	  and	  RCZ20	  are	  likely	  to	  bind	  to	  EspD	  COIL1	  
region,	  since	  the	   loss	  of	  activity	  was	  only	  detected	   for	  EspD-­‐HAΔ138-­‐171.	  Attenuation	  of	  activity	  against	  EspD-­‐HAΔ333-­‐356	  
suggests	   that	  COIL2	  is	  also	  partially	   involved	   in	  the	   interaction	  or	   that	   the	  structural	  modifications	  induced	  by	  RCZ12	  




compounds	   and	   supports	   the	   major	   conclusion	   from	   the	   pull-­‐down	   experiments.	   In	  
addition,	  we	  can	  postulate	  that	  RCZ12	  and	  RCZ20	  are	   likely	  to	  bind	  to	  EspD	   in	  the	  COIL1	  
region,	  since	  only	  the	  deletion	  of	  this	  functional	  area	  resulted	  in	  a	  marked	  loss	  of	  activity.	  
Attenuation	   of	   the	   compound’s	   activity	   against	   EspD-­‐HAΔ333-­‐356,	   where	   the	   COIL2	   is	  
deleted,	  may	  indicates	  that	  both	  coiled-­‐coil	  domains	  could	  be	  involved	  in	  the	  interaction	  or	  
that	   the	   structural	  modifications	   induced	   by	   RCZ12	   and	   RCZ20	   also	   influence	   the	   COIL2	  
domain	  to	  stop	  the	  secretion.	  
	  
8.9	  Conclusions	  and	  future	  work	  
RCZ12	  and	  RCZ20	  demonstrated	  to	  be	  promising	  T3SS	   inhibitors,	  primarily	  blocking	  EspD	  
secretion	   and	   acting	   also	   on	   Tir	   expression	   and	   secretion	   at	   200	   μM.	   Both	   compounds	  
were	  designed	  and	  synthesised	  as	  ME0055	  more	  stable	  derivatives,	  but	  displayed	  a	  distinct	  
and	  more	  specific	  activity	  on	  EHEC	  T3SS	  than	  the	  SA	  compound.	  These	  encouraging	  results	  
provided	   by	   the	   transcriptional	   and	   post-­‐transcriptional	   experiments	   drove	   us	   to	  
investigate	   in	  details	   the	  mode	  of	  action	  of	   these	  new	  active	  molecules.	  A	  new	  synthetic	  
route	   was	   firstly	   planned	   and	   carried	   out	   to	   obtain	   RCZ12	   and	   RCZ20	   in	   good	   yields.	  
Replacement	   of	   the	   methyl	   ethers	   with	   weaker	   iso-­‐propyl	   ethers	   afforded	   a	   longer	  
synthetic	   route,	   but	   faster	   and	   easier	   purification	   steps.	   Labelled	   derivatives	   of	   our	  
compounds	  were	  designed	  in	  order	  to	  perform	  various	  binding	  techniques	  to	  identify	  the	  
protein	  target.	   It	  was	  decided	  to	   install	   the	  tags	  onto	  the	   left-­‐hand	  side	  of	   the	  molecule,	  
since	   di-­‐hydroxyl	   compounds	   resulted	   to	   be	   more	   active	   than	   di-­‐methoxyl	   ones	   in	   our	  
preliminary	  screening.	  
Following	  previous	  studies	  by	  our	  group	  125,	  it	  was	  decided	  to	  carry	  out	  a	  pull-­‐down	  assay	  
against	   a	   TUV	  93-­‐0	  whole	   cell	   lysate	   to	   try	   and	   identify	   the	  bacterial	   protein	   specifically	  
bound	   to	   our	   compounds.	   Biotinylated	   versions	   of	   RCZ12	   and	   RCZ20	   were	   obtained	  
through	   a	   Huisgen	   copper-­‐catalysed	   1,3-­‐dipolar	   cycloaddition	   in	   5	   steps	   starting	   from	  
RCZ12	   and	   RCZ20.	   By	   means	   of	   streptavidin-­‐coated	   magnetic	   beads,	   a	   pull-­‐down	  
experiment	  that	  identified	  EspD	  as	  the	  only	  bona	  fide	  T3SS-­‐related	  protein	  target	  bound	  to	  
both	   biotin-­‐RCZ12	   and	   biotin-­‐RCZ20.	   Other	   proteins	   that	   were	   identified	   through	   this	  
procedure	  could	  be	  eliminated	  as	  being	   involved	   in	  the	  mode	  of	  action	  as	  they	  were	  not	  
related	  to	  T3SS	  apparatus	  and	  not	  consistent	  with	  the	  phenotype	  of	  accumulated	  EspD	  in	  
the	  bacterial	   cytoplasm.	  From	  this	   result,	  we	  deduced	   that	  RCZ12	  and	  RCZ20	  shared	   the	  




the	   virulence	   protein	   EspD	   inside	   the	   cell	   to	   block	   its	   secretion.	   Metabolomics	   analysis	  
demonstrated	  that	  the	  derivatives	  accumulated	  within	  the	  bacterial	  cytoplasm,	  consistent	  
with	  the	  hypothesis	   that	   the	  compound-­‐EspD	   interaction	  has	  to	  occur	   inside	  the	  cytosol.	  
To	   further	   validate	   our	   hypothesis,	   other	   binding	   techniques	   were	   carried	   out.	   Surface	  
plasmon	   resonance	   (SPR)	   with	   gold	   chips	   was	   attempted	   with	   both	   biotin-­‐labelled	   and	  
amino-­‐labelled	  molecules,	  but	   it	  provided	  only	   inconclusive	   results	  due	   to	  dilution	   issues	  
required	   for	   the	   instrument	   protocols.	   Microscale	   thermophoresis	   (MST)	   was	   also	  
performed	  with	  BODIPY-­‐labelled	  molecules	  against	  a	  TUV	  93-­‐0	  whole	  cell	   lysate	  and	  with	  
EspD-­‐GFP	   whole	   cell	   lysate,	   but	   unfortunately	   highlighted	   the	   unsuitability	   of	   our	  
compounds	  with	  most	  of	  the	  buffer	  systems	  used	  for	  the	  experiment.	  Both	  SPR	  and	  MST	  
techniques	  were	   then	  considered	   inconclusive	  and	  underlined	   the	  problematic	  biological	  
properties	  of	  EspD	  and	  the	  poor	  solubility	  of	  RCZ12	  and	  RCZ20.	  Generation	  of	  truncated-­‐
EspD-­‐HA	  strains	  was	  carried	  out	  by	  means	  of	  allelic	  exchange,	  in	  order	  to	  create	  4	  different	  
strains	  producing	  various	  EspD	  mutants	  labelled	  with	  HA.	  Once	  the	  strains	  were	  obtained,	  
western	  blot	  analyses	  of	  the	  new	  clones	  were	  performed	  with	  and	  without	  the	  presence	  of	  
RCZ12	  at	  200	  μM	  to	  evaluate	  changing	  or	  loss	  of	  activity.	  Retention	  of	  a	  normal	  inhibition	  
on	  the	  new	  constructs	  secretion	  was	  detected	  for	  all	  the	  new	  strains	  beside	  EspD-­‐HAΔ138-­‐
171.	   Equal	   amounts	  of	   EspD-­‐HAΔ138-­‐171	  were	   found	   in	   the	  untreated	  and	   treated	   samples,	  
indicating	   a	   complete	   loss	   of	   activity	   by	   RCZ12.	   The	   results	   showed	   how	   a	   selective	  
modification	   in	  the	  EspD	  structure	  can	  affect	  our	  compound’s	  activity,	  hence,	  confirming	  
EspD	  as	  the	  main	  protein	  target	  for	  RCZ12	  and	  RCZ20.	  Furthermore,	  the	  experiment	  also	  
suggested	   that	  our	  derivatives	  might	  bind	   to	  EspD	   in	   the	  COIL1	  domain	   (138-­‐171),	   since	  
only	  the	  deletion	  of	  this	   functional	  region	  reverted	  RCZ12	  effect	  on	  secretion.	  This	  detail	  
can	   only	   be	   fully	   confirmed	   by	   crystallographic	   data,	   which	   are	   still	   unavailable	   for	   this	  
protein,	  but	   it	   is	  also	  a	  clear	   indication	  on	  RCZ12	  and	  RCZ20	  binding	   site.	  An	  attenuated	  
inhibitory	  effect	  was	  also	  detected	   for	   the	  strain	  producing	  EspD-­‐HAΔ333-­‐356,	  where	  COIL2	  
was	  deleted.	  This	  also	  suggest	  that	  both	  coiled-­‐coil	  domains	  are	  involved	  in	  the	  interaction	  
or	  that	  our	  compounds	  induce	  conformational	  changes	  that	  also	  influence	  COIL2	  to	  block	  
EspD	  secretion.	  
From	  these	  experiments,	  we	   identified	  and	  validated	  EspD	  as	   the	  main	  protein	   target	  of	  
both	   RCZ12	   and	   RCZ20.	   It	   is	   likely	   that	   our	   compounds	   cross	   E.	   coli’s	   membrane	   and	  
directly	   interact	  with	  the	  protein	  either	   in	   its	  “native”	  or	  chaperone-­‐bound	  conformation	  




coli	   incubated	  with	  both	  RCZ12	  and	  RCZ20,	  while	   the	  EspD	  binding	  detected	   in	   the	  pull-­‐
down	  assay	  was	  validated	  by	  the	  western	  blot	  experiments	  on	  truncated-­‐EspD-­‐HA	  strains.	  
The	  latter	  experiment	  also	  highlighted	  the	  possibility	  that	  the	  derivatives	  might	  bind	  to	  the	  
coiled-­‐coil	  domain	  (COIL1)	  of	  EspD	  to	  exhibit	  their	  effect	  against	  EHEC	  T3SS.	  In	  the	  future,	  
efforts	   focused	   on	   purifying	   this	   challenging	   protein	   should	   be	   attempted	   in	   order	   to	  
confirm	  the	  exact	  interaction	  site	  of	  RCZ12	  and	  RCZ20	  in	  EspD	  structure.	  Crystallographic	  
data	  of	  the	  virulence	  protein	  EspD	  will	  also	  provide	  useful	   information	  for	  new	  and	  more	  
potent	  compounds	  based	  on	  the	  THP	  and	  DHP	  scaffolds.	  	  	  	  	  	  	  	  	  	  	  	  	  	  




9	  RCZ12	  and	  RCZ20	  Derivatives	  
9.1	  Structural	  analysis	  on	  RCZ12	  and	  RCZ20	  
Our	   THP	   and	   DHP	   derivatives	   demonstrated	   to	   possess	   selective	   activity	   against	   EHEC	  
T3SS,	   especially	   blocking	   EspD	   secretion	   and	   down-­‐regulating	   T3SS-­‐related	   genes.	   The	  
main	  protein	  target	  resulted	  to	  be	  the	  virulence	  protein	  EspD,	  which	  was	  firstly	  identified	  
by	  pull-­‐down	  experiments	  and	  then	  validated	  by	  western	  blot	  analyses	  on	  truncated-­‐EspD-­‐
HA	  strains.	   It	   is	  thought	  that	  RCZ12	  and	  RCZ20	  are	  able	  to	  cross	  the	  bacterial	  membrane	  
and	  directly	   interact	  with	  EspD	   to	  block	   its	   secretion.	  Despite	   the	  promising	  activity,	  our	  
compounds	  also	  displayed	  poor	  solubility	  in	  biological	  media,	  which	  interfered	  with	  binding	  
experiments	  during	  the	   investigation	  of	  the	  candidates’	  mode	  of	  action.	  However,	  RCZ12	  
and	  RCZ20	  can	  be	  considered	  an	  excellent	  starting	  point	   for	  chemical	  optimisation,	  since	  
they	  both	  include	  new	  biologically	  active	  scaffolds	  against	  T3SS.	  
Fig.	  35:	  Rational	  design	  of	  RCZ12	  and	  RCZ20	  derivatives:	  Due	  to	  our	  previous	  findings,	  the	   left-­‐hand	  side	  phenyl	  
ring	  A	  (red)	  was	  modified	   in	  order	  to	  build	  a	  small	  library	  focused	  on	  the	  THP	  and	  DHP	  scaffolds.	  Removal	  of	  the	  
nitro	   group	  was	   first	   planned	   (RCZ30	   and	  RCZ40),	   then	   the	  whole	  phenyl	   ring	  was	   removed	  and	   replaced	   by	   a	  
methyl	  group	  (RCZ31	   and	  RCZ41).	  Substitution	  with	  a	  small	   (methyl	  group)	   (RCZ32	   and	  RCZ42)	   and	  a	  bulky	   (iso-­‐
propyl	  group)	  (RCZ33	  and	  RC43)	  alkyl	  group	  was	  planned	  to	  evaluate	  the	  influence	  of	  electron-­‐donating	  groups	  on	  
ring	  A.	  A	  trifluoromethyl	  group	  (RCZ34	  and	  RCZ44)	  was	  then	  placed	  in	  the	  same	  position	  of	  the	  nitro	  group	  to	  have	  
an	   inducing	   electron-­‐withdrawing	  effect	   on	   the	  molecule.	  A	   long	   alkyl	  chain	   (RCZ35	   and	  RCZ45)	  was	   introduced	  
instead	  of	  the	  whole	  ring	  A	  to	  investigate	  the	  impact	  of	  a	  more	  lipophilic	  derivative	  with	  a	  flexible	  carbon	  chain.	  At	  
last,	   the	  nitro	   group	  was	  moved	   in	  meta	   (RCZ36	   and	  RCZ46)	   and	   in	  ortho	   (RCZ37	  and	  RCZ47)	   to	  assess	   the	  best	  





Our	  preliminary	  evaluation	  of	   the	  THP	  and	  DHP	  series	   (Paragraph	  7.3.2)	  highlighted	   that	  
the	  two	  hydroxyl	  groups	  on	  the	  right-­‐hand	  side	  of	  the	  molecule	  were	  essential	  for	  activity	  
against	   EspD	   secretion.	   Di-­‐methoxyl	   derivatives	   showed	   a	   reduced	   activity	   against	   the	  
virulence	   protein	   than	   the	   di-­‐hydroxyl	   analogues,	   which	   suggested	   that	   the	   hydroxyl	  
groups	  could	  take	  part	  in	  key	  hydrogen	  bond	  interactions	  with	  EspD.	  The	  geometry	  of	  the	  
sulphone	   was	   also	   considered	   relevant	   for	   the	   activity,	   as	   the	   sulphonyl	   di-­‐hydroxyl	  
molecules	  were	  found	  to	  be	  more	  potent	  than	  the	  carbonyl	  di-­‐hydroxyl	  counterpart.	  Due	  
to	  these	  data,	   it	  was	  decided	  to	  modify	  the	   left-­‐hand	  side	  phenyl	   ring	   (Fig.	  35,	   ring	  A)	  of	  
both	  RCZ12	  and	  RCZ20.	  This	  ring	  is	  thought	  to	  be	  the	  recognition	  site	  of	  the	  molecule	  and	  
modification	  of	  the	  substituents	  could	  bring	  to	  more	  soluble	  and	  active	  derivatives	  against	  
T3SS.	  
It	  was	  firstly	  planned	  to	  remove	  the	  nitro	  group	  from	  ring	  A	  (RCZ30	  and	  RCZ40),	  in	  order	  to	  
observe	   the	   lack	   of	   the	   electron-­‐withdrawing	   effect	   on	   the	  molecules’	   activity	   (Fig.	   35).	  
Removal	   of	   the	   whole	   ring	   A	   was	   designed	   and	   replaced	   with	   a	   simple	   methyl	   group	  
(RCZ31	   and	   RCZ41)	   to	   investigate	   the	   relevance	   of	   this	   phenyl	   ring.	  We	   also	  wanted	   to	  
evaluate	   electron-­‐donating	   groups	   on	   this	   phenyl	   ring	   and	   how	   they	   could	   affect	   the	  
activity	  against	  EspD.	  Therefore,	   the	   replacement	  of	   the	  nitro	  group	  with	  a	   small	  methyl	  
group	  (RCZ32	  and	  RCZ42)	  was	  planned	  as	  well	  as	  the	  replacement	  with	  a	  bulky	  iso-­‐propyl	  
group	   (RCZ33	   and	  RCZ43).	   Both	   alkyl	   substituents	   induce	   an	  electron-­‐donating	   effect	   on	  
ring	  A	  and	  on	  the	  whole	  molecule,	  but	  differ	   in	  dimensions,	  which	  can	  be	  crucial	   for	   the	  
EspD	   interaction.	   To	   compare	   different	   electron-­‐withdrawing	   groups,	   it	   was	   opted	   to	  
replace	  the	  nitro	  group	  with	  a	  trifluoromethyl	  group	  (RCZ34	  and	  RCZ44);	  in	  this	  case,	  this	  
new	  functional	  group	  exhibit	  an	  inducing	  electron-­‐withdrawing	  effect	  on	  ring	  A	  rather	  than	  
a	   resonance	   electron-­‐withdrawing	   effect	   like	   the	   nitro	   group.	   An	   alkyl	   chain	   was	   also	  
introduced	   to	   substitute	   ring	   A	   (RCZ35	   and	   RCZ45)	   to	   confer	   more	   lipophilicity	   to	   the	  
molecule	  and	  to	  assess	  the	  compounds’	  activity	  in	  the	  presence	  of	  a	  long	  and	  flexible	  alkyl	  
chain.	  At	   last,	   it	  was	  also	  decided	  to	  move	  the	  nitro	  group	  around	  ring	  A	   in	  meta	   (RCZ36	  
and	  RCZ46)	  and	  ortho	  (RCZ37	  and	  RCZ47)	  position	  to	  identified	  the	  most	  active	  position	  on	  






9.2	  Synthesis	  of	  RCZ12	  and	  RCZ20	  derivatives	  
Synthesis	  of	  RCZ12	  derivatives	  started	  from	  the	  previously	  obtained	  amine	  28	  (Paragraph	  
7.2),	   which	   was	   sulphonylated	   with	   various	   sulphonyl	   chlorides	   following	   our	   standard	  
conditions	  used	  before	  for	  the	  synthesis	  of	  the	  THP	  compound	  (Fig.	  36).	  These	  protected	  
intermediates	   were	   then	   immediately	   de-­‐protected	   by	   BBr3	   in	   DCM	   to	   afford	   the	  
corresponding	  RCZ12	  analogues	  in	  moderate	  yield.	  RCZ20	  derivatives	  were	  synthesised	  in	  a	  
similar	   way.	   Amine	   35	   was	   sulphonylated	   with	   different	   sulphonyl	   chlorides	   and	   the	  
intermediates	   were	   treated	   with	   AlCl3	   overnight	   to	   afford	   the	   corresponding	   RCZ20	  
analogues.	  
	  
In	  both	  cases,	  the	  creation	  of	  the	  ortho-­‐nitro	  (RCZ37	  and	  RCZ47)	  derivatives	  was	  found	  to	  
be	  problematic	  as	  the	  protected	  intermediates	  were	  found	  to	  be	  extremely	  sensitive	  and	  
decomposed	   during	   the	   de-­‐protection	   step.	   For	   these	   reasons,	   we	   were	   unable	   to	  
synthesise	  RCZ37	  and	  RCZ47	  (Table	  9).	  However,	  the	  synthetic	  route	  proved	  to	  be	  fast	  and	  
easy	   to	   generate	   a	   moderate	   number	   of	   derivatives	   from	   the	   two	   amines	   previously	  
obtained,	  making	  this	  route	  ideal	  for	  the	  creation	  of	  extensive	  libraries	  based	  on	  the	  THP	  






Fig.	   36:	   Synthetic	   route	   for	   RCZ12	   and	   RCZ20	   derivatives:	   Amine	   28	   and	   35	   were	   sulphonylated	   with	   different	  
commercially	   available	   sulphonyl	   chlorides	   following	   our	   previous	   conditions.	   The	   intermediates	   thus	   obtained	   were	  
immediately	  subjected	  to	  a	  de-­‐protection	  step	  with	  BBr3	  for	  THP	  analogues	  and	  with	  AlCl3	  for	  DHP	  derivatives.	  The	  route	  
proved	   to	   be	   fast	   and	   easy	   to	   create	   a	   moderate	   number	   of	   new	   compounds	   and	   it	   can	   be	   used	   to	   build	   extensive	  





R	   Entry	  (THP/DHP)	   Yield	  (THP/DHP)	  
	  
RCZ30/RCZ40	   57%/49%	  
	   RCZ31/RCZ41	   31%/60%	  
	  
RCZ32/RCZ42	   23%/55%	  
	  
RCZ33/RCZ43	   22%/44%	  
	  
RCZ34/RCZ44	   20%/34%	  
	   RCZ35/RCZ45	   33%/58%	  
	  
RCZ36/RCZ46	   32%/24%	  
	  
RCZ37/RCZ47	   N/A	  
	  
Table	  9:	  RCZ12	  and	  RCZ20	  derivatives	  yields:	  The	  yields	  for	  the	  new	  RCZ12	  and	  RCZ20	  derivatives	  are	   listed	  above.	  All	  
the	   yields	   are	   reported	   as	   an	   over	   two	   steps	   yield.	   RCZ37	   and	   RCZ47	   were	   not	   synthesised	   due	   to	   starting	  material	  
decomposition.	  
	  
9.3	  Conclusions	  and	  future	  work	  
A	  total	  of	  14	  new	  RCZ12	  and	  RCZ20	  derivatives	  were	  synthesised	  in	  order	  to	  investigate	  the	  
structure-­‐activity	   relationship	   between	   the	   THP	   and	   DHP	   scaffold	   and	   EspD.	   Due	   to	   the	  
results	  obtained	  in	  our	  preliminary	  screening,	  it	  was	  decided	  to	  modify	  the	  left-­‐hand	  side	  
phenyl	   ring	   (ring	   A),	   replacing	   it	   with	   small	   and	   long	   alkyl	   chains	   or	   introducing	   new	  
substituents	   in	   place	   of	   the	   nitro	   group.	   The	   new	   series	  was	   afforded	   starting	   from	   the	  
previously	   synthesised	   amines	   28	   and	   35	   and	   followed	   our	   standard	   protocols	   for	  
sulphonylation	  and	  de-­‐protection	  of	  the	  iso-­‐propyl	  groups.	  The	  route	  was	  found	  to	  be	  fast	  
and	   with	   easy	   purification	   steps.	   Unfortunately,	   intermediates	   for	   the	   synthesis	   of	   the	  
ortho-­‐nitro	  derivative	   (RCZ37	  and	  RCZ47)	  proved	   to	  be	  unstable	  and	  decomposed	   in	   the	  
de-­‐protection	   step.	   Other	   de-­‐protecting	   agents	   were	   used,	   but	   they	   either	   displayed	  
partial	   or	   unsuccessful	   de-­‐protection.	   Both	   2-­‐	   and	   4-­‐nitrobenzenesulphonyl	   groups	   are	  
extensively	  used	  as	  protecting	  groups	  for	  the	  preparation	  of	  secondary	  amines	  due	  to	  their	  




the	  4-­‐nitrobenzenesulphonyl	  group,	   it	   is	  possible	   that	  our	  de-­‐protection	  conditions	  were	  
too	  harsh	  for	  this	  group	  and	  caused	  its	  removal.	  
This	   new	   series	   based	   on	   RCZ12	   and	   RCZ20	   structural	   features	   was	   designed	   and	  
synthesised	   to	   obtain	   structure-­‐activity	   relationship	   data	   from	   the	   compound-­‐EspD	  
interaction	  and	  it	  will	  be	  tested	  in	  the	  near	  future.	  The	  various	  substituents	  installed	  on	  the	  
left-­‐hand	  side	  of	  the	  molecule	  will	  provide	  new	  information	  of	  the	  intracellular	  interaction	  
with	   EspD	   and	   their	   different	   chemical	   nature	   will	   evaluate	   which	   substituents	   is	   best-­‐
suited	  against	  EHEC	  T3SS.	  The	  series	  could	  also	  be	  evaluated	  against	  the	  truncated-­‐EspD-­‐
HA	   strains	   to	   assess	   if	   a	   change	   in	   substituents	   or	   structure	   on	   the	   ring	   A	   affects	   the	  
interaction	   site	   affinity.	   The	   biological	   evaluation	   of	   this	   series	   will	   provide	   essential	  
information	  on	  the	  structure-­‐activity	  relationship	  between	  RCZ12/RCZ20-­‐EspD	  interaction	  
and	  its	  influence	  on	  the	  T3SS	  apparatus.	  




10	  [1,2,4]-­‐Triazolo[4,3-­‐b]pyridazine	  (TZP)	  Derivatives	  
10.1	  Design	  and	  rationale	  of	  the	  TZP	  core	  
The	   inclusion	  of	   the	  hydrazide	  moiety	   in	   a	   hydrazine-­‐containing	   heterocycle	   such	   as	   the	  
THP	  and	   the	  DHP	  cores	   yielded	   stable	  and	  effective	  SA	   compounds	  derivatives.	   The	  THP	  
and	   DHP	   derivatives	   resulted	   to	   be	   chemically	   more	   stable	   than	   the	   lead	   compound	  
ME0055	   and	   also	   showed	   a	   more	   selective	   effect	   on	   EHEC	   T3SS	   with	   no	   impact	   on	  
bacterial	   growth,	   even	   at	   higher	   concentrations.	   In	   particular,	   RCZ12	   and	   RCZ20	  
demonstrated	   a	   significant	   activity	   on	   the	   secretion	   of	   EspD,	   which	   caused	   intracellular	  
retention	  of	  the	  virulence	  protein.	  A	  total	  inhibition	  of	  secretion	  was	  detected	  at	  200	  µM,	  
which	  proved	  to	  be	  the	  ideal	  concentrations	  for	  these	  compounds	  to	  block	  the	  assembly	  of	  
the	  T3SS	  and	   the	   consequent	   colonisation.	  A	   significant	  down-­‐regulation	  of	   T3SS-­‐related	  
genes	  was	  also	  detected	  and,	  in	  particular,	  Tir	  expression	  and	  secretion	  was	  found	  greatly	  
reduced.	  The	  intracellular	  interaction	  between	  our	  derivatives	  and	  EspD	  was	  highlighted	  by	  
pull-­‐down	   analyses	   and	   confirmed	   by	   western	   blot	   using	   truncated-­‐EspD-­‐HA	   producing	  
strains.	   Although	  both	  RCZ12	   and	  RCZ20	  displayed	   an	   improved	   chemical	   stability	   and	   a	  
promising	   activity	   as	   anti-­‐virulence	   compounds	   against	  E.	   coli	   O157	   TUV	   93-­‐0,	   they	   also	  
showed	  poor	  solubility	  when	  diluted	  in	  biological	  media	  for	  binding	  assay	  techniques	  such	  
as	  MST	  and	  SPR,	  precipitating	  at	  high	  concentrations.	   ITC	  and	  NMR	  binding	  experiments	  
were	   considered	   but	   not	   attempted	   due	   to	   this	   issue;	   although	   it	   should	   be	   noted	   that	  
NMR	   chemical	   shift	   provided	   successful	   for	   investigating	   the	   interaction	   of	   the	   SA	  
compounds	  with	  putative	  target	  proteins	  125.	  
	  
Fig.	  37:	  Design	  of	  the	  TZP	  core:	  To	  improve	  the	  solubility	  of	  our	  compounds,	  it	  was	  decided	  to	  replace	  the	  sulphonyl	  
motif	  of	  RCZ12	  with	  a	   [1,2,4]-­‐triazolo[4,3-­‐b]pyridazine	   (TZP)	   ring.	  The	  hydrazine	  moiety	   (highlighted	   in	  red)	   has	  been	  
retained	  throughout	  both	  modifications	  (THP	  and	  TZP).	  The	  additional	  six-­‐membered	  ring	  (blue),	  introduced	  in	  the	  THP	  
scaffold,	  has	  been	  flattened	  by	  the	  new	  aromatic	  ring	  system	  TZP.	  The	  sulphonyl	  feature	  (green),	  which	  demonstrated	  
to	  be	  essential	  for	  a	  significant	  activity,	  has	  been	  replaced	  by	  the	  triazole	  ring	  of	  the	  TZP	  core,	  preserving	  the	  hydrogen	  




To	   improve	  the	  solubility	  of	  our	  candidates,	   it	  was	  decided	  to	   further	  modify	   the	  central	  
core	   of	   the	   structure	   of	   our	   hydrazine-­‐containing	   heterocycles	   (Fig.	   37).	   [1,2,4]-­‐
Triazolo[4,3-­‐b]pyridazines	   (TZP)	   are	  well-­‐known	  biologically	   active	   heterocycles	   and	  have	  
been	   employed	   in	   the	   last	   decades	   in	   modern	   medicinal	   chemistry	   as	   successful	  
bioisosteres	   for	   anti-­‐tumoral	   and	   sedative	   activity	   167–169.	   It	   was	   opted	   to	   replace	   the	  
sulphonyl	  motif	  of	  RCZ12	  with	  a	  TZP	  core	  in	  order	  to	  lower	  the	  lipophilicity	  of	  our	  scaffold.	  
This	  ortho-­‐fused	  ring	  system	  is	  more	  than	  optimal	  to	  enhance	  the	  hydrophilic	  nature	  of	  our	  
candidate	   due	   to	   the	   high	   number	   of	   nitrogen,	   which	   provide	   interactions	   with	   protic	  
solvents	   through	   hydrogen	   bonding.	   At	   the	   same	   time,	   the	   triazole	   ring	   mimics	   the	  
geometric	   features	   of	   the	   sulphonyl	   group,	   which	   proved	   to	   be	   relevant	   for	   a	   marked	  
activity	   in	  our	   first	  biological	  evaluation	   (Paragraph	  7.3.2).	  The	  TZP	  core	  also	   flattens	   the	  
original	   THP	   scaffold,	   since	   a	   fully	   aromatic	   ring	   system	   is	   introduced,	   leading	   to	   new	  
potential	  pi-­‐stacking	   interactions	  with	  EspD.	  All	   substituents	  on	   the	   left	   and	   right	  phenyl	  
rings	  were	  retained,	  as	  in	  our	  previous	  modifications,	  in	  order	  to	  have	  a	  direct	  comparison	  
between	  the	  candidates’	  effects.	  Only	  the	  RCZ12	  TZP	  analogue	  was	  firstly	  designed,	  while	  
the	  RCZ20	  analogue	  was	  not	   considered,	  as	  an	  additional	  phenyl	   ring	  could	   increase	   the	  
lipophilicity	  and	  bulk	  of	  the	  scaffold.	  
	  
10.2	  Synthesis	  of	  the	  TZP	  derivative	  
The	  synthesis	  of	  the	  TZP	  derivative	  started	  from	  the	  previously	  afforded	  3-­‐chloropyridazine	  
intermediate	   26	   (Paragraph	   8.3),	   which	   underwent	   condensation	   with	   4-­‐
nitrobenzhydrazide	  in	  refluxing	  n-­‐butanol	  170	  (Fig.	  38).	  
Fig.	  38:	  Synthetic	  route	  for	  the	  TZP	  derivative:	  Starting	  from	  intermediate	  26,	  previously	  obtained	  for	  the	  synthesis	  of	  
RCZ12,	   adduct	   50	   was	   obtained	   by	   means	   of	   condensation	   with	   4-­‐nitrobenzhydrazide	   in	   refluxing	   n-­‐butanol.	   The	  
protected	   TZP	   derivative	  underwent	   iso-­‐propyl	   de-­‐protection	   in	   the	   presence	  of	   aluminium	   trichloride	   to	   yield	   the	  




The	   protected	   [1,2,4]-­‐triazolo[4,3-­‐b]pyridazine	   adduct	   50,	   thus	   obtained,	   was	   easily	   de-­‐
protected	  with	   aluminium	   trichloride	   to	   yield	   the	   desired	   TZP	   analogue	   RCZ57	   in	   only	   2	  
steps.	  
	  	  
10.3	  Biological	  evaluation	  of	  RCZ57	  
The	  biological	  evaluation	  of	  RCZ57	  was	  firstly	  compared	  against	  the	  SA	  compound	  ME0055	  
and	  it	  followed	  our	  previous	  experimental	  procedures	  used	  for	  the	  assessment	  of	  the	  THP	  
and	   DHP	   derivatives.	   The	   target	   concentration	   of	   200	   µM	   was	   chosen	   for	   all	   the	  
preliminary	  tests,	  since	  RCZ12	  and	  RCZ20	  displayed	  an	  ideal	  inhibitory	  effect	  against	  T3SS	  
at	  this	  concentration	  without	  affecting	  any	  other	  essential	  bacterial	  pathway	  or	  growth.	  
	  
10.3.1	  Bacterial	  growth	  
E.	   coli	   O157	   TUV	   93-­‐0	  was	   cultured	   in	   the	   presence	   of	   RCZ57	   in	   order	   to	   evaluate	   any	  
unwanted	  effects	  of	  the	  new	  candidate	  on	  the	  bacterial	  growth,	  as	  performed	  before	  for	  
the	  THP	  and	  DHP	  derivatives.	  Optical	  density	  (OD600)	  was	  calculated	  hourly	  by	  means	  of	  a	  
refractometer	   and	   the	   growth	   curve	  was	   then	   interpolated	   accordingly	  with	   the	  desired	  
time-­‐point	  (Fig.	  39).	  
Fig.	   39:	   Bacterial	   growth	   evaluation:	   Bacterial	   growth	   curves	   at	   200	   µM	   are	   represented	   in	   the	   graph	   on	   the	   left.	  
Standard	  deviation	   from	  the	  mean	  of	  each	  time	  point	   is	  shown	  by	  error	  bars.	  The	  curves	   thus	  obtained	  were	   analysed	  
through	   linear	   regression	   interpolated	   with	   a	   determined	   time	   value	   (6	   hours).	   Interpolated	   OD600	   mean	   values	   are	  
represented	  in	  the	  graph	  on	  the	  right.	  Standard	  deviation	  from	  the	  mean	  is	  shown	  by	  error	  bars.	  OD600	  values	  of	  treated	  
samples	   were	   compared	   to	   the	   control	   sample	   (WT)	   by	   Student’s	   t-­‐test	   for	   statistical	   significance	   (P	   value	   <	   0.05).	  
Significant	   samples	   are	   indicated	   by	   an	   asterisk.	   ME0055	   bacterial	   growth	   inhibition	   resulted	   to	   be	   very	   statistically	  





As	   shown	  before,	  ME0055	  affected	   the	  bacterial	   growth	   rate	  at	   a	  high	   concentration	  by	  
2.5-­‐fold.	  RCZ57	  did	  not	  display	  any	  effects	  on	  E.	  coli	  O157	  growth,	  demonstrating	  to	  be	  a	  
suitable	  molecule	  for	  further	  biological	  evaluation.	  
	  
10.3.2	  RCZ57	  vs.	  ME0055	  
RCZ12	   and	   RCZ20	   showed	   to	   inhibit	   the	   secretion	   of	   EspD,	   causing	  withholding	   of	   such	  
virulence	   protein	   inside	   the	   bacterial	   cytosol,	   and	   to	   down-­‐regulate	   Tir	   expression	   and	  
secretion	  at	  200	  µM.	  Since	  these	  effects	  are	  essential	   for	   the	  activity	   for	  our	  derivatives,	  
Western	  blot	  experiments	  were	  carried	  out	  to	  evaluate	  RCZ57	  influence	  on	  the	  expression	  
and	   secretion	   of	   T3SS	   proteins.	   ME0055	   was	   firstly	   taken	   as	   a	   reference	   for	   direct	  
comparison	  (Fig.	  40).	  
	  
At	   200	   µM,	   ME0055	   demonstrated	   to	   totally	   inhibit	   EspD	   secretion,	   as	   expected,	   and	  
RCZ57	  encouragingly	  displayed	  a	  similar	  activity	  with	  a	  25-­‐fold	  reduction	  of	  EspD	  protein	  
secretion.	  The	  phenotype	  of	  EspD	  retention	  inside	  the	  bacterial	  cells	  by	  RCZ12	  and	  RCZ20	  
was	  also	  observed	  for	  RCZ57,	  while	  a	  total	  lack	  of	  such	  virulence	  protein	  was	  registered	  for	  
Fig.	  40:	  α-­‐EspD,	  α-­‐Tir	  and	  α-­‐GroeL	  Western	  blot	  for	  ME0055	  and	  RCZ57	  at	  200	  µM	  (left)	  and	  α-­‐EspD	  Western	  blot	  
with	   decreasing	   concentrations	   of	   RCZ57	   (right):	   Western	   blot	   analysis	   were	   carried	   out	   according	   to	   standard	  
procedure	   (see	   Experimental	   Part	   for	  methods	   and	  Ab	  dilutions).	   Both	   supernatant	   proteins	   (S/N)	   and	  whole	   cell	  
lysate	  solution	   (W/C)	  were	   analysed	   in	  repeats	  of	   three	   independent	  experiments.	  RCZ57	  demonstrated	  to	   inhibit	  
EspD	   secretion	   with	   consequent	   retention	   of	   such	   protein	   inside	   the	   cell,	   while	   Tir	   secretion	   was	   not	   affected.	  
Interestingly,	  our	  new	  TZP	  derivative	  did	  not	  influence	  other	  T3SS	  proteins,	  such	  as	  Tir,	  like	  RCZ12	  and	  RCZ20	  at	  200	  
µM.	  Withholding	  of	  EspD	  was	  also	  found	  to	  be	  well-­‐marked,	  indicating	  accumulation	  of	  the	  protein	  into	  the	  cytosol.	  
Decreasing	   concentrations	   of	   RCZ57	   showed	   a	   concentration-­‐dependant	   effect	   on	   EspD	   secretion	   similar	   to	   the	  
observed	  activity	  of	  RCZ12	  and	  RCZ20.	  In	  this	  case,	  RCZ57	  proved	  to	  very	  potent	  against	  the	  virulence	  protein	  even	  
at	  100	  µM,	  reducing	  its	  secretion	  by	  20-­‐fold.	  Weak	  activity	  was	  detected	  at	  50	  and	  25	  µM,	  while	  the	  new	  compound	  




ME0055.	  Intracellular	  accumulation	  of	  EspD	  was	  also	  very	  clear	  for	  RCZ57,	  consistent	  with	  
a	  retention	  of	  the	  protein	  into	  the	  cytosol.	  Tir	  secretion	  was	  also	  assessed	  by	  western	  blot	  
in	  order	  to	  evaluate	  the	  selectivity	  of	  RCZ57	  with	  other	  T3SS	  protein	  of	   interest.	  ME0055	  
showed	  strong	  inhibition	  of	  Tir	  secretion,	  while	  our	  TZP	  derivative	  did	  not	  affect	  secretion	  
of	  this	  protein.	  This	  result	  differed	  from	  what	  observed	  for	  RCZ12	  and	  RCZ20	  at	  200	  µM,	  as	  
the	  two	  derivatives	  inhibited	  both	  Tir	  secretion	  at	  high	  concentration.	  GroEL	  analyses	  were	  
carried	  out	  as	  an	  experimental	  reference	  to	  confirm	  the	  selectivity	  of	  our	  new	  candidate.	  
Bacteria	   were	   treated	   with	   decreasing	   concentrations	   of	   RCZ57	   and	   immunoblotted	  
against	  GroEL	   to	  confirm	  the	  effect	  on	  EspD	  secretion.	  Total	   inhibition	  of	  EspD	  secretion	  
was	   observed	   at	   200	   µM,	   as	   previously	   evaluated.	   RCZ57	   demonstrated	   to	   block	   the	  
secretion	  significantly	  also	  at	  100	  µM	  (20-­‐fold),	  while	  the	  molecule	  only	  had	  a	  very	  weak	  
effect	  at	  50	  µM	  (2-­‐fold)	  and	  25	  µM	  (1.5-­‐fold).	  The	  new	  compound	  was	  found	  to	  be	  inactive	  
against	  EspD	  secretion	  at	  10	  µM.	  As	  previously	  reported	  for	  our	  THP	  and	  DHP	  derivatives,	  
the	  new	  TZP	  compound	  showed	  a	  concentration-­‐dependent	  effect	  on	  EspD	  secretion.	  
	  
10.3.3	  RCZ57	  vs.	  RCZ12	  
RCZ57	   demonstrated	   to	   have	   a	   similar	   selective	   activity	   against	   EspD	   as	   previously	  
reported	  for	  RCZ12	  and	  RCZ20	  beside	  its	  effect	  on	  Tir	  secretion.	  To	  directly	  compare	  our	  
new	  candidate	  with	   the	  THP	  derivative,	  western	  blot	  analyses	  were	  also	  performed	  with	  
RCZ12	  and	  RCZ57	  at	  200	  µM	  to	  compare	  the	  ability	  of	  blocking	  EHEC	  T3SS	  apparatus	  (Fig.	  
41).	   As	   expected,	   both	   candidates	   showed	   a	   strong	   inhibition	   (approximately	   25-­‐fold	  
reduction)	   of	   the	   virulence	   protein	   EspD,	   with	   the	   characteristic	   retention	   inside	   the	  
bacterial	  cell.	  In	  this	  case,	  RCZ57	  displayed	  a	  marked	  accumulation	  of	  this	  protein	  with	  an	  
EspD	  concentration	  2-­‐fold	  higher	  than	  the	  untreated	  wild	  type.	  As	  mentioned	  before,	  the	  
new	  TZP	  derivative	  did	  not	  affect	  Tir	  secretion,	  while	  RCZ12	  exhibited	  a	  total	  inhibition	  of	  
such	  protein	  secretion.	  Tir	  expression	  was	  also	  normal	  for	  RCZ57,	  while	  the	  THP	  compound	  
down-­‐regulated	  the	  transcription	  as	  previously	  observed	  (Paragraph	  7.3.5).	  The	  structural	  
modification	  applied	  to	  the	  TZP	  compound	  seemed	  to	  have	  improved	  the	  selectivity	  of	  the	  
inhibitory	   effect	   on	   EspD,	   while	   reducing	   the	   transcriptional	   influence	   on	   T3SS-­‐related	  
genes.	   In	   addition,	   RCZ57	   demonstrated	   to	   cause	   a	   well-­‐marked	   accumulation	   of	   EspD	  




secretion	   still	   remained	   similar	   to	   RCZ12	   and	   RCZ20	   and,	   therefore,	   RCZ57	   can	   be	  
considered	  an	  excellent	  derivative	  with	  enhanced	  solubility	  in	  biological	  media.	  	  
	  
10.3.4	  Transcriptional	  effects	  of	  RCZ57	  
The	  effects	  of	  our	  new	  promising	  derivative	  on	  T3SS	  gene	  expression	  were	  also	  evaluated	  
through	   a	   GFP	   reporter	   fusion	   assay,	   as	   previously	   performed	   for	   the	   THP	   and	   DHP	  
compounds	   (Fig.	   42).	   LEE1:gfp	   and	   rpsM:gfp	   were	   used	   in	   order	   to	   assess	   the	   global	  
influence	   of	   RCZ57	   on	   T3SS-­‐related	   and	   non	   T3SS-­‐related	   genes	   transcription.	   It	   was	  
already	  highlighted	  by	  the	  western	  blot	  results	  that	  RCZ57	  did	  not	  affect	  Tir	  expression	  at	  
200	   µM;	   therefore,	   it	  was	   opted	   to	   test	   the	   new	   compound	   against	   LEE1	   to	   confirm	   its	  
selectivity.	   As	   previously	   shown,	   ME0055	   demonstrated	   to	   significantly	   down-­‐regulate	  
both	  rpsM	  and	  LEE1	  promoter	  activity	  at	  200	  µM.	  RCZ57	  did	  not	  show	  significant	  activity	  
against	  the	  promoters	  of	  both	  genes,	  supporting	  the	  results	  shown	  in	  the	  previous	  western	  
blot.	   From	   these	  data,	   it	   seems	   that	   the	  effects	  of	  our	  new	  compound	  were	   focused	  on	  
EspD	  secretion	  at	  post-­‐transcriptional	  level,	  without	  any	  side-­‐effect	  on	  transcription.	  	  
	  
	  
Fig.	   41:	   α-­‐EspD,	   α-­‐Tir	   and	   α-­‐GroeL	  Western	   blot	   for	   RCZ12	   and	   RCZ57	   at	   200	   µM	   (left):	   Western	   blot	  
analysis	   were	   carried	   out	   according	   to	   standard	   procedure	   (see	   Experimental	   Part	   for	   methods	   and	   Ab	  
dilutions).	  Both	  supernatant	  proteins	  (S/N)	  and	  whole	  cell	  lysate	  solution	  (W/C)	  were	  analysed	  in	  repeats	  of	  
three	   independent	   experiments.	   RCZ57	   demonstrated	   to	   inhibit	   EspD	   secretion	   as	   RCZ12	   and	   to	  
accumulate	  such	  protein	   in	   a	  more	  marked	  way	  than	  the	  THP	  molecule.	  Tir	  expression	  and	  secretion	  was	  
found	   to	   be	   similar	   to	   the	   wild	   type	   when	   EHEC	   was	   treated	   with	   RCZ57,	   while	   RCZ12	   inhibit	   both	  
expression	  and	  secretion	  as	  previously	  observed.	  It	  seems	  that	  the	  structural	  modification	  applied	  to	  RCZ57	  






10.3.5	  Secreted	  protein	  profile	  
RCZ57	  exhibited	  a	  promising	   specific	  activity	  on	  EHEC	  T3SS	  similar	   to	  both	  THP	  and	  DHP	  
derivatives.	   Total	   inhibition	   of	   EspD	   secretion,	   with	   characteristic	   intracellular	  
accumulation,	  and	  no	   influence	  on	  Tir	   transcription	  were	  observed	  through	  western	  blot	  
and	   GFP	   reporter	   fusion	   assays.	   To	   complete	   the	   biological	   characterisation	   of	   our	   TZP	  
compound	   and	   investigate	   further	   its	   very	   specific	   effects	   on	   EspD,	   it	   was	   decided	   to	  
examine	   the	   secreted	   proteins	   profile	   by	   SDS-­‐PAGE	   electrophoresis.	   Once	   the	   secreted	  
proteins	  were	  denatured	  in	  SDS,	  the	  samples	  were	  run	  on	  a	  SDS-­‐PAGE	  gel	  and	  stained	  with	  
Coomassie	   Brilliant	   Blue	   (Fig.	   43).	   RCZ57	   showed	   a	   completely	   different	   protein	   profile	  
than	  the	  wild	  type.	  As	  expected,	  EspD	  (39	  kDa)	  was	  absent	  from	  the	  TZP	  compound	  profile,	  
but	   high	   concentrations	   of	   unusual	   protein	   bands	   were	   also	   visualised.	   Some	   of	   these	  
bands	  were	  removed	  and	  analysed	  by	  means	  of	  tandem	  mass	  spectrometry.	  Interestingly,	  
all	   the	   unfamiliar	   secreted	   proteins	   were	   classified	   as	   either	   outer	   membrane	   or	  
periplasmic	  proteins.	  Intimin	  (band	  number	  1),	  the	  outer	  membrane	  protein	  responsible	  of	  
intimate	  attachment	  to	  the	  host	  cell	   through	   Intimin-­‐Tir	   interactions	   171,	  was	  detected	   in	  
high	  amount	  in	  the	  secreted	  protein	  samples	  as	  well	  as	  the	  receptor	  for	  ferric	  enterobactin	  
Fig.	  42:	  rpsM:gfp	  and	   LEE1:gfp	   promoter	  activity	   at	  OD600	  =	  0.6	  with	  ME0055	  and	  RCZ57	   at	  200	  µM:	  
GFP-­‐reporter	   fusion	   assays	   analyses	   were	   carried	   out	   according	   to	   standard	   procedure	   (see	  
Experimental	   Part	   for	   methods).	   The	   promoter	   activity	   was	   measured	   for	   every	   sample	   plotting	  
fluorescence	   (RFU)	   against	   OD600.	   The	   curves	   thus	   obtained	   were	   analysed	   through	   linear	   regression	  
interpolated	  with	  a	  determined	  OD600	  value	  (0.6).	  Interpolated	  RFU	  mean	  values	  are	  represented	  in	  the	  
graphs	  above.	  Standard	  deviation	  from	  the	  mean	  is	  shown	  by	  error	  bars.	  RFU	  values	  of	  treated	  samples	  
were	  compared	  to	  the	  control	  sample	  (WT)	  by	  Student’s	  t-­‐test	  for	  statistical	  significance	  (P	  value	  <	  0.05).	  
Significant	  samples	  are	  indicated	  by	  an	  asterisk,	  very	  significant	  samples	  by	  two	  asterisks	  and	  extremely	  
significant	  samples	  by	  three	   asterisks.	  RCZ57	  did	  not	  show	  any	   significant	   influence	  on	  both	  rpsM	   and	  
LEE1	   transcription,	   supporting	   the	   Western	   blot	   findings,	   where	   our	   new	   compound	   was	   found	   to	  
selective	  inhibit	  EspD	  secretion,	  while	  no	  activity	  on	  Tir	  was	  detected.	  Unlike	  RCZ12,	  which	  also	  inhibited	  




and	  colicins	  B	  and	  D	  (band	  number	  2),	  which	  is	  usually	  located	  in	  the	  outer	  membrane	  to	  
allow	  the	  transport	  of	  enterobactin	  and	  colicins	  172.	  The	  outer	  membrane	  protein	  C,	  known	  
as	  OmpC	  (band	  number	  3),	  was	  also	  detected	  in	  the	  samples.	  OmpC	  is	  one	  of	  the	  main	  E.	  
coli	   porins	   together	   with	   OmpF	   and	   regulates	   the	   passive	   diffusion	   of	   nutrients	   and	  
antibiotics	  173–175.	  
	  
As	   the	   name	   infers,	   even	   this	   protein	   is	   always	   located	   in	   the	   outer	  membrane	   and	   its	  
presence	   in	   the	   secreted	   protein	   samples	   is	   rather	   unusual.	   In	   addition,	   OmpC	   is	   a	   key	  
protein	  for	  traditional	  antibiotics	  diffusion	  and	  it	  has	  been	  demonstrated	  that	  a	  lack	  of	  this	  
porin	   is	   one	   of	   the	  main	  mechanism	   for	   the	   development	   of	   resistance	   176	   and	   also	   for	  
enhancing	   the	   bacterium’s	   sensitivity	   to	   acidic	   environments	   177.	   	   The	   lysine-­‐arginine-­‐
ornithine	   binding	   protein	   (band	   number	   4)	   was	   also	   identified	   in	   the	   secreted	   protein	  
Fig.	   43:	   SDS-­‐PAGE	   electrophoresis	   of	   secreted	   proteins	   (left)	   and	   the	   list	   of	   identified	   proteins	   by	   tandem	   mass	  
spectrometry	  (right):	  Many	  unusual	  protein	  bands	  were	  visualised	  by	  SDS-­‐PAGE	  electrophoresis	  when	  E.coli	  was	  treated	  
with	  RCZ57	  at	  200	  μM.	  The	  most	  concentrated	  bands	  were	  excised	  and	  analysed	  by	  tandem	  mass-­‐spectrometry	  to	  reveal	  
the	   identity	   of	   4	   outer	  membranes	  proteins.	   This	  membrane	  protein	   shedding	  outside	   the	   cell	   can	  be	   linked	   to	   either	  
vesicles	  formation	  or	  key	  changing	  in	  bacterial	  permeability.	  It	  is	  possible	  that	  RCZ57	  might	  bind	  to	  various	  permeability	  
regulators,	   inducing	  porins	   over-­‐expression	   and,	   therefore,	   enhancing	   the	   bacterium’s	   permeability.	   Cell	   lysis	  was	  not	  
included	  as	  a	  hypothesis	  as	  RCZ57	  did	  not	  inhibit	  bacterial	  growth.	  A	  list	  of	  the	  4	  outer	  membrane	  proteins	  visualised	  in	  
the	  secreted	  protein	  samples.	  Protein	  Genbank	  ID,	  MOWSE	  score,	  number	  of	  peptides	  matched	  and	  gene	  of	  origin	  are	  
listed	   in	   the	   table.	   All	   the	   entries	   were	   identified	   as	   either	   outer	  membrane	   or	   periplasmic	   proteins,	   which	   is	   rather	  





samples,	   a	   portion	   of	   an	   ABC	   amino	   acids	   transporter,	   which	   is	   usually	   located	   in	   the	  
periplasmic	  space	  between	  inner	  and	  outer	  membrane	  in	  the	  bacterium	  178,179.	  These	  are	  
just	  some	  of	  the	  most	  abundant	  protein	  bands	  detected	  from	  the	  RCZ57	  treatment,	  but	  it	  
is	  clear	  that	  many	  other	  outer	  membrane	  and	  periplasmic	  proteins	  were	  released	  into	  the	  
media	   from	   the	   bacterial	   membrane,	   since	   the	   two	   secreted	   proteins	   profile	   did	   not	  
match.	  It	  can	  be	  postulated	  that	  high	  concentrations	  of	  RCZ57	  might	  cause	  the	  formation	  
and	   release	   of	   vesicles	   thereby	   resulting	   on	   the	   detection	   of	   the	   membrane	   proteins	  
outside	   the	   cell.	   Modification	   of	   the	   bacterium’s	   membrane	   permeability	   can	   also	   be	  
associated	  with	  high	  concentrations	  of	  RCZ57,	  which	  can	  bind	  or	  interfere	  with	  regulators	  
associated	   with	   osmotic	   control,	   EnvZ/OmpR,	   causing	   over-­‐expression	   of	   porins	   and,	  
therefore,	   shedding	   of	   proteins	   in	   the	   secretion	  media	   180,181.	   Cell	   lysis	   can,	   instead,	   be	  
ruled	  out,	  since	  RCZ57	  does	  not	  affect	  bacterial	  growth	  at	  200	  μM,	  as	  lysis	  is	  always	  linked	  
to	  growth	  inhibition.	  	  	  
	  
10.3.6	  Transmission	  electron	  microscopy	  (TEM)	  analysis	  
The	  unusual	  shedding	  of	  outer	  membrane	  proteins	  was	  observed	  from	  the	  SDS-­‐PAGE	  gel,	  
when	  E.	  coli	  O157	  TUV	  93-­‐0	  was	  treated	  with	  RCZ57	  at	  200	  μM.	  To	  further	  investigate	  this	  
effect,	   it	  was	   decided	   to	   analyse	   the	   bacterial	  membrane	   through	   transmission	   electron	  
microscopy	  (TEM).	  Bacteria	  were	  treated	  with	  our	  TZP	  compound	  and	  untreated	  TUV	  93-­‐0	  
was	  employed	  as	  the	  negative	  control.	  Bacterial	  sections	  were	  analysed	  and	  resulted	  that	  
RCZ57	  did	  not	  cause	  any	  vesicle	   formation	  or	  perturbation	  of	   the	  membranes,	  excluding	  
the	  possibility	  of	  vesicle	  formation	  by	  high	  concentrations	  of	  the	  compound	  (see	  Appendix,	  
Fig.	   51).	   TEM	   analyses	   were	   also	   used	   to	   assess	   the	   ability	   of	   RCZ57	   to	   block	   the	   EspA	  
filament	  formation,	  as	  performed	  for	  RCZ12	  and	  RCZ20	  (Paragraph	  7.3.7).	  RCZ12	  was	  used	  
as	  a	  direct	  comparison.	  RCZ57	   inhibited	  the	  formation	  of	  the	  EspA	  filaments	  by	  5-­‐fold	  as	  
well	  as	   the	  THP	  derivative.	  This	   result	   suggested	   that	   the	  TZP	  compound	  might	  have	   the	  





10.3.7	  Metabolomics	  analysis	  for	  RCZ57	  
RCZ57	  displayed	  a	  similar	  activity	  profile	  to	  RCZ12	  on	  EspD	  at	  200	  μM.	  The	  new	  compound	  
also	   did	   not	   show	   any	   transcriptional	   effects,	   unlike	   the	   THP	   derivative	   which	   down-­‐
regulated	   T3SS-­‐realted	   genes.	   After	   these	   biological	   evaluation,	  we	   assumed	   that	   RCZ57	  
mechanism	   of	   action	  might	   be	   analogous	   to	   both	   RCZ12	   and	   RCZ20;	   therefore,	   the	   TZP	  
compound	  might	  directly	  bind	  to	  EspD	  to	  block	  its	  correct	  secretion.	  It	  was	  then	  opted	  to	  
perform	  the	  previous	  metabolomics	  analysis	  (Paragraph	  8.5)	  to	  confirm	  RCZ57	  uptake	  by	  E.	  
coli	  O157	  TUV	  93-­‐0	  (Table	  10).	  Even	  in	  this	  case,	  high	  concentrations	  of	  the	  molecule	  were	  
found	  inside	  the	  cell	  pellets,	  clearly	  showing	  bacterial	  membrane	  crossing	  and	  supporting	  




Fig.	  44:	   TEM	   images	   of	   EspA	   filaments	   with	   RCZ57:	   Bacteria	   were	   grown	   in	   T3SS-­‐inducing	  media	   and	   immobilised	   in	  
paraformaldehyde.	  Before	  exposure	  on	  the	  microscope,	  the	  samples	  were	  incubated	  with	  a	  α-­‐EspA	  primary	  antibody	  and	  
then	   with	   the	   corresponding	   secondary	   antibody	   conjugated	   with	   gold	   nanoparticle.	   The	   black	   dots	   on	   the	   images	  
represents	  the	  gold	  particle,	  which	  specifically	  identify	  EspA.	  RCZ12	  and	  RCZ57	  demonstrated	  to	  reduce	  the	  correct	  EspA	  




Entry	   Experimental	  Blank	   Supernatant	   Bacterial	  pellets	  
RCZ57	   0	   1.14*107	  ±	  2.14*106	   3.73*109	  ±	  5.76*108	  
	  
Table	   10:	  Metabolomics	   data	   for	   RCZ12	   and	   RCZ20	   cellular	   uptake:	   Average	   intensities	   of	   RCZ57	   and	   corresponding	  
standard	   deviation	   in	   Supernatant	   and	   Bacterial	   pellets	   samples	   are	   represented	   in	   the	   table	   above.	   Experimental	  
triplicates	  were	  prepared	  and	  analysed	  through	  hydrophilic	  interaction	  liquid	  chromatography	  (HILIC).	  A	  three	  magnitude	  
increase	  of	  the	  compounds’	  concentration	  was	  registered	  for	  the	  Bacterial	  pellets	  samples,	  indicating	  a	  cellular	  uptake	  of	  
both	  drugs	  inside	  the	  bacteria.	  This	  confirms	  that	  also	  RCZ57	  is	  taken	  up	  by	  the	  bacteria.	  
	  
10.4	  Synthesis	  of	  RCZ57	  modular	  derivatives	  
RCZ57	  was	  found	  to	  be	  selectively	  active	  against	  EspD	  secretion,	  as	  RCZ12	  and	  RCZ20,	  with	  
no	   significant	   transcriptional	   effect	   on	   T3SS-­‐related	   genes.	   The	   new	   TZP	   derivative	  
exhibited	  a	  strong	  inhibition	  of	  secretion	  (20-­‐	  to	  25-­‐fold)	  at	  both	  200	  and	  100	  µM	  with	  an	  
obvious	   accumulation	   of	   the	   protein	   into	   the	   bacterial	   cytosol.	  No	   significant	   effect	  was	  
observed	   on	   bacterial	   growth,	   other	   T3SS	   proteins	   of	   interests	   or	   essential	   cellular	  
pathway.	   Due	   to	   these	   promising	   data,	   it	   was	   planned	   to	   synthesise	   few	   modular	  
derivatives	  to	  investigate	  the	  structure-­‐activity	  relationship	  of	  our	  new	  active	  compound.	  
	  
Fig.	   45:	   Structural	   design	   of	   RCZ57	   modular	   derivatives:	   Ring	   A,	   B	   and	   C	   were	   selected	   as	   RCZ57	   essential	   features	   for	  
modular	  modifications.	  Firstly,	  the	  nitro	  group	  on	  ring	  A	  (red)	  was	  removed	  to	  investigate	  the	  activity	  of	  the	  compound	  with	  
no	  substituents	  on	  the	  right-­‐hand	  side	  of	  the	  molecule	  (RCZ58).	  An	  ortho-­‐fused	  ring	  system	  was	  then	  introduced	  into	  RCZ57	  
central	   ring	   C	   (green)	   to	   evaluate	   the	   bulk	   of	   this	   conjugated	   aromatic	   system	   and	   also	   the	   effects	   on	   solubility	   (RCZ59).	  
Lastly,	  synthetic	  intermediate	  41	  was	  also	  employed	  in	  this	  modular	  series	  to	  assess	  the	  relevance	  of	  the	  two	  hydroxyl	  groups	  
on	   ring	  B	   (blue)	   (RCZ60).	   In	   this	   case,	   the	   two	   iso-­‐propyl	   groups	   eliminate	   the	   hydrogen	   bond	  acceptor	   properties	   of	   the	  




Three	  different	  structural	   features	  of	  RCZ57	  were	  selected:	   the	  nitro-­‐bearing	  phenyl	   ring	  
(Fig.	  45,	  Ring	  A,	  red),	  the	  hydroxyl-­‐bearing	  phenyl	  ring	  (Fig.	  45,	  Ring	  B,	  blue)	  and	  the	  central	  
pyridazine	  ring	  (Fig.	  45,	  Ring	  C,	  green).	  
	  
Since	   the	   hydroxyl	   groups	   were	   previously	   found	   to	   be	   essential	   for	   RCZ12	   and	   RCZ20	  
activity,	   it	   was	   firstly	   decided	   to	   use	   the	   iso-­‐propyl	   protected	   intermediate	   50	   as	   a	  
modification	   of	   ring	   B	   (RCZ60)	   to	   evaluate	   the	   two	   hydroxyl	   groups	   relevance	   in	   the	  
inhibitory	   effect.	   The	  nitro	   group	  on	   ring	  A	  was	   then	   removed	   to	   investigate	   the	   lack	  of	  
substituents	   on	   the	   right-­‐hand	   side	   of	   the	  molecule	   (RCZ58)	   and	   to	   lower	   the	   electron-­‐
withdrawing	   effect	   of	   the	   nitro	   group	   on	   the	   whole	   structure.	   Finally,	   an	   ortho-­‐fused	  
phenyl	   ring	   was	   added	   to	   ring	   C	   to	   create	   the	   direct	   TZP	   derivative	   of	   RCZ20	   (RCZ59),	  
introducing	  more	  bulk	  to	  the	  structure	  and	  decreasing	  the	  hydrophilicity	  of	  the	  compound.	  
	  
RCZ58	  synthesis	  started	  from	  the	  previously	  obtained	  intermediate	  26,	  which	  reacted	  with	  
benzhydrazide	   in	  refluxing	  n-­‐butanol	  to	  afford	   intermediate	  51	   in	  good	  yield	  170	   (Fig.	  46).	  
The	  adduct,	  thus	  obtained,	  was	  then	  treated	  with	  aluminium	  trichloride	  to	  yield	  RCZ58	  in	  
only	  2	  steps	  from	  intermediate	  26.	  RCZ59	  synthesis	  was	  performed	  in	  a	  similar	  way	  starting	  
from	  intermediate	  33,	  obtained	  for	  the	  alternative	  synthesis	  of	  RCZ20	  (see	  Paragraph	  8.3)	  
(Fig.	  47).	  The	  chloro-­‐pyridazine	  33	  underwent	  condensation	  with	  4-­‐nitrobenzhydrazide	   in	  
Fig.	   46:	   RCZ58	   synthesis:	   RCZ58	   synthesis	   follows	   our	   previous	   synthesis	   of	   RCZ57.	   In	   brief,	   intermediate	   26	  
underwent	   condensation	   with	   benzhydrazide	   to	   obtain	   adduct	   51,	   which	   was	   consequently	   de-­‐protected	   with	  
aluminium	  trichloride	  in	  good	  yield.	  
Fig.	  47:	  RCZ59	   synthesis:	   RCZ59	   synthesis	   follows	  our	  previous	   synthesis	   of	   RCZ57.	   In	   brief,	   intermediate	   33	  
underwent	  condensation	  with	  4-­‐nitrobenzhydrazide	  to	  obtain	  adduct	  52,	  which	  was	  consequently	  de-­‐protected	  





refluxing	  n-­‐butanol	  to	  obtain	  intermediate	  52,	  which	  was	  consequently	  de-­‐protected	  with	  
aluminium	  trichloride	  to	  yield	  the	  desired	  compound.	  
	  	  
10.5	  Biological	  evaluation	  of	  RCZ57	  modular	  derivatives	  
In	  order	  to	  overcome	  the	  solubility	  issues	  encountered	  during	  RCZ12	  and	  RCZ20	  biological	  
evaluation,	  it	  was	  planned	  to	  design	  and	  synthesise	  a	  new	  more	  hydrophilic	  T3SS	  inhibitor,	  
RCZ57.	  RCZ57	  showed	  a	   similar	  activity	   to	   the	  THP	  and	  DHP	  compounds,	   inhibiting	  EspD	  
secretion	  and	  increasing	  the	  concentration	  of	  the	  T3SS	  protein	  inside	  the	  bacterium	  at	  200	  
µM	  and	  in	  a	  concentration-­‐dependent	  manner.	  Modular	  derivatives	  of	  the	  TZP	  candidate	  
were	   generated	   to	   investigate	   the	   structure-­‐activity	   relationship	   of	   this	   new	   active	  
scaffold.	  
	  
10.5.1	  Bacterial	  growth	  
The	   ability	   of	   our	   modular	   analogues	   to	   interfere	   with	   the	   bacterial	   growth	   was	   firstly	  
evaluated	   at	   200	   µM	   as	   performed	   before	   with	   all	   our	   synthetic	   compounds	   (Fig.	   48).	  
RCZ57	  was	  taken	  as	  a	  reference.	  After	  6	  hours	  of	   incubation,	  none	  of	  our	  new	  molecules	  
significantly	  affected	  E.	  coli	  O157	  TUV	  93-­‐0	  growth	  rate,	  making	  them	  suitable	  candidates	  
for	  further	  testing.	  
	  
Fig.	   48:	   Bacterial	   growth	   evaluation:	   Bacterial	   growth	   curves	   at	   200	   µM	   are	   represented	   in	   the	   graph	   on	   the	   left.	  
Standard	  deviation	   from	  the	  mean	  of	  each	  time	  point	   is	  shown	  by	  error	  bars.	  The	  curves	   thus	  obtained	  were	   analysed	  
through	   linear	   regression	   interpolated	   with	   a	   determined	   time	   value	   (6	   hours).	   Interpolated	   OD600	   mean	   values	   are	  
represented	  in	  the	  graph	  on	  the	  right.	  Standard	  deviation	  from	  the	  mean	  is	  shown	  by	  error	  bars.	  OD600	  values	  of	  treated	  
samples	  were	   compared	   to	   the	   control	   sample	   (WT)	  by	   Student’s	   t-­‐test	   for	   statistical	   significance	   (P	  value	  <	   0.05).	  No	  





10.5.2	  Virulence	  protein	  secretion	  
RCZ57	   was	   found	   to	   inhibit	   EspD	   secretion	   significantly	   at	   200	   µM,	   while	   accumulating	  
such	  virulence	  protein	  inside	  the	  bacterial	  cells.	  In	  order	  to	  further	  investigate	  this	  mode	  of	  
action,	  all	  our	  modular	  derivatives	  were	  evaluated	  on	  their	  ability	  of	  blocking	  the	  secretion	  
of	   T3SS	   proteins	   by	   means	   of	   western	   blot	   experiments.	   EspD	   concentrations	   were	  
analysed	   in	  presence	  of	  our	  compounds	  at	  200	  µM	  both	  outside	  and	   inside	  the	  cell	   (Fig.	  
49).	  RCZ57	  displayed	  a	  total	  inhibition	  of	  EspD	  secretion	  (more	  than	  25-­‐fold	  inhibition)	  and	  
a	  2-­‐fold	  accumulation	  of	  the	  protein	  in	  the	  whole	  cell	  lysate,	  as	  previously	  obtained.	  RCZ58	  
showed	   a	  moderate	   inhibitory	   activity	   (10-­‐fold	   inhibition)	  with	   a	   slight	   increase	   of	   EspD	  
concentration	  inside	  the	  cell	  (1.2-­‐fold	  increase),	  while	  RCZ59	  demonstrated	  to	  have	  a	  very	  
weak	  activity	  (1.5-­‐fold	  reduction)	  and	  also	  a	  poor	  solubility	  in	  biological	  media.	  RCZ60	  did	  
not	  affect	  the	  virulence	  protein	  secretion	  or	  expression.	  Western	  blot	  analyses	  were	  also	  
performed	   for	   the	   translocated	   intimin	   receptor	   (Tir)	   in	  order	   to	  assess	   the	  selectivity	  of	  
our	   modular	   compounds	   in	   inhibiting	   only	   EspD	   secretion.	   RCZ57	   did	   not	   affect	   Tir	  
secretion,	   as	   evaluated	   before,	   even	   though	   a	   slight	   increased	   concentration	   of	   such	  
virulence	  protein	  was	  found	  outside	  the	  cells.	  Despite	  its	  poor	  solubility	  and	  weak	  effect	  on	  
EspD	  secretion,	  RCZ59	  proved	  to	  significantly	   increase	   (2-­‐fold)	  Tir	   secretion,	  while	  RCZ58	  
and	  RCZ60	  did	  not	  influence	  the	  secretion.	  The	  data	  highlighted	  the	  relevance	  of	  the	  two	  
hydroxyl	  groups	  in	  RCZ57	  activity,	  as	  RCZ60	  resulted	  to	  be	  completely	  inactive	  against	  EspD	  
secretion.	   RCZ59	   showed	   how	   modifications	   on	   the	   central	   ring	   C	   can	   influence	   the	  
solubility	  of	  the	  molecule	  and,	  therefore,	  its	  effect	  on	  EspD.	  Removal	  of	  the	  nitro	  group	  on	  
ring	  A	  (RCZ58)	  resulted	  in	  a	  compound	  with	  slightly	  attenuated	  activity	  probably	  due	  to	  the	  





10.5.3	  Structure-­‐activity	  relationship	  (SAR)	  
RCZ58,	   RCZ59	   and	   RCZ60	   were	   specifically	   designed	   and	   synthesise	   to	   evaluate	   RCZ57	  
preliminary	  structure-­‐activity	   relationship,	   in	  order	   to	  highlight	   the	  active	   features	  of	   the	  
molecule.	   Western	   blot	   experiments	   were	   carried	   out	   to	   assess	   the	   effect	   of	   the	   new	  
analogues	  on	  T3SS	  proteins	  of	  interest.	  In	  our	  previous	  biological	  tests,	  RCZ57	  displayed	  a	  
very	  strong	   inhibition	  of	  EspD	  secretion	  (more	  than	  25-­‐fold	   inhibition)	  at	  200	  µM	  and	  an	  
obvious	  accumulation	  (2-­‐fold)	  of	  the	  same	  protein	  inside	  the	  bacterial	  cytosol.	  No	  effect	  on	  
growth	   was	   detected	   against	   E.	   coli	   O157:H7	   and	   an	   interesting	   slight	   increase	   in	   Tir	  
secretion	  was	  also	  observed	  from	  the	  western	  blot	  analyses.	  
Removal	  of	  the	  nitro	  group	  on	  ring	  A	  (RCZ58)	  produced	  an	  active	  compound	  against	  EspD	  
secretion,	  which	   retained	   a	   good	   activity	   profile	   similar	   to	   RCZ57.	   A	   slight	   decrement	   in	  
potency	   was	   detected	   compared	   to	   RCZ57;	   probably,	   due	   to	   the	   lack	   of	   the	   strong	  
electron-­‐withdrawing	  effects	  induced	  by	  the	  nitro	  group.	  In	  addition,	  RCZ58	  did	  not	  affect	  
Tir	   secretion	   neither	   positively	   or	   negatively.	   These	   data	   suggest	   that	   ring	   A	  might	   be	   a	  
recognition	  site,	  which	  gives	  selectivity	  to	  the	  compound,	  but	  it	  is	  not	  directly	  involved	  in	  
the	  essential	  interactions.	  
Fig.	  49:	  α-­‐EspD	  α-­‐Tir	  and	  α-­‐GroEL	  Western	  blot	  for	  RCZ57	  modular	  derivatives	  RCZ58,	  RCZ59	  and	  RCZ60	  
at	   200	  μM:	  Western	  blot	   analysis	  were	   carried	  out	   according	   to	   standard	  procedure	   (see	   Experimental	  
Part	  for	  methods	  and	  Ab	  dilutions).	  Both	  supernatant	  proteins	  (S/N)	  and	  whole	  cell	  lysate	  solution	  (W/C)	  
were	   analysed	   in	   repeats	   of	   three	   independent	   experiments.	   RCZ58	   demonstrated	   to	   have	   a	   similar	  
activity	   to	  RCZ57,	   significantly	   reducing	   EspD	   secretion	   (10-­‐fold),	   while	   retaining	   such	   virulence	   protein	  
inside	   the	   cell.	   RCZ59	   had	   just	   a	   very	   weak	   effect	   on	   EspD	   secretion	   due	   to	   its	   very	   poor	   solubility	   in	  
biological	  media,	  while	  RCZ60	   resulted	   to	  be	   completely	   inactive,	   highlighting	   the	   relevance	  of	   the	   two	  




Introduction	  of	  an	  ortho-­‐fused	  phenyl	  ring	  on	  the	  pyridazine	  ring	  C	  (RCZ59)	  yielded	  a	  flat,	  
bulky	  and	  non-­‐polar	  RCZ57	  derivative,	  which	   resulted	   just	   slightly	   soluble	   in	   the	  western	  
blot	  biological	  media.	  Due	  to	  this	  solubility	  issue,	  RCZ59	  activity	  was	  limited	  to	  a	  very	  weak	  
effect	  on	  EspD	  secretion	  (1.5-­‐fold	  reduction)	  and	  considered	  partially	  reliable.	  Tir	  analysis	  
revealed	  an	  obvious	  increased	  concentration	  of	  the	  protein	  outside	  the	  bacterial	  cell	  than	  
RCZ57.	   The	   pyridazine	   ring	   C	   cannot	   be	   considered	   as	   an	   essential	   feature	   for	   the	   TZP	  
compound	  activity,	  but	  it	  surely	  plays	  a	  relevant	  role	  for	  the	  solubility	  in	  biological	  media.	  
Addition	   of	   bulky	   and	   lipophilic	   substituents	   resulted	   in	   a	   decreased	   solubility	   and,	  
therefore,	  in	  a	  barely	  active	  derivative.	  This	  site	  can	  be	  modified	  for	  achieving	  even	  more	  
hydrophilic	  versions	  of	  RCZ57	  without	  influencing	  the	  activity	  of	  the	  compound.	  
Alkylation	  of	  the	  two	  hydroxyl	  groups	  on	  ring	  B	  (RCZ60)	  resulted	   in	  a	  completely	   inactive	  
analogue.	  RCZ60	  did	  not	  affect	  EspD	  or	  Tir	  secretion.	  The	  data	  suggest	  that,	  whenever	  the	  
hydroxyl	  groups	  on	  ring	  B	  are	  unable	  of	  interacting	  through	  hydrogen	  bond,	  RCZ57	  loses	  its	  
activity	  against	  EspD	  secretion.	  Therefore,	  the	  hydroxyl	  groups	  are	  to	  be	  considered	  as	  the	  
active	  site	  of	  the	  molecule	  as	  their	  inability	  of	  accepting/donating	  hydrogen	  bonds	  resulted	  
in	  a	  total	  loss	  of	  activity.	  	  
	  
10.6	  Conclusions	  and	  future	  work	  
In	  order	  to	  overcome	  the	  solubility	   issues	  encountered	  during	  the	   investigation	  of	  RCZ12	  
and	  RCZ20	  mode	  of	  action,	  it	  was	  planned	  to	  modify	  the	  THP	  core	  with	  a	  new	  hydrazine-­‐
containing	   heterocycles.	   Due	   to	   its	   well-­‐known	   biological	   activity,	   a	   [1,2,4]-­‐triazolo[4,3-­‐
b]pyridazine	  (TZP)	  core	  was	  installed	  in	  the	  central	  part	  of	  the	  molecule	  to	  generate	  a	  new	  
TZP	   derivative	   (RCZ57).	   The	   synthesis	   of	   this	   new	   analogue	   started	   from	   the	   previously	  
obtained	  chloro-­‐pyridazine	  26	  and	  yielded	  the	  desired	  product	  in	  just	  2	  steps.	  RCZ57	  was	  
firstly	   tested	   against	   ME0055	   and	   then	   against	   RCZ12	   at	   200	   μM.	   The	   TZP	   compound	  
demonstrated	  to	  have	  the	  same	  activity	  against	  EspD	  secretion	  as	  RCZ12	  and	  to	  cause	  an	  
even	  more	  marked	   characteristic	   EspD	   accumulation	   inside	   the	   cell.	   The	   new	   derivative	  
also	  proved	   to	  be	  more	  potent	   than	  RCZ12,	  as	   it	  exhibited	  a	   strong	  20-­‐fold	   reduction	  of	  
EspD	   at	   100	   μM.	   In	   addition,	   RCZ57	   did	   not	   influence	   the	   transcription	   of	   T3SS-­‐related	  
genes,	   unlike	   observed	   for	   the	   THP	   compound	   at	   200	   μM.	   Interestingly,	   analysis	   of	   the	  
secreted	   protein	   profile	   revealed	   a	   totally	   different	   protein	   pattern	   for	   bacteria	   treated	  
with	   RCZ57.	   Mass	   spectrometry	   identified	   at	   least	   4	   outer	   membrane	   and	   periplasmic	  




Microscopy	   visualisation	   excluded	   a	   plausible	   vesicles	   formation	   caused	   by	   high	  
concentrations	  of	   the	   TZP	   compound.	   It	   can	  be	   speculated	   that,	   at	   200	  μM,	  RCZ57	  may	  
bind	  or	  interfere	  with	  osmolarity	  regulators	  and	  then	  modify	  the	  bacterium’s	  permeability.	  
An	   indication	   of	   this	   can	   be	   linked	   to	   the	   abnormal	   concentrations	   of	   the	   porin	   OmpC	  
found	  in	  the	  secreted	  media	  samples,	  but	  it	  will	  have	  to	  be	  studied	  in	  more	  details	  in	  the	  
future.	   Permeability	  modification	   can	  be	  evaluated	   through	  dye	   leakage	  assays	   and	   flow	  
cytometry	  experiments.	  
To	   further	   investigate	   the	   structure-­‐activity	   relationship	   of	   RCZ57,	   a	   small	   series	   of	   3	  
derivatives	  was	   designed	   and	   synthesised	  modifying	   three	   TZP	  main	   structural	   features.	  
RCZ58	  (modification	  on	  ring	  A),	  RCZ59	  (modification	  on	  ring	  C)	  and	  RCZ60	  (modification	  on	  
the	   hydroxyl	   groups	   on	   ring	   B)	   were	   tested	   together	   with	   RCZ57	   through	   western	   blot	  
analyses.	   From	   the	   data	   obtained	   from	   this	   experiment,	   we	   summarised	   that	   the	   two	  
hydroxyl	  groups	  on	  ring	  B	  are	  essential	  for	  RCZ57,	  since	  RCZ60	  was	  found	  to	  be	  completely	  
inactive.	  Modifications	  on	   ring	  A,	   instead,	   resulted	   in	  an	  active	  compound	  with	  a	   slightly	  
attenuated	  activity	  against	  EspD	  secretion,	  while	   installation	  of	  another	  aromatic	   ring	  on	  
ring	  C	  yielded	  an	  inactive	  compound	  due	  to	  its	  very	  poor	  solubility.	  Due	  to	  RCZ57	  relative	  
ease	  of	  synthesis,	  an	  extensive	   library	  of	  analogues	  can	  be	  easily	  build	  to	  obtain	  relevant	  
structure-­‐activity	  relationship	  data	  and	  to	  optimise	  this	  very	  promising	  T3SS	  inhibitor	  in	  a	  
more	   potent	   and	   “drug-­‐like”	   compound.	   Furthermore,	   the	   synthesis	   of	   RCZ57	   labelled	  
version	  will	   help	   to	   confirm	   that	   the	   TZP	   compound	   shares	   the	   same	  mode	  of	   action	  of	  
RCZ12	  and	  RCZ20.	   Thanks	   to	  our	  preliminary	   structure-­‐activity	   relationship	   investigation,	  
the	  molecular	  probe	  can	  be	  installed	  on	  ring	  A	  without	  affecting	  the	  compound’s	  inhibitory	  
effects.	  	  




11	  Final	  Discussion	  
Escherichia	  coli	  O157:H7	   is	   considered	  one	  of	   the	  most	  dangerous	   serotype	  of	   the	  EHEC	  
family	  9.	  Its	  infection	  can	  cause	  bloody	  diarrhoea,	  haemolytic	  colitis	  and	  haemolytic	  uremic	  
syndrome	   (HUS),	   which	   can	   lead	   to	   death.	   The	   mode	   of	   action	   of	   bactericidal	   and	  
bacteriostatic	   compounds	   to	   eradicate	   E.	   coli	  O157:H7	   infections	   triggers	   bacterial	   SOS	  
responses	  and	  results	  in	  an	  increased	  Shiga	  toxin	  release,	  worsening	  the	  clinical	  symptoms	  
and	   leading	   to	   development	   of	   resistant	   clones.	   Consequently,	   traditional	   antibiotic	  
treatments	  must	  be	  avoided	  for	  E.	  coli	  O157:H7	  infections.	  Anti-­‐virulence	  compounds	  are	  
considered	   as	   a	   promising	   alternative	   to	   overcome	   this	   problem.	   These	   compounds	  
selectively	  inhibit	  the	  virulence	  weapons	  of	  the	  bacterium,	  resulting	  in	  a	  mild	  evolutionary	  
pressure	  and,	  therefore,	   leading	  to	  less	  chances	  to	  develop	  resistance	  182–184.	  Salicylidene	  
acylhydrazide	  (SA)	  compounds	  were	  one	  of	  the	  first	  class	  of	  anti-­‐virulence	  compounds	  with	  
activity	   against	   the	   Type	  Three	   Secretion	   System	   (T3SS)	   in	  many	  Gram-­‐negative	  bacteria	  
114,118,185.	  Studies	  to	  identify	  the	  main	  protein	  target	  of	  SA	  compounds	  were	  made	  by	  Wang	  
et	  al.,	   leading	  to	  the	  conclusion	  that	  the	  mode	  of	  action	  of	  these	  potent	  molecules	  was	  a	  
result	   of	   a	  modulation	   of	   several	  metabolic	   pathways	   rather	   than	   a	   direct	   influence	   on	  
T3SS	   125.	   This	   study	   aimed	   to	   modify	   the	   chemical	   structure	   of	   one	   of	   the	   best	   SA	  
compounds	  against	  EHEC,	  ME0055,	  in	  order	  to	  overcome	  its	  limitation	  and	  to	  discover	  new	  
potential	  T3SS	  inhibitors.	  
	  
11.1	  RCZ12	  and	  RCZ20	  
The	   first	   design	  we	   applied	   to	   the	  ME0055	   scaffold	  was	   to	   include	   the	   imine	  motif	   in	   a	  
more	  stable	  heterocycle.	   Incorporating	  the	  hydrazine	  feature	   in	  a	  cycle	  strengthened	  the	  
whole	   acylhydrazone	   structure,	   which	   was	   previously	   prone	   to	   hydrolysis.	   1,4,5,6-­‐
tetrahydro-­‐pyridazine	  (THP)	  and	  1,2-­‐dihydrophthalazine	  (DHP)	  cores	  were	  selected	  as	  main	  
new	   scaffolds.	   A	   small	   library	   (8	   compounds)	   based	   on	   these	   two	   heterocycles	   was	  
synthesised	  and	  tested	  against	  EHEC	  T3SS	  with	  ME0055	  for	  direct	  comparison.	  RCZ12	  and	  
RCZ20	  resulted	  to	  have	  comparable	  activity	  to	  the	  SA	  compound	  inhibiting	  the	  secretion	  of	  
the	  protein	  EspD.	  Further	  testing	  displayed	  that	  the	  two	  compounds	  were	  strongly	  active	  
against	   the	   T3SS.	   At	   200	   μM,	   both	   RCZ12	   and	   RCZ20	   blocked	   EspD	   secretion,	   causing	  
retention	  of	  such	  protein	  inside	  the	  bacterial	  cells,	  and	  down-­‐regulated	  T3SS-­‐related	  genes	  




addition,	  the	  THP	  and	  DHP	  compounds	  did	  not	  show	  to	  interfere	  with	  the	  bacterial	  growth	  
even	  at	  high	  concentrations,	  while	  ME0055	  previously	  demonstrated	  to	  already	  influence	  
the	  growth	  at	  50	  μM	  118.	  The	  modifications	  applied	  for	  the	  THP	  and	  DHP	  resulted	   in	  two	  
active	   compounds	   with	   slightly	   different	   effects	   on	   T3SS	   than	   the	   SA	   compound.	  While	  
ME0055	   showed	   to	   inhibit	  both	   transcription	  and	   secretion	  of	  T3SS	  proteins,	  RCZ12	  and	  
RCZ20	   revealed	   to	   primarily	   block	   EspD	   secretion	   only	   and	   then	   to	   down-­‐regulate	   the	  
transcription	   of	   other	   T3SS	   proteins.	   The	   transcriptional	   effect	   of	   the	   new	   compounds,	  
investigated	   by	   RNAseq	   and	   GFP	   reporter	   analyses,	   resulted	   to	   be	   weaker	   than	   the	   SA	  
compound	   influence.	   Furthermore,	   RCZ12	   and	   RCZ20	   selectively	   down-­‐regulated	   T3SS-­‐
related	  genes,	  while	  the	  data	  registered	  for	  ME0055	  suggested	  a	  broader	  down-­‐regulation	  
of	  other	  non	  T3SS-­‐related	  genes.	   It	   is	  easy	  to	  speculate	  that	  the	  retention	  of	  EspD	  inside	  
the	  cell,	  caused	  by	  our	  compounds,	  could	  trigger	  a	  negative	  feedback	  circuit	  against	  T3SS-­‐
related	  genes.	  This	  signalling	  could	  stop	  the	  production	  of	  EspD	  and	  other	  T3SS	  proteins	  in	  
order	   to	   avoid	   toxic	   levels	   of	   the	   accumulating	   protein.	   Evidences	   of	   this	   pathway	  were	  
found	   using	   a	   ΔespD	   tif:gfp	   strain,	   which	   demonstrated	   to	   have	   an	   attenuated	   tir	  
expression	   than	   the	   TUV	  93-­‐0	   counterpart.	  However,	   both	  RCZ12	   and	  RCZ20	   showed	   to	  
down-­‐regulate	   the	   LEE	   even	   in	   the	   absence	   of	   the	   main	   target	   EspD,	   supporting	   the	  
hypothesis	  of	  a	  transcriptional	  influence	  as	  a	  secondary	  effect.	  This	  feedback	  circuit	  could	  
be	  investigated	  in	  the	  near	  future	  to	  elucidate	  the	  phenotype	  observed.	  Immuno-­‐labelling	  
microscope	  experiment	  (TEM)	  also	  highlighted	  the	  ability	  of	  our	  compounds	  to	  block	  the	  
correct	  assembly	  of	  functioning	  EspA	  filaments,	  a	  phenotype	  already	  associated	  with	  EspD	  
malfunction	  33.	  
Due	   to	   our	   findings,	   it	   was	   clear	   that	   our	   new	   THP	   and	   DHP	   compounds	   might	   act	  
differently	  and	  more	  selectively	  on	  the	  T3SS	  than	  the	  SA	  compound.	  The	  enhanced	  degree	  
of	  selectivity	  achieved	  by	  our	  chemical	  modifications	  onto	  ME0055	  structure	  drove	  us	  to	  
examine	   the	  mode	  of	   action	  of	   the	  THP	  and	  DHP	  derivatives.	   Following	  previous	   studies	  
conducted	   by	   Wang	   et	   al.,	   labelled	   version	   of	   RCZ12	   and	   RCZ20	   were	   synthesised	   to	  
perform	  affinity	  pull-­‐down	  experiments	  125.	  EspD	  was	  identified	  as	  the	  only	  bona	  fide	  T3SS-­‐
related	  protein	   to	   specifically	  bound	   to	  our	   labelled	   compounds.	   The	   fact	   that	   the	   same	  
virulence	   protein	   was	   found	   to	   be	   bound	   with	   both	   RCZ12	   and	   RCZ20,	   confirmed	   the	  
hypothesis	  of	  a	  common	  mechanism	  of	  action	  by	  our	  molecules.	  In	  addition,	  the	  few	  non	  
T3SS-­‐related	  proteins	  bound	  to	  our	  compounds	  also	  confirmed	  the	  increased	  selectivity	  of	  




intracellular	  interaction	  between	  our	  compounds	  and	  EspD.	  Metabolomics	  data	  supported	  
this	   hypothesis,	   since	   high	   concentrations	   of	   the	   compounds	   were	   found	   inside	   the	  
bacteria	   by	   hydrophilic	   interaction	   liquid	   chromatography.	   E.	   coli	   strains	   producing	   a	  
truncated-­‐EspD-­‐HA	  constructs	  were	  generated	  by	  allelic	  exchange	  and	   then	   treated	  with	  
RCZ12	  at	  200	  μM.	  The	  experiment	  validated	  EspD	  as	  the	  main	  target	  of	  both	  THP	  and	  DHP	  
compounds,	  since	  a	  modification	  in	  the	  protein	  structure	  lead	  to	  a	  complete	  loss	  of	  activity	  
and	  restored	  a	  normal	  secretion	  of	  the	  construct	  outside	  the	  bacterium.	  In	  addition,	  from	  
this	  analysis	  we	  postulated	  that	  RCZ12	  and	  RCZ20	  might	  bind	  to	  the	  predicted	  coiled-­‐coil	  
domain	  1	  (COIL1)	  of	  EspD,	  since	  only	  deletion	  of	  this	  region	  completely	  reversed	  the	  THP	  
compound	  effect.	  
	  
11.2	  The	  future	  of	  RCZ12	  and	  RCZ20	  	  
Our	   THP	   and	   DHP	   compounds	   demonstrated	   to	   be	   a	   promising	   class	   of	   EHEC	   T3SS	  
inhibitors.	  The	  enhanced	  selective	  mode	  of	  action	  make	  them	  a	  more	  than	  optimal	  starting	  
point	  for	  new	  structural	  optimisation	  to	  build	  more	  potent	  inhibitors	  against	  EspD.	  A	  small	  
series	   based	   on	   RCZ12	   and	   RCZ20	  was	   also	   synthesised	   in	   a	   fast	   and	   efficient	  way.	   The	  
modifications	  were	  mostly	   performed	  on	   the	   left-­‐hand	   side	  phenyl	   ring,	  where	  different	  
substituents	  were	  placed	  instead	  of	  the	  nitro	  group	  or	  the	  entire	  ring	  was	  exchanged	  with	  
either	  a	  small	  or	  long	  alkyl	  chain.	  Testing	  of	  these	  new	  derivatives	  will	  be	  useful	  in	  terms	  of	  
structure-­‐activity	   relationship	   (SAR)	   data	   that	   could	   lead	   to	   more	   selective	   and	   active	  
molecules.	   Due	   to	   the	   easy	   synthetic	   route,	   an	   expanded	   library	   focused	   on	   RCZ12	   and	  
RCZ20	  can	  be	  built	  for	  extensive	  SAR	  information.	  
Attempting	   in	   crystallising	   EspD	   bound	   to	   our	   THP	   and	   DHP	   compounds	   should	   also	   be	  
carried	   out	   in	   order	   to	   confirm	   the	   binding	   site	   of	   these	  molecules.	   Unfortunately,	   the	  
biological	   properties	   of	   this	   membrane	   protein	   will	   provide	   several	   issues	   to	   the	  
purification	  and	  crystallisation	  processes.	  Not	  surprisingly,	  all	  our	  efforts	  in	  purifying	  EspD	  
failed	   due	   to	   its	   physical	   and	   biological	   properties	   and	   the	   protein	   itself	   resulted	   to	   be	  
extremely	  hard	  to	  work	  with.	  
After	  our	  results,	  adhesion	  assays	  could	  be	  performed	  with	  RCZ12	  and	  RCZ20	  in	  order	  to	  
verify	  the	  reduced	  intimate	  attachment	  of	  the	  bacterium	  to	  intestinal	  epithelial	  cells.	  Since	  
EspD	   functions	  as	  an	  anchor	   for	   the	  bacteria	  colonisation,	   it	   is	   likely	   that	   treatment	  with	  
our	   compounds	  will	   lead	   to	   a	   less	   invasive	  bacterial	   phenotype.	   The	  data	  obtained	   from	  




assembled	  EspA	   filaments,	  which	  will	   likely	   result	   in	  an	   impaired	  attachment	   to	   the	  host	  
cells.	   The	  data	   gathered	  with	   the	   adhesion	   experiment	  will	   be	   completing	   the	  biological	  
profile	  of	  RCZ12	  and	  RCZ20	  and	  will	  also	  encourage	  testing	  in	  infection	  mouse	  models	  for	  
assessing	  the	  in	  vivo	  efficacy.	  
The	   THP	   and	   DHP	   compounds	   could	   also	   undergo	   testing	   against	   other	   Gram-­‐negative	  
bacterial	  strains	  that	  harbours	  the	  T3SS.	  Since	  this	  virulence	  weapon	  is	  highly	  conserved	  in	  
more	  than	  25	  species	  of	  bacteria	  186,	  it	  is	  possible	  that	  RCZ12	  and	  RCZ20	  will	  also	  interact	  
with	  the	  corresponding	  EspD	  homologue	  in	  other	  species	  such	  as	  Salmonella	  sp.,	  Yersinia	  
sp.,	  S.	  flexneri,	  P.	  aeuroginosa	  and	  Chlamidya	  sp.	  (see	  Appendix	  for	  EspD	  alignment).	  The	  
possibility	  of	  activity	  against	  other	  bacterial	  strain	   is	  very	  attractive	   for	   the	  generation	  of	  
broad-­‐spectrum	   anti-­‐virulence	   compounds	   and	   the	   scaffolds	   can	   be	   easily	   modified	   to	  
achieved	  selective	  compounds	  for	  individual	  strains.	  
	  
11.3	  RCZ57	  
It	  was	  opted	  to	  install	  a	  new	  hydrazine-­‐containing	  heterocycle	  into	  the	  ME0055	  structure	  
based	  on	  RCZ12	  and	  RCZ20	  features.	  A	  [1,2,4]-­‐triazolo[4,3-­‐b]pyridazine	  (TZP)	  ring	  was	  then	  
introduced	  to	  create	  a	  new	  potential	  T3SS	  inhibitor,	  RCZ57.	  The	  synthesis	  of	  this	  molecule	  
started	  from	  the	  previously	  obtained	  intermediate	  28	  and	  employed	  only	  2	  steps	  to	  yield	  
the	  desired	  compound.	  RCZ57	  was	  tested	  against	  ME0055	  and	  RCZ12	  and	  demonstrated	  
to	   be	   an	   excellent	   T3SS	   inhibitor.	   At	   200	   μM,	   the	   TZP	   compound	   displayed	   a	   strong	  
inhibition	  of	  EspD	  secretion	  with	  the	  characteristic	  intracellular	  retention	  and,	  surprisingly,	  
did	  not	  show	  any	  significant	  effects	  on	  the	  transcription	  of	  T3SS-­‐related	  genes.	  Further	  GFP	  
reporter	  analyses	  confirmed	  the	  inactivity	  of	  RCZ57	  at	  transcriptional	  level	  and	  suggested	  
an	   even	   more	   selective	   post-­‐transcriptional	   effect	   on	   EspD.	   While	   investigating	   the	  
secreted	   proteins	   profile,	   an	   unusual	   protein	   pattern	   was	   detected	   for	   the	   RCZ57	  
treatment.	  Mass	  spectrometry	  analyses	  identified	  many	  outer	  membrane	  and	  periplasmic	  
proteins	  shedding	  in	  the	  secretion	  media.	  This	  unusual	  behaviour	  was	  firstly	  linked	  to	  the	  
possibility	   of	   vesicle	   formation	   by	   high	   concentration	   of	   RCZ57,	   but	  microscopy	   studies,	  
focused	   on	   the	   morphology	   of	   the	   bacterial	   membrane,	   did	   not	   show	   any	   vesicle	  
formation.	   It	   was	   hypothesised	   that	   the	   TZP	   compound	  might	   interfere	   with	   osmolarity	  
regulators	   in	   order	   to	   over-­‐express	   porins	   (such	   as	   OmpC)	   and,	   therefore,	   change	   the	  
bacterial	  membrane’s	  permeability.	  Evidence	  of	  this	  unusual	  effect	  will	  be	  investigated	  in	  




Modular	  analogues	  of	  RCZ57	  were	  also	  designed	  and	  synthesised	  for	  preliminary	  structure-­‐
activity	   relationship	   (SAR)	   studies.	  Western	   blot	   analysis	   confirmed	   the	   relevance	   of	   the	  
two	   hydroxyl	   groups	   on	   ring	   B,	   since	   etherification	   of	   such	   groups	   lead	   to	   an	   inactive	  
derivative,	  and	  also	  showed	  that	  the	  removal	  of	  the	  nitro	  group	  on	  ring	  A	  yielded	  another	  
strong	  T3SS	  inhibitors.	  These	  preliminary	  results	  addressed	  future	  modifications	  of	  the	  TZP	  
scaffold	  and	  suggested	  that,	  as	  for	  RCZ12	  and	  RCZ20,	  the	  hydroxyl	  groups	  are	  essential	  for	  
interaction	  with	  EspD.	  
	  
11.4	  The	  future	  of	  RCZ57	  
RCZ57	  demonstrated	  to	  be	  an	  excellent	  ME0055	  derivative,	  with	  enhanced	  selectivity	  and	  
solubility	  in	  biological	  media.	  The	  effects	  observed	  for	  this	  new	  molecule	  were	  all	  focused	  
on	   blocking	   EspD	   secretion,	   while	   no	   transcriptional	   activity	   was	   detected	   by	   our	  
experiments.	  After	  the	  data	  obtained,	  we	  hypothesised	  that	  the	  TZP	  derivative	  could	  share	  
the	   same	   intracellular	  EspD	   interaction	  of	  both	  THP	  and	  DHP	  compounds	  and	   in	  a	  more	  
selective	  manner.	  Metabolomics	   data	   confirmed	   the	   uptake	   of	   our	   new	  molecule	   inside	  
the	  bacteria	  and	  supported	  such	  hypothesis.	  RCZ57	  labelled	  version	  should	  be	  synthesised	  
in	   the	   future	   to	   replicate	   the	  pull-­‐down	  assay	  against	  EHEC	  whole	   cell	   lysate	   in	  order	   to	  
confirm	  EspD	  as	  target	  or	  to	  identify	  the	  compound’s	  new	  mode	  of	  action.	  
Due	   to	   ease	   of	   synthesis,	   an	   expanded	   library	   of	   RCZ57	   derivatives	   could	   also	   be	   easily	  
synthesised.	   Different	   substituents	   can	   be	   installed	   on	   ring	   A,	   which	   proved	   to	   be	   the	  
recognition	  site	  of	  the	  molecule.	  In	  addition,	  it	  would	  be	  very	  useful	  to	  change	  the	  hydroxyl	  
groups	  position	  across	  ring	  B	  in	  order	  to	  identify	  the	  most	  potent	  position	  and	  combination	  
against	  EspD	  secretion.	  
Adhesion	  assays	  on	  epithelial	  cells	  should	  also	  be	  performed	  to	  evaluate	  the	  efficacy	  of	  this	  
new	  molecule	  as	  well	  as	  in	  vivo	  experiment	  in	  infection	  mouse	  models.	  
The	   unusual	   outer	   membrane	   proteins	   shedding	   observed	   by	   SDS-­‐PAGE	   could	   be	  
investigated	  by	  dye	  leakage	  assays	  or	  by	  treatment	  of	  porins	  null	  mutant,	  such	  as	  ΔompC,	  
ΔompF	  and	  ΔompR,	  with	  RCZ57	  and	  analyses	  on	  the	  secreted	  protein	  profiles.	  This	  effect	  
might	   be	   linked	   to	   a	   plausible	   interaction	   of	   the	   TZP	   compound	  with	   off-­‐target	   proteins	  






This	   study	   provided	   the	   synthesis	   and	   the	   biological	   evaluation	   of	   three	   new	   potential	  
classes	  of	  anti-­‐virulence	  compounds.	  The	  scaffold	  designed	  on	  ME0055	  proved	  to	  be	  more	  
selective	  and	  potent	  of	   the	   starting	  compound	  and	   lead	   to	   the	  discovery	  of	  EspD	  as	   the	  
main	   protein	   target.	   The	   biological	   and	   chemical	   results	   obtained,	   yielded	   a	   solid	  
framework	  for	  future	  research	  focused	  on	  the	  development	  of	  T3SS	  inhibitors.	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sucA	   gi|15800430	   1716	   106	  
2	   Elongation	  factor	  Tu	   tufA/B	   gi|26110363	   745	   75	  
3	   EspD	   espD	   gi|15804216	   1266	   45	  
3’	   EspD	   espD	   gi|15804216	   1174	   40	  
4	   30S	  Ribosomal	  subunit	   rpsJ	   gi|15803848	   235	   10	  
	  
Table	   11:	   List	   of	   protein	   identified	   by	   the	   first	   pull-­‐down	   assay	   with	   biotin-­‐RCZ12	   and	   biotin-­‐RCZ20:	   The	   protein	  
identified	  by	  tandem	  mass	  spectrometry	  for	  the	  pull-­‐down	  assay	  (Paragraph	  8.4.2)	  is	  listed	  above.	  Band	  numbers	  refer	  to	  












sucA	   gi|15800430	   481	   57	  
2	   EspB	   espB	   gi|188016858	   1154	   78	  
3	   EspD	   espD	   gi|15804216	   672	   55	  
4	   30S	  Ribosomal	  subunit	   rpsJ	   gi|15803848	   173	   15	  
	  
Table	   12:	   List	   of	   protein	   identified	   by	   the	   second	   pull-­‐down	   assay	   with	   biotin-­‐RCZ12	   and	   biotin-­‐RCZ20:	   The	   protein	  
identified	  by	  tandem	  mass	  spectrometry	  for	  the	  pull-­‐down	  assay	  (Paragraph	  8.7.5)	  is	  listed	  above.	  Band	  numbers	  refer	  to	  





P	  value	   Function	  
torC	   15.97	   8.48E-­‐13	   Cytochrome	  C-­‐type	  protein	  
torA	   13.44	   3.01E-­‐35	   Trimethylamine-­‐N-­‐oxide	  reductase	  
yjiY	   6.64	   6.93E-­‐20	   Carbon	  starvation	  protein	  CstA	  
metF	   4.83	   4.38E-­‐12	   5,10-­‐Methylenetetrahydrofolate	  reductase	  
bssR	   4.51	   5.43E-­‐09	   Biofilm	  regulator	  BssR	  
Z2427	   2.64	   2.01E-­‐19	   Amidohydrolase	  
metE	   2.61	   4.25E-­‐19	  
5-­‐Methyltetrahydropteroyltriglutamate-­‐	  homocysteine	  
methyltransferase	  
yhiW	   2.48	   5.54E-­‐06	   DNA-­‐binding	  transcriptional	  activator	  
ydaJ	   2.38	   1.36E-­‐18	   Putative	  aminohydrolase	  
yhfC	   2.37	   7.00E-­‐10	   Hypothetical	  protein	  




ycfS	   1.89	   2.94E-­‐04	   Hypothetical	  protein	  
htrL	   1.79	   7.26E-­‐04	   Putative	  lipopolysaccharide	  biosynthesis	  protein	  
metK	   1.75	   1.53E-­‐07	   S-­‐Adenosylmethionine	  synthetase	  
ydeA	   1.75	   8.08E-­‐04	   Putative	  substrate	  translocation	  pore	  
yjbA	   1.75	   7.44E-­‐05	   Phosphate-­‐starvation-­‐inducible	  protein	  PsiE	  
gcd	   1.72	   1.23E-­‐06	   Glucose	  dehydrogenase	  
metN	   1.71	   5.91E-­‐04	   DL-­‐Methionine	  transporter	  subunit	  
yihE	   1.66	   8.37E-­‐06	   Serine/threonine	  protein	  kinase	  
yojH	   1.64	   3.17E-­‐06	   Malate:quinone	  oxidoreductase	  
cpxP	   1.62	   7.57E-­‐06	   Periplasmic	  repressor	  CpxP	  
dps	   1.6	   1.23E-­‐06	   DNA	  protection	  during	  starvation	  conditions	  
yfiA	   1.57	   2.75E-­‐06	   Translation	  inhibitor	  protein	  RaiA	  
folE	   1.57	   8.17E-­‐05	   GTP	  cyclohydrolase	  I	  
ompC	   1.52	   2.35E-­‐04	   Outer	  membrane	  protein	  C,	  porin	  
ompX	   1.52	   5.90E-­‐06	   Outer	  membrane	  protein	  X	  
Z2779	   1.38	   2.47E-­‐04	   Arginine	  succinyltransferase	  
ydjS	   1.38	   3.61E-­‐04	   Succinylglutamate	  desuccinylase	  
Z2777	   1.37	   2.39E-­‐04	   Succinylarginine	  dihydrolase	  
astD	   1.37	   2.30E-­‐04	   Succinylglutamic	  semialdehyde	  dehydrogenase	  
argD_1	   1.35	   3.33E-­‐04	  
Bifunctional	  succinylornithine	  transaminase/acetylornithine	  
transaminase	  
ptsH	   -­‐1.4	   2.41E-­‐04	  
Phosphohistidinoprotein-­‐hexose	  phosphotransferase	  component	  of	  
PTS	  system	  (Hpr)	  
Z1824	   -­‐1.4	   2.13E-­‐04	   Hypothetical	  protein	  
Z5137	   -­‐1.53	   6.46E-­‐04	   Hypothetical	  protein	  
Z5125	   -­‐1.53	   3.24E-­‐04	   Hypothetical	  protein	  
Z6020	   -­‐1.54	   6.78E-­‐04	   Hypothetical	  protein	  
Z5115	   -­‐1.59	   7.15E-­‐05	   Hypothetical	  protein	  
Z3920	   -­‐1.59	   8.01E-­‐06	   Hypothetical	  protein	  
Z5352	   -­‐1.6	   1.25E-­‐04	   Esterases	  and	  lipases	  
Z3644	   -­‐1.6	   7.36E-­‐05	   Aspartate	  aminotransferase	  
ptsG	   -­‐1.63	   1.40E-­‐07	   Phosphotransferase	  system,	  EIIC	  
Z5123	   -­‐1.65	   4.13E-­‐05	   Hypothetical	  protein	  
Z3071	   -­‐1.66	   2.51E-­‐05	   Hypothetical	  protein	  
manZ	   -­‐1.71	   1.03E-­‐08	   Mannose-­‐specific	  PTS	  system	  protein	  IID	  
Z5102	   -­‐1.72	   4.03E-­‐05	   Hypothetical	  protein	  
manY	   -­‐1.75	   1.54E-­‐08	   PTS	  system	  sorbose-­‐specific	  iic	  component	  




Z0955	   -­‐1.76	   4.77E-­‐07	   Hypothetical	  protein	  
Z4326	   -­‐1.79	   3.69E-­‐04	   ShET2	  enterotoxin	  
manX	   -­‐1.88	   1.27E-­‐11	   PTS	  system,	  mannose-­‐specific	  IIAB	  component	  
Z5142	   -­‐1.9	   8.39E-­‐06	   Hypothetical	  protein	  
rcsA	   -­‐1.94	   9.40E-­‐08	  
Response	  regulator	  containing	  a	  CheY-­‐like	  receiver	  domain	  and	  an	  
HTH	  DNA-­‐binding	  domain	  
Z5128	   -­‐1.95	   1.42E-­‐07	   Hypothetical	  protein	  
Z5138	   -­‐1.97	   1.01E-­‐05	   Hypothetical	  protein	  
gcvH	   -­‐2	   6.07E-­‐04	   Glycine	  cleavage	  system	  protein	  H	  
rrsE	   -­‐2.02	   7.62E-­‐06	   16S	  ribosomal	  RNA	  
Z5136	   -­‐2.04	   4.19E-­‐10	   Hypothetical	  protein	  
ssrS	   -­‐2.28	   1.14E-­‐07	   6S	  RNA	  
Z5143	   -­‐2.31	   2.80E-­‐04	   Hypothetical	  protein	  
wcaI	   -­‐2.4	   2.03E-­‐04	   Putative	  glycosyl	  transferase	  
Z5139	   -­‐2.42	   2.14E-­‐09	   Hypothetical	  protein	  
wcaD	   -­‐2.47	   3.77E-­‐04	   Putative	  colanic	  acid	  biosynthesis	  protein	  
fruA	   -­‐2.49	   7.70E-­‐10	   Fructose-­‐specific	  PTS	  system	  IIBC	  component	  
cpsB	   -­‐2.54	   8.22E-­‐05	   Mannose-­‐1-­‐phosphate	  guanyltransferase	  
wcaG	   -­‐2.67	   3.23E-­‐07	   Putative	  nucleotide	  di-­‐P-­‐sugar	  epimerase	  or	  dehydratase	  
Z3921	   -­‐2.74	   1.93E-­‐05	   Hypothetical	  protein	  
Z2151	   -­‐2.79	   3.35E-­‐05	   Hypothetical	  protein	  
fruK	   -­‐3.15	   1.89E-­‐06	   1-­‐Phosphofructokinase	  
Z2339	   -­‐3.16	   1.28E-­‐05	   Hypothetical	  protein	  
gmd	   -­‐3.39	   3.63E-­‐13	   GDP-­‐D-­‐mannose	  dehydratase	  
Z6024	   -­‐3.52	   1.14E-­‐14	   Hypothetical	  protein	  
fruB	   -­‐3.75	   3.65E-­‐11	   Bifunctional	  fructose-­‐specific	  PTS	  IIA/HPr	  protein	  
wcaH	   -­‐4.26	   4.24E-­‐05	   GDP-­‐mannose	  mannosyl	  hydrolase	  
ffs	   -­‐4.73	   3.72E-­‐04	   4.5S	  RNA,	  component	  of	  ribonucleoprotein	  
	  
Table	  13:	   List	  of	  additional	  genes	   influenced	  by	  RCZ20	  at	  50	  μM:	  The	   list	  of	   the	  non-­‐LEE-­‐related	  genes	   influenced	  by	  














Sample	   n°	  EspA	  filaments	  (>500	  nm)	   SD	   N	  
WT	   5.600	   ±	  2.345	   25	  
RCZ12	   1.320	   ±	  1.249	   25	  
RCZ57	   0.960	   ±	  0.935	   25	  
	  
Table	   14:	   Functioning	   EspA	   filaments	   (>500	   nm)	   for	   the	   TEM	   experiment	   with	   RCZ57:	   The	   average	   number	   of	   EspA	  
filaments	  (>500	  nm)	  for	  the	  TEM	  samples	  is	  shown	  in	  the	  table	  above.	  The	  values	  have	  been	  calculated	  from	  25	  different	  
images	  taken	  from	  5	  independent	  experiments.	  Standard	  deviation	  from	  the	  mean	  value	  is	  also	  shown	  in	  the	  table.	  
Fig.	   51:	   Alignment	   of	   EspD	   amino	   acid	   sequence	   from	   EHEC,	   EPEC,	  C.	   rodentium,	   Y.	   pseudotuberculosis	   and	   S.	  
typhimurium	  and	  calculated	  percentage	  of	   homology:	  A)	  EspD	  sequence	  alignment.	  Amino	  acids	   sequences	  were	  
obtained	   from	  NCBI	   and	  Colibase	   and	   the	   alignment	  was	  performed	  by	  Clustal	  Omega.	  Asterisks	   (*)	   underneath	  
determined	   amino	   acids	   indicate	   a	   fully	   conserved	   site,	   colon	   (:)	   specify	   a	   conservation	  between	  groups	   of	   very	  
similar	   properties	   and	   period	   (.)	  mean	   conservation	   between	   groups	  of	   different	   properties.	   Amino	   acids	   in	   the	  
sequence	   are	  colour	  coded	  according	  to	   their	  chemical	   nature:	   red,	  small	   and	  aromatic	  amino	   acids;	  blue,	  acidic	  
amino	  acids;	  green,	  hydroxyl-­‐,	   sulfhydryl-­‐	   and	  amine-­‐bearing	   amino	  acids;	  magenta,	  basic	  amino	   acids.	  A	  dash	   (-­‐)	  
indicates	   a	   gap	   in	   the	   sequence.	   B)	   Homology	   percentage	   calculated	   by	   Clustal	   Omega.	   A	   strong	   sequence	  
homology	  was	  detected	   for	   EspD	   in	  EHEC,	  EPEC	   and	  C.	   rodentium	  of	  75%	  and	  70%,	  while	   a	   poor	  homology	  was	  
found	  between	  EHEC	  EspD	  and	  YopB	  and	  SipB	  (20%	  and	  24%	  homology	  respectively).	  
Fig.	   50:	   TEM	   images	   of	   sectioned	   bacteria	   treated	   with	   RCZ57:	   Bacterial	   membrane	   were	   analysed	   to	   assess	   any	  
perturbances	   or	   vesicle	   formation	   in	   the	   presence	   of	   RCZ57	   at	   200	   uM.	   No	   substantial	   differences	   were	   observed	  











12	  Chemistry	  experimental	  part	  
All	   chemicals	   used	   in	   this	   study	   were	   purchased	   from	   Sigma-­‐Aldrich®,	   Acros	   Organics®,	  
Fisher	   Scientific®	   and	   Life	  Technologies®	   and	  used	  as	   sold.	  All	   reactions	  were	  performed	  
under	  a	  dry	  argon	  atmosphere,	  unless	  otherwise	   stated,	  and	  monitored	  using	  aluminum	  
TLC	   pre-­‐coated	   with	   silica	   (Merck®),	   visualised	   under	   UV	   light	   at	   256	   nm.	   Proton	   NMR	  
spectra	  were	  recorded	  on	  a	  Bruker	  AM-­‐400	  and	  carbon	  NMR	  spectra	  on	  a	  Bruker	  AM-­‐500.	  
All	  chemical	  shifts	  (δ)	  are	  reported	  in	  parts	  per	  million	  (ppm).	  IR	  spectra	  were	  recorded	  on	  
a	  Shimadtzu	  FT-­‐IR	  8000S®	  with	  neat	  samples.	  Uncorrected	  melting	  points	  were	  performed	  
with	   a	   Stuart	   Scientific	   Melting	   Point	   SMP1.	   All	   flash	   columns	   chromatography	   were	  
performed	  using	  Merck®	  Silica.	  
	  
12.1	  Procedure	  for	  Friedel-­‐Crafts	  acylation:	  
The	   desired	   anhydride	   (48	   mmol)	   was	   dissolved	   in	   dry	   DCE	   (100	   mL)	   and	   anhydrous	  
aluminium	  chloride	  (61	  mmol)	  was	  added	  at	  0	  °C	  in	  one	  portion.	  After	  being	  stirred	  for	  15	  
minutes,	   1,3-­‐dimethoxybenzene	   (43	   mmol)	   was	   added	   dropwise	   at	   0	   °C	   through	   30	  
minutes.	   The	   ice	   bath	   was	   removed	   and	   the	   reaction	   mixture	   was	   stirred	   at	   room	  
temperature	   for	   5	   hours.	   Water	   (200	   mL)	   was	   added	   carefully	   at	   0	   °C	   to	   quench	   the	  
aluminium	  chloride	  and	  the	  aqueous	  layer	  was	  extracted	  with	  DCM	  (3x100	  mL),	  dried	  over	  
Na2SO4,	   filtered	   and	   concentrated.	   The	   product	   was	   purified	   through	   flash	   column	  
chromatography.	  
	  
4-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐4-­‐oxo-­‐butyric	   acid	   (18):	   The	   product	  
was	   purified	   through	   flash	   column	   chromatography	   (2%	  
methanol	   in	  DCM)	   to	  afford	  an	  off-­‐white	  solid	   (6.8	  g,	  29	  mmol	  
from	  6	  g,	  43	  mmol	  of	  17)	  in	  65%	  yield.	  m.p.	  138	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  7.81	  (1H,	  d,	  
J	  =	  8.8	  Hz,	  C(CO)CHCH),	  6.45	  (1H,	  dd,	  J	  =	  8.8	  Hz,	  2.3	  Hz,	  CHCHC(OMe)),	  6.38	  (1H,	  d,	  J	  =	  2.3	  
Hz,	   C(OMe)CHC(OMe)),	   3.83	   (3H,	   s,	   OCH3),	   3.78	   (3H,	   s,	   OCH3),	   3.22	   (2H,	   t,	   J	   =	   6.6	   Hz,	  
COCH2),	  2.66	  (2H,	  t,	  J	  =	  6.6	  Hz,	  COOHCH2).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  197.5	  (CO),	  178.7	  
(COOH),	  161.2	  (CHC(OMe)CH),	  155.6	  (C(CO)C(OMe)CH),	  132.9	  (C(CO)CHH),	  108.3	  (C(CO)),	  
105.2	  (C(CO)CHCH),	  98.3	  (C(OMe)CHC(OMe)),	  55.5	  (OCH3),	  55.4	  (OCH3),	  38.4	  (COCH2),	  28.7	  
(COOHCH2).	   IR	   (neat)	   νmax:	   2878,	   1606,	   1498,	   1100,	   998	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  




2-­‐(2,4-­‐Dimethoxy-­‐benzoyl)-­‐benzoic	   acid	   (19):	   The	   product	   was	  
purified	   through	   flash	   column	   chromatography	   (5%	  methanol	   in	  
DCM)	  to	  afford	  an	  off-­‐white	  solid	   (5.1	  g,	  18	  mmol	   from	  4.5	  g,	  32	  
mmol	  of	  17)	  in	  54%	  yield.	  m.p.	  134	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  7.93	  (1H,	  d,	  J	  =	  6.7	  Hz,	  
C(COOH)CH),	   7.67	   (1H,	   d,	   J	   =	   8.1	   Hz,	   C(OMe)C(CO)CH),	   7.50	   (1H,	   t,	   J	   =	   6.7	   Hz,	  
C(COOH)CHCHCH),	   7.39	   (1H,	   t,	   J	   =	   7.5	   Hz,	   C(COOH)CHCH),	   7.21	   (1H,	   d,	   J	   =	   7.4	   Hz,	  
C(COOH)C(CO)CH),	   6.44	   (1H,	   d,	   J	   =	   8.0	  Hz,	   C(CO)CHCH),	   6.30	   (1H,	   s,	   C(OMe)CHC(OMe)),	  
3.77	   (3H,	   s,	   OCH3),	   3.47	   (3H,	   s,	   OCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   194.6	   (CO),	   170.9	  
(COOH),	   165.0	   (CHC(OMe)CH),	   161.3	   (C(CO)C(OMe)),	   145.8	   (CHC(CO)C(COOH)),	   133.9	  
(C(COOH)),	   133.1	   (C(OMe)C(CO)CH),	   130.2	   (C(COOH)CHCHCH),	   128.5	   (C(COOH)CHCH),	  
127.4	   (C(COOH)C(CO)CH),	   126.8	   (C(COOH)CH),	   120.0	   (C(OMe)C(CO)),	   105.2	  
(CHC(OMe)CH),	   98.6	   (C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.4	   (OCH3).	   IR	   (neat)	   νmax:	   3001,	  
1721,	   1595,	   1261,	   1122	   cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	  C16H13O5	   [M-­‐H]-­‐	   285.0768	  m/z	   found	  
285.0755	  m/z.	  
	  
12.2	  Procedure	  for	  hydrazine	  coupling:	  
The	   desired	   carboxylic	   acid	   (9	   mmol)	   was	   suspended	   in	   absolute	   ethanol	   (25	   mL)	   and	  
hydrazine	  hydrate	  (17	  mmol)	  was	  added	  via	  syringe.	  The	  reaction	  mixture	  was	  refluxed	  at	  
100	   °C	   until	   total	   consumption	   of	   the	   starting	  material,	  monitored	  by	   TLC	   (normally	   3-­‐4	  
hours).	  The	  solvent	  was	  then	  removed	  and	  the	  product	  was	  dried	  under	  vacuum	  pump	  to	  
obtain	  the	  desired	  product	  in	  excellent	  purity.	  
	  
6-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐4,5-­‐dihydro-­‐2H-­‐pyridazin-­‐3-­‐one	   (20):	  
The	   product	   was	   obtained	   as	   a	   yellowish	   solid	   in	   96%	   yield	   in	   2	  
hours	  (470	  mg,	  2	  mmol	  from	  500	  mg,	  2	  mmol	  of	  18).	  m.p.	  121	  °C.	  
1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.60	  (1H,	  s,	  NH),	  7.33	  (1H,	  d,	  J	  =	  8.4	  Hz,	  
C(CN)CH),	   6.44	   (1H,	   dd,	   J	   =	   8.4	   Hz,	   2.4	   Hz,	   C(OMe)CHCH),	   6.40	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OMe)CHC(OMe)),	  3.76	  (6H,	  s,	  OCH3),	  2.86	  (2H,	  t,	  J	  =	  8.2	  Hz,	  CONHCH2),	  2.44	  (2H,	  t,	  J	  =	  
8.4	   Hz,	   CONHCH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   168.2	   (CONH),	   162.2	  
(C(OMe)CHC(OMe)),	   158.6	   (C(CN)C(OMe)CH),	   153.5	   (CNNH),	   130.0	   (C(CN)CH),	   118.9	  
(C(CN)),	   104.8	   (C(CN)CHCH),	   98.7	   (C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.4	   (OCH3),	   26.6	  
(CONHCH2),	  25.7	  (CONHCH2CH2).	  IR	  (neat)	  νmax:	  3274,	  2935,	  1672,	  1334,	  1207	  cm-­‐1.	  HRMS	  





4-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐2H-­‐phthalazin-­‐1-­‐one	   (21):	   The	   product	  
was	  obtained	  as	  an	  off-­‐white	  solid	  (2	  g,	  7	  mmol	  from	  2.5	  g,	  9	  mmol	  
of	   19)	   in	   85%	   yield	   in	   4	   hours.	   m.p.	   256	   °C.	   1H-­‐NMR	   (CDCl3	   400	  
MHz)	   δ	   10.43	   (1H,	   s,	   NH),	   8.40	   (1H,	   dd,	   J	   =	   7.5	   Hz,	   1.8	   Hz,	  
C(CO)CCH),	  7.70	  -­‐	  7.65	  (2H,	  m,	  ArH,	  ArH),	  7.32	  (1H,	  dd,	  J	  =	  7.6	  Hz,	  1.8	  Hz,	  C(CN)CCH),	  7.21	  
(1H,	  d,	  J	  =	  8.2	  Hz,	  C(CN)CH),	  6.55	  (1H,	  dd,	  J	  =	  8.2	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.52	  (1H,	  d,	  J	  =	  
2.3	   Hz,	   C(OMe)CHC(OMe)),	   3.81	   (3H,	   s,	   OCH3),	   3.63	   (3H,	   s,	   OCH3).	   13C-­‐NMR	   (CDCl3	   126	  
MHz)	  δ	  162.0	  (CONH),	  160.4	  (C(CN)C(OMe)CH),	  158.6	  (C(OMe)CHC(OMe)),	  146.6	  (CNNH),	  
133.0	   (Ar-­‐CC),	   131.8	   (Ar-­‐CC),	   131.2	   (Ar-­‐CH),	   130.8	   (Ar-­‐CH),	   127.9	   (Ar-­‐CH),	   127.4	   (Ar-­‐CH),	  
126.3	   (Ar-­‐CH),	   116.7	   (C(CN)C(OMe)),	   104.8	   (C(CN)CHCH),	   98.8	   (C(OMe)CHC(OMe)),	   55.5	  
(OCH3),	  55.4	  (OCH3).	   IR	   (neat)	  νmax:	  3142,	  2922,	  1676,	  1208,	  1157	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  
for	  C16H14N2NaO3	  [M+Na]+	  305.0897	  m/z	  found	  305.0895	  m/z.	  	  
	  
12.3	  Procedure	  for	  LiAlH4	  reduction	  
135:	  
LiAlH4	  (6	  mmol)	  was	  suspended	  in	  dry	  THF	  (10	  mL)	  and	  a	  solution	  of	  the	  desired	  amide	  (2	  
mmol)	  in	  dry	  THF	  (10	  mL)	  was	  added	  dropwise	  at	  room	  temperature.	  The	  reaction	  mixture	  
was	   refluxed	   at	   80	   °C	   for	   5	   hours.	   Water	   (20	   mL)	   was	   added	   very	   carefully	   at	   0	   °C	   to	  
quench	  the	  excess	  of	  LiAlH4	  and	  the	  aqueous	  layer	  was	  extracted	  with	  ethyl	  acetate	  (3x30	  
mL),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  desired	  products	  were	  pure	  enough	  
(by	  NMR)	  and	  were	  used	  in	  the	  next	  step	  without	  any	  further	  purification.	  
	  
3-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐1,4,5,6-­‐tetrahydro-­‐pyridazine	   (22):	   The	  
product	  was	  obtained	   as	   a	   yellow	   thick	   oil	   (360	  mg,	   2	  mmol	   from	  
500	  mg,	   2	  mmol	   of	   20)	   in	   81%	   yield	   and	   it	  was	   used	  without	   any	  
further	  purification.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  7.30	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  6.50	  (1H,	  
dd,	  J	  =	  8.3	  Hz,	  2.4	  Hz,	  C(CN)CHCH),	  6.47	  (1H,	  d,	  J	  =	  2.4	  Hz,	  C(OMe)CHC(OMe)),	  3.84	  (3H,	  s,	  
OCH3),	  3.83	  (3H,	  s,	  OCH3),	  3.18	  (2H,	  t,	  J	  =	  5.5	  Hz,	  NHCH2),	  2.60	  (2H,	  t,	  J	  =	  6.8	  Hz,	  C(CN)CH2),	  
2.03	  (2H,	  dddd,	  J	  =	  6.7	  Hz,	  6.7	  Hz,	  5.5	  Hz,	  5.5	  Hz,	  NHCH2CH2).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  
162.0	   (CHC(OMe)CH),	   160.4	   (C(CN)C(OMe)),	   158.6	   (CNNH),	   146.6	   (C(CN)CHCH),	   116.7	  
(C(CN)),	   104.8	   (C(CN)CHCH),	   98.8	   (C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.4	   (OCH3),	   45.6	  
(NHCH2),	   25.5	   (C(CN)CH2),	   19.1	   (NHCH2CH2).	   IR	   (neat)	   νmax:	   3366,	  2935,	  1609,	  1206,	  919	  





4-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐1,2-­‐dihydro-­‐phthalazine	  (23):	  The	  product	  
was	  obtained	  as	  a	  yellowish	  solid	  (627	  mg,	  2	  mmol	  from	  700	  mg,	  2	  
mmol	  of	  21)	  in	  94%	  yield	  and	  with	  excellent	  purity.	  m.p.	  124	  °C.	  1H-­‐
NMR	  (CDCl3	  400	  MHz)	  δ	  7.37	  (1H,	  d,	  J	  =	  8.3	  Hz,	  C(CN)CH),	  7.34	  (1H,	  
t,	   J	   =	   7.5	  Hz,	   CNCCHCH),	   7.21	   (1H,	   t,	   J	   =	   7.7	  Hz,	  NHCH2CCHCH),	   7.15	   (1H,	   d,	   J	   =	   7.5	  Hz,	  
CNCCH),	  6.89	  (1H,	  d,	  J	  =	  7.7	  Hz,	  NHCH2CCH),	  6.60	  (1H,	  dd,	  J	  =	  8.3	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  
6.56	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OMe)CHC(OMe)),	  6.06	  (1H,	  s,	  NH),	  4.31	  (2H,	  s,	  NHCH2),	  3.88	  (3H,	  
s,	   OCH3),	   3,72	   (3H,	   s,	   OCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.2	   (CHC(OMe)CH),	   158.8	  
(C(CN)C(OMe)),	   147.8	   (CNNH),	   131.5	   (Ar-­‐CC),	   131.4	   (C(CN)CH),	   129.8	   (Ar-­‐CC),	   127.5	   (Ar-­‐
CH),	   127.4	   (2xAr-­‐CH),	   124.8	   (Ar-­‐CH),	   118.6	   (C(CN)),	   104.6	   (C(CN)CHCH),	   98.8	  
(C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.4	   (OCH3),	   45.6	   (NHCH2).	   IR	   (neat)	   νmax:	   3364,	   2936,	  
1608,	   1207,	   826	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C16H17N2O2	   [M+H]+	   269.1285	   m/z	   found	  
269.1279	  m/z.	  
	  	  	  	  
12.4	  Procedure	  for	  acylation/sulphonylation:	  
The	   desired	   amine	   derivatives	   (1.63	  mmol)	   was	   dissolved	   in	   dry	   DCM	   (10	  mL)	   and	   TEA	  
(3.42	   mmol)	   and	   DMAP	   (0.16	   mmol)	   were	   added	   subsequently.	   After	   5	   minutes,	   the	  
desired	   acid/sulphonyl	   chloride	   (1.79	   mmol)	   was	   added	   and	   the	   reaction	   mixture	   was	  
stirred	  at	  room	  temperature	  until	  the	  starting	  material	  was	  no	  longer	  detectable	  by	  TLC	  (2-­‐
16	   hours).	   The	   solvent	  was	   then	   removed	   and	   the	   crude	  material	   was	   purified	   through	  
direct	  flash	  column	  chromatography.	  
	  
[3-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐pyridazin-­‐1-­‐
yl]-­‐(4-­‐nitro-­‐phenyl)-­‐methanone	   (RCZ09):	   The	   product	  
was	  purified	  with	  direct	   flash	   column	   chromatography	  
(from	  10%	  to	  20%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  
afford	  a	  yellow	  solid	  (361	  mg,	  0.97	  mmol	  from	  360	  mg,	  1.63	  mmol	  of	  22)	  in	  60%	  yield.	  m.p.	  
152	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.13	  (2H,	  d,	  J	  =	  8.8	  Hz,	  2xC(NO2)CH),	  7.78	  (2H,	  d,	  J	  =	  8.9	  
Hz,	   2xC(CO)CH),	   7.06	   (1H,	   d,	   J	   =	   8.2	   Hz,	   C(CN)CH),	   6.35	   (1H,	   d,	   J	   =	   2.4	   Hz,	  
C(OMe)CHC(OMe)),	  6.34	   (1H,	  dd,	   J	  =	  8.3	  Hz,	  2.4	  Hz,	  C(CN)CHCH),	  3.93	   (2H,	   t,	   J	  =	  5.9	  Hz,	  
NCH2),	   3.72	   (3H,	   s,	  OCH3),	   3.71	   (3H,	   s,	  OCH3),	   2.65	   (2H,	   t,	   J	   =	   6.3	  Hz,	   CNCH2),	   1.95	   (2H,	  




(CON),	  161.7	  (CHC(OMe)CH),	  158.8	  (C(CN)C(OMe)),	  151.2	  (C(NO2)),	  148.2	  (CNNCO),	  141.9	  
(C(CO)),	  130.5	  (C(CN)CH),	  129.7	  (2xC(CO)CH),	  122.5	  (2xC(NO2)CH,	  120.3	  (C(CN)CH),	  104.6	  
(C(CN)CHCH),	   98.8	   (C(OMe)CHC(OMe)),	   55.4	   (OCH3),	   55.3	   (OCH3),	   40.1	   (NCH2),	   26.8	  
(CNCH2),	   17.6	   (NCH2CH2).	   IR	   (neat)	   νmax:	   2838,	   1647,	   1520,	   1344,	   1160	   cm-­‐1.	  HRMS	   (ESI)	  
calcd	  for	  C19H19N3NaO5	  [M+Na]+	  392.1217	  m/z	  found	  392.1200	  m/z.	  
	  
3-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐1-­‐(4-­‐nitro-­‐benzenesulphonyl)-­‐
1,4,5,6-­‐tetrahydro-­‐pyridazine	   (RCZ11):	   The	   product	   was	  
purified	   with	   direct	   flash	   column	   chromatography	   (20%	  
ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  a	  brownish	  solid	  (310	  mg,	  0.76	  mmol	  from	  250	  
mg,	  1.13	  mmol	  of	  22)	  in	  67%	  yield.	  m.p.	  168	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.27	  (2H,	  d,	  J	  =	  
9.0	  Hz,	  2xC(NO2)CH),	  8.04	  (2H,	  d,	  J	  =	  8.9	  Hz,	  2xC(CO)CH),	  7.15	  (1H,	  d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  
6.40	  (1H,	  dd,	   J	  =	  8.4	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.34	  (1H,	  d,	   J	  =	  2.3	  Hz,	  C(OMe)CHC(OMe)),	  
3.75	  (3H,	  s,	  OCH3),	  3.66	  (3H,	  s,	  OCH3),	  3.39	  (2H,	  t,	  J	  =	  5.6	  Hz,	  NCH2),	  2.49	  (2H,	  t,	  J	  =	  6.6	  Hz,	  
CNCH2),	  1.97	  (2H,	  dddd,	  J	  =	  6.6	  Hz,	  6.6	  Hz,	  5.6	  Hz,	  5.6	  Hz,	  NCH2CH2).	  13C-­‐NMR	  (CDCl3	  126	  
MHz)	  δ	  161.8	  (C(OMe)CHC(OMe)),	  158.6	  (C(CN)C(OMe)),	  154.7	  (CNNSO2),	  150.2	  (C(NO2)),	  
142.0	   (C(SO2)),	   130.4	   (C(CN)CH),	   129.7	   (2xC(SO2)CH),	   123.8	   (2xC(NO2)CH),	   120.1	   (C(CN)),	  
104.6	  (C(CN)CHCH),	  98.7	  (C(OMe)CHC(OMe)),	  55.4	  (OCH3),	  55.3	  (OCH3),	  43.1	  (NCH2),	  25.1	  
(CNCH2),	   19.0	   (NCH2CH2).	   IR	   (neat)	   νmax:	   2925,	   1606,	   1527,	   1308,	   1172	   cm-­‐1.	  HRMS	   (ESI)	  
calcd	  for	  C18H19N3NaO6S	  [M+Na]+	  428.0887	  m/z	  found	  428.0892	  m/z.	  
	  
[4-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐1H-­‐phthalazin-­‐2-­‐yl]-­‐(4-­‐nitro-­‐
phenyl)-­‐methanone	   (RCZ17):	   The	   product	   was	   purified	  
with	   direct	   flash	   column	   chromatography	   (20%	   ethyl	  
acetate	   in	   petroleum	   ether)	   to	   give	   a	   bright	   yellow	   solid	  
(212	  mg,	  0.50	  mmol	   from	  250	  mg,	  0.93	  mmol	  of	  23)	   in	  54%	  yield.	  m.p.	  183	   °C.	   1H-­‐NMR	  
(CDCl3	  400	  MHz)	  δ	  8.26	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(NO2)CH),	  7.96	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(CO)CH),	  
7.50	  (1H,	  t,	  J	  =	  7.5	  Hz,	  NCH2CCHCH),	  7.33	  (1H,	  t,	  J	  =	  7.5	  Hz,	  CNCCHCH),	  7.32	  (1H,	  d,	  J	  =	  7.8	  
Hz,	  NCH2CCH),	  7.20	  (1H,	  d,	  J	  =	  8.2	  Hz,	  C(CN)CH),	  7.06	  (1H,	  d,	  J	  =	  7.8	  Hz,	  CNCCH),	  6.58	  (1H,	  
dd,	  J	  =	  8.1	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.55	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OMe)CHC(OMe)),	  5.20	  (2H,	  s,	  
NCH2),	   3.87	   (3H,	   s,	  OCH3),	   3.75	   (3H,	   s,	  OCH3).	   13C-­‐NMR	   (CDCl3	   126	  MHz)	  δ	  168.5	   (CON),	  
162.1	   (C(OMe)CHC(OMe)),	   158.9	   (C(CN)C(OMe)),	   151.8	   (C(NO2)),	   148.7	   (CNN),	   140.6	  




127.3	   (Ar-­‐CH),	   126.8	   (Ar-­‐CH),	   125.9	   (Ar-­‐CH),	   122.6	   (2xC(NO2)CH),	   116.6	   (C(CN)),	   104.8	  
(C(CN)CHCH),	   98.9	   (C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.4	   (OCH3),	   42.7	   (NCH2).	   IR	   (neat)	  
νmax:	   2926,	   1651,	   1520,	   1344,	   1209	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C23H19N3NaO5	   [M+Na]+	  
440.1217	  m/z	  found	  440.1202	  m/z.	  	  	  
	  
4-­‐(2,4-­‐Dimethoxy-­‐phenyl)-­‐2-­‐(4-­‐nitro-­‐
benzenesulphonyl)-­‐1,2-­‐dihydro-­‐phthalazine	   (RCZ19):	  
The	   product	   was	   purified	   by	   direct	   flash	   column	  
chromatography	  (20%	  ethyl	  acetate	  in	  petroleum	  ether)	  
to	  afford	  a	  bright	  yellow	  solid	  (235	  mg,	  0.51	  mmol	  from	  250	  mg,	  0.93	  mmol	  of	  23)	  in	  75%	  
yield.	  m.p.	  186	  °C.	   1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.38	  (2H,	  d,	   J	  =	  8.9	  Hz,	  2xC(NO2)CH),	  8.21	  
(2H,	  d,	  J	  =	  8.9	  Hz,	  2xC(CO)CH),	  7.44	  (1H,	  t,	  J	  =	  7.4	  Hz,	  NCH2CCHCH),	  7.42	  (1H,	  d,	  J	  =	  8.4	  Hz,	  
C(CN)CH),	  7.27	  (1H,	  t,	  J	  =	  7.4	  Hz,	  CNCCHCH),	  7.25	  (1H,	  d,	  J	  =	  7.4	  Hz,	  NCH2CCH),	  6.98	  (1H,	  d,	  
J	  =	  7.4	  Hz,	  CNCCH),	  6.62	  (1H,	  dd,	  J	  =	  8.4	  Hz,	  2.4	  Hz,	  C(CN)CHCH),	  6.51	  (1H,	  d,	   J	  =	  2.4	  Hz,	  
C(OMe)CHC(OMe)),	   4.53	   (2H,	   s,	   NCH2),	   3.90	   (3H,	   s,	   OCH3),	   3.60	   (3H,	   s,	   OCH3).	   13C-­‐NMR	  
(CDCl3	  126	  MHz)	  δ	  162.3	  (C(OMe)CHCC(OMe)),	  158.8	  (C(CN)C(OMe)),	  154.3	  (CNN),	  150.4	  
(C(NO2)),	  141.3	  (C(SO2)),	  132.0	  (Ar-­‐CC),	  131.4	  (C(CN)CH,	  130.3	  (Ar-­‐CC),	  130.0	  (2xC(NO2)CH),	  
128.2	   (Ar-­‐CH),	   126.6	   (Ar-­‐CH),	   126.1	   (Ar-­‐CH),	   125.5	   (Ar-­‐CH),	   123.9	   (2xC(SO2)CH),	   116.6	  
(C(CN)),	   104.9	   (C(CN)CHCH),	   98.8	   (C(OMe)CHC(OMe)),	   55.5	   (OCH3),	   55.3	   (OCH3),	   45.8	  
(NCH2).	  IR	  (neat)	  νmax:	  2936,	  1608,	  1348,	  1177,	  738	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C22H20N3O6S	  
[M+H]+	  454.0995	  m/z	  found	  454.0999	  m/z.	  
	  
12.5	  Procedure	  for	  de-­‐methylation:	  
The	   desired	   di-­‐methoxyl	   analogue	   (RCZ09,	   RCZ11,	   RCZ17	   or	   RCZ19)	   (0.24	   mmol)	   was	  
dissolved	   in	   dry	  DCM	   (6	  mL)	   and	   a	   1	  M	   solution	   of	   BBr3	   in	  DCM	   (2.4	  mmol)	  was	   added	  
dropwise	  at	  0	  °C.	  The	  reaction	  mixture	  was	  then	  heated	  to	  40	  °C	  until	  starting	  material	  was	  
consumed	  (ca.	  3-­‐36	  hours),	  as	  monitored	  by	  TLC.	  After	  cooling	  to	  room	  temperature,	  the	  
excess	  of	  BBr3	  was	  quenched	  with	  careful	  addition	  of	  water	  (20	  mL)	  and	  the	  organic	  and	  
aqueous	  layers	  were	  separated.	  The	  aqueous	  layer	  was	  then	  washed	  with	  DCM	  (2x20	  mL)	  
and	  the	  combined	  organic	   layers	  were	  dried	  over	  Na2SO4,	   filtered	  and	  concentrated.	  The	  






(4-­‐nitro-­‐phenyl)-­‐methanone	   (RCZ10):	   The	   product	   was	  
purified	   through	   flash	   column	   chromatography	   (1%	  
methanol	   in	   DCM)	   to	   give	   a	   yellow	   solid	   (45	   mg,	   0.13	  
mmol	   from	  90	  mg,	  0.24	  mmol	  of	  RCZ09)	   in	  55%	  yield.	  m.p.	  231	   °C.	   1H-­‐NMR	   (DMSO	  400	  
MHz)	  δ	  10.60	   (1H,	  s,	  COH),	  9.83	   (1H,	  s,	  COH),	  8.33	   (2H,	  d,	   J	  =	  8.6	  Hz,	  2xC(NO2)CH),	  7.79	  
(2H,	  d,	  J	  =	  8.6	  Hz,	  2xC(CO)CH),	  7.33	  (1H,	  d,	  J	  =	  8.8	  Hz,	  C(CN)CH),	  6.27	  (1H,	  dd,	  J	  =	  8.8	  Hz,	  2.2	  
Hz,	  C(CN)CHCH),	  6.03	  (1H,	  d,	  J	  =	  2.2	  Hz,	  C(OH)CHC(OH)),	  3.91	  (2H,	  t,	  J	  =	  5.7	  Hz,	  NCH2),	  2.76	  
(2H,	  t,	  J	  =	  6.9	  Hz,	  CNCH2),	  2.04	  (2H,	  dddd,	  J	  =	  6.8	  Hz,	  6.8	  Hz,	  5.7	  Hz,	  5.7	  Hz,	  NCH2CH2).	  13C-­‐
NMR	  (DMSO	  126	  MHz)	  δ	  167.1	  (CON),	  160.1	  (C(OH)CHC(OH)),	  158.7	  (C(CN)C(OH)),	  153.8	  
(C(NO2)),	   147.8	   (CNN),	   142.2	   (C(CO)),	   128.9	   (C(CN)CH),	   128.8	   (2xC(NO2)CH),	   123.6	  
(2xC(CO)CH),	  110.9	  (C(CN)),	  107.1	  (C(CN)CHCH),	  102.7	  (C(OH)CHC(OH)),	  44.1	  (NCH2),	  22.7	  
(CNCH2),	   16.8	   (NCH2CH2).	   IR	   (neat)	   νmax:	   3385,	   2359,	   1627,	   1518,	   1349	   cm-­‐1.	  HRMS	   (ESI)	  
calcd	  for	  C17H15N3NaO5	  [M+Na]+	  364.0904	  m/z	  found	  364.0890	  m/z.	  
	  
4-­‐[1-­‐(4-­‐Nitro-­‐benzenesulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐
pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ12):	   The	   product	  
was	   purified	   through	   flash	   column	   chromatography	  
(50%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  a	  bright	  
yellow	  foam	  (14	  mg,	  0.036	  mmol	  from	  100	  mg,	  0.24	  mmol	  of	  23)	  in	  15%.	  1H-­‐NMR	  (CDCl3	  
400	  MHz)	  δ	  11.79	  (1H,	  s,	  COH),	  8.30	  (2H,	  d,	  J	  =	  9.0	  Hz,	  2xC(NO2)CH),	  8.01	  (2H,	  d,	  J	  =	  9.0	  Hz,	  
2xC(SO2)CH),	  7.08	  (1H,	  d,	  J	  =	  8.7	  Hz,	  C(CN)CH),	  6.36	  (1H,	  d,	  J	  =	  2.5	  Hz,	  C(OH)CHC(OH)),	  6.27	  
(1H,	  dd,	  J	  =	  8.5	  Hz,	  2.5	  Hz,	  C(CN)CHCH),	  4.98	  (1H,	  s,	  COH),	  3.40	  (2H,	  t,	   J	  =	  6.9	  Hz,	  NCH2),	  
2.51	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.11	  (2H,	  dddd,	  J	  =	  6.9	  Hz,	  6.9	  Hz,	  6.7	  Hz,	  6.7	  Hz,	  NCH2CH2).	  
13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.8	   (C(OH)CHC(OH)),	   158.6	   (C(CN)C(OH)),	   154.7	   (CNN),	  
150.2	  (C(NO2)),	  142.0	  (C(SO2)),	  130.4	  (C(CN)CH),	  129.7	  (C(NO2)CH),	  123.8	  (C(SO2)CH),	  120.1	  
(C(CN)),	   104.6	   (C(CN)CHCH),	   98.7	   (C(OH)CHC(OH)),	   43.1	   (NCH2),	   25.1	   (CNCH2),	   19.0	  
(NCH2CH2).	   IR	   (neat)	   νmax:	   3431,	   2924,	   1627,	   1530,	   1349	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  








phenyl)-­‐methanone	   (RCZ18):	   The	   product	   was	   purified	  
through	   flash	   column	  chromatography	   (1%	  methanol	   in	  
DCM)	   to	   give	  an	  bright	   yellow	   solid	   (87	  mg,	  0.22	  mmol	  
from	  127	  mg,	  0.30	  mmol	  of	  RCZ17)	  in	  74%	  yield.	  m.p.	  253	  °C.	  1H-­‐NMR	  (DMSO	  400	  MHz)	  δ	  
9.60	  (1H,	  s,	  COH),	  9.51	  (1H,	  s,	  COH),	  8.28	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(NO2)CH),	  7.93	  (2H,	  d,	  J	  =	  
8.9	  Hz,	  2xC(CO)CH),	  7.53	  (1H,	  t,	  J	  =	  7.6	  Hz,	  NCH2CCHCH),	  7.49	  (1H,	  d,	  J	  =	  7.2	  Hz,	  NCH2CCH),	  
7.36	  (1H,	  t,	  J	  =	  7.7	  Hz,	  CNCCHCH),	  7.07	  (1H,	  d,	  J	  =	  7.2	  Hz,	  CNCCH),	  7.05	  (1H,	  d,	  J	  =	  8.3	  Hz,	  
C(CN)CH),	   6.35	   (1H,	   d,	   J	   =	   2.3	   Hz,	   C(OH)CHC(OH)),	   6.29	   (1H,	   dd,	   J	   =	   8.3	   Hz,	   2.3	   Hz,	  
C(CN)CHCH),	   5.09	   (2H,	   s,	   NCH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   167.8	   (CON),	   159.5	  
(C(OH)CHC(OH)),	   156.8	   (C(CN)C(OH)),	   151.8	   (C(NO2)),	   148.0	   (CNN),	   140.8	   (C(CO)),	   131.4	  
(Ar-­‐CC),	  131.2	  (C(CN)CH),	  130.7	  (2xC(NO2)CH),	  130.4	  (Ar-­‐CC),	  127.9	  (Ar-­‐CH),	  126.7	  (Ar-­‐CH),	  
126.1	  (Ar-­‐CH),	  125.3	  (Ar-­‐CH),	  122.7	  (2xC(CO)CH),	  112.7	  (C(CN),	  106.8	  (C(CN)CHCH),	  102.5	  
(C(OH)CHC(OH)),	   42.1	   (NCH2).	   IR	   (neat)	   νmax:	   2931,	   2355,	   1622,	   1348,	   1103	   cm-­‐1.	   HRMS	  
(ESI)	  calcd	  for	  C21H14N3O5	  [M-­‐H]-­‐	  388.0939	  m/z	  found	  388.0931	  m/z.	  
	  
4-­‐[3-­‐(4-­‐Nitro-­‐benzenesulphonyl)-­‐3,4-­‐dihydro-­‐phthalazin-­‐
1-­‐yl]-­‐benzene-­‐1,3-­‐diol	  (RCZ20):	  The	  product	  was	  purified	  
through	   flash	   column	  chromatography	   (1%	  methanol	   in	  
DCM)	  to	  afford	  a	  yellow	  foam	  (15	  mg,	  0.035	  mmol	  from	  
70	  mg,	  0.15	  mmol	  of	  RCZ19)	  in	  25%	  yield.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  10.34	  (1H,	  s,	  COH),	  
8.33	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(NO2)CH),	  8.09	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(SO2)CH),	  7.48	  (1H,	  t,	  J	  =	  7.5	  
Hz,	  NCH2CCHCH),	  7.43	  (1H,	  d,	  J	  =	  7.5	  Hz,	  NCH2CCH),	  7.35	  (1H,	  t,	  J	  =	  7.7	  Hz,	  CNCCHCH),	  7.26	  
(1H,	   d,	   J	   =	   7.7	   Hz,	   CNCCH),	   7.18	   (1H,	   d,	   8.5	   Hz,	   C(CN)CH),	   6.50	   (1H,	   d,	   2.3	   Hz,	  
C(OH)CHC(OH)),	  6.33	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  5.10	  (1H,	  s,	  COH),	  4.29	  (2H,	  s,	  
NCH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.5	   (C(OH)CHC(OH)),	   160.3	   (C(CN)C(OH)),	   157.7	  
(CNN),	  152.0	   (C(NO2)),	  140.9	   (C(SO2)),	  134.0	   (Ar-­‐CC),	  133.3	   (Ar-­‐CC),	  133.0	   (2xC(NO2)CH)),	  
131.9	   (C(CN)CH),	   129.3	   (Ar-­‐CH),	   128.6	   (Ar-­‐CH),	   127.4	   (Ar-­‐CH),	   125.5	   (Ar-­‐CH),	   125.4	  
(2xC(SO2)CH),	   110.5	   (C(CN)),	   108.0	   (C(CN)CHCH),	   104.6	   (C(OH)CHC(OH)),	   47.3	   (NCH2).	   IR	  
(neat)	   νmax:	   3122,	   2926,	   2363,	   1356,	   652	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C20H15N3NaO6S	  





12.6	  Alternative	  synthesis	  of	  RCZ12	  and	  RCZ20	  
	  
4-­‐(6-­‐Chloro-­‐pyridazin-­‐3-­‐yl)-­‐benzene-­‐1,3-­‐diol	   187	   (25):	   3,6-­‐
Dichloropyridazine	   (24)	   (2.9	   g,	   19.98	  mmol)	  was	   dissolved	   in	   dry	  
DCE	   (70	  mL)	   and	   resorcinol	   (2.0	   g,	   18.16	  mmol)	   and	   anhydrous	  
aluminium	   trichloride	   (3.39	   g,	   25.42	   mmol)	   were	   added	  
subsequently.	   The	   reaction	  mixture	  was	   refluxed	   (80	   °C)	   for	   18	   hours.	   The	  mixture	  was	  
then	   poured	   into	   a	   stirring	   3	  M	   solution	   of	   HCl	   and	   crushed	   ice.	   The	   yellow	   solid	   thus	  
formed	  was	  collected	  through	  suction	  filtration,	  washed	  with	  water	  (3x100	  mL)	  and	  dried	  
under	  high	  vacuum	  to	  afford	  a	  yellow	  solid	  (3.7	  g,	  16.66	  mmol,	  93%).	  Characterisation	  data	  
matched	  with	  the	  results	  previously	  reported	  187.	  1H-­‐NMR	  (DMSO	  500	  MHz)	  δ	  8.38	  (1H,	  d,	  J	  
=	  9.3	  Hz,	  ClCNCH),	  7.95	  (1H,	  d,	  J	  =	  9.3	  Hz,	  CNCH),	  7.82	  (1H,	  d,	  J	  =	  9.3	  Hz,	  C(CN)CH),	  6.47	  -­‐	  
6.40	   (2H,	   m,	   C(CN)CHCH,	   C(OH)CHC(OH)).	   13C-­‐NMR	   (DMSO	   126	   MHz)	   δ	   161.8	  
(C(OH)CHC(OH)),	   159.8	   (CNN),	   159.7	   (C(CN)C(OH)),	   153.5	   (ClCN),	   130.4	   (ClCNCH),	   129.9	  
(CNCH),	  128.8	  (C(CN)CH),	  110.3	  (C(CN)),	  108.5	  (C(CN)CHCH),	  103.8	  (C(OH)CHC(OH)).	  
	  
3-­‐Chloro-­‐6-­‐(2,4-­‐diisopropoxy-­‐phenyl)-­‐pyridazine	   (26):	   4-­‐(6-­‐
Chloro-­‐pyridazin-­‐3-­‐yl)-­‐benzene-­‐1,3-­‐diol	  (222	  mg,	  1.00	  mmol)	  was	  
dissolved	  in	  dry	  DMF	  (10	  mL)	  and	  anhydrous	  potassium	  carbonate	  
(552	   mg,	   4.00	   mmol)	   was	   added.	   After	   15	   minutes,	   2-­‐bromo	  
propane	  (375	  μL,	  4.00	  mmol)	  was	  added	  slowly	  to	  the	  reaction,	  which	  was	  stirred	  at	  50	  °C	  
for	  18	  hours.	  Water	  (25	  mL)	  was	  added	  and	  extracted	  with	  ether	  (3x50	  mL).	  The	  organic	  
phase	  was	  then	  washed	  with	  brine	  (5x50	  mL),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated	  
to	  yield	  the	  desired	  compound	  as	  a	  white	  paste	  (261	  mg,	  0.85	  mmol,	  85%).	  1H-­‐NMR	  (CDCl3	  
400	  MHz)	  δ	  8.07	  (1H,	  d,	  J	  =	  9.0	  Hz,	  ClCNCH),	  7.98	  (1H,	  d,	  J	  =	  8.7	  Hz,	  C(CN)CH),	  7.45	  (1H,	  d,	  J	  
=	   9.0	   Hz,	   CNCH),	   6.65	   (1H,	   dd,	   J	   =	   8.8	   Hz,	   2.3	   Hz,	   C(CN)CHCH),	   6.55	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OiPr)CHC(OiPr)),	  4.70	  -­‐	  4.55	  (2H,	  m,	  2xCH3CHCH3),	  1.40	  (6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3),	  1.34	  
(6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  160.9	  (C(OiPr)CHC(OiPr)),	  158.0	  
(CNN),	  156.7	  (C(CN)C(OiPr)),	  154.1	  (ClCN),	  132.1	  (ClCNCH),	  130.2	  (C(CN)CH),	  126.7	  (CNCH),	  
118.0	   (C(CN)),	  107.2	   (C(CN)CHCH),	  102.5	   (C(OiPr)CHC(OiPr)),	  71.0	   (CH3CH),	  70.1	   (CH3CH),	  
22.1	   (2xCHCH3),	  22.0	   (2xCHCH3).	   IR	   (neat)	  νmax:	  2980,	  1605,	  1399,	  1192,	  840	  cm-­‐1.	  HRMS	  






6-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐2H-­‐pyridazin-­‐3-­‐one	   187	   (27):	   3-­‐
Chloro-­‐6-­‐(2,4-­‐diisopropoxy-­‐phenyl)-­‐pyridazine	  (26)	  (657	  mg,	  2.14	  
mmol)	   was	   dissolved	   in	   glacial	   acetic	   acid	   (20	   mL)	   and	   sodium	  
acetate	  (352	  mg,	  4.29	  mmol)	  was	  added	  one	  pot.	  The	  reaction	  mixture	  was	  stirred	  at	  110	  
°C	   for	   18	   hours.	  Water	   (50	  mL)	   was	   added	   to	   the	  mixture	   and	   the	   aqueous	   phase	  was	  
washed	  with	  DCM	   (3x50	  mL),	   dried	  over	  Na2SO4,	   filtered	   and	   concentrated.	   The	   residue	  
was	   further	  dried	  under	  high	  vacuum	  to	  afford	   the	  desired	  product	  with	  excellent	  purity	  
(by	  NMR)	   as	   a	  white	   solid	   (585	  mg,	   2.03	  mmol,	   94%).	  m.p.	   155	   °C.	   1H-­‐NMR	   (CDCl3	   500	  
MHz)	  δ	  10.39	  (1H,	  s,	  NH),	  7.80	  (1H,	  d,	  J	  =	  9.9	  Hz,	  ClCNCH),	  7.49	  (1H,	  d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  
6.92	  (1H,	  d,	  J	  =	  9.9	  Hz,	  CNCH),	  6.57	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.51	  (1H,	  d,	  J	  =	  
2.2	  Hz,	  C(OiPr)CHC(OiPr)),	  4.66	  -­‐	  4.51	  (2H,	  m,	  2xCH3CH),	  1.38	  (6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3),	  
1.35	   (6H,	   d,	   J	   =	   6.1	   Hz,	   2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   160.5	   (CON),	   160.4	  
(C(OiPr)CHC(OiPr)),	   156.5	   (C(CN)C(OiPr)),	   145.8	   (CNN),	   136.0	   (CNCH),	   130.7	   (CONHCH),	  
128.2	   (C(CN)CH),	   117.5	   (C(CN)),	   107.1	   (C(CN)CHCH),	   102.6	   (C(OiPr)CHC(OiPr)),	   70.9	  
(CH3CH),	  70.1	  (CH3CH),	  22.0	  (4xCHCH3).	   IR	  (neat)	  νmax:	  3079,	  1524,	  1282,	  1109,	  949	  cm-­‐1.	  
HRMS	  (ESI)	  calcd	  for	  C16H20N2NaO3	  [M+Na]+	  311.1366	  m/z	  found	  311.1348	  m/z.	  
	  
3-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1,4,5,6-­‐tetrahydro-­‐pyridazine	   135	   (28):	  
6-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐2H-­‐pyridazin-­‐3-­‐one	  (27)	  (250	  mg,	  0.86	  
mmol)	  was	  dissolved	  in	  dry	  THF	  (30	  mL)	  and	  LiAlH4	   (263	  mg,	  8.63	  
mmol)	  was	  added	  portion-­‐wise.	  The	  reaction	  mixture	  was	  refluxed	  at	  80	  °C	  for	  18	  hours.	  
Water	  (60	  mL)	  was	  added	  carefully	  at	  0	  °C	  to	  quench	  the	  excess	  of	  LiAlH4	  and	  the	  mixture	  
was	   then	  extracted	  with	  DCM	  (3x100	  mL),	  dried	  over	  Na2SO4,	   filtered	  and	  concentrated.	  
The	  desired	  amine	  was	  obtained	  as	  thick	  greenish	  oil	  with	  excellent	  purity	  (by	  NMR)	  and	  it	  
was	  used	  without	  any	  further	  purification	  (214	  mg,	  0.77	  mmol,	  90%).	  1H-­‐NMR	  (CDCl3	  500	  
MHz)	  δ	  7.18	  (1H,	  d,	  J	  =	  9.6	  Hz,	  C(CN)CH),	  6.38	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.34	  
(1H,	   d,	   J	   =	   2.3	  Hz,	   C(OiPr)CHC(OiPr)),	   4.51	   -­‐	   4.38	   (2H,	  m,	   2xCH3CH),	   3.10	   -­‐	   3.04	   (2H,	  m,	  
NHCH2),	  2.53	  (2H,	  t,	  J	  =	  6.9	  Hz,	  CNCH2),	  1.95	  -­‐	  1.87	  (2H,	  m,	  NHCH2CH2),	  1.25	  (12H,	  d,	  J	  =	  6.1	  
Hz,	  4xCHCH3).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  158.7	  (C(OiPr)CHC(OiPr)),	  156.5	  (C(CN)C(OiPr)),	  
148.5	   (CNN),	   129.9	   (C(CN)CH),	   123.6	   (C(CN)),	   106.7	   (C(CN)CHCH),	   102.9	  
(C(OiPr)CHC(OiPr)),	   70.4	   (CH3CH),	   69.9	   (CH3CH),	   42.2	   (NHCH2),	   25.8	   (CNCH2),	   22.1	  




cm-­‐1.	  IR	  (neat)	  νmax:	  2999,	  1715,	  1346,	  1018,	  789	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C16H20N2NaO2	  
[M+Na]+	  311.1366	  m/z	  found	  311.1348	  m/z.	  
	  
3-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1-­‐(4-­‐nitro-­‐
benzenesulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐pyridazine	   (29):	  
3-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1,4,5,6-­‐tetrahydro-­‐
pyridazine	   (28)	   (200	  mg,	  0.72	  mmol)	  was	  dissolved	   in	  
dry	  DCM	  (10	  mL)	  and	  TEA	  (200	  μL,	  1.44	  mmol)	  and	  DMAP	  (1	  mg,	  0.072	  mmol)	  were	  added	  
subsequently.	  After	  5	  minutes,	  4-­‐nitrobenzenesulphonyl	  chloride	  (192	  mg,	  0.86	  mmol)	  was	  
added	   and	   the	   reaction	   mixture	   was	   stirred	   at	   room	   temperature	   until	   the	   starting	  
material	  was	  no	  longer	  detectable	  by	  TLC	  (16	  hours).	  The	  solvent	  was	  then	  removed	  and	  
the	   product	   was	   purified	   by	   direct	   flash	   column	   chromatography	   (30%	   ethyl	   acetate	   in	  
petroleum	  ether)	  to	  afford	  a	  yellow	  oil	  (206	  mg,	  0.44	  mmol)	  in	  62%	  yield.	  1H-­‐NMR	  (CDCl3	  
400	  MHz)	  δ	  8.37	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(NO2)CH),	  8.14	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(SO2)CH),	  7.19	  
(1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  6.45	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.2	  Hz,	  C(CN)CHCH),	  6.39	  (1H,	  d,	  J	  =	  
2.2	  Hz,	  C(OiPr)CHC(OiPr)),	  4.56	  (1H,	  dt,	  J	  =	  12.6	  Hz,	  6.0	  Hz,	  CH3CH),	  4.49	  (1H,	  dt,	  J	  =	  12.5	  
Hz,	  6.0	  Hz,	  CH3CH),	  3.49	  (2H,	  t,	  J	  =	  5.6	  Hz,	  NCH2),	  2.60	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.04	  (2H,	  
dddd,	  J	  =	  6.8	  Hz,	  6.8	  Hz,	  5.7	  Hz,	  5.7	  Hz,	  NCH2CH2),	  1.36	  (6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3),	  1.27	  
(6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  160.0	  (C(OiPr)CHC(OiPr)),	  157.0	  
(C(CN)C(OiPr)),	   155.4	   (CNN),	   150.4	   (C(NO2)),	   142.1	   (C(SO2)),	   130.4	   (C(CN)CH),	   129.7	  
(2xC(NO2)CH),	   123.8	   (2xC(SO2)CH),	   120.7	   (C(CN)),	   106.3	   (C(CN)CHCH),	   102.3	  
(C(OiPr)CHC(OiPr)),	   70.4	   (CH3CH),	   70.0	   (CH3CH),	   43.2	   (NCH2),	   26.0	   (CNCH2),	   22.1	  
(2xCHCH3),	  22.0	  (2xCHCH3),	  19.0	  (NCH2CH2).	   IR	  (neat)	  νmax:	  2977,	  1606,	  1570,	  1372,	  1188	  
cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C22H27N3O6S	  [M+H]+	  462.1616	  m/z	  found	  462.1634	  m/z.	  
	  
4-­‐[1-­‐(4-­‐Nitro-­‐benzenesulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐
pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ12):	   3-­‐(2,4-­‐
Diisopropoxy-­‐phenyl)-­‐1-­‐(4-­‐nitro-­‐benzenesulphonyl)-­‐
1,4,5,6-­‐tetrahydro-­‐pyridazine	  (29)	   (100	  mg,	  0.21	  mmol)	  was	  dissolved	   in	  dry	  DCM	  (6	  mL)	  
and	  a	  1	  M	  solution	  of	  BBr3	   in	  DCM	  (1.68	  mL,	  1.68	  mmol)	  was	  added	  slowly	  at	  0	   °C.	  The	  
reaction	  mixture	  was	  stirred	  at	  0	   °C	   for	  30	  minutes	  and	  then	  at	   room	  temperature	   for	  3	  
hours.	   Water	   (20	   mL)	   was	   added	   and	   the	   layers	   separated.	   The	   aqueous	   phase	   was	  




filtered	  and	  concentrated.	  The	  product	  was	  purified	  through	  flash	  column	  chromatography	  
(40%	  ethyl	   acetate	   in	  petroleum	  ether)	   to	   afford	  RCZ12	  as	   a	   yellow	   foam	   (50	  mg,	  0.132	  
mmol,	   58%).	   NMR,	   IR	   and	   mass	   spectrometry	   matches	   with	   the	   compound	   previously	  
obtained.	  
	  
1,4-­‐Dichloro-­‐phthalazine	   (31):	   The	   synthesis	   of	   this	   compound	   was	  
achieved	   through	   a	   modified	   known	   protocol	   138.	   An	   oven	   dried	   round	  
bottom	  flask	  was	  loaded	  with	  phthalhydrazide	  (30)	  (5	  g,	  30.86	  mmol)	  and	  
POCl3	   (30	   mL).	   The	   reaction	   mixture	   was	   stirred	   for	   4	   hours	   at	   110	   °C	   under	   argon	  
atmosphere.	  The	  mixture	  was	  then	  added	  dropwise	  to	  stirring	  solution	  of	  crushed	  ice	  and	  
saturated	  NaHCO3	  (500	  mL)	  to	  quench	  the	  POCl3	  excess.	  The	  pH	  was	  then	  adjusted	  to	  8/9	  
with	  a	  3	  M	  solution	  of	  NaOH	  (200	  mL)	  and	  the	  aqueous	  solution	  was	  extracted	  with	  DCM	  
(3x250	   mL),	   dried	   over	   Na2SO4,	   filtered	   and	   concentrated	   to	   afford	   the	   product	   as	   a	  
yellowish	  solid	  (5.4	  g,	  27.13	  mmol)	  in	  87%	  yield.	  The	  product	  was	  used	  without	  any	  further	  
purification.	   Characterisation	   data	  matched	  with	   the	   results	   previously	   reported	   138.	   1H-­‐
NMR	  (CDCl3	  400	  MHz)	  δ	  8.39	  -­‐	  8.32	  (2H,	  m),	  8.14	  -­‐	  8.08	  (2H,	  m).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  
δ	  155.0,	  134.4,	  127.3,	  125.9.	  
	  
4-­‐(4-­‐Chloro-­‐phthalazin-­‐1-­‐yl)-­‐benzene-­‐1,3-­‐diol	   187	   (32):	  1,4-­‐Dichloro-­‐
phthalazine	   (31)	   (1.5	   g,	   7.53	  mmol)	   was	   dissolved	   in	   dry	   DCE	   (35	  
mL)	  and	  resorcinol	  (753	  mg,	  6.85	  mmol)	  and	  anhydrous	  aluminium	  
trichloride	   (1.22	   g,	   9.59	   mmol)	   were	   added	   subsequently.	   The	  
reaction	  mixture	  was	   refluxed	   (80	   °C)	   for	  18	  hours.	  The	  mixture	  was	   then	  poured	   into	  a	  
stirring	  3	  M	  solution	  of	  HCl	  and	  crushed	   ice.	  The	  yellow	  solid	   thus	   formed	  was	  collected	  
through	  suction	  filtration,	  washed	  with	  water	  (3x50	  mL)	  and	  dried	  under	  high	  vacuum	  to	  
afford	  a	  yellow/orange	  solid	  (1.61	  g,	  5.91	  mmol,	  78%).	  Characterisation	  data	  matched	  with	  
the	   results	   previously	   reported	   187.	   1H-­‐NMR	   (DMSO	  500	  MHz)	   δ	   8.37	   (1H,	   d,	   J	   =	   8.1	  Hz,	  
ClCNCCH),	  8.20	  (1H,	  t,	  J	  =	  8.2	  Hz,	  ClCNCCHCH),	  8.12	  (1H,	  t,	  J	  =	  7.1	  Hz,	  CNCCHCH),	  7.91	  (1H,	  
d,	   J	   =	   7.2	   Hz,	   CNCCH),	   7.22	   (1H,	   d,	   J	   =	   8.3	   Hz,	   C(CN)CH),	   6.58	   (1H,	   d,	   J	   =	   2.2	   Hz,	  
C(OH)CHC(OH)),	  6.47	  (1H,	  dd,	  J	  =	  8.3	  Hz,	  2.2	  Hz,	  C(CN)CHCH).	  13C-­‐NMR	  (DMSO	  126	  MHz)	  δ	  
161.1	   (C(OH)CHC(OH)),	  159.8	   (CNN),	  157.0	   (C(CN)CH),	  154.1	   (ClCN),	  135.4	   (Ar-­‐CC),	  134.6	  
(Ar-­‐CC),	  132.7	  (C(CN)CH),	  129.1	  (Ar-­‐CH),	  128.3	  (Ar-­‐CH),	  125.9	  (Ar-­‐CH),	  125.2	  (Ar-­‐CH),	  111.3	  




	  	  	  
1-­‐Chloro-­‐4-­‐(2,4-­‐diisopropoxy-­‐phenyl)-­‐phthalazine	   (33):	   4-­‐(4-­‐
Chloro-­‐phthalazin-­‐1-­‐yl)-­‐benzene-­‐1,3-­‐diol	   (32)	   (1.35	   g,	   4.77	   mmol)	  
was	   dissolved	   in	   dry	   DMF	   (35	   mL)	   and	   anhydrous	   potassium	  
carbonate	   (2.60	   g,	   19.11	  mmol)	  was	   added.	   After	   15	  minutes,	   2-­‐
bromo	  propane	  (1.7	  mL,	  19.11	  mmol)	  was	  added	  slowly	  to	  the	  reaction,	  which	  was	  stirred	  
at	  50	  °C	  for	  18	  hours.	  Water	  (70	  mL)	  was	  added	  and	  extracted	  with	  ether	  (3x80	  mL).	  The	  
organic	   phase	   was	   then	   washed	   with	   brine	   (5x80	   mL),	   dried	   over	   Na2SO4,	   filtered	   and	  
concentrated	   to	   yield	   the	   desired	   compound	   as	   a	   colourless	   paste	   (1.68	   g,	   4.71	  mmol,	  
98%).	   1H-­‐NMR	   (CDCl3	  500	  MHz)	  δ	  8.33	   (1H,	  d,	   J	  =	  8.3	  Hz,	  ClCNCCH),	  8.00	   -­‐	  7.91	   (1H,	  m,	  
ClCNCCHCH),	  7.87	  -­‐	  7.80	  (2H,	  m,	  CNCCH,	  CNCCHCH),	  7.43	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  6.67	  
(1H,	  dd,	  J	  =	  8.4	  Hz,	  2.2	  Hz,	  C(CN)CHCH),	  6.59	  (1H,	  d,	  J	  =	  2.2	  Hz,	  C(OiPr)CHC(OiPr)),	  4.66	  (1H,	  
dt,	  J	  =	  12.1	  Hz,	  6.0	  Hz,	  CH3CH),	  4.44	  (1H,	  dt,	  J	  =	  12.1	  Hz,	  6.1	  Hz,	  CH3CH),	  1.46	  -­‐	  1.35	  (6H,	  m,	  
CHCH3)	  1.11	  -­‐	  1.07	  (6H,	  m,	  CHCH3).	  13C-­‐NMR	  (CDCl3	  126	  MHz)	  δ	  160.5	  (C(OiPr)CHC(OiPr)),	  
159.4	   (C(CN)C(OiPr)),	   156.7	   (CNN),	   154.3	   (ClCN),	   132.7	   (Ar-­‐CC),	   132.4	   (Ar-­‐CC),	   132.1	  
(C(CN)CH),	  128.3	  (Ar-­‐CH),	  128.2	  (Ar-­‐CH),	  125.6	  (Ar-­‐CH),	  124.8	  (Ar-­‐CH),	  118.2	  (C(CN)),	  107.0	  
(C(CN)CHCH),	  102.6	  (C(OiPr)CHC(OiPr)),	  70.7	  (CH3CH),	  70.1	  (CH3CH),	  22.1	  (2xCHCH3),	  21.7	  
(2xCHCH3).	   IR	   (neat)	   νmax:	   2977,	   1606,	   1382,	   1287,	   1007	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  
C20H21N2NaO235Cl	  [M+Na]+	  379.1184	  m/z	  found	  379.1169	  m/z.	  
	  
4-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐2H-­‐phthalazin-­‐1-­‐one	   187	   (34):	   1-­‐
Chloro-­‐4-­‐(2,4-­‐diisopropoxy-­‐phenyl)-­‐phthalazine	   (33)	   (500	  mg,	  1.40	  
mmol)	   was	   dissolved	   in	   glacial	   acetic	   acid	   (40	   mL)	   and	   sodium	  
acetate	   (230	   mg,	   2.80	   mmol)	   was	   added	   one	   pot.	   The	   reaction	  
mixture	  was	  stirred	  at	  110	  °C	  for	  18	  hours.	  Water	  (70	  mL)	  was	  added	  to	  the	  mixture	  and	  
the	   aqueous	   phase	   was	   washed	   with	   DCM	   (3x70	   mL),	   dried	   over	   Na2SO4,	   filtered	   and	  
concentrated.	  The	  residue	  was	  further	  dried	  under	  high	  vacuum	  to	  afford	  the	  product	   in	  
excellent	  purity	  as	  a	  white	  solid	   (455	  mg,	  1.34	  mmol,	  96%).	  m.p.	  182	   °C.	   1H-­‐NMR	  (CDCl3	  
500	   MHz)	   δ	   9.94	   (1H,	   s,	   NH),	   8.47	   (1H,	   d,	   J	   =	   7.9	   Hz,	   CONHCCH),	   7.82	   -­‐	   7.67	   (2H,	   m,	  
CONHCCHCH,	  CNCCHCH),	  7.50	  (1H,	  d,	  J	  =	  6.9	  Hz,	  CNCCH),	  7.29	  (1H,	  d,	  J	  =	  8.3	  Hz,	  C(CN)CH)	  
(solvent	  peak	  overlap),	  6.62	  (1H,	  dd,	  J	  =	  8.4	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.57	  (1H,	  d,	  J	  =	  2.2	  Hz,	  
C(OiPr)CHC(OiPr)),	  4.64	  (1H,	  dt,	  J	  =	  12.1	  Hz,	  6.1	  Hz,	  CH3CH),	  4.47	  (1H,	  dt,	  J	  =	  12.1	  Hz,	  6.1	  




(CDCl3	   126	  MHz)	   δ	   168.3	   (CONH),	   160.2	   (C(OiPr)CHC(OiPr)),	   157.0	   (C(CN)C(OiPr)),	   154.7	  
(CNNH),	  132.7	  (Ar-­‐CC),	  131.7	  (C(CN)CH),	  131.1	  (Ar-­‐CC),	  130.7	  (Ar-­‐CH),	  128.0	  (Ar-­‐CH),	  127.7	  
(Ar-­‐CH),	  126.1	   (Ar-­‐CH),	  117.5	   (C(CN)),	  106.7	   (C(CN)CHCH),	  102.6	   (C(OiPr)CHC(OiPr)),	  70.6	  
(CH3CH),	  70.1	  (CH3CH),	  22.1	  (CHCH3),	  22.0	  (CHCH3),	  21.9	  (CHCH3),	  21.6	  (CHCH3).	   IR	  (neat)	  
νmax:	   3130,	   1658,	   1506,	   1193,	   950	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C20H22N2NaO3	   [M+Na]+	  
361.1523	  m/z	  found	  361.1505	  m/z.	  
	  
4-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1,2-­‐dihydro-­‐phthalazine	   135	   (35):	  4-­‐(2,4-­‐
Diisopropoxy-­‐phenyl)-­‐2H-­‐phthalazin-­‐1-­‐one	  (34)	  (500	  mg,	  1.47	  mmol)	  
was	  dissolved	  in	  dry	  THF	  (30	  mL)	  and	  LiAlH4	  (168	  mg,	  4.43	  mmol)	  was	  
added	  portion-­‐wise.	  The	  reaction	  mixture	  was	  refluxed	  at	  80	  °C	  for	  3	  
hours.	  Water	  (60	  mL)	  was	  added	  carefully	  at	  0	  °C	  to	  quench	  the	  excess	  of	  LiAlH4	  and	  the	  
mixture	   was	   then	   extracted	   with	   DCM	   (3x100	   mL),	   dried	   over	   Na2SO4,	   filtered	   and	  
concentrated.	  The	  desired	  amine	  was	  obtained	  as	  yellowish	  oil	  with	  excellent	  purity	  and	  it	  
was	  used	  without	  any	  further	  purification	  (444	  mg,	  1.37	  mmol,	  93%).	  1H-­‐NMR	  (CDCl3	  500	  
MHz)	  δ	  7.37	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  7.32	  (1H,	  td,	  J	  =	  7.5	  Hz,	  1.2	  Hz,	  NHCH2CCHCH),	  
7.19	  (1H,	  td,	  J	  =	  7.6	  Hz,	  1.1	  Hz,	  CNCCHCH),	  7.14	  (1H,	  d,	  J	  =	  7.4	  Hz,	  CNCCH),	  6.95	  (1H,	  d,	  J	  =	  
7.7	  Hz,	  NHCH2CCH),	  6.58	  (1H,	  dd,	  J	  =	  8.4	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.50	  (1H,	  d,	  J	  =	  2.3	  Hz,	  
C(OiPr)CHC(OiPr)),	  6.00	  (1H,	  s,	  NH),	  4.60	  (1H,	  dt,	  J	  =	  12.1	  Hz,	  6.1	  Hz,	  CH3CH),	  4.40	  (1H,	  dt,	  J	  
=	  12.1	  Hz,	  6.0	  Hz,	  CH3CH),	  4.26	  (2H,	  s,	  NHCH2),	  1.39	  (6H,	  d,	  J	  =	  6.1	  Hz,	  2xCHCH3),	  1.08	  (6H,	  
d,	   J	   =	   6.0	   Hz,	   2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   159.4	   (C(OiPr)CHC(OiPr)),	   157.1	  
(C(CN)C(OiPr)),	   157.1	   (CNNH),	   131.6	   (Ar-­‐CC),	   131.4	   (C(CN)CH),	   131.3	   (Ar-­‐CC),	   129.7	   (Ar-­‐
CH),	  127.1	  (Ar-­‐CH),	  125.4	  (Ar-­‐CH),	  124.5	  (Ar-­‐CH),	  115.5	  (C(CN)),	  107.1	  (C(CN)CHCH),	  103.4	  
(C(OiPr)CHC(OiPr)),	   70.6	   (CH3CH),	   69.9	   (CH3CH),	   45.7	   (NHCH2),	   22.1	   (2xCHCH3),	   21.8	  
(2xCHCH3).	   IR	   (neat)	   νmax:	   2976,	   2365,	   1618,	   1173,	   1095	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  






Diisopropoxy-­‐phenyl)-­‐1,2-­‐dihydro-­‐phthalazine	   (35)	   (150	  




TEA	  (128	  μL,	  0.92	  mmol)	  and	  DMAP	  (1	  mg,	  0.046	  mmol)	  were	  added	  subsequently.	  After	  5	  
minutes,	   4-­‐nitrobenzenesulphonyl	   chloride	   (112	   mg,	   0.50	   mmol)	   was	   added	   and	   the	  
reaction	  mixture	  was	  stirred	  at	  room	  temperature	  until	  the	  starting	  material	  was	  no	  longer	  
detectable	  by	  TLC	  (16	  hours).	  The	  solvent	  was	  then	  removed	  and	  the	  product	  was	  purified	  
by	  direct	  flash	  column	  chromatography	  (20%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  a	  
yellow	   foam	   (150	  mg,	  0.29	  mmol)	   in	  64%	  yield.	   The	  product	  was	  purified	  by	  direct	   flash	  
column	  chromatography	   (20%	  ethyl	  acetate	   in	  petroleum	  ether)	   to	  afford	  a	  yellow	  oil	   in	  
64%	  yield.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.40	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(NO2)CH),	  8.26	  (2H,	  d,	  J	  =	  
8.8	  Hz,	  2xC(SO2)CH),	  7.47	  (1H,	  t,	  J	  =	  7.5	  Hz,	  NCH2CCHCH),	  7.48	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  
7.31	  (1H,	  t,	  J	  =	  7.5	  Hz,	  CNCCHCH),	  7.27	  (1H,	  d,	  J	  =	  7.6	  Hz,	  NCH2CCH),	  7.02	  (1H,	  d,	  J	  =	  7.6	  Hz,	  
CNCCH),	   6.68	   (1H,	   dd,	   J	   =	   2.3	   Hz,	   8.4	   Hz,	   C(CN)CHCH),	   6.55	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OiPr)CHC(OiPr)),	  4.65	  (1H,	  dt,	  J	  =	  13.1	  Hz,	  6.1	  Hz,	  CH3CH),	  4.53	  (2H,	  s,	  NCH2),	  4.42	  (1H,	  dt,	  
J	   =	   12.8	   Hz,	   6.0	   Hz,	   CH3CH),	   1.33	   (6H,	   d,	   J	   =	   6.0	   Hz,	   2xCHCH3),	   1.27	   (6H,	   d,	   J	   =	   6.0	   Hz,	  
2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   159.6	   (C(OiPr)CHC(OiPr)),	   158.7	   (C(CN)C(OiPr)),	  
156.9	   (CNN),	   150.8	   (C(NO2)),	   140.2	   (C(SO2)),	   132.4	   (2xAr-­‐CC),	   132.0	   (2xC(NO2)CH),	   130.0	  
(C(CN)CH),	  128.6	  (Ar-­‐CH),	  128.1	  (Ar-­‐CH),	  126.5	  (Ar-­‐CH),	  124.5	  (Ar-­‐CH),	  124.4	  (2xC(SO2)CH),	  
110.0	   (C(CN)),	   106.9	   (C(CN)CH),	   104.4	   (C(OiPr)CHC(OiPr)),	   65.8	   (2xCH3CH),	   46.4	   (NCH2),	  
15.2	   (4xCHCH3).	   IR	   (neat)	   νmax:	   2979,	  1648,	  1522,	  1374,	  1136	   cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	  
C26H27N3NaO6S	  [M+Na]+	  532.1513	  m/z	  found	  532.1504	  m/z.	  
	  
4-­‐[3-­‐(4-­‐Nitro-­‐benzenesulphonyl)-­‐3,4-­‐dihydro-­‐phthalazin-­‐
1-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ20):	   4-­‐(2,4-­‐Diisopropoxy-­‐
phenyl)-­‐2-­‐(4-­‐nitro-­‐benzenesulphonyl)-­‐1,2-­‐dihydro-­‐
phthalazine	   (36)	   (100	  mg,	   0.19	  mmol)	  was	   dissolved	   in	  
dry	  DCM	  (6	  mL)	  and	  aluminium	  trichloride	  (157	  mg,	  1.17	  mmol)	  was	  added.	  The	  reaction	  
mixture	  was	  stirred	  at	  room	  temperature	  overnight.	  The	  solvent	  was	  then	  evaporated	  off	  
under	   reduced	   pressure	   and	   the	   product	   was	   purified	   through	   direct	   flash	   column	  
chromatography	  (50%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  RCZ20	  as	  a	  yellow	  foam	  






12.7	  Procedure	  for	  allylation:	  
RCZ12	  or	  RCZ20	  (0.26	  mmol)	  were	  dissolved	  in	  dry	  DMF	  (12	  mL)	  and	  anhydrous	  potassium	  
carbonate	  (0.78	  mmol)	  was	  added.	  After	  15	  minutes,	  allyl	  bromide	  (1.06	  mmol)	  was	  added	  
slowly	   to	   the	  reaction,	  which	  was	  stirred	  at	   room	  temperature	  overnight.	  Water	   (10	  mL)	  
was	  added	  and	  extracted	  with	  ether	  (3x15	  mL).	  The	  organic	  phase	  was	  then	  washed	  with	  
brine	  (5x30	  mL),	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  product	  thus	  obtained	  
was	  used	  in	  the	  next	  step	  without	  further	  purification.	  
	  
3-­‐(2,4-­‐Bis-­‐allyloxy-­‐phenyl)-­‐1-­‐(4-­‐nitro-­‐
benzenesulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐pyridazine	   (37):	  
The	   product	   was	   obtained	   as	   a	   yellow	   oil	   (106	   mg,	  
0.231	  mmol,	  89%).	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.27	  (2H,	  d,	  J	  =	  8.9	  Hz,	  2xC(NO2)CH),	  8.03	  
(2H,	  d,	  J	  =	  8.9	  Hz,	  2xC(SO2)CH),	  7.14	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  6.41	  (1H,	  dd,	  J	  =	  8.4	  Hz,	  
2.3	  Hz,	  C(CN)CHCH),	  6.36	  (1H,	  d,	  J	  =	  2.2	  Hz,	  C(OAllyl)CHC(OAllyl)),	  5.97	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  
10.6	  Hz,	  5.2	  Hz,	  OCH2CHCH2),	  5.87	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  10.1	  Hz,	  5.3	  Hz,	  OCH2CHCH2),	  5.35	  
(1H,	   dd,	   J	   =	   17.2	   Hz,	   1.5	   Hz,	   OCH2CHCHH	   (trans)),	   5.23	   (1H,	   dd,	   J	   =	   9.8	   Hz,	   1.2	   Hz,	  
OCH2CHCHH	  (cis)),	  5.22	  (1H,	  dd,	  J	  =	  15.6	  Hz,	  1.3	  Hz,	  OCH2CHCHH	  (trans)),	  5.15	  (1H,	  dd,	  J	  =	  
10.4	  Hz,	  1.2	  Hz,	  OCH2CHCHH	  (cis)),	  4.46	  (2H,	  dt,	  J	  =	  5.4	  Hz,	  1.4	  Hz,	  OCH2CHCH2),	  4.39	  (2H,	  
dt,	  J	  =	  5.2	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  3.40	  (2H,	  t,	  J	  =	  5.6	  Hz,	  NCH2),	  2.51	  (2H,	  t,	  J	  =	  6.6	  Hz,	  
CNCH2),	  1.97	  (2H,	  dddd,	  J	  =	  6.6	  Hz,	  6.6	  Hz,	  5.7	  Hz,	  5.7	  Hz,	  NCH2CH2).	  13C-­‐NMR	  (CDCl3	  126	  
MHz)	  δ	  160.7	   (C(OAllyl)CHC(OAllyl)),	   157.4	   (C(CN)C(OAllyl)),	   154.7	   (CNN),	  150.3	   (C(NO2)),	  
142.1	   (C(SO2)),	   132.8	   (OCH2CHCH2),	   132.7	   (OCH2CHCH2),	   130.3	   (C(CN)CH),	   129.7	  
(2xC(NO2)CH),	   123.8	   (2xC(SO2)CH),	   118.2	   (OCH2CHCH2),	   117.7	   (OCH2CHCH2),	   105.8	  
(C(CN)CHCH),	   100.6	   (C(OAllyl)CHC(OAllyl)),	   69.1	   (OCH2CHCH2),	   68.9	   (OCH2CHCH2),	   43.1	  
(NCH2),	   26.0	   (CNCH2),	   18.9	   (NCH2CH2).	   IR	   (neat)	   νmax:	   2359,	   1607,	   1529,	   1349,	   930	   cm-­‐1.	  




benzenesulphonyl)-­‐1,2-­‐dihydro-­‐phthalazine	   (38):	   The	  
product	   was	   obtained	   as	   a	   yellow	   oil	   (89	   mg,	   0.176	  
mmol,	  99%).	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.27	  (2H,	  d,	  J	  =	  




7.33	  (1H,	  t,	  J	  =	  7.7	  Hz,	  CNCCHCH),	  7.15	  (2H,	  m,	  NCH2CCH,	  NCH2CCHCH),	  6.92	  (1H,	  d,	  J	  =	  7.6	  
Hz,	   CNCCH),	   6.54	   (1H,	   dd,	   J	   =	   8.5	   Hz,	   2.3	   Hz,	   C(CN)CHCH),	   6.42	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OAllyl)CHC(OAllyl)),	   6.01	   (1H,	  ddt,	   J	   =	  17.2	  Hz,	  10.6	  Hz,	  5.4	  Hz,	  OCH2CHCH2),	   5.51	   (1H,	  
ddt,	   J	   =	   17.1	   Hz,	   10.6	   Hz,	   4.4	   Hz,	   OCH2CHCH2),	   5.38	   (1H,	   dq,	   J	   =	   17.1	   Hz,	   1.5	   Hz,	  
OCH2CHCHH	  (trans)),	  5.27	  (1H,	  dq,	  J	  =	  10.5	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (cis)),	  4.83	  (1H,	  dq,	  J	  =	  
10.8	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (cis)),	  4.69	  (1H,	  dq,	  J	  =	  17.2	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (trans)),	  
4.51	  (2H,	  dt,	  J	  =	  5.2	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  4.41	  (2H,	  s,	  NCH2),	  4.24	  (2H,	  dt,	  J	  =	  4.4	  Hz,	  1.5	  
Hz,	   OCH2CHCH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.2	   (C(OAllyl)CHC(OAllyl)),	   157.7	  
(C(CN)C(OAllyl)),	  157.6	  (CNN),	  148.4	  (C(NO2)),	  141.3	  (C(SO2)),	  132.9	  (Ar-­‐CC),	  132.3	  (Ar-­‐CC),	  
131.9	  (OCH2CHCH2),	  131.8	  (OCH2CHCH2),	  131.4	  (C(CN)CH),	  130.3	  (2xC(NO2)CH),	  130.1	  (Ar-­‐
CH),	  128.2	  (Ar-­‐CH),	  127.5	  (Ar-­‐CH),	  126.7	  (Ar-­‐CH),	  125.4	  (2xC(SO2)CH),	  123.9	  (C(CN)),	  118.0	  
(OCH2CHCH2),	   116.3	   (OCH2CHCH2),	   106.1	   (C(CN)CHCH),	  100.6	   (C(OAllyl)CHC(OAllyl)),	   69.0	  
(OCH2CHCH2),	  68.6	  (OCH2CHCH2),	  45.8	  (NCH2).	  IR	  (neat)	  νmax:	  2359,	  1608,	  1356,	  1171,	  1029	  
cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C26H23N3NaO6S	  [M+Na]+	  528.1200	  m/z	  found	  528.1186	  m/z.	  
	  
12.8	  Procedure	  for	  nitro	  reduction:	  
The	  desired	  bis-­‐allyloxy	  derivative	  (0.23	  mmol)	  was	  dissolved	  in	  absolute	  ethanol	  (12	  mL)	  
and	   iron	  powder	   (0.92	  mmol)	  was	  added.	  A	  saturated	  solution	  of	  ammonium	  chloride	   (4	  
mL)	  was	   subsequently	  added	  until	   a	  white	  precipitate	   formed.	  The	   reaction	  mixture	  was	  
then	   refluxed	   at	   80	   °C	   for	   16	   hours.	   After	   cooling	   to	   room	   temperature,	   the	   red/brown	  
solution	  was	  filtered	  through	  a	  short	  pad	  of	  Celite	  and	  the	  residue	  washed	  with	  ethanol	  (25	  
mL)	  and	  ethyl	  acetate	   (25	  mL).	  The	  solution	  was	  concentrated	  to	  dryness	  under	  reduced	  
pressure,	   a	  mixture	  of	  DCM/water	   (30	  mL)	  was	  added	   to	   the	   solid	   and	   the	  phases	  were	  
separated.	   The	   aqueous	   phase	   was	   extracted	   with	   DCM	   (2x15	   mL)	   and	   the	   combined	  
organic	   phases	   were	   dried	   over	   Na2SO4,	   filtered	   and	   concentrated.	   The	   product	   thus	  
obtained	  was	  used	  in	  the	  next	  step	  without	  further	  purification.	  
	  
4-­‐[3-­‐(2,4-­‐Bis-­‐allyloxy-­‐phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐
pyridazine-­‐1-­‐sulphonyl]-­‐phenylamine	  (39):	  The	  product	  
was	   afforded	   as	   a	   yellow/brown	   oil	   (75	   mg,	   0.175	  
mmol,	  85%).1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  7.63	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(SO2)CH),	  7.16	  (1H,	  d,	  J	  
=	  8.5	  Hz,	  C(CN)CH),	  6.61	  (2H,	  d,	  J	  =	  8.7	  Hz,	  2xC(NH2)CH),	  6.38	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.3	  Hz,	  




2xOCH2CHCH2),	   5.33	   (1H,	  dd,	   J	   =	  17.2	  Hz,	  1.6	  Hz,	  OCH2CHCHH	   (trans)),	   5.25	   (1H,	  dd,	   J	   =	  
16.4	  Hz,	  1.4	  Hz,	  OCH2CHCHH	  (trans)),	  5.22	  (1H,	  dd,	  J	  =	  10.4	  Hz,	  1.4	  Hz,	  OCH2CHCHH	  (cis)),	  
5.17	   (1H,	   dd,	   J	   =	   10.5	   Hz,	   1.5	   Hz,	   OCH2CHCHH	   (cis)),	   4.45	   (2H,	   dt,	   J	   =	   6.5	   Hz,	   1.4	   Hz,	  
OCH2CHCH2),	  4.39	  (2H,	  dt,	  J	  =	  5.0	  Hz,	  1.4	  Hz,	  OCH2CHCH2),	  4.03	  (2H,	  s,	  NH2),	  3.29	  (2H,	  t,	  J	  =	  
5.6	  Hz,	  NCH2),	  2.48	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  1.94	  (2H,	  dddd,	  J	  =	  6.7	  Hz,	  6.7	  Hz,	  5.6	  Hz,	  5.6	  
Hz,	   NCH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   160.3	   (C(OAllyl)CHC(OAllyl)),	   157.6	  
(C(CN)C(OAllyl),	   153.3	   (CNN),	   150.6	   (C(NH2)),	   133.0	   (OCH2CHCH2),	   132.9	   (OCH2CHCH2),	  
130.7	   (C(SO2)),	   130.6	   (2xC(SO2)CH),	   121.4	   (C(CN)CH),	   117.8	   (OCH2CHCH2),	   117.6	  
(OCH2CHCH2),	   113.9	   (C(CN)),	   113.7	   (2xC(NH2)CH),	   105.9	   (C(CN)CHCH),	   100.6	  
(C(OAllyl)CHC(OAllyl)),	   69.3	   (OCH2CHCH2),	   68.9	   (OCH2CHCH2),	   43.1	   (NCH2),	   25.8	   (CNCH2),	  
19.2	   (NCH2CH2).	   IR	   (neat)	   νmax:	   3451,	  2390,	  1616,	  1189,	  1054	  cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	  
C22H25N3NaO4S	  [M+Na]+	  450.1554	  m/z	  found	  450.1576	  m/z.	  	  
	  
4-­‐[4-­‐(2,4-­‐Bis-­‐allyloxy-­‐phenyl)-­‐1H-­‐phthalazine-­‐2-­‐
sulphonyl]-­‐phenylamine	  (40):	  The	  product	  was	  afforded	  
as	   a	   yellow/brown	   oil	   (81	   mg,	   0.170	   mmol,	   99%).	   1H-­‐
NMR	   (CDCl3	   400	   MHz)	   δ	   7.67	   (2H,	   d,	   J	   =	   8.6	   Hz,	  
2xC(SO2)CH),	  7.37	  (1H,	  d,	  J	  =	  8.3	  Hz,	  C(CN)CH),	  7.28	  (1H,	  t,	  J	  =	  7.4	  Hz,	  NCH2CCHCH),	  7.17	  -­‐	  
7.11	  (2H,	  m,	  NCH2CCH,	  CNCCHCH),	  6.89	  (1H,	  d,	  J	  =	  7.6	  Hz,	  CNCCH),	  6.58	  (2H,	  d,	  J	  =	  8.7	  Hz,	  
2xC(NH2)CH),	   6.52	   (1H,	   dd,	   J	   =	   8.3	   Hz,	   2.3	   Hz,	   C(CN)CHCH),	   6.42	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OAllyl)CHC(OAllyl)),	   6.01	   (1H,	  ddt,	   J	   =	  17.1	  Hz,	  10.5	  Hz,	  5.6	  Hz,	  OCH2CHCH2),	   5.54	   (1H,	  
ddt,	   J	   =	   17.2	   Hz,	   10.6	   Hz,	   4.8	   Hz,	   OCH2CHCH2),	   5.37	   (1H,	   dd,	   J	   =	   17.2	   Hz,	   1.4	   Hz,	  
OCH2CHCHH	  (trans)),	  5.25	  (1H,	  dd,	  J	  =	  10.5	  Hz,	  1.4	  Hz,	  OCH2CHCHH	  (cis)),	  4.85	  (1H,	  dd,	  J	  =	  
10.6	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (cis)),	  4.75	  (1H,	  dd,	  J	  =	  17.2	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (trans)),	  
4.50	  (2H,	  dt,	  J	  =	  5.4	  Hz,	  1.4	  Hz,	  OCH2CHCH2),	  4.30	  (2H,	  s,	  NCH2),	  4.25	  (2H,	  dt,	  J	  =	  4.5	  Hz,	  1.4	  
Hz,	   OCH2CHCH2),	   4.03	   (2H,	   s,	   NH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   160.8	  
(C(OAllyl)CHC(OAllyl)),	  157.7	   (C(CN)C(OAllyl)),	  152.7	   (CNN),	  150.9	   (C(NH2)),	  133.0	   (Ar-­‐CC),	  
132.5	   (2xC(SO2)CH),	   132.1	   (OCH2CHCH2),	   131.2	   (OCH2CHCH2),	   130.9	   (C(SO2)),	   130.8	   (Ar-­‐
CC),	  127.7	  (Ar-­‐CH),	  126.6	  (Ar-­‐CH),	  126.3	  (Ar-­‐CH),	  125.3	  (Ar-­‐CH),	  118.0	  (OCH2CHCH2),	  117.9	  
(OCH2CHCH2),	   116.4	   (C(CN)),	   113.8	   (2xC(NH2)CH),	   106.1	   (C(CN)CHCH),	   100.8	  
(C(OAllyl)CHC(OAllyl)),	   69.0	   (OCH2CHCH2),	   68.8	   (OCH2CHCH2),	   45.7	   (NCH2).	   IR	   (neat)	   νmax:	  
3374,	  2359,	  1623,	  1594,	  1163	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C26H25N3NaO4S	  [M+Na]+	  498.1458	  





12.9	  Procedure	  for	  hex-­‐5-­‐ynoyl	  chloride	  coupling:	  
Hex-­‐5-­‐ynoyl	   Chloride:	   Hex-­‐5-­‐ynoic	   acid	   (0.495	   mL,	   4.45	   mmol)	   was	  
dissolved	  in	  dry	  DCM	  (20	  mL)	  and	  two	  drops	  of	  dry	  DMF	  were	  added.	  
Oxalyl	  chloride	  (0.421	  mL,	  4.90	  mmol)	  was	  added	  drop-­‐wise	  at	  0	  °C	  through	  10	  minutes.	  
The	   reaction	   mixture	   was	   then	   allowed	   to	   stir	   at	   room	   temperature	   until	   the	   carbon	  
dioxide	   bubbling	   ceased	   (2	   hours).	   The	   solution	   was	   then	   concentrated	   under	   reduced	  
pressure	  to	  afford	  a	  red	  oil	  which	  was	  used	  immediately	  for	  the	  next	  step.	  
	  
The	   desired	   aniline	   derivative	   (0.60	   mmol)	   was	   dissolved	   in	   dry	   DCM	   (10	   mL)	   and	  
anhydrous	  pyridine	  (0.64	  mmol)	  was	  added.	  After	  10	  minutes,	  a	  freshly	  prepared	  solution	  
of	   hex-­‐5-­‐ynoyl	   chloride	   (0.32	  mmol)	   in	   dry	   DCM	   (3	  mL)	  was	   added	   slowly.	   The	   reaction	  
mixture	  was	  allowed	  to	  stir	  at	  room	  temperature	  for	  3	  hours.	  The	  solvent	  was	  evaporated	  
off	   under	   reduced	   pressure	   and	   the	   product	   was	   purified	   through	   direct	   flash	   column	  
chromatography.	  
	  
Hex-­‐5-­‐ynoic	   acid	   {4-­‐[3-­‐(2,4-­‐bis-­‐allyloxy-­‐
phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐pyridazine-­‐1-­‐
sulphonyl]-­‐phenyl}-­‐amide	   (RCZ12	   Synthon):	  
The	   product	   was	   purified	   through	   direct	  
flash	  column	  chromatography	  (30%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  a	  colourless	  
oil	   (75	   mg,	   0.143	   mmol,	   89%).1H-­‐NMR	   (CDCl3	   400	   MHz)	   δ	   7.90	   (2H,	   d,	   J	   =	   8.6	   Hz,	  
2xC(CONH)CH),	  7.69	  (2H,	  d,	  J	  =	  8.6	  Hz,	  2xC(SO2)CH),	  7.39	  (1H,	  s,	  CONH),	  7.23	  (1H,	  d,	  J	  =	  8.5	  
Hz,	   C(CN)CH),	   6.48	   (1H,	   dd,	   J	   =	   8.5	   Hz,	   2.3	   Hz,	   C(CN)CHCH),	   6.44	   (1H,	   d,	   J	   =	   2.3	   Hz,	  
C(OAllyl)CHC(OAllyl)),	   6.06	   (1H,	  ddt,	   J	   =	  15.8	  Hz,	  10.6	  Hz,	  5.6	  Hz,	  OCH2CHCH2),	   5.98	   (1H,	  
ddt,	   J	   =	   15.9	   Hz,	   10.8	   Hz,	   5.6	   Hz,	   OCH2CHCH2),	   5.42	   (1H,	   dd,	   J	   =	   17.2	   Hz,	   1.5	   Hz,	  
OCH2CHCHH	  (trans)),	  5.33	  (1H,	  dd,	  J	  =	  17.2	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (trans)),	  5.30	  (1H,	  dd,	  J	  
=	  10.6	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (cis)),	  5.25	  (1H,	  dd,	  J	  =	  10.5	  Hz,	  1.3	  Hz,	  OCH2CHCHH	  (cis)),	  
4.55	  (2H,	  dt,	  J	  =	  5.5	  Hz,	  1.3	  Hz,	  OCH2CHCH2),	  4.48	  (2H,	  dt,	  J	  =	  5.2	  Hz,	  1.3	  Hz,	  OCH2CHCH2),	  
3.42	   (2H,	   t,	   J	  =	  5.6	  Hz,	  NCH2),	  2.67	   (2H,	   t,	   J	  =	  7.4	  Hz,	  CONHCH2),	  2.54	   (2H,	   t,	   J	  =	  7.3	  Hz,	  
CNCH2),	  2.05	  -­‐	  1.95	  (5H,	  m,	  CCH,	  CHCCH2,	  CHCCH2CH2),	  1.89	  (2H,	  dddd,	  J	  =	  7.3	  Hz,	  7.3	  Hz,	  
5.9	   Hz,	   5.9	   Hz,	   NCH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   166.8	   (CONH),	   160.7	  




(C(SO2)),	   133.0	   (OCH2CHCH2),	   132.8	   (OCH2CHCH2),	   130.6	   (2xC(SO2)CH),	   129.8	   (C(CN)CH),	  
118.9	  (OCH2CHCH2),	  117.9	  (OCH2CHCH2),	  117.6	  (2xC(CONH)CH),	  105.9	  (C(CN)CHCH),	  100.6	  
(C(OAllyl)CHC(OAllyl)),	   91.1	   (CHCCH2),	   69.2	   (OCH2CHCH2),	   68.9	   (OCH2CHCH2),	   60.5	  
(CHCCH2),	   43.1	   (NCH2),	   31.8	   (CONHCH2),	   25.9	   (CNCH2),	   23.6	   (CONHCH2CH2),	   23.3	  
(CHCCH2),	  17.7	  (NCH2CH2).	   IR	  (neat)	  νmax:	  3209,	  2357,	  1701,	  1590,	  1166	  cm-­‐1.	  HRMS	  (ESI)	  
calcd	  for	  C28H31N3NaO5S	  [M+Na]+	  544.1919	  m/z	  found	  544.1922	  m/z.	  	  
	  
Hex-­‐5-­‐ynoic	   acid	   {4-­‐[4-­‐(2,4-­‐bis-­‐allyloxy-­‐
phenyl)-­‐1H-­‐phthalazine-­‐2-­‐sulphonyl]-­‐
phenyl}-­‐amide	  (RCZ20	  Synthon):	  The	  product	  
was	   purified	   through	   direct	   flash	   column	  
chromatography	  (30%	  ethyl	  acetate	  in	  petroleum	  ether)	  to	  afford	  a	  colourless	  oil	  (61	  mg,	  
0.107	  mmol,	  73%).	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  7.94	  (2H,	  d,	  J	  =	  8.8	  Hz,	  2xC(CONH)CH),	  7.68	  
(2H,	  d,	  J	  =	  8.8	  Hz,	  2xC(SO2)CH),	  7.51	  (1H,	  s,	  NH),	  7.45	  (1H,	  d,	  J	  =	  8.1	  Hz,	  C(CN)CH),	  7.40	  (1H,	  
t,	   J	   =	   7.2	   Hz,	   NCH2CCHCH),	   7.23	   (2H,	   m,	   NCH2CCH,	   CNCCHCH),	   7.00	   (1H,	   d,	   J	   =	   7.2	  
Hz,CNCCH),	   6.62	   (1H,	   dd,	   J	   =	   8.3	   Hz,	   2.1	   Hz,	   C(CN)CHCH),	   6.51	   (1H,	   d,	   J	   =	   2.1	   Hz,	  
C(OAllyl)CHC(OAllyl)),	   6.11	   (1H,	  ddt,	   J	   =	  17.2	  Hz,	  10.6	  Hz,	  5.4	  Hz,	  OCH2CHCH2),	   5.62	   (1H,	  
ddt,	   J	   =	   17.2	   Hz,	   10.5	   Hz,	   4.7	   Hz,	   OCH2CHCH2),	   5.48	   (1H,	   dq,	   J	   =	   17.3	   Hz,	   1.6	   Hz,	  
OCH2CHCHH	  (trans)),	  5.36	  (1H,	  dq,	  J	  =	  10.5	  Hz,	  1.4	  Hz,	  OCH2CHCHH	  (cis)),	  4.94	  (1H,	  dq,	  J	  =	  
10.6	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (cis)),	  4.82	  (1H,	  dq,	  J	  =	  17.2	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (trans)),	  
4.60	  (2H,	  dt,	  J	  =	  5.6	  Hz,	  1.4	  Hz,	  OCH2CHCH2),	  4.45	  (2H,	  s,	  NCH2),	  4.34	  (2H,	  dt,	  J	  =	  4.7	  Hz,	  1.6	  
Hz,	   OCH2CHCH2),	   2.57	   (2H,	   t,	   J	   =	   7.2	   Hz,	   CONHCH2),	   2.34	   (2H,	   dt,	   J	   =	   6.7	   Hz,	   2.7	   Hz,	  
CHCCH2),	  2.03	  (1H,	  t,	  J	  =	  2.6	  Hz,	  CCH),	  1.96	  (2H,	  quint.,	  J	  =	  7.0	  Hz,	  CONHCH2CH2).	  13C-­‐NMR	  
(CDCl3	   126	   MHz)	   δ	   170.9	   (CONH),	   160.9	   (C(OAllyl)CHC(OAllyl)),	   157.7	   (C(CN)C(OAllyl)),	  
153.5	   (CNN),	   142.4	   (C(CONH)),	   133.0	   (C(SO2)),	   132.4	   (C(CN)CH),	   132.0	   (Ar-­‐CC),	   131.1	  
(OCH2CHCH2),	  130.6	  (OCH2CHCH2),	  130.3	  (2xC(SO2)CH),	  130.0	  (Ar-­‐CC),	  127.9	  (Ar-­‐CH),	  126.5	  
(Ar-­‐CH),	   126.4	   (Ar-­‐CH),	   125.3	   (Ar-­‐CH),	   119.0	   (C(CN)),	   118.0	   (OCH2CHCH2),	   117.6	  
(OCH2CHCH2),	  116.4	  (2xC(CONH)CH),	  106.0	  (C(CN)CHCH),	  100.7	  C(OAllyl)CHC(OAllyl)),	  83.2	  
(CHCCH2),	   69.5	   (OCH2CHCH2),	   69.0	   (OCH2CHCH2),	   68.7	   (CHCCH2),	   45.8	   (NCH2),	   35.9	  
(CONHCH2),	   23.6	   (CHCCH2),	   17.7	   (CONHCH2CH2).	   IR	   (neat)	   νmax:	   3298,	   2924,	   2360,	   1606,	  






(+)-­‐Biotin	  N-­‐succinimidyl	  ester	  140	  (41):	  (+)-­‐Biotin	  (600	  mg,	  2.45	  
mmol)	   was	   dissolved	   in	   dry	   DMF	   (10	   mL)	   and	   EDC	   (370	  mg,	  
3.68	   mmol)	   and	   NHS	   (424	   mg,	   3.68	   mmol)	   were	   added	  
subsequently.	  The	  reaction	  mixture	  was	  allowed	  to	  stir	  at	  room	  
temperature	  overnight.	   The	   solution	  was	   then	  poured	   into	   ice	  and	   the	  white	  precipitate	  
formed	   was	   filtered	   by	   suction	   filtration.	   The	   solid	   thus	   obtained	   was	   dried	   under	   high	  
vacuum	  to	  afford	  an	  off-­‐white	  powder	  (520	  mg,	  1.52	  mmol,	  62%),	  which	  matched	  all	  the	  
analytical	  data	  of	  previously	  reported	  characterisation	  140.	  1H-­‐NMR	  (MeOD	  400	  MHz)	  δ	  4.52	  
(1H,	  dd,	  J	  =	  8.0	  Hz,	  5.1	  Hz),	  4.35	  (1H,	  dd,	  J	  =	  7.8	  Hz,	  4.9	  Hz),	  3.27	  -­‐	  3.22	  (1H,	  m),	  2.96	  (1H,	  
dd,	  J	  =	  12.5	  Hz,	  4.7	  Hz),	  2.86	  (4H,	  s),	  2.73	  (1H,	  d,	  J	  =	  12.5	  Hz),	  2.69	  (2H,	  t,	  J	  =	  6.8	  Hz),	  1.86	  -­‐	  
1.78	  (3H,	  m),	  1.68	  -­‐	  1.56	  (3H,	  m).	  13C-­‐NMR	  (MeOD	  126	  MHz)	  δ,	  170.6,	  169.1,	  163.1,	  61.8,	  
59.7,	  55.6,	  31.4,	  28.9,	  28.1,	  25.0,	  24.1.	  
	  
3-­‐Azidopropylamine	   188	   (43):	   3-­‐Chloropropylamine	   hydrochloride	   (42)	  
(1.12	  g,	  8.62	  mmol)	  was	  dissolved	   in	  water	   (25	  mL)	  and	   sodium	  azide	  
(1.68	  g,	  25.8	  mmol)	  was	  added	  at	  room	  temperature.	  The	  reaction	  mixture	  was	  stirred	  at	  
80	  °C	  overnight	  and	  then	  sodium	  hydroxide	  (pellets)	  (5	  g)	  was	  added	  to	  basify	  the	  solution.	  
The	  basic	  aqueous	  layer	  was	  extracted	  with	  diethyl	  ether	  (3x30	  mL)	  and	  the	  organic	  phase	  
was	   dried	   over	   Na2SO4,	   filtered	   and	   concentrated,	   to	   afford	   3-­‐azidopropylamine	   as	   a	  
yellowish	  liquid	  (450	  mg,	  4.510	  mmol,	  52%).	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  3.30	  (2H,	  t,	  J	  =	  6.4	  







acid	   (3-­‐azido-­‐propyl)-­‐amide	   (Biotin	   Synthon):	   3-­‐
Azidopropylamine	  (43)	  (112	  mg,	  1.12	  mmol)	  was	  dissolved	  
in	  dry	  methanol	   (8	  mL).	   TEA	   (0.234	  mL,	   1.68	  mmol)	  was	  
added	  at	  room	  temperature	  and	  then	  (+)-­‐biotin	  N-­‐succinimidyl	  ester	  (200	  mg,	  0.56	  mmol)	  
was	  added	  one	  pot.	  The	  reaction	  mixture	  was	  stirred	  at	  room	  temperature	  for	  24	  hours.	  




chromatographed	  (from	  0%	  to	  10%	  methanol	  in	  ethyl	  acetate)	  to	  afford	  a	  white	  solid	  (185	  
mg,	  0.567	  mmol,	  91%).	  The	  compound	  obtained	  matched	  the	  known	  characterisation	  data	  
previously	   reported	   189.	   1H-­‐NMR	   (MeOD	   400	   MHz)	   δ	   4.50	   (1H,	   dd,	   J	   =	   7.8	   Hz,	   4.9	   Hz,	  
CONHCH),	  4.32	   (1H,	  dd,	   J	  =	  8.0	  Hz,	  4.5	  Hz,	  CONHCH),	  3.37	   (2H,	   t,	   J	  =	  6.7	  Hz,	  CONHCH2),	  
3.26	  (2H,	  t,	  J	  =	  6.7	  Hz,	  N3CH2),	  3.22	  -­‐	  3.19	  (1H,	  m,	  SCH),	  2.94	  (1H,	  dd,	  J	  =	  12.6	  Hz,	  4.9	  Hz,	  
SCHH),	  2.72	  (1H,	  d,	  J	  =	  12.6	  Hz,	  SCHH),	  2.22	  (2H,	  t,	  J	  =	  7.5	  Hz,	  CONHCH2),	  1.80	  -­‐	  1.58	  (6H,	  
m,	  N3CH2CH2,	  SCHCH2,	  SCHCH2CH2),	  1.45	   (2H,	  quint.,	   J	  =	  7.5	  Hz,	  CONHCH2CH2).	   13C-­‐NMR	  
(MeOD	  126	  MHz)	   δ	   175.2	   (CONH),	   172.6	   (CONH),	   61.8	   (CONHCH),	   59.9	   (CONHCH),	   55.3	  
(SCH),	  51.3	  (CONHCH2),	  39.9	  (SCH2),	  38.2	  (CONHCH2),	  35.6	  (N3CH2),	  28.7	  (N3CH2CH2),	  28.0	  
(SCHCH2),	  25.4	  (SCHCH2CH2),	  24.7	  (CONHCH2CH2).	   IR	  (neat)	  νmax:	  3025,	  2359,	  2100,	  1678,	  
1465	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C13H22N6NaO2S	   [M+Na]+	   349.1417	  m/z	   found	   349.1415	  
m/z.	  
	  
12.10	  Procedure	  for	  click	  reaction	  (Biotin	  Labelling):	  
Oxo-­‐hexahydro-­‐thieno[3,4-­‐d]imidazol-­‐4-­‐yl)-­‐pentanoic	   acid	   (3-­‐azido-­‐propyl)-­‐amide	   (Biotin	  
Synthon)	  (0.09	  mmol)	  and	  the	  desired	  alkyne	  derivative	  (RCZ	  Synthon)	  (0.11	  mmol)	  were	  
dissolved	   in	   a	   3:1	   mixture	   of	   THF:H2O	   (4	   mL)	   and	   copper(II)sulfate	   (0.10	   mmol)	   and	  
sodium-­‐(L)-­‐ascorbate	  (0.21	  mmol)	  were	  added	  subsequently	  to	  the	  solution.	  The	  reaction	  
mixture	  was	  stirred	  at	  50	  °C	  for	  18	  hours.	  Solvents	  were	  removed	  under	  reduced	  pressure	  











amide	  (44):	  The	  product	  was	  purified	  through	  flash	  column	  chromatography	  (from	  0%	  to	  
5%	  methanol	   in	   DCM)	   to	   afford	   a	   colourless	   foam	   (69	  mg,	   0.081	  mmol,	   90%).	   1H-­‐NMR	  




C(CN)CH),	  6.54	  -­‐	  6.51	  (2H,	  m,	  C(CN)CHCH,	  C(OAllyl)CHC(OAllyl)),	  6.06	  (1H,	  ddt,	  J	  =	  17.3	  Hz,	  
10.5	  Hz,	  5.2	  Hz,	  OCH2CHCH2),	  5.98	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  10.4	  Hz,	  5.1	  Hz,	  OCH2CHCH2),	  5.40	  
(1H,	   dq,	   J	   =	   17.2	   Hz,	   1.5	   Hz,	   OCH2CHCHH	   (trans)),	   5.30	   (1H,	   dq,	   J	   =	   17.2	   Hz,	   1.6	   Hz,	  
OCH2CHCHH	  (trans)),	  5.27	  (1H,	  dq,	  J	  =	  10.5	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (cis)),	  5.21	  (1H,	  dq,	  J	  =	  
10.6	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (cis)),	  4.55	  (2H,	  dt,	  J	  =	  5.2	  Hz,	  1.6	  Hz,	  OCH2CHCH2),	  4.50	  (2H,	  
dt,	  J	  =	  5.0	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  4.48	  (1H,	  dd,	  J	  =	  7.8	  Hz,	  4.2	  Hz,	  CONHCH),	  4.40	  (2H,	  t,	  J	  
=	   6.8	   Hz,	   NNNCH2),	   4.29	   (1H,	   dd,	   J	   =	   7.7	   Hz,	   4.3	   Hz,	   CONHCH),	   3.38	   (2H,	   t,	   J	   =	   5.6	   Hz,	  
CONHCH2),	  3.21	  -­‐	  3.16	  (3H,	  m,	  NCH2,	  SCH),	  2.91	  (1H,	  dd,	  J	  =	  12.7	  Hz,	  4.9	  Hz,	  SCHH),	  2.80	  
(2H,	  t,	  J	  =	  7.3	  Hz,	  NNNCCH2),	  2.70	  (1H,	  d,	  J	  =	  12.7	  Hz,	  SCHH),	  2.54	  (2H,	  t,	  J	  =	  6.6	  Hz,	  COCH2),	  
2.47	  (2H,	  t,	  J	  =	  7.3	  Hz,	  CNCH2),	  2.21	  (2H,	  t,	  J	  =	  7.3	  Hz,	  COCH2),	  2.11	  -­‐	  1.98	  (4H,	  m,	  NCH2CH2,	  
COCH2CH2),	  1.75	  -­‐	  1.55	  (6H,	  m,	  3xCH2CH2CH2),	  1.44	  (2H,	  quint.,	  J	  =	  7.5	  Hz,	  CONHCH2CH2).	  
13C-­‐NMR	   (MeOD	   126	   MHz)	   δ	   174.7	   (CONH),	   172.8	   (CONH),	   164.6	   (CONH),	   160.6	  
(C(OAllyl)CHC(OAllyl)),	   157.4	   (C(CN)C(OAllyl)),	   155.1	   (CNN),	   143.4	   (C(CONH)),	   133.3	  
(OCH2CHCH2),	   133.0	   (OCH2CHCH2),	   129.9	   (C(SO2)),	   129.7	   (NNNCHCCH2),	   129.2	  
(2xC(SO2)CH),	  128.9	  (NNNCHCCH2),	  122.2	  (C(CN)CH),	  120.9	  (2xC(CONH)CH),	  118.8	  (C(CN)),	  
116.3	  (OCH2CHCH2),	  116.2	  (OCH2CHCH2),	  106.0	  (C(CN)CHCH),	  100.2	  (C(OAllyl)CHC(OAllyl)),	  
68.9	   (OCH2CHCH2),	  68.5	   (OCH2CHCH2),	  61.9	   (CONHCH),	  60.2	   (CONHCH),	  55.5	   (SCH),	  43.2	  
(NCH2),	  39.6	  (SCH2),	  35.9	  (NNNCH2),	  35.7	  (CONHCH2),	  35.3	  (CONHCH2),	  29.6	  (SCHCH2),	  28.3	  
(NNNCCH2),	   28.0	   (SCHCH2CH2),	   25.8	   (CH2CH2CH2),	   25.3	   (CH2CH2CH2),	   24.8	   (CH2CH2CH2),	  
24.2	   (CNCH2),	   18.6	   (NCH2CH2).	   IR	   (neat)	   νmax:	   3311,	   2391,	   2060,	   1684,	   1162	   cm-­‐1.	  HRMS	  









sulphonyl]-­‐phenylcarbamoyl}-­‐propyl)-­‐[1,2,3]triazol-­‐1-­‐yl]-­‐propyl}-­‐amide	   (45):	   The	   product	  
was	  purified	  through	  flash	  column	  chromatography	  (from	  0%	  to	  5%	  methanol	  in	  DCM)	  to	  
afford	  a	   colourless	   foam	   (40	  mg,	  0.044	  mmol,	   45%).	   1H-­‐NMR	   (Acetone	  400	  MHz)	  δ	  9.95	  




7.80	   (1H,	   s,	   NNNCH),	   7.49	   (1H,	   t,	   J	   =	   7.3	   Hz,	   NCH2CCHCH),	   7.44	   (1H,	   d,	   J	   =	   7.1	   Hz,	  
NCH2CCH),	  7.39	  (1H,	  d,	  J	  =	  8.2	  Hz,	  C(CN)CH),	  7.32	  (1H,	  t,	  J	  =	  7.5	  Hz,	  CNCCHCH),	  7.00	  (1H,	  d,	  
J	  =	  7.5	  Hz,	  CNCCH),	  6.73	  (1H,	  dd,	  J	  =	  8.2	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.67	  (1H,	  d,	   J	  =	  2.2	  Hz,	  
C(OAllyl)CHC(OAllyl)),	  6.14	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  10.5	  Hz,	  5.2	  Hz,	  OCH2CHCH2),	  5.99	  (1H,	  s,	  
CONH),	  5.78	  (1H,	  s,	  CONH),	  5.63	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  10.8	  Hz,	  4.7	  Hz,	  OCH2CHCH2),	  5.48	  
(1H,	   dq,	   J	   =	   17.2	   Hz,	   1.6	   Hz,	   OCH2CHCHH	   (trans)),	   5.31	   (1H,	   dq,	   J	   =	   10.5	   Hz,	   1.6	   Hz,	  
OCH2CHCHH	  (cis)),	  4.88	   (1H,	  dq,	   J	  =	  10.6	  Hz,	  1.7	  Hz,	  OCH2CHCHH	  (cis)),	  4.82	   (1H,	  dq,	   J	  =	  
17.3	  Hz,	  1.8	  Hz,	  OCH2CHCHH	  (trans)),	  4.68	  (2H,	  dt,	  J	  =	  5.4	  Hz,	  1.6	  Hz,	  OCH2CHCH2),	  4.54	  -­‐	  
4.50	  (1H,	  m,	  CONHCH),	  4.47	  (2H,	  s,	  NCH2),	  4.44	  -­‐	  4.39	  (4H,	  m,	  OCH2CHCH2,	  NNNCH2),	  4.37	  -­‐	  
4.32	  (1H,	  m,	  CONHCH),	  3.23	  -­‐	  3.15	  (5H,	  m,	  NCH2,	  SCH,	  CONHCH2),	  2.94	  (1H,	  dd,	  J	  =	  12.5	  Hz,	  
4.9	  Hz,	  SCHH),	  2.75	  (2H,	  t,	  J	  =	  7.1	  Hz,	  NNNCCH2),	  2.71	  (1H,	  d,	  J	  =	  12.5	  Hz,	  SCHH),	  2.45	  (2H,	  
t,	  J	  =	  7.3	  Hz,	  COCH2),	  2.22	  (2H,	  t,	  J	  =	  7.0	  Hz,	  COCH2),	  2.03	  (2H,	  quint.,	  J	  =	  7.0	  Hz,	  COCH2CH2),	  
1.86	   -­‐	   1.40	   (8H,	   m,	   3xCH2CH2CH2,	   CONHCH2CH2).	   13C-­‐NMR	   (Acetone	   126	  MHz)	   δ	   172.8	  
(CONH),	  171.6	  (CONH),	  164.0	  (CONH),	  161.1	  (C(OAllyl)CHC(OAllyl)),	  157.8	  (C(CN)C(OAllyl)),	  
156.9	   (CNN),	   146.4	   (C(CONH)),	   146.2	   (NNNCCH2),	   144.4	   (Ar-­‐CC),	   133.6	   (C(SO2)),	   132.8	  
(NNNCH),	  131.5	  (C(CN)CH),	  131.2	  (OCH2CHCH2),	  131.1	  (OCH2CHCH2),	  129.9	  (2xC(SO2)CH),	  
128.8	   (Ar-­‐CC),	   128.0	   (Ar-­‐CH),	   126.5	   (Ar-­‐CH),	   126.0	   (Ar-­‐CH),	   125.5	   (Ar-­‐CH),	   121.9	  
(C(CONH)CH),	  118.5	  (OCH2CHCH2),	  118.4	  (OCH2CHCH2),	  116.7	  (C(CONH)CH),	  115.6	  (C(CN)),	  
106.5	   (C(CN)CHCH),	   100.4	   (C(OAllyl)CHC(OAllyl)),	   68.6	   (OCH2CHCH2),	   68.4	   (OCH2CHCH2),	  
61.4	  (CONHCH),	  60.0	  (CONHCH),	  55.4	  (SCH),	  47.1	  (SCH2),	  45.9	  (NCH2),	  40.1	  (NNNCH2),	  35.8	  
(CONHCH2),	   35.7	   (CONHCH2),	   35.3	   (SCHCH2),	   30.1	   (NNNCCH2),	   28.0	   (SCHCH2CH2),	   25.4	  
(CH2CH2CH2),	  24.8	  (CH2CH2CH2),	  24.4	  (CH2CH2CH2).	  IR	  (neat)	  νmax:	  3288,	  2359,	  1692,	  1590,	  
1166	   cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	  C45H53N9NaO7S2	   [M+Na]+	   918.3433	  m/z	   found	  918.3476	  
m/z.	  
	  
12.11	  Procedure	  for	  click	  reaction	  (BODIPY	  Labelling):	  
The	   desired	   alkyne	   derivative	   (0.02	  mmol)	  was	   dissolved	   in	   dry	   THF	   (2	  mL)	   and	   BODIPY	  
azide	   (0.03	   mmol)	   161	   was	   added	   one	   pot.	   Copper	   iodide	   and	   DIPEA	   were	   added	  
subsequently	   in	   catalytic	   amount	   and	   the	   reaction	   mixture	   was	   stirred	   at	   50	   °C	   for	   18	  
hours.	   The	   solvent	   was	   removed	   under	   reduced	   pressure	   and	   the	   residue	   was	   purified	  





BODIPY-­‐Allyl-­‐RCZ12	   (48):	  
The	   product	   was	   purified	  
through	   flash	   column	  
chromatography	  (from	  0%	  to	  1%	  methanol	  in	  DCM)	  to	  afford	  an	  orange	  oil	  (18	  mg,	  0.021	  
mmol,	   84%).	   1H-­‐NMR	   (CDCl3	   400	   MHz)	   δ	   9.39	   (1H,	   s,	   CONH),	   7.74	   (2H,	   d,	   J	   =	   8.9	   Hz,	  
2xC(CONH)CH),	   7.66	   (2H,	   d,	   J	   =	   8.8	   Hz,	   2xC(SO2)CH),	   7.34	   (1H,	   s,	   C(CH3)C(N)CHC(N)CH),	  
7.14	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  7.02	  (1H,	  s,	  NNNCHCH2),	  6.81	  (1H,	  d,	  J	  =	  4.0	  Hz,	  C(N)CH),	  
6.40	  (1H,	  dd,	  J	  =	  8.4	  Hz,	  2.2	  Hz,	  C(CN)CHCH),	  6.34	  (1H,	  d,	  J	  =	  2.2	  Hz,	  C(OAllyl)CHC(OAllyl)),	  
6.18	  (1H,	  d,	   J	  =	  3.9	  Hz,	  C(N)CH),	  6.01	  (1H,	  s,	  C(CH3)CHC(CH3)),	  5.96	  (1H,	  ddt,	   J	  =	  17.0	  Hz,	  
10.5	  Hz,	  5.2	  Hz,	  OCH2CHCH2),	  5.87	  (1H,	  ddt,	  J	  =	  17.0	  Hz,	  10.4	  Hz,	  5.1	  Hz,	  OCH2CHCH2),	  5.33	  
(1H,	   dd,	   J	   =	   17.2	   Hz,	   1.5	   Hz,	   OCH2CHCHH	   (trans)),	   5.23	   (1H,	   dd,	   J	   =	   17.1	   Hz,	   1.5	   Hz,	  
OCH2CHCHH	  (trans)),	  5.22	  (1H,	  dd,	  J	  =	  10.5	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (cis)),	  5.15	  (1H,	  dd,	  J	  =	  
10.5	  Hz,	  1.3	  Hz,	  OCH2CHCHH	   (trans)),	  4.45	   (2H,	  dt,	   J	  =	  5.3	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  4.38	  
(4H,	   m,	   NNNCH2,	   OCH2CHCH2),	   3.31	   (2H,	   t,	   J	   =	   5.5	   Hz,	   NCH2),	   2.90	   (2H,	   t,	   J	   =	   7.3	   Hz,	  
C(N)CH2),	  2.89	  -­‐	  2.78	  (2H,	  m,	  CONHCH2),	  2.48	  (2H,	  t,	  J	  =	  6.8	  Hz,	  CNCH2),	  2.43	  (3H,	  s,	  CCH3),	  
2.45	   -­‐	   2.34	   (4H,	   m,	   CH2CH2CH2,	   NNNCCH2),	   2.18	   (3H,	   s,	   CCH3),	   2.02	   -­‐	   1.92	   (4H,	   m,	  
CH2CH2CH2,	   NCH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   170.2	   (CONH),	   161.9	  
(C(OAllyl)CHC(OAllyl)),	   157.4	   (C(CN)C(OAllyl)),	   156.2	   (CNN),	   146.1	   (C(CONH)),	   145.1	  
(NNNCCH2),	   144.7	   (NNNCHCCH2),	   139.3	   (C(SO2)),	   134.5	   (Ar-­‐CC),	   133.0	   (Ar-­‐CC),	   131.9	  
(OCH2CHCH2),	   131.8	   (OCH2CHCH2),	   130.6	   (C(CN)CH),	   129.6	   (2xC(SO2)CH),	   126.7	   (Ar-­‐CC),	  
125.8	   (Ar-­‐CC),	   123.1	   (Ar-­‐CC),	   121.5	   (Ar-­‐CH),	   120.9	   (Ar-­‐CH),	   118.7	   (C(CN)),	   117.7	  
(OCH2CHCH2),	   117.5	   (OCH2CHCH2),	   115.9	   (Ar-­‐CH),	   115.2	   (Ar-­‐CH),	   110.0	  
(C(OAllyl)CHC(OAllyl)),	   105.9	   (C(CN)CHCH),	   69.2	   (OCH2CHCH2),	   68.9	   (OCH2CHCH2)	   ,	   50.3	  
(NNNCH2),	   42.5	   (NCH2),	   35.3	   (NNNCH2CH2),	   35.2	   (CONHCH2),	   31.8	   (NNNCCH2),	   	   25.3	  
(CH2CH2CH2),	  23.1	  (CH2CH2CH2),	  21.0	  (CNCH2),	  17.5	  (NCH2CH2),	  15.0	  (CCH3),	  11.3	  (CCH3).	  IR	  
(neat)	   νmax:	   3033,	   2489,	   1604,	   1166,	   974	   cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	   C42H47F2N8NaO5S10B	  
[M+Na]+	  846.3380	  m/z	  found	  846.3347	  m/z.	  
	  
BODIPY-­‐Allyl-­‐RCZ20	   (49):	  
The	  product	  was	  purified	  
through	   flash	   column	  
chromatography	   (from	  




(Acetone	  400	  MHz)	  δ	  9.59	  (1H,	  s,	  NH),	  7.88	  (4H,	  s,	  2xC(CONH)CH,	  2xC(SO2)CH),	  7.78	  (1H,	  s,	  
C(N)CHC(N)),	  7.54	  (1H,	  s,	  NNNCH),	  7.49	  (1H,	  t,	  J	  =	  7.5	  Hz,	  NCH2CCHCH),	  7.44	  (1H,	  d,	  J	  =	  7.0	  
Hz,	  NCH2CCH),	  7.39	  (1H,	  d,	   J	  =	  8.3	  Hz,	  C(CN)CH),	  7.32	  (1H,	   t,	   J	  =	  7.5	  Hz,	  CNCCHCH),	  7.07	  
(1H,	  d,	  J	  =	  3.8	  Hz,	  C(N)CH),	  7.00	  (1H,	  d,	  J	  =	  7.5	  Hz,	  CNCCH),	  6.72	  (1H,	  dd,	  J	  =	  8.3	  Hz,	  2.3	  Hz,	  
C(CN)CHCH),	  6.66	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OAllyl)CHC(OAllyl)),	  6.42	  (1H,	  d,	  J	  =	  3.9	  Hz,	  C(N)CH),	  
6.25	  (1H,	  s,	  C(CH3)CHC(CH3)),	  6.13	  (1H,	  ddt,	  J	  =	  17.1	  Hz,	  10.4	  Hz,	  5.4	  Hz,	  OCH2CHCH2),	  5.62	  
(1H,	   ddt,	   J	   =	   17.3	   Hz,	   10.4	   Hz,	   4.7	   Hz,	   OCH2CHCH2),	   5.48	   (1H,	   dq,	   J	   =	   17.3	   Hz,	   1.7	   Hz,	  
OCH2CHCHH	  (trans)),	  5.30	  (1H,	  dq,	  J	  =	  10.5	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (cis)),	  4.87	  (1H,	  dq,	  J	  =	  
10.6	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (cis)),	  4.82	  (1H,	  dq,	  J	  =	  17.2	  Hz,	  1.7	  Hz,	  OCH2CHCHH	  (trans)),	  
4.67	  (2H,	  dt,	  J	  =	  5.6	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  4.49	  (2H,	  t,	  J	  =	  7.0	  Hz,	  NNNCH2),	  4.45	  (2H,	  s,	  
NCH2),	  4.41	  (2H,	  dt,	  J	  =	  4.6	  Hz,	  1.6	  Hz,	  OCH2CHCH2),	  2.99	  (2H,	  t,	  J	  =	  7.6	  Hz,	  C(N)CH2),	  2.75	  
(2H,	  t,	  J	  =	  7.3	  Hz,	  NNNCCH2),	  2.51	  (3H,	  s,	  CCH3),	  2.47	  (2H,	  t,	  J	  =	  7.3	  Hz,	  CONHCH2),	  2.35	  (2H,	  
quint.,	  J	  =	  7.3	  Hz,	  CH2CH2CH2),	  2.30	  (3H,	  s,	  CCH3),	  2.03	  (2H,	  quint.,	  J	  =	  7.4	  Hz,	  CH2CH2CH2).	  
13C-­‐NMR	   (Acetone	   126	   MHz)	   δ	   171.4	   (CONH),	   161.1	   (C(OAllyl)CHC(OAllyl)),	   159.8	  
(C(CN)C(OAllyl)),	   157.8	   (CNN),	   146.6	   (C(CONH)),	   144.3	   (NNNCCH2),	   144.0	   (NNNCHCCH2),	  
135.0	   (C(SO2)),	   133.6	   (Ar-­‐CC),	   133.4	   (Ar-­‐CC),	   132.8	   (Ar-­‐CC),	   131.5	   (C(CN)CH),	   131.2	  
(OCH2CHCH2),	  131.1	  (OCH2CHCH2),	  129.9	  (2xC(SO2)CH),	  128.9	  (Ar-­‐CC),	  128.5	  (Ar-­‐CH),	  128.0	  
(Ar-­‐CH),	  126.6	   (Ar-­‐CH),	  126.0	   (Ar-­‐CH),	  125.5	   (Ar-­‐CH),	  124.8	   (Ar-­‐CH),	  121.3	   (Ar-­‐CH),	  120.2	  
(Ar-­‐CH),	   118.4	   (Ar-­‐CC),	   118.3	   (2xC(CONH)CH),	   117.4	   (Ar-­‐CC),	   116.7	   (OCH2CHCH2),	   116.5	  
(OCH2CHCH2),	   115.5	   (C(CN)),	   106.5	   (C(CN)CHCH),	   100.4	   (C(OAllyl)CHC(OAllyl)),	   68.6	  
(OCH2CHCH2),	   68.4	   (OCH2CHCH2),	   49.1	   (NNNCH2),	   45.9	   (NCH2),	   35.9	   (NNNCH2CH2),	   35.7	  
(CONHCH2),	   25.3	   (NNNCCH2),	   24.9	   (CH2CH2CH2),	   24.5	   (CH2CH2CH2),	   13.9	   (CCH3),	   10.3	  
(CCH3).	   IR	   (neat)	   νmax:	   2389,	   1615,	   1187,	   1011,	   789	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  
C46H47F2N8NaO5S10B	  [M+Na]+	  894.3380	  m/z	  found	  894.3351	  m/z.	  
	  
12.12	  Procedure	  for	  de-­‐allylation:	  
The	  desired	   labelled	  bis-­‐allyloxy	  derivative	   (0.07	  mmol)	  was	  dissolved	   in	  dry	  methanol	   (5	  
mL)	   and	   a	   catalytic	   amount	   of	   tetrakis(triphenylposphine)palladium	   was	   added.	   The	  
reaction	  mixture	  was	  stirred	  at	  60	  °C	  until	  total	  consumption	  of	  the	  starting	  material	  (2-­‐3	  
hours).	   After	   cooling	   to	   room	   temperature,	   the	   solvent	   was	   removed	   under	   reduced	  











phenylcarbamoyl}-­‐propyl)-­‐[1,2,3]triazol-­‐1-­‐yl]-­‐propyl}-­‐amide	   (Biotin-­‐RCZ12):	   The	   product	  
was	  purified	  through	  flash	  column	  chromatography	  (from	  0%	  to	  7%	  methanol	  in	  DCM)	  to	  
afford	  a	  white	  paste	  (28	  mg,	  0.035	  mmol,	  42%).	  1H-­‐NMR	  (MeOD	  400	  MHz)	  δ	  7.80	  (5H,	  m,	  
2xC(CONH)CH,	  2xC(SO2)CH,	  NNNCH),	  7.24	  (1H,	  d,	  J	  =	  9.2	  Hz,	  C(CN)CH),	  6.32	  -­‐	  6.30	  (2H,	  m,	  
C(CN)CHCH,	  C(OH)CHC(OH)),	  4.61	  (1H,	  s),	  4.48	  (1H,	  dd,	  J	  =	  7.6	  Hz,	  4.4	  Hz,	  CONHCH),	  4.38	  
(2H,	  t,	  J	  =	  6.8	  Hz,	  NNNCH2),	  4.28	  (1H,	  dd,	  J	  =	  7.8	  Hz,	  4.4	  Hz,	  CONHCH),	  3.38	  (2H,	  t,	  J	  =	  5.4	  
Hz,	  CONHCH2),	  3.20	   -­‐	  3.17	   (3H,	  m,	  NCH2,	  SCH),	  2.90	   (1H,	  dd,	   J	  =	  12.8	  Hz,	  5.0	  Hz,	  SCHH),	  
2.78	  (2H,	  t,	  J	  =	  7.4	  Hz,	  NNNCCH2),	  2.69	  (2H,	  d,	  J	  =	  12.9	  Hz,	  SCHH),	  2.60	  (2H,	  t,	  J	  =	  6.6	  Hz,	  
SCHCH2),	  2.44	  (2H,	  t,	  J	  =	  7.4	  Hz,	  CNCH2),	  2.21	  (2H,	  t,	  J	  =	  7.4	  Hz,	  CONHCH2),	  2.14	  -­‐	  2.02	  (4H,	  
m,	  NCH2CH2,	  SCHCH2CH2),	  1.76	  -­‐	  1.55	  (4H,	  m,	  2xCH2CH2CH2),	  1.43	  (2H,	  quint.,	   J	  =	  7.6	  Hz,	  
CH2CH2CH2).	   13C-­‐NMR	   (MeOD	   126	  MHz)	   δ	   174.8	   (CONH),	   174.0	   (CONH),	   172.8	   (CONH),	  
160.1	  (C(OH)CHC(OH)),	  159.9	  (C(CN)C(OH)),	  155.4	  (CNN),	  146.8	  (C(CONH)),	  143.7	  (C(SO2)),	  
134.5	   (NNNCCH2),	   128.9	   (2xC(SO2)CH),	   127.9	   (NNNCH),	   125.8(C(CN)CH),	   122.2	  
(2xC(CONH)CH),	   119.1	   (C(CN)),	   106.7	   (C(CN)CHCH),	   102.9	   (C(OH)CHC(OH)),	   61.9	  
(CONHCH),	   60.2	   (CONHCH),	   55.5	   (SCH),	   49.8	   (CONHCH2),	   42.9	   (NCH2),	   39.6	   (SCH2),	   35.9	  
(CONHCH2),	   35.5	   (CONHCH2),	   35.3	   (NNNCCH2),	   29.5	   (SCHCH2),	   28.3	   (NNNCH2CH2),	   28.0	  
(SCHCH2CH2),	  25.3	   (CH2CH2CH2),	  24.7	   (CH2CH2CH2),	  24.2	   (CNCH2),	  21.5	   (CH2CH2CH2),	  18.2	  
(NCH2CH2).	   IR	   (neat)	   νmax:	   3283,	   2932,	   2359,	   1676,	   1355	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  












was	  purified	  through	  flash	  column	  chromatography	  (from	  0%	  to	  7%	  methanol	  in	  DCM)	  to	  
afford	  a	  white	  paste	  (8	  mg,	  0.009	  mmol,	  47%).	  1H-­‐NMR	  (MeOD	  400	  MHz)	  δ	  7.91	  (2H,	  d,	  J	  =	  
9.1	  Hz,	  2xC(CONH)CH),	  7.83	   (2H,	  d,	   J	  =	  8.9	  Hz,	  2xC(SO2)CH),	  7.79	   (1H,	   s,	  NNNCH),	  7.57	   -­‐	  
7.54	  (1H,	  m,	  NCH2CCHCH),	  7.45	  -­‐	  7.41	  (3H,	  m,	  CNCCH,	  CNCCHCH,	  NCH2CCH),	  7.26	  (1H,	  d,	  J	  
=	  8.6	  Hz,	  C(CN)CH),	  6.44	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OH)CHC(OH)),	  6.39	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.3	  Hz,	  
C(CN)CHCH),	  4.47	  (1H,	  dd,	  J	  =	  7.8	  Hz,	  4.2	  Hz,	  CONHCH),	  4.37	  (2H,	  t,	  J	  =	  7.0	  Hz,	  NNNCH2),	  
4.31	   (2H,	   s,	  NCH2),	   4.28	   (1H,	   dd,	   J	   =	   8.0	  Hz,	   4.4	  Hz,	   CONHCH),	   3.20	   -­‐	   3.15	   (3H,	  m,	   SCH,	  
CONHCH2),	  2.90	  (1H,	  dd,	  J	  =	  12.6	  Hz,	  4.8	  Hz,	  SCHH),	  2.78	  (2H,	  t,	  J	  =	  7.4	  Hz,	  NNNCCH2),	  2.68	  
(1H,	  d,	  J	  =	  12.6	  Hz,	  SCHH),	  2.45	  (2H,	  t,	  J	  =	  7.4	  Hz,	  COCH2),	  2.20	  (2H,	  t,	  J	  =	  7.4	  Hz,	  COCH2),	  
2.04	  (2H,	  quint.,	  J	  =	  6.9	  Hz,	  COCH2CH2),	  1.75	  -­‐	  1.55	  (6H,	  m,	  CONHCH2CH2,	  2xCH2CH2CH2),	  
1.43	  (2H,	  quint.,	  J	  =	  7.1	  Hz,	  CH2CH2CH2).	  13C-­‐NMR	  (MeOD	  126	  MHz)	  δ	  172.7	  (CONH),	  171.6	  
(CONH),	   163.3	   (CONH),	   160.3	   (C(OH)CHC(OH)),	   157.8	   (C(CN)C(OH)),	   155.7	   (CNN),	   147.4	  
(C(CONH)),	   146.2	   (NNNCCH2),	   144.9	   (Ar-­‐CC),	   	   133.5	   (C(SO2)),	   132.1	   (NNNCH),	   131.8	  
(C(CN)CH),	  129.8	  (2xC(SO2)CH),	  128.2	  (Ar-­‐CC),	  127.4	  (Ar-­‐CH),	  126.5	  (Ar-­‐CH),	  125.8	  (Ar-­‐CH),	  
124.7	   (Ar-­‐CH),	   122.0	   (2xC(CONH)CH),	   118.4	   (C(CN)),	   106.9	   (C(CN)CHCH),	   103.7	  
(C(OH)CHC(OH)),	   61.3	   (CONHCH),	   60.3	   (CONHCH),	   55.4	   (SCH),	   47.0	   (SCH2),	   46.4	   (NCH2),	  
40.0	   (NNNCH2),	   35.8	   (CONHCH2),	   35.6	   (CONHCH2),	   35.3	   (SCHCH2),	   30.0	   (NNNCCH2),	   29.2	  
(SCHCH2CH2),	  25.4	  (CH2CH2CH2),	  24.7	  (CH2CH2CH2),	  24.4	  (CH2CH2CH2).	  IR	  (neat)	  νmax:	  3263,	  
2929,	  2361,	  1629,	  1166	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C39H45N9NaO7S2	  [M+Na]+	  838.2891	  m/z	  
found	  838.2911	  m/z.	  
	  
	  
BODIPY-­‐RCZ12:	   The	  
product	   was	   purified	  
through	   flash	   column	  
chromatography	  (from	  0%	  to	  1%	  methanol	  in	  DCM)	  to	  afford	  a	  red	  oil	  (12	  mg,	  0.016	  mmol,	  
63%).	  1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  12.19	  (1H,	  s,	  COH),	  9.39	  (1H,	  s,	  CONH),	  7.79	  -­‐	  7.66	  (4H,	  
m,	   2xC(CONH)CH,	   2xC(SO2)CH),	   7.42	   (1H,	   s,	   C(N)CHC(N)),	   7.16	   -­‐	   7.09	   (2H,	   m,	   C(CN)CH,	  
NNNCH),	   6.90	   (1H,	   d,	   J	   =	   4.0	   Hz,	   C(N)CH),	   6.69	   (1H,	   s,	   COH),	   6.46	   (1H,	   d,	   J	   =	   2.4	   Hz,	  
C(OH)CHC(OH)),	  6.36	  (1H,	  dd,	  J	  =	  8.6,	  2.4	  Hz,	  C(CN)CHCH),	  6.27	  (1H,	  d,	  J	  =	  3.9	  Hz,	  C(N)CH),	  
6.13	  (1H,	  s,	  C(CH3)CHC(CH3)),	  4.44	  (2H,	  t,	  J	  =	  6.5	  Hz,	  NNNCH2),	  3.42	  -­‐	  3.33	  (2H,	  m,	  NCH2),	  
2.98	  (2H,	  t,	  J	  =	  7.3	  Hz,	  C(N)CH2),	  2.85	  -­‐	  2.72	  (2H,	  m,	  CONHCH2),	  2.53	  (3H,	  s,	  CCH3),	  2.47	  -­‐	  




2.00	   (2H,	   m,	   CNCH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   172.2	   (CONH),	   160.1	  
(C(OH)CHC(OH)),	   156.3	   (C(CN)C(OH)),	   154.2	   (CNN),	   146.6	   (C(CONH)),	   144.4	   (NNNCCH2),	  
143.2	  (NNNCHCCH2),	  135.3	  (C(SO2)),	  134.0	  (Ar-­‐CC),	  133.1	  (Ar-­‐CC),	  129.3	  (C(CN)CH),	  128.6	  
(2xC(SO2)CH),	   128.2	   (Ar-­‐CC),	   127.8	   (Ar-­‐CC),	   123.9	   (Ar-­‐CC),	   121.8	   (Ar-­‐CH),	   120.6	   (Ar-­‐CH),	  
119.3	   (C(CN)),	   116.9	   (Ar-­‐CH),	   116.4	   (Ar-­‐CH),	   106.8	   (C(CN)CHCH),	   104.0	   (C(OH)CHC(OH)),	  
49.8	  (NNNCH2),	  42.8	  (NCH2),	  35.9	  (NNNCH2CH2),	  35.7	  (CONHCH2),	  29.6	  (NNNCCH2),	   	  25.5	  
(CH2CH2CH2),	   23.4	   (CH2CH2CH2),	   21.9	   (CNCH2),	   18.6	   (NCH2CH2),	   14.9	   (CCH3),	   11.3	   (CCH3).	  
HRMS	  (ESI)	  calcd	  for	  C36H39F2N8NaO5S11B	  [M+Na]+	  767.2717	  m/z	  found	  767.2702	  m/z.	  
	  
	  
BODIPY-­‐RCZ20:	   The	  
product	   was	   purified	  
through	   flash	   column	  
chromatography	  (from	  0%	  
to	  1%	  methanol	   in	  DCM)	   to	  afford	  a	   red	  oil	   (5	  mg,	  0.006	  mmol,	  85%).	   1H-­‐NMR	  (Acetone	  
400	  MHz)	  δ	  10.52	  (1H,	  s,	  COH),	  9.51	  (1H,	  s,	  CONH),	  7.70	  (2H,	  d,	  J	  =	  8.9	  Hz,	  2xC(CONH)CH),	  
7.75	   (2H,	   d,	   J	   =	   8.7	   Hz,	   2xC(SO2)CH),	   7.62	   (1H,	   s,	   C(N)CHC(N)),	   7.58	   -­‐	   7.54	   (1H,	   m,	  
NCH2CCHCH),	   7.48	   (1H,	   t,	   J	   =	   7.5	  Hz,	   CNCCHCH),	   7.43	   -­‐	   7.33	   (3H,	  m,	  NNNCH,	  NCH2CCH,	  
CNCCH),	  7.15	  (1H,	  d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  6.92	  (1H,	  d,	  J	  =	  3.8	  Hz,	  C(N)CH),	  6.38	  (1H,	  d,	  J	  =	  
2.3	  Hz,	  C(OH)CHC(OH)),	  6.30	  (1H,	  dd,	  J	  =	  2.3	  Hz,	  8.5	  Hz,	  C(CN)CHCH),	  6.26	  (1H,	  d,	  J	  =	  3.9	  Hz,	  
C(N)CH),	  6.10	  (1H,	  s,	  C(CH3)CHC(CH3)),	  4.32	  (2H,	  t,	  J	  =	  7.1	  Hz,	  NNNCH2),	  4.23	  (2H,	  s,	  NCH2),	  
2.82	  (2H,	  t,	  J	  =	  7.5	  Hz,	  C(N)CH2),	  2.59	  (2H,	  t,	  J	  =	  7.4	  Hz,	  CONHCH2),	  2.35	  (3H,	  s,	  CCH3),	  2.32	  
(2H,	  t,	  J	  =	  7.2	  Hz,	  NNNCCH2),	  2.19	  (2H,	  quint.,	  J	  =	  7.4	  Hz,	  CH2CH2CH2),	  2.15	  (3H,	  s,	  CCH3),	  
1.87	   (2H,	   quint.,	   J	   =	   7.2	   Hz,	   CH2CH2CH2).	   13C-­‐NMR	   (Acetone	   126	  MHz)	   δ	   170.4	   (CONH),	  
160.3	   (C(OH)CHC(OH)),	   159.0	   (C(CN)C(OH)),	   158.2	   (CNN),	   146.6	   (C(CONH)),	   145.7	  
(NNNCCH2),	  144.3	   (NNNCHCCH2),	  133.8	   (Ar-­‐CC),	  132.9	   (C(SO2)),	  132.5	   (Ar-­‐CC),	  132.1	   (Ar-­‐
CC),	   131.9	   (C(CN)CH),	   129.8	   (2xC(SO2)CH),	   128.5	   (Ar-­‐CC),	   128.4	   (Ar-­‐CH),	   128.2	   (Ar-­‐CH),	  
127.4	   (Ar-­‐CH),	  126.5	   (Ar-­‐CH),	  124.8	   (Ar-­‐CH),	  121.8	   (Ar-­‐CH),	  121.3	   (Ar-­‐CH),	  120.2	   (Ar-­‐CH),	  
118.8	   (Ar-­‐CC),	   118.7	   (2xC(CONH)CH),	   117.1	   (Ar-­‐CC),	   115.8	   (C(CN)),	   106.9	   (C(CN)CHCH),	  
101.9	  (C(OH)CHC(OH)),	  49.1	  (NNNCH2),	  46.4	  (NCH2),	  35.9	  (NNNCH2CH2),	  35.4	  (CONHCH2),	  
25.3	  (NNNCCH2),	  24.8	  (CH2CH2CH2),	  24.5	  (CH2CH2CH2),	  13.9	  (CCH3),	  10.3	  (CCH3).	   IR	  (neat)	  
νmax:	  3235,	  2955,	  2390,	  1676,	  1270	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C40H39F2N8NaO5S10B	  [M+Na]+	  





12.13	  Procedure	  for	  6-­‐azido-­‐hexanoyl	  chloride	  coupling:	  
6-­‐Azido-­‐hexanoic	   acid	   154:	   6-­‐Bromo-­‐hexanoic	   acid	   (3	   g,	   15.38	  
mmol)	  was	  dissolved	   in	  dry	  DMF	   (30	  mL)	  and	  sodium	  azide	   (2	  g,	  
30.76	  mmol)	  was	   then	   added.	   The	   reaction	  mixture	  was	   allowed	   to	   stir	   at	   80	   °C	   for	   18	  
hours.	   A	   0.1	  M	   solution	  of	  HCl	   (100	  mL)	   and	   ethyl	   acetate	   (100	  mL)	  were	   added	   to	   the	  
mixture	  and	  the	  aqueous	  phase	  was	  discarded.	  The	  organic	  phase	  was	  washed	  with	  a	  0.1	  
M	   solution	   of	   HCl	   (2x100	   mL)	   and	   brine	   (5x100	   mL),	   dried	   over	   Na2SO4,	   filtered	   and	  
concentrated	  to	  afford	  the	  desired	  compounds	  as	  a	  colourless	  oil	  (2.28	  g,	  14.52	  mmol)	  in	  
94%	   yield	   with	   excellent	   purity.	   Characterisation	   data	   matched	   the	   ones	   previously	  
reported.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  11.56	  (1H,	  bs);	  3.31	  (2H,	  t,	  J	  =	  6.9	  Hz);	  2.40	  (2H,	  t,	  J	  =	  
7.4	  Hz,),	  1.73	  -­‐	  1.61	  (4H,	  m),	  1.50	  -­‐	  1.42	  (2H,	  m).	  13C	  NMR	  (CDCl3	  126	  MHz)	  δ	  179.6,	  51.2,	  
33.8,	  28.5,	  26.1,	  24.1.	  
	  
6-­‐Azido-­‐hexanoyl	   chloride:	   6-­‐Azido-­‐hexanoic	   acid	   (66	   mg,	   0.42	  
mmol)	  was	  dissolved	  in	  dry	  DCM	  (8	  mL)	  and	  two	  drops	  of	  dry	  DMF	  
were	  added.	  Oxalyl	   chloride	   (50	  μL,	  0.50	  mmol)	  was	  added	  dropwise	  at	  0	   °C	   through	  10	  
minutes.	   The	   reaction	   mixture	   was	   then	   allowed	   to	   stir	   at	   room	   temperature	   until	   the	  
carbon	   dioxide	   bubbling	   ceased	   (2	   hours).	   The	   solution	   was	   then	   concentrated	   under	  
reduced	  pressure	  to	  afford	  a	  red	  oil	  which	  was	  used	  immediately	  for	  the	  next	  step.	  
	  
The	  desired	  aniline	  derivative	  (39	  or	  40)	  (0.21	  mmol)	  was	  dissolved	  in	  dry	  DCM	  (10	  mL)	  and	  
anhydrous	  pyridine	  (0.84	  mmol)	  was	  added.	  After	  10	  minutes,	  a	  freshly	  prepared	  solution	  
of	   6-­‐azido-­‐hexanoyl	   chloride	   (0.42	   mmol)	   in	   dry	   DCM	   (4	   mL)	   was	   added	   slowly.	   The	  
reaction	  mixture	  was	  allowed	  to	  stir	  at	   room	  temperature	   for	  18	  hours.	  The	  solvent	  was	  
evaporated	  off	  under	  reduced	  pressure	  and	  the	  product	  was	  purified	  through	  direct	  flash	  
column	  chromatography.	  
	  
6-­‐Azido-­‐hexanoic	   acid	   {4-­‐[3-­‐(2,4-­‐bis-­‐
allyloxy-­‐phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐pyridazine-­‐
1-­‐sulphonyl]-­‐phenyl}-­‐amide	   (46):	   The	  
product	  was	  purified	   through	  direct	   flash	   column	  chromatography	   (20%	  ethyl	   acetate	   in	  




NMR	   (CDCl3	   400	  MHz)	  δ	  7.79	   (2H,	  d,	   J	   =	   8.8	  Hz,	   2xC(CONH)CH),	   7.60	   (2H,	  d,	   J	   =	   8.8	  Hz,	  
2xC(SO2)CH),	  7.40	  (1H,	  s,	  CONH),	  7.12	  (1H,	  d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  6.38	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  
2.3	   Hz,	   C(CN)CHCH),	   6.35	   (1H,	   d,	   J	   =	   2.3	   Hz,	   C(OAllyl)CHC(OAllyl)),	   6.04	   -­‐	   5.83	   (2H,	   m,	  
2xOCH2CHCH2),	  5.34	  (1H,	  ddd,	  J	  =	  17.3	  Hz,	  3.1	  Hz,	  1.6	  Hz,	  OCH2CHCHH	  (trans)),	  5.27	  -­‐	  5.20	  
(2H,	  m,	  OCH2CHCHH	  (trans),	  OCH2CHCHH	  (cis)),	  5.16	  (1H,	  ddd,	  J	  =	  10.5	  Hz,	  2.7	  Hz,	  1.3	  Hz,	  
OCH2CHCHH	  (cis)),	  4.45	  (2H,	  dt,	  J	  =	  5.3	  Hz,	  1.5	  Hz,	  OCH2CHCH2),	  4.39	  (2H,	  dt,	  J	  =	  5.2	  Hz,	  1.5	  
Hz,	  OCH2CHCH2),	  3.36	  -­‐	  3.29	  (2H,	  m,	  NNNCH2),	  3.22	  (2H,	  t,	  J	  =	  6.8	  Hz,	  NCH2),	  2.49	  (2H,	  t,	  J	  =	  
6.7	   Hz,	   CNCH2),	   2.34	   (2H,	   t,	   J	   =	   7.4	   Hz,	   CONHCH2),	   1.95	   (2H,	   dt,	   J	   =	   12.8	   Hz,	   6.1	   Hz,	  
CNCH2CH2),	  1.69	  (2H,	  dt,	  J	  =	  15.2	  Hz,	  7.5	  Hz,	  NNNCH2CH2),	  1.62	  -­‐	  1.53	  (2H,	  m,	  CH2CH2CH2),	  
1.45	   -­‐	   1.34	   (2H,	   m,	   CH2CH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   171.2	   (CONH),	   160.4	  
(C(OAllyl)CHC(OAllyl)),	   157.6	   (C(CN)C(OAllyl)),	   154.0	   (CNN),	   142.1	   (C(SO2)),	   132.9	  
(OCH2CHCH2),	  132.8	  (OCH2CHCH2),	  130.7	  (C(CONH)),	  130.5	  (C(CN)CH),	  129.7	  (2xC(SO2)CH),	  
121.0	   (2xC(CONH)CH),	   118.9	   (C(CN)),	   117.9	   (OCH2CHCH2),	   117.6	   (OCH2CHCH2),	   105.8	  
(C(CN)CHCH),	   100.5	   (C(OAllyl)CHC(OAllyl)),	   69.2	   (OCH2CHCH2),	   68.9	   (OCH2CHCH2),	   51.2	  
(NNNCH2),	   43.2	   (NCH2),	   37.4	   (CONHCH2),	   28.6	   (NNNCH2CH2),	   26.3	   (CH2CH2CH2),	   25.9	  
(CH2CH2CH2),	  24.7	  (CNCH2),	  19.1	  (CNCH2CH2).	  IR	  (neat)	  νmax:	  2927,	  2096,	  1591,	  1352,	  1166	  




6-­‐Azido-­‐hexanoic	  acid	   {4-­‐[4-­‐(2,4-­‐bis-­‐allyloxy-­‐
phenyl)-­‐1H-­‐phthalazine-­‐2-­‐sulphonyl]-­‐
phenyl}-­‐amide	   (47):	   The	   product	   was	  
purified	   through	   direct	   flash	   column	  
chromatography	   (40%	   ethyl	   acetate	   in	   petroleum	   ether)	   to	   afford	   a	   yellow	   oil	   (125	  mg,	  
0.20	  mmol)	  in	  96%	  yield.	  1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  7.94	  (2H,	  d,	  J	  =	  8.8	  Hz,	  2xC(CONH)CH),	  
7.68	  (2H,	  d,	  J	  =	  8.8	  Hz,	  2xC(SO2)CH),	  7.45	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  7.42	  -­‐	  7.37	  (2H,	  m,	  
NCH2CCH,	  NCH2CCHCH),	  7.23	  (1H,	  m,	  CNCCHCH),	  7.00	  (1H,	  d,	  J	  =	  7.1	  Hz,	  CNCCH),	  6.61	  (1H,	  
dd,	  J	  =	  8.4	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.51	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OAllyl)CHC(OAllyl))),	  6.11	  (1H,	  
ddt,	  J	  =	  17.2	  Hz,	  10.6	  Hz,	  5.4	  Hz,	  OCH2CHCH2),	  5.62	  (1H,	  ddt,	  J	  =	  17.2	  Hz,	  10.6	  Hz,	  4.7	  Hz,	  
OCH2CHCH2),	  5.47	  (1H,	  ddd,	  J	  =	  17.3	  Hz,	  3.0	  Hz,	  1.5	  Hz,	  OCH2CHCHH	  (trans)),	  5.35	  (1H,	  ddd,	  
J	  =	  10.5	  Hz,	  2.6	  Hz,	  1.3	  Hz,	  OCH2CHCHH	  (cis)),	  4.93	  (1H,	  ddd,	   J	  =	  10.7	  Hz,	  3.0	  Hz,	  1.5	  Hz,	  




(2H,	   dt,	   J	   =	   5.4	   Hz,	   1.4	   Hz,	   OCH2CHCH2),	   4.45	   (2H,	   s,	   NCH2),	   4.36	   -­‐	   4.31	   (2H,	   m,	  
OCH2CHCH2),	  3.30	  (2H,	  t,	  J	  =	  6.8	  Hz,	  NNNCH2),	  2.42	  (2H,	  t,	  J	  =	  7.4	  Hz,	  CONHCH2),	  1.77	  (2H,	  
dt,	  J	  =	  15.3	  Hz,	  7.5	  Hz,	  CH2CH2CH2),	  1.69	  -­‐	  1.61	  (2H,	  m,	  CH2CH2CH2),	  1.47	  (2H,	  dt,	  J	  =	  15.2	  
Hz,	   7.6	   Hz,	   CH2CH2CH2).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   171.2	   (CONH),	   160.9	  
(C(OAllyl)CHC(OAllyl)),	   157.7	   (C(CN)C(OAllyl)),	   153.5	   (CNN),	   142.3	   (C(SO2)),	   132.9	  
(C(CONH)),	  132.4	  (OCH2CHCH2),	  132.0	  (OCH2CHCH2),	  131.1	  (Ar-­‐CC),	  130.6	  (C(CN)CH),	  130.4	  
(Ar-­‐CC),	   130.0	   (2xC(SO2)CH),	   129.4	   (Ar-­‐CC),	   127.9	   (Ar-­‐CH),	   126.5	   (Ar-­‐CH),	   125.4	   (Ar-­‐CH),	  
118.9	   (Ar-­‐CH),	   118.0	   (OCH2CHCH2),	   117.9	   (OCH2CHCH2),	   117.6	   (2xC(CONH)CH),	   116.4	  
(C(CN)),	   106.0	   (C(CN)CHCH),	   100.6	   (C(OAllyl)CHC(OAllyl)),	   69.0	   (OCH2CHCH2),	   68.6	  
(OCH2CHCH2),	   51.2	   (NNNCH2),	   45.8	   (NCH2),	   37.4	   (CONHCH2),	   28.6	   (CH2CH2CH2),	   26.2	  
(CH2CH2CH2),	  24.7	  (CH2CH2CH2).	  IR	  (neat)	  νmax:	  2998,	  2095,	  1698,	  1590,	  1167	  cm-­‐1.	  HRMS	  
(ESI)	  calcd	  for	  C32H34N6NaO5S	  [M+Na]+	  637.2204	  m/z	  found	  637.2186	  m/z.	  
	  
6-­‐Azido-­‐hexanoic	   acid	   {4-­‐[3-­‐(2,4-­‐dihydroxy-­‐
phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐pyridazine-­‐1-­‐
sulphonyl]-­‐phenyl}-­‐amide:	   The	   product	   was	  
obtained	   following	   Procedure	   12.12	   and	  
purified	   through	   direct	   flash	   column	   chromatography	   (50%	   ethyl	   acetate	   in	   petroleum	  
ether)	  to	  afford	  a	  colourless	  oil	  (40	  mg,	  0.082	  mmol)	   in	  43%	  yield.	  1H-­‐NMR	  (Acetone	  400	  
MHz)	  δ	  12.03	  (1H,	  s,	  COH),	  9.49	  (1H,	  s,	  COH),	  7.75	  (2H,	  d,	  J	  =	  9.0	  Hz,	  2xC(SO2)CH),	  7.69	  -­‐	  
7.63	   (2H,	   m,	   2xC(CONH)CH),	   7.10	   (1H,	   d,	   J	   =	   8.6	   Hz,	   C(CN)CH),	   6.28	   -­‐	   6.14	   (2H,	   m,	  
C(CN)CHCH,	  C(OH)CHC(OH)),	  3.29	  -­‐	  3.23	  (2H,	  m,	  NNNCH2),	  3.19	  (2H,	  t,	   J	  =	  6.9	  Hz,	  NCH2),	  
2.50	   (2H,	   t,	   J	   =	   6.7	   Hz,	   CONHCH2),	   2.28	   (2H,	   t,	   J	   =	   7.4	   Hz,	   CNCH2),	   2.05	   -­‐	   1.96	   (2H,	  m,	  
CNCH2CH2),	  1.56	  (2H,	  dt,	  J	  =	  15.0	  Hz,	  7.4	  Hz,	  CH2CH2CH2),	  1.51	  -­‐	  1.42	  (2H,	  m,	  CH2CH2CH2),	  
1.34	   -­‐	   1.25	   (2H,	   m,	   CH2CH2CH2).	   13C-­‐NMR	   (Acetone	   101	   MHz)	   δ	   171.6	   (CONH),	   160.5	  
(C(OH)CHC(OH)),	  160.2	  (C(CN)C(OH)),	  155.4	  (CNN),	  144.3	  (C(SO2)),	  131.9	  (C(CONH)),	  131.7	  
(C(CN)CH),	  129.2	   (2xC(SO2)CH),	  118.7	   (2xC(CONH)CH),	  111.5	   (C(CN)),	  106.7	   (C(CN)CHCH),	  
103.4	   (C(OH)CHC(OH)),	   50.9	   (NNNCH2),	   43.0	   (NCH2),	   36.6	   (CONHCH2),	   28.1	   (CH2CH2CH2),	  
26.0	  (CH2CH2CH2),	  24.5	  (CH2CH2CH2),	  21.7	  (CNCH2),	  18.4	  (CNCH2CH2).	  IR	  (neat)	  νmax:	  3209,	  
2350,	  1653,	  1233,	  1080	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C22H26N6NaO5S	  [M+Na]+	  509.1578	  m/z	  





6-­‐Azido-­‐hexanoic	   acid	   {4-­‐[4-­‐(2,4-­‐dihydroxy-­‐
phenyl)-­‐1H-­‐phthalazine-­‐2-­‐sulphonyl]-­‐
phenyl}-­‐amide:	   The	   product	   was	   obtained	  
following	   Procedure	   12.12	   and	   purified	  
through	   direct	   flash	   column	   chromatography	   (40%	   ethyl	   acetate	   in	   petroleum	   ether)	   to	  
afford	   a	   white	   paste	   (40	  mg,	   0.074	  mmol)	   in	   37%	   yield.	   1H-­‐NMR	   (Acetone	   400	  MHz)	   δ	  
10.52	  (1H,	  s,	  COH),	  9.45	  (1H,	  s,	  COH),	  7.84	  -­‐	  7.71	  (4H,	  m,	  2xC(CONH)CH,	  2xC(SO2)CH),	  7.53	  
-­‐	  7.45	  (1H,	  m,	  NCH2CCHCH),	  7.44	  -­‐	  7.32	  (3H,	  m,	  NCH2CCH,	  CNCCH,	  CNCCCHCH),	  7.16	  (1H,	  
d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  6.38	  (1H,	  d,	  J	  =	  2.4	  Hz,	  C(OH)CHC(OH)),	  6.31	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.5	  
Hz,	  C(CN)CHCH),	  4.24	  (2H,	  s,	  NCH2),	  3.19	  (2H,	  t,	  J	  =	  6.9	  Hz,	  NNNCH2),	  2.29	  (2H,	  t,	  J	  =	  7.4	  Hz,	  
CONHCH2),	  1.57	  (2H,	  dt,	  J	  =	  15.0	  Hz,	  7.4	  Hz,	  CH2CH2CH2),	  1.48	  (2H,	  dt,	  J	  =	  14.5	  Hz,	  7.1	  Hz,	  
CH2CH2CH2),	  1.34	  -­‐	  1.26	  (2H,	  m,	  CH2CH2CH2).	  13C-­‐NMR	  (Acetone	  126	  MHz)	  δ	  171.6	  (CONH),	  
160.3	  (C(OH)CHC(OH)),	  159.7	  (C(CN)C(OH)),	  155.8	  (CNN),	  144.6	  (C(SO2)),	  133.5	  (C(CONH)),	  
132.1	   (Ar-­‐CC),	  131.9	   (C(CN)CH),	  129.9	   (2x(C(SO2)CH),	  128.2	   (Ar-­‐CC),	  127.9	   (Ar-­‐CH),	  127.4	  
(Ar-­‐CH),	   126.6	   (Ar-­‐CH),	   124.7	   (Ar-­‐CH),	   118.7	   (2xC(CONH)CH),	   109.5	   (C(CN)),	   106.9	  
(C(CN)CHCH),	  103.7	   (C(OH)CHC(OH)),	  50.9	   (NNNCH2),	  46.4	   (NCH2),	  36.6	   (CONHCH2),	  36.5	  
(NNNCH2CH2),	  26.0	  (CH2CH2CH2),	  24.5	  (CH2CH2CH2).	  IR	  (neat)	  νmax:	  3170,	  2099,	  1589,	  1167,	  
1025	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C26H26N6NaO5S	   [M+Na]+	   557.1578	  m/z	   found	   557.1562	  
m/z.	  
	  
12.14	  Procedure	  for	  Staudinger	  reaction:	  
The	   desired	   diol	   derivative	   (0.082	   mmol)	   was	   dissolved	   in	   THF:H2O	   (10:1)	   (5	   mL)	   and	  
polymer	   bound	   triphenylphosphine	   (0.41	   mmol)	   was	   added.	   The	   reaction	   mixture	   was	  
allowed	  to	  stir	  for	  18	  hours	  at	  50	  °C	  and	  then	  filtered	  through	  a	  sinter	  funnel.	  The	  beads	  
were	  further	  washed	  with	  methanol	  (25	  mL)	  and	  with	  a	  7	  N	  solution	  of	  NH3	   in	  methanol	  
(10	  mL).	   The	   solution	   thus	  obtained	  was	  evaporated	   to	  dryness	  under	   reduced	  pressure	  
and	  the	  residue	  was	  purified	  through	  flash	  column	  chromatography.	  
	  
6-­‐Amino-­‐hexanoic	   acid	   {4-­‐[3-­‐(2,4-­‐
dihydroxy-­‐phenyl)-­‐5,6-­‐dihydro-­‐4H-­‐
pyridazine-­‐1-­‐sulphonyl]-­‐phenyl}-­‐amide	  
(NH2-­‐RCZ12):	   The	   product	   was	   purified	  




paste	  (15	  mg,	  0.032	  mmol)	  in	  40%	  yield.	  1H-­‐NMR	  (Acetone	  400	  MHz)	  δ	  12.03	  (1H,	  s,	  COH),	  
9.49	   (1H,	   s,	   COH),	   7.76	   (2H,	   d,	   J	   =	   8.9	   Hz,	   2xC(CONH)CH),	   7.66	   (2H,	   d,	   J	   =	   8.9	   Hz,	  
2xC(SO2)CH),	   7.10	   (1H,	   d,	   J	   =	   8.6	   Hz,	   C(CN)CH),	   6.25	   -­‐	   6.14	   (2H,	   m,	   C(CN)CHCH,	  
C(OH)CHC(OH)),	  3.29	  -­‐	  3.22	  (2H,	  m,	  NCH2),	  2.95	  (2H,	  dd,	  J	  =	  12.4	  Hz,	  6.6	  Hz,	  NH2CH2),	  2.50	  
(2H,	  t,	  J	  =	  6.7	  Hz,	  CONHCH2),	  2.24	  (2H,	  t,	  J	  =	  7.4	  Hz,	  CNCH2),	  2.05	  -­‐	  1.96	  (2H,	  m,	  NCH2CH2),	  
1.60	  -­‐	  1.46	  (4H,	  m,	  2xCH2CH2CH2),	  1.31	  (2H,	  dt,	  J	  =	  13.9	  Hz,	  7.1	  Hz,	  CH2CH2CH2).	  13C-­‐NMR	  
(Acetone	  101	  MHz)	  δ	  171.9	  (CONH),	  160.3	  (C(OH)CHC(OH)),	  160.0	  (C(CN)CH),	  155.4	  (CNN),	  
144.4	   (C(SO2)),	   129.2	   (2xC(SO2)CH),	   128.4	   (C(CONH)),	   128.2	   (C(CN)CH),	   118.7	  
(2xC(CONH)CH),	   111.5	   (C(CN)),	   106.7	   (C(CN)CHCH),	   103.3	   (C(OH)CHC(OH)),	   43.0	   (NCH2),	  
39.4	   (NH2CH2),	  36.8	   (CONHCH2),	  29.9	   (NH2CH2CH2),	  26.0	   (CH2CH2CH2),	  24.7	   (CH2CH2CH2),	  
21.7	  (CNCH2),	  18.4	  (CNCH2CH2).	   IR	  (neat)	  νmax:	  3453,	  3347,	  1663,	  1437,	  1042	  cm-­‐1.	  HRMS	  
(ESI)	  calcd	  for	  C22H28N4NaO5S	  [M+Na]+	  483.4511	  m/z	  found	  483.4523	  m/z.	  
	  
6-­‐Amino-­‐hexanoic	   acid	   {4-­‐[4-­‐(2,4-­‐
dihydroxy-­‐phenyl)-­‐1H-­‐phthalazine-­‐2-­‐
sulphonyl]-­‐phenyl}-­‐amide	  (NH2-­‐RCZ20):	  
The	   product	   was	   purified	   through	  
direct	  flash	  column	  chromatography	  (5%	  methanol	  in	  DCM)	  to	  afford	  a	  colourless	  oil	  (7	  mg,	  
0.013	  mmol)	   in	  19%	  yield.	  1H-­‐NMR	  (Acetone	  400	  MHz)	  δ	  10.51	  (1H,	  s,	  COH),	  9.50	  (1H,	  s,	  
COH),	  7.81	  (2H,	  d,	   J	  =	  9.0	  Hz,	  2xC(SO2)CH),	  7.76	  (2H,	  d,	   J	  =	  9.0	  Hz,	  2xC(CONH)CH),	  7.52	  -­‐	  
7.44	  (1H,	  m,	  NCH2CCHCH),	  7.44	  -­‐	  7.31	  (3H,	  m,	  NCH2CCH,	  CNCCH,	  CNCCHCH),	  7.15	  (1H,	  d,	  J	  
=	  8.6	  Hz,	  C(CN)CH),	  6.37	  (1H,	  d,	  J	  =	  2.4	  Hz,	  C(OH)CHC(OH)),	  6.30	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.5	  Hz,	  
C(CN)CHCH),	  4.24	  (2H,	  s,	  NCH2),	  2.94	  (2H,	  dd,	  J	  =	  12.4	  Hz,	  6.6	  Hz,	  NH2CH2),	  2.24	  (2H,	  t,	  J	  =	  
7.4	  Hz,	  CONHCH2),	  1.58	  -­‐	  1.42	  (4H,	  m,	  2xCH2CH2CH2),	  1.32	  -­‐	  1.22	  (2H,	  m,	  CH2CH2CH2).	  13C-­‐
NMR	   (Acetone	   126	   MHz)	   δ	   172.0	   (CONH),	   160.3	   (C(OH)CHC(OH)),	   159.5	   (C(CN)C(OH)),	  
155.3	   (CNN),	   143.9	   (C(SO2)),	   132.7	   (C(CONH)),	   132.1	   (Ar-­‐CC),	   131.9	   (Ar-­‐CC),	   129.4	  
(2xC(SO2)CH),	  128.2	  (C(CN)CH),	  127.9	  (Ar-­‐CH),	  127.1	  (Ar-­‐CH),	  125.6	  (Ar-­‐CH),	  124.7	  (Ar-­‐CH),	  
118.9	   (2xC(CONH)CH),	   109.5	   (C(CN)),	   106.9	   (C(CN)CHCH),	   103.7	   (C(OH)CHC(OH)),	   46.4	  
(NCH2),	   36.9	   (NH2CH2),	   36.5	   (CONHCH2),	   29.5	   (NH2CH2CH2),	   26.0	   (CH2CH2CH2),	   24.5	  
(CH2CH2CH2).	   IR	   (neat)	   νmax:	   3295,	   2919,	   1590,	   1167,	   1025	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  





12.15	  General	  Procedure	  for	  sulphonylation/de-­‐protection:	  
3-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1,4,5,6-­‐tetrahydro-­‐pyridazine	  (0.7	  mmol)	  was	  dissolved	  in	  dry	  
DCM	  (10	  mL)	  and	  TEA	  (1.54	  mmol)	  and	  DMAP	  (0.07	  mmol)	  were	  added	  subsequently.	  After	  
5	  minutes,	  the	  desired	  sulphonyl	  chloride	  (0.9	  mmol)	  was	  added	  and	  the	  reaction	  mixture	  
was	  allowed	  to	  stir	  overnight.	  The	  mixture	  was	  washed	  with	  a	  3	  M	  solution	  of	  HCl	   (1x25	  
mL),	  a	  5	  M	  solution	  of	  NaOH	  (1x25	  mL)	  and	  with	  water	  (2x25	  mL).	  The	  organic	  phase	  was	  
then	  dried	  over	  Na2SO4,	   filtered	  and	  concentrated.	  The	   residue	  was	   loaded	  onto	  a	   short	  
pad	  of	   silica	  and	   filtered	  with	  a	  20%	  ethyl	  acetate	   in	  petroleum	  ether	   solution	   to	  yield	  a	  
yellow	   oil.	   The	   crude	   product	   was	   dried	   under	   high	   vacuum	   and	   used	   without	   further	  
purification.	  The	  crude	  (0.4	  mmol)	  was	  dissolved	  in	  dry	  DCM	  (8	  mL)	  and	  a	  1	  M	  solution	  of	  
BBr3	  (2.6	  mmol)	  was	  added	  slowly	  at	  0	  °C.	  The	  reaction	  mixture	  was	  stirred	  for	  30	  minutes	  
at	  0	  °C	  and	  then	  at	  room	  temperature	  until	  starting	  material	  consumption,	  monitored	  by	  
TLC	   (3-­‐6	   hours).	  Water	   (50	  mL)	  was	   added	   to	   quench	   the	   excess	   of	   BBr3	   and	   the	   layers	  
were	   separated.	   The	   aqueous	   phase	   was	   back-­‐extracted	   with	   DCM	   (2x50	   mL)	   and	   the	  
combined	  organic	  phases	  were	  dried	  over	  Na2SO4,	  filtered	  and	  concentrated.	  The	  residue	  





benzene-­‐1,3-­‐diol	   (RCZ30):	   The	   product	   was	   purified	   by	  
flash	   column	   chromatography	   (40%	   ethyl	   acetate	   in	  
petroleum	   ether)	   to	   obtain	   a	   brownish	   oil	   (150	  mg,	   0.45	  
mmol)	  in	  57%	  yield	  over	  two	  steps.	  1H-­‐NMR	  (Acetone	  400	  MHz)	  δ	  12.17	  (1H,	  s,	  COH),	  9.35	  
(1H,	  s,	  COH),	  7.90	  (2H,	  d,	  J	  =	  7.1	  Hz,	  2xC(SO2)CH),	  7.75	  (2H,	  m,	  C(CN)CH,	  Ar-­‐CH),	  7.67	  (2H,	  t,	  
J	  =	  7.5	  Hz,	  2xC(SO2)CHCH),	  6.56	   (2H,	  m,	  C(CN)CHCH,	  C(OH)CHC(OH)),	  3.50	   -­‐	  3.42	   (2H,	  m,	  
NCH2),	  2.69	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.24	  -­‐	  2.12	  (2H,	  m,	  NCH2CH2).	  13C-­‐NMR	  (Acetone	  101	  
MHz)	  δ	  159.1	  (C(OH)CHC(OH)),	  156.0	  (C(CN)C(OH)),	  154.4	  (CNN),	  135.2	  (C(SO2)),	  133.7	  (Ar-­‐
CH),	   130.9	   (C(CN)CH),	   129.4	   (2xC(SO2)CH),	   127.9	   (2xC(SO2)CHCH),	   113.3	   (C(CN)),	   104.1	  
(C(CN)CHCH),	  98.7	  (C(OH)CHC(OH)),	  42.9	  (NCH2),	  21.6	  (CNCH2),	  18.2	  (NCH2CH2).	   IR	  (neat)	  
νmax:	   3031,	   2564,	   1620,	   1383,	   1016	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C16H16N2NaO4S	   [M+Na]+	  






3-­‐yl]-­‐benzene-­‐1,3-­‐diol	  (RCZ32):	  The	  product	  was	  purified	  
by	   flash	   column	   chromatography	   (40%	   ethyl	   acetate	   in	  
petroleum	   ether)	   to	   obtain	   a	   beige	   solid	   (51	   mg,	   0.14	  
mmol)	  in	  23%	  yield	  over	  two	  steps.	  m.p.	  186	  °C.	  1H-­‐NMR	  (Acetone	  400	  MHz)	  δ	  12.18	  (1H,	  
s,	  COH),	  7.78	  (2H,	  d,	  J	  =	  8.3	  Hz,	  2xC(SO2)CH),	  7.45	  (2H,	  d,	  J	  =	  8.0	  Hz,	  2xC(CH3)CH),	  7.26	  (1H,	  
d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  6.39	  -­‐	  6.31	  (2H,	  m,	  C(CN)CHCH,	  C(OH)CHC(OH)),	  5.64	  (1H,	  s,	  COH),	  
3.44	  -­‐	  3.38	  (2H,	  m,	  NCH2),	  2.65	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.42	  (3H,	  s,	  CCH3),	  2.16	  (2H,	  dt,	  J	  
=	  11.4	  Hz,	  6.7	  Hz,	  NCH2CH2).	  13C-­‐NMR	  (Acetone	  126	  MHz)	  δ	  160.3	  (C(OH)CHC(OH)),	  160.1	  
(C(CN)C(OH)),	   155.4	   (CNN),	   144.6	   (C(SO2)),	   132.2	   (C(CN)CH),	   129.8	   (2xC(SO2)CH),	   128.2	  
(C(CH3)),	   128.0	   (2xC(CH3)CH),	   111.5	   (C(CN)),	   106.7	   (C(CN)CHCH),	   103.3	   (C(OH)CHC(OH)),	  
43.0	  (NCH2),	  21.7	  (CNCH2),	  20.5	  (CCH3),	  18.4	  (NCH2CH2).	  IR	  (neat)	  νmax:	  3387,	  2917,	  1627,	  




benzene-­‐1,3-­‐diol	   (RCZ31):	   The	   product	   was	   purified	   by	   flash	  
column	  chromatography	  (40%	  ethyl	  acetate	  in	  petroleum	  ether)	  
to	  obtain	  a	  white	  solid	  (41	  mg,	  0.15	  mmol)	   in	  31%	  yield	  over	  two	  steps.	  m.p.	  141	  °C.	  1H-­‐
NMR	  (Acetone	  500	  MHz)	  δ	  11.95	  (1H,	  s,	  COH),	  8.75	  (1H,	  s,	  COH),	  7.37	  (1H,	  d,	  J	  =	  8.7	  Hz,	  
C(CN)CH),	   6.40	   (1H,	   dd,	   J	   =	   9.3	   Hz,	   1.8	   Hz,	   C(CN)CHCH),	   6.36	   (1H,	   d,	   J	   =	   2.5	   Hz,	  
C(OH)CHC(OH)),	   3.69	   -­‐	   3.55	   (2H,	   m,	   NCH2),	   3.01	   (3H,	   s,	   CCH3),	   2.78	   (2H,	   t,	   J	   =	   6.7	   Hz,	  
CNCH2),	  2.21	  (2H,	  dt,	  J	  =	  13.5	  Hz,	  6.7	  Hz,	  NCH2CH2).	  13C-­‐NMR	  (Acetone	  126	  MHz)	  δ	  160.3	  
(C(OH)CHC(OH)),	  160.1	  (C(CN)C(OH)),	  154.9	  (CNN),	  128.3	  (C(CN)CH),	  111.7	  (C(CN)),	  106.7	  
(C(CN)CHCH),	   103.3	   (C(OH)CHC(OH)),	   42.4	   (NCH2),	   33.5	   (SO2CH3),	   21.8	   (CNCH2),	   18.6	  
(NCH2CH2).	   IR	   (neat)	   νmax:	   3043,	   1627,	   1351,	   1257,	   970	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  
C11H14N2NaO4S	  [M+Na]+	  293.0566	  m/z	  found	  293.0562	  m/z.	  
	  
4-­‐[1-­‐(Octane-­‐1-­‐sulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐
pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ35):	   The	  
product	   was	   purified	   by	   flash	   column	  
chromatography	   (40%	   ethyl	   acetate	   in	  




1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  11.81	  (1H,	  s,	  COH),	  7.14	  (1H,	  d,	  J	  =	  8.7	  Hz,	  C(CN)CH),	  6.35	  (1H,	  
d,	   J	   =	  2.5	  Hz,	  C(OH)CHC(OH)),	   6.31	   (1H,	  dd,	   J	   =	  8.7	  Hz,	   2.6	  Hz,	  C(CN)CHCH),	   5.53	   (1H,	   s,	  
COH),	   3.61	   -­‐	   3.48	   (2H,	   m,	   NCH2),	   3.10	   -­‐	   2.98	   (2H,	   m,	   SO2CH2),	   2.60	   (2H,	   t,	   J	   =	   6.7	   Hz,	  
CNCH2),	  2.14	   -­‐	  2.05	   (2H,	  m,	  NCH2CH2),	  1.83	   -­‐	  1.70	   (2H,	  m,	  CH2CH2CH2),	  1.33	   (2H,	  dt,	   J	   =	  
15.0	  Hz,	   7.3	  Hz,	  CH2CH2CH2),	   1.25	   -­‐	   1.10	   (8H,	  m,	  4x	  CH2CH2CH2),	   0.79	   (3H,	   t,	   J	   =	  7.0	  Hz,	  
CH2CH3).	   13C-­‐NMR	   (CDCl3	   126	  MHz)	   δ	   159.9	   (C(OH)CHC(OH)),	   158.4	   (C(CN)C(OH)),	   153.4	  
(CNN),	   127.8	   (C(CN)CH),	   112.4	   (C(CN)),	   106.9	   (C(CN)CHCH),	   104.0	   (C(OH)CHC(OH)),	   49.1	  
(SO2CH2),	   42.2	   (NCH2),	   31.6	   (SO2CH2CH2),	   28.9	   (CH2CH2CH2),	   28.9	   (CH2CH2CH2),	   28.3	  
(CH2CH2CH2),	   22.8	   (CH2CH2CH2),	   22.5	   (CH2CH2CH2),	   22.2	   (CNCH2),	   18.9	   (NCH2CH2),	   14.0	  
(CH2CH3).	   IR	   (neat)	   νmax:	   3279,	   2926,	   1627,	   1350,	   1180	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  
C18H28N2NaO4S	  [M+Na]+	  391.1662	  m/z	  found	  391.1644	  m/z.	  
	  
4-­‐[1-­‐(4-­‐Trifluoromethyl-­‐benzenesulphonyl)-­‐1,4,5,6-­‐
tetrahydro-­‐pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ34):	  
The	   product	   was	   purified	   by	   flash	   column	  
chromatography	   (40%	   ethyl	   acetate	   in	   petroleum	  
ether)	  to	  obtain	  a	  white	  solid	  (54	  mg,	  0.13	  mmol)	  in	  20%	  yield	  over	  two	  steps.	  m.p.	  190	  °C.	  
1H-­‐NMR	  (Acetone	  400	  MHz)	  δ	  12.03	  (1H,	  s,	  COH),	  8.79	  (1H,	  s,	  COH),	  8.12	  (2H,	  d,	  J	  =	  7.8	  Hz,	  
2xC(CF3)CH),	  8.04	  (2H,	  d,	  J	  =	  8.3	  Hz,	  2xC(SO2)CH),	  7.28	  (1H,	  d,	  J	  =	  8.8	  Hz,	  C(CN)CH),	  6.44	  -­‐	  
6.33	  (2H,	  m,	  C(CN)CHCH,	  C(OH)CHC(OH)),	  3.57	  -­‐	  3.43	  (2H,	  m,	  NCH2),	  2.68	  (2H,	  t,	  J	  =	  6.7	  Hz,	  
CNCH2),	  2.18	  (2H,	  dt,	  J	  =	  12.4	  Hz,	  6.7	  Hz,	  NCH2CH2).	  13C-­‐NMR	  (Acetone	  101	  MHz)	  δ	  160.4	  
(C(OH)CHC(OH)),	   160.3	   (C(CN)C(OH)),	   156.3	   (CNN),	   139.1	   (C(SO2)),	   128.8	   (2xC(CF3)CH,	  
2xC(SO2)CH),	   128.4	   (C(CN)CH),	   126.5	   (t,	   J	   =	   3.8	   Hz)	   (CCF3),	   111.4	   (C(CN)),	   106.8	  
(C(CN)CHCH),	  103.3	  (C(OH)CHC(OH)),	  43.0	  (NCH2),	  21.7	  (CNCH2),	  18.3	  (NCH2CH2).	  IR	  (neat)	  
νmax:	  3121,	  2487,	  1628,	  1322,	  1173	  cm-­‐1.	  HRMS	   (ESI)	   calcd	   for	  C17H22F3N2NaO4S	   [M+Na]+	  
423.0597	  m/z	  found	  423.0.579	  m/z.	  
	  
4-­‐[1-­‐(4-­‐Isopropyl-­‐benzenesulfonyl)-­‐1,4,5,6-­‐
tetrahydro-­‐pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ33):	  
The	   product	   was	   purified	   by	   flash	   column	  
chromatography	   (40%	   ethyl	   acetate	   in	   petroleum	  
ether)	  to	  obtain	  a	  colourless	  oil	  (55	  mg,	  0.14	  mmol)	  in	  22%	  yield	  over	  two	  steps.	  1H-­‐NMR	  




2xC(SO2)CH),	  7.53	  (2H,	  d,	  J	  =	  8.3	  Hz,	  2xC(iPr)CH),	  7.27	  (1H,	  d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  6.41	  -­‐	  
6.29	  (2H,	  m,	  C(CN)CHCH,	  C(OH)CHC(OH)),	  3.46	  -­‐	  3.38	  (2H,	  m,	  NCH2),	  3.02	  (2H,	  quint.,	   J	  =	  
6.9	  Hz,	  CH3CH),	  2.66	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.16	  (2H,	  dt,	  J	  =	  13.5	  Hz,	  6.7	  Hz,	  NCH2CH2),	  
1.26	   (6H,	  d,	   J	  =	  6.9	  Hz,	  2xCHCH3).	   13C-­‐NMR	  (Acetone	  101	  MHz)	  δ	  160.4	   (C(OH)CHC(OH)),	  
160.1	   (C(CN)C(OH)),	   155.3	   (CNN),	   155.1	   (C(SO2)),	   132.7	   (C(CN)CH),	   128.5	   (C(iPr)),	   128.2	  
(2xC(SO2)CH),	   127.3	   (2xC(iPr)CH),	   111.5	   (C(CN)),	   106.7	   (C(CN)CHCH),	   103.3	  
(C(OHCHC(OH)),	  42.9	  (NCH2),	  33.9	  (CH3CH),	  22.8	  (2xCHCH3),	  21.6	  (CNCH2),	  18.4	  (NCH2CH2).	  
IR	   (neat)	   νmax:	   3070,	   1628,	   1357,	   1170,	   781	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C19H22N2NaO4S	  
[M+Na]+	  397.1192	  m/z	  found	  397.1174	  m/z.	  
	  
4-­‐[1-­‐(3-­‐Nitro-­‐benzenesulphonyl)-­‐1,4,5,6-­‐tetrahydro-­‐
pyridazin-­‐3-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ36):	  The	  product	  was	  
purified	   by	   flash	   column	   chromatography	   (40%	   ethyl	  
acetate	   in	   petroleum	   ether)	   to	   obtain	   a	   yellow	   paste	   (87	  
mg,	   0.23	   mmol)	   in	   32%	   yield	   over	   two	   steps.	   1H-­‐NMR	  
(Acetone	  400	  MHz)	  δ	  12.00	  (1H,	  s,	  COH),	  8.66	  (1H,	  t,	   J	  =	  1.9	  Hz,	  C(SO2)CHC(NO2)),	  8.61	  -­‐	  
8.53	  (1H,	  m,	  C(NO2)CH),	  8.33	  -­‐	  8.24	  (1H,	  m,	  C(SO2)CH),	  8.01	  (1H,	  t,	  J	  =	  8.1	  Hz,	  C(NO2)CHCH),	  
7.28	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  6.39	  (1H,	  d,	  J	  =	  2.4	  Hz,	  C(OH)CHC(OH)),	  6.36	  (1H,	  dd,	  J	  =	  
8.6	  Hz,	  2.5	  Hz,	  C(CN)CHCH),	  3.63	  -­‐	  3.51	  (2H,	  m,	  NCH2),	  2.68	  (2H,	  t,	  J	  =	  6.7	  Hz,	  CNCH2),	  2.19	  
(2H,	   dt,	   J	   =	   11.4	   Hz,	   6.7	   Hz,	   NCH2CH2).	   13C-­‐NMR	   (Acetone	   101	   MHz)	   δ	   160.4	  
(C(OH)CHC(OH),	   160.1	   (C(CN)C(OH)),	   156.7	   (CNN),	   148.5	   (C(NO2)),	   136.9	   (C(SO2)),	   133.6	  
(C(SO2)CHCH),	   131.3	   (C(SO2)CHCH),	   128.4	   (C(CN)CH),	   128.1	   (C(SO2)CHC(NO2)),	   122.7	  
(C(NO2)CH),	   111.3	   (C(CN)),	   106.9	   (C(CN)CHCH),	   103.3	   (C(OH)CHC(OH)),	   43.1	   (NCH2),	   21.7	  
(CNCH2),	   18.3	   (NCH2CH2).	   IR	   (neat)	   νmax:	   3211,	   2984,	   1672,	   1315,	   846	   cm-­‐1.	   HRMS	   (ESI)	  
calcd	  for	  C16H15N3NaO6S	  [M+Na]+	  400.0574	  m/z	  found	  400.0557	  m/z.	  
	  
12.16	  General	  Procedure	  for	  sulphonylation/de-­‐protection:	  
4-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐1,2-­‐dihydro-­‐phthalazine	  (0.6	  mmol)	  was	  dissolved	  in	  dry	  DCM	  
(10	  mL)	  and	  TEA	   (1.22	  mmol)	  and	  DMAP	   (0.06	  mmol)	  were	  added	  subsequently.	  After	  5	  
minutes,	   the	  desired	   sulphonyl	   chloride	   (0.7	  mmol)	  was	  added	  and	   the	   reaction	  mixture	  
was	  allowed	  to	  stir	  overnight.	  The	  mixture	  was	  washed	  with	  a	  3	  M	  solution	  of	  HCl	   (1x25	  
mL),	  a	  5	  M	  solution	  of	  NaOH	  (1x25	  mL)	  and	  with	  water	  (2x25	  mL).	  The	  organic	  phase	  was	  




of	  silica	  and	  filtered	  with	  a	  20%	  ethyl	  acetate	  in	  petroleum	  ether	  solution	  to	  yield	  a	  yellow	  
oil.	  The	  crude	  product	  was	  dried	  under	  high	  vacuum	  and	  used	  without	  further	  purification.	  
The	   crude	   (0.3	   mmol)	   was	   dissolved	   in	   dry	   DCM	   (6	   mL)	   and	   anhydrous	   aluminium	  
trichloride	   (1.8	  mmol)	  was	  added	  one	  portion.	  The	   reaction	  mixture	  was	  stirred	  at	   room	  
temperature	   until	   starting	   material	   consumption,	   monitored	   by	   TLC	   (3-­‐12	   hours).	  
Methanol	   (20	   mL)	   was	   added	   to	   quench	   the	   excess	   of	   aluminium	   trichloride	   and	   the	  
mixture	   was	   evaporated	   off	   under	   reduced	   pressure.	   The	   residue	   was	   purified	   by	   flash	  
column	  chromatography	  to	  afford	  the	  desired	  final	  product.	  
	  
4-­‐(3-­‐Benzenesulphonyl-­‐3,4-­‐dihydro-­‐phthalazin-­‐1-­‐yl)-­‐
benzene-­‐1,3-­‐diol	  (RCZ40):	  The	  product	  was	  purified	  by	  flash	  
column	   chromatography	   (50%	   ethyl	   acetate	   in	   petroleum	  
ether)	   to	   obtain	   a	  white	   solid	   (84	  mg,	   0.22	  mmol)	   in	   49%	  
yield	  over	  two	  steps.	  m.p.	  195	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz):	  δ	  10.73	  (1H,	  s,	  COH),	  8.02	  (2H,	  
d,	  J	  =	  8.4	  Hz,	  2xC(SO2)CH),	  7.67	  (1H,	  t,	  J	  =	  7.4	  Hz,	  NCH2CCHCH),	  7.62	  -­‐	  7.51	  (4H,	  m,	  Ar-­‐CH,	  
2xC(SO2)CHCH,	   CNCCH),	   7.43	   (1H,	   t,	   J	   =	   7.8	   Hz,	   CNCCHCH),	   7.34	   (1H,	   d,	   J	   =	   7.5	   Hz,	  
NCH2CCH),	  7.31	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  6.59	  (1H,	  d,	  J	  =	  2.5	  Hz,	  C(OH)CHC(OH)),	  6.42	  
(1H,	   dd,	   J	   =	   8.6	  Hz,	   2.5	  Hz,	   C(CN)CHCH),	   5.03	   (1H,	   s,	   COH),	   4.35	   (2H,	   s,	  NCH2).	   13C-­‐NMR	  
(CDCl3	   126	   MHz):	   δ	   159.8	   (C(OH)CHC(OH)),	   158.4	   (C(CN)C(OH)),	   155.7	   (CNN),	   134.5	  
(C(SO2)),	   133.8	   (C(SO2)CHCHCH),	   133.0	   (Ar-­‐CC),	   132.0	   (Ar-­‐CC),	   131.8	   (Ar-­‐CH),	   129.2	  
(2xC(SO2)CH),	  128.8	  (2xC(SO2)CHCH),	  128.3	  (C(CN)CH),	  127.8	  (Ar-­‐CH),	  126.4	  (Ar-­‐CH),	  124.6	  
(Ar-­‐CH),	  110.3	   (C(CN)),	  106.6	   (C(CN)CHCH),	  104.4	   (C(OH)CHC(OH)),	  46.3	   (NCH2).	   IR	   (neat)	  
νmax:	   3397,	   2358,	   1624,	   1347,	   1170	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C20H16N2O4S	   [M+H]+	  
383.0831	  m/z	  found	  383.0833	  m/z.	  
	  
4-­‐[3-­‐(Toluene-­‐4-­‐sulphonyl)-­‐3,4-­‐dihydro-­‐phthalazin-­‐1-­‐yl]-­‐
benzene-­‐1,3-­‐diol	   (RCZ42):	   The	   product	   was	   purified	   by	  
flash	   column	   chromatography	   (50%	   ethyl	   acetate	   in	  
petroleum	   ether)	   to	   obtain	   a	   brownish	   solid	   (122	   mg,	  
0.30	  mmol)	   in	  55%	  yield	  over	   two	  steps.	  m.p.	  202	  °C.	   1H-­‐NMR	  (CDCl3	  400	  MHz):	  δ	  10.78	  
(1H,	   s,	   COH),	   7.89	   (2H,	   d,	   J	   =	   8.2	   Hz,	   2xC(SO2)CH),	   7.56	   -­‐	   7.51	   (2H,	   m,	   NCH2CCHCH,	  
NCH2CCH),	  7.42	   (1H,	   t,	   J	  =	  7.3	  Hz,	  CNCCHCH),	  7.38	   (2H,	  d,	   J	  =	  7.9	  Hz,	  2xC(CH3)CH),	  7.34	  




C(OH)CHC(OH)),	  6.42	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.5	  Hz,	  C(CN)CHCH),	  4.99	  (1H,	  s,	  COH),	  4.33	  (2H,	  s,	  
NCH2),	   2.45	   (3H,	   s,	   CCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz):	   δ	   159.9	   (C(OH)CHC(OH)),	   158.1	  
(C(CN)C(OH)),	  155.5	  (CNN),	  144.8	  (C(SO2)),	  133.1	  (Ar-­‐CC),	  132.0	  (Ar-­‐CC),	  131.8	  (C(CN)CH),	  
131.5	   (C(CH3)),	   129.9	   (2xC(SO2)CH),	   128.8	   (2xC(CH3)CH),	   128.2	   (Ar-­‐CH),	   127.7	   (Ar-­‐CH),	  
126.4	   (Ar-­‐CH),	   124.7	   (Ar-­‐CH),	   110.5	   (C(CN)),	   106.5	   (C(CN)CHCH),	   104.4	   (C(OH)CHC(OH)),	  
46.3	   (NCH2),	   21.6	   (CCH3).	   IR	   (neat)	   νmax:	   3420,	   2363,	   1625,	   1168,	   732	   cm-­‐1.	   HRMS	   (ESI)	  
calcd	  for	  C21H18N2O4S	  [M+H]+	  394.0987	  m/z	  found	  394.0992	  m/z.	  
	  
4-­‐(3-­‐Methanesulphonyl-­‐3,4-­‐dihydro-­‐phthalazin-­‐1-­‐yl)-­‐benzene-­‐
1,3-­‐diol	   (RCZ41):	   The	   product	   was	   purified	   by	   flash	   column	  
chromatography	   (50%	   ethyl	   acetate	   in	   petroleum	   ether)	   to	  
obtain	  a	  white	  foam	  (95	  mg,	  0.29	  mmol)	  in	  60%	  yield	  over	  two	  
steps.	   1H-­‐NMR	   (CDCl3	   400	   MHz):	   δ	   10.34	   (1H,	   s,	   COH),	   7.59	   -­‐	   7.55	   (2H,	   m,	   NCH2CCH,	  
NCH2CCHCH),	  7.46	  (1H,	  t,	  J	  =	  7.6	  Hz,	  CNCCHCH),	  7.38	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  7.36	  (1H,	  
d,	  J	  =	  7.3	  Hz,	  CNCCH),	  6.58	  (1H,	  d,	  J	  =	  2.3	  Hz,	  C(OH)CHC(OH)),	  6.47	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.5	  
Hz,	  C(CN)CHCH),	  5.10	  (1H,	  s,	  COH),	  4.55	  (2H,	  s,	  NCH2),	  3.10	  (3H,	  s,	  SO2CH3).	  13C-­‐NMR	  (CDCl3	  
126	  MHz):	  δ	  159.6	  (C(OH)CHC(OH)),	  158.5	  (C(CN)C(OH)),	  156.1	  (CNN),	  132.8	  (Ar-­‐CC),	  132.3	  
(Ar-­‐CC),	  131.9	  (C(CN)CH),	  128.5	  (Ar-­‐CH),	  127.9	  (Ar-­‐CH),	  126.5	  (Ar-­‐CH),	  124.7	  (Ar-­‐CH),	  110.4	  
(C(CN)),	  106.9	  (C(CN)CHCH),	  104.4	  (C(OH)CHC(OH)),	  46.0	  (NCH2),	  34.3	  (SO2CH3).	   IR	   (neat)	  
νmax:	  3345,	  1624,	  1343,	  1219,	  952	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C15H14N2O4S	  [M+H]+	  318.0674	  
m/z	  found	  318.0675	  m/z.	  
	  
4-­‐[3-­‐(Octane-­‐1-­‐sulphonyl)-­‐3,4-­‐dihydro-­‐
phthalazin-­‐1-­‐yl]-­‐benzene-­‐1,3-­‐diol	  (RCZ45):	  The	  
product	   was	   purified	   by	   flash	   column	  
chromatography	   (50%	   ethyl	   acetate	   in	  
petroleum	  ether)	  to	  obtain	  a	  white	  foam	  (83	  mg,	  0.19	  mmol)	  in	  58%	  yield	  over	  two	  steps.	  
1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  10.38	  (1H,	  s,	  COH),	  7.60	  -­‐	  7.52	  (2H,	  m,	  NCH2CCH,	  NCH2CCHCH),	  
7.45	  (1H,	  td,	  J	  =	  7.8	  Hz,	  1.1	  Hz,	  CNCCHCH),	  7.39	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  7.35	  (1H,	  d,	  J	  =	  
7.5	  Hz,	  CNCCH),	  6.58	  (1H,	  d,	   J	  =	  2.5	  Hz,	  C(OH)CHC(OH)),	  6.47	  (1H,	  dd,	   J	  =	  8.6	  Hz,	  2.6	  Hz,	  
C(CN)CHCH),	  5.05	  (1H,	  s,	  COH),	  4.61	  (2H,	  s,	  NCH2),	  3.28	  -­‐	  3.21	  (2H,	  m,	  SO2CH2),	  2.02	  -­‐	  1.90	  
(2H,	  m,	  CH2CH2CH2),	   1.52	   -­‐	   1.43	   (2H,	  m,	  CH2CH2CH2),	   1.37	   -­‐	   1.26	   (8H,	  m,	  4xCH2CH2CH2),	  




(C(CN)C(OH)),	  155.6	   (CNN),	  132.9	   (Ar-­‐CC),	  132.1	   (Ar-­‐CC),	  131.9	   (C(CN)CH),	  128.3	   (Ar-­‐CH),	  
127.8	   (Ar-­‐CH),	   126.3	   (Ar-­‐CH),	   124.8	   (Ar-­‐CH),	   110.6	   (C(CN)),	   106.7	   (C(CN)CHCH),	   104.4	  
(C(OH)CHC(OH)),	   48.5	   (SO2CH2),	   46.0	   (NCH2),	   31.6	   (SO2CH2CH2),	   28.9	   (CH2CH2CH2),	   28.8	  
(CH2CH2CH2),	   28.4	   (CH2CH2CH2),	   22.6	   (CH2CH2CH2),	   22.5	   (CH2CH2CH2),	   15.2	   (CH2CH3).	   IR	  
(neat)	   νmax:	   3241,	   2952,	   1574,	   1337,	   968	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C22H28N2NaO4S	  
[M+Na]+	  439.1662	  m/z	  found	  439.1643	  m/z.	  
	  
4-­‐[3-­‐(4-­‐Trifluoromethyl-­‐benzenesulphonyl)-­‐3,4-­‐
dihydro-­‐phthalazin-­‐1-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ44):	  
The	   product	   was	   purified	   by	   flash	   column	  
chromatography	   (25%	   ethyl	   acetate	   in	   petroleum	  
ether)	   to	  obtain	  a	  white	   foam	  (72	  mg,	  0.16	  mmol)	   in	  34%	  yield	  over	   two	  steps.	   1H-­‐NMR	  
(CDCl3	  500	  MHz)	  δ	  10.65	  (1H,	  s,	  COH),	  8.05	  (2H,	  d,	  J	  =	  8.6	  Hz,	  2xC(CF3)CH),	  7.79	  (2H,	  d,	  J	  =	  
8.4	  Hz,	  2xC(SO2)CH),	  7.55	  (1H,	  td,	  J	  =	  7.5	  Hz,	  1.2	  Hz,	  NCH2CCHCH),	  7.52	  (1H,	  d,	  J	  =	  7.2	  Hz,	  
NCH2CCH),	  7.43	  (1H,	  t,	  J	  =	  7.6	  Hz,	  CNCCHCH),	  7.34	  (1H,	  d,	  J	  =	  7.1	  Hz,	  CNCCH),	  7.31	  (1H,	  d,	  J	  
=	  8.6	  Hz,	  C(CN)CH),	  6.73	  (1H,	  s,	  COH),	  6.59	  (1H,	  d,	  J	  =	  2.6	  Hz,	  C(OH)CHC(OH)),	  6.42	  (1H,	  dd,	  
J	   =	   8.6	   Hz,	   2.6	   Hz,	   C(CN)CHCH),	   4.36	   (2H,	   s,	   NCH2).	   13C-­‐NMR	   (CDCl3	   126	  MHz)	   δ	   159.8	  
(C(OH)CHC(OH)),	   159.6	   (C(CN)C(OH)),	   158.4	   (CNN),	   149.4	   (C(SO2)),	   145.3	   (Ar-­‐CC),	   132.8	  
(Ar-­‐CC),	  132.2	  (Ar-­‐CH),	  131.9	  (Ar-­‐CH),	  129.3	  (2xC(CF3)CH),	  128.4	  (C(CN)CH),	  127.9	  (Ar-­‐CH),	  
127.1	   (2xC(SO2)CH),	   126.4	   (t,	   J	   =	   4.0	   Hz)	   (CCF3),	   124.6	   (Ar-­‐CH),	   109.2	   (C(CN)),	   106.7	  
(C(CN)CHCH),	  104.4	  (C(OH)CHC(OH)),	  46.4	  (NCH2).	  IR	  (neat)	  νmax:	  3087,	  1606,	  1404,	  1284,	  




phthalazin-­‐1-­‐yl]-­‐benzene-­‐1,3-­‐diol	   (RCZ43):	   The	  
product	  was	  purified	  by	  flash	  column	  chromatography	  
(45%	   ethyl	   acetate	   in	   petroleum	   ether)	   to	   obtain	   a	  
yellow/brownish	   solid	   (71	  mg,	  0.16	  mmol)	   in	  44%	  yield	  over	   two	  steps.	  m.p.	  180	   °C.	   1H-­‐
NMR	  (CDCl3	  400	  MHz):	  δ	  10.72	   (1H,	  s,	  COH),	  7.81	   (2H,	  d,	   J	  =	  8.6	  Hz,	  2xC(SO2)CH),	  7.45	   -­‐	  
7.39	  (2H,	  m,	  NCH2CCH,	  NCH2CCHCH),	  7.34	  -­‐	  7.30	  (3H,	  m,	  2xC(iPr)CH,	  CNCCHCH),	  7.25	  (1H,	  
d,	   J	   =	   7.5	   Hz,	   CNCCH),	   7.22	   (1H,	   d,	   J	   =	   8.6	   Hz,	   C(CN)CH),	   6.49	   (1H,	   d,	   J	   =	   2.3	   Hz,	  




NCH2),	  2.89	  (1H,	  quint.,	  J	  =	  7.0	  Hz,	  CH3CH),	  1.18	  (6H,	  d,	  J	  =	  7.0	  Hz,	  CHCH3).	  13C-­‐NMR	  (CDCl3	  
126	  MHz):	  δ	  159.9	   (C(OH)CHC(OH)),	  158.6	   (C(CN)CH),	  156.9	   (CNN),	  148.3	   (C(SO2)),	  134.4	  
(Ar-­‐CC),	  132.5	  (Ar-­‐CC),	  132.0	  (C(CN)CH),	  130.8	  (Ar-­‐CH),	  128.5	  (2xC(SO2)CH),	  128.2(C(iPr)),	  
128.1	   (Ar-­‐CH),	   126.5	   (2xC(iPr)CH),	   124.5	   (Ar-­‐CH),	   123.6	   (Ar-­‐CH),	   110.2	   (C(CN)),	   106.8	  
(C(CN)CHCH),	  104.4	  (C(OH)CHC(OH)),	  65.8	  (CH3CH),	  46.3	  (NCH2),	  23.5	  (2xCHCH3).	  IR	  (neat)	  
νmax:	   3161,	   1602,	   1460,	   1052,	   943	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C23H22N2NaO4S	   [M+Na]+	  
445.1192	  m/z	  found	  445.1177	  m/z.	  
	  
4-­‐[3-­‐(3-­‐Nitro-­‐benzenesulphonyl)-­‐3,4-­‐dihydro-­‐phthalazin-­‐1-­‐
yl]-­‐benzene-­‐1,3-­‐diol	  (RCZ46):	  The	  product	  was	  purified	  by	  
flash	   column	   chromatography	   (40%	   ethyl	   acetate	   in	  
petroleum	  ether)	   to	  obtain	   a	   yellow	  paste	   (35	  mg,	   0.082	  
mmol)	   in	  24%	  yield	  over	   two	  steps.	   1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  10.42	   (1H,	  s,	  COH),	  8.81	  
(1H,	  t,	  J	  =	  1.9	  Hz,	  C(NO2)CHC(SO2)),	  8.55	  -­‐	  8.47	  (1H,	  m,	  C(NO2)CH),	  8.34	  (1H,	  d,	  J	  =	  7.9	  Hz,	  
C(SO2)CH),	  7.83	  (1H,	  t,	  J	  =	  8.0	  Hz,	  C(SO2)CHCH),	  7.58	  (1H,	  t,	  J	  =	  7.5	  Hz,	  NCH2CCHCH),	  7.52	  
(1H,	  d,	   J	  =	  7.1	  Hz,	  NCH2CCH),	  7.45	   (1H,	   t,	   J	  =	  7.6	  Hz,	  CNCCHCH),	  7.37	   (1H,	  d,	   J	  =	  7.5	  Hz,	  
CNCCH),	  7.27	  (1H,	  d,	   J	  =	  8.6	  Hz,	  C(CN)CH)	  (solvent	  peak	  overlap),	  6.59	  (1H,	  d,	   J	  =	  2.5	  Hz,	  
C(OH)CHC(OH)),	  6.42	  (1H,	  dd,	  J	  =	  8.6	  Hz,	  2.6	  Hz,	  C(CN)CHCH),	  4.42	  (2H,	  s,	  NCH2).	  13C-­‐NMR	  
(CDCl3	   126	   MHz)	   δ	   159.7	   (C(OH)CHC(OH)),	   158.6	   (C(CN)C(OH)),	   156.8	   (CNN),	   148.3	  
(C(NO2)),	  136.8	  (C(SO2)),	  134.4	  (Ar-­‐CC),	  132.5	  (Ar-­‐CC),	  132.4	  (Ar-­‐CH),	  132.0	  (Ar-­‐CH),	  130.8	  
(C(SO2)CH),	  128.5	  (C(CN)CH),	  128.1	  (C(NO2)CH),	  128.0	  (C(SO2)CHCH),	  126.5	  (Ar-­‐CH),	  124.5	  
(Ar-­‐CH),	   123.6	   (C(SO2)CHC(NO2)),	   110.2	   (C(CN)),	   106.8	   (C(CN)CHCH),	   104.4	  
(C(OH)CHC(OH)),	   46.5	   (NCH2).	   IR	   (neat)	   νmax:	   3042,	   2399,	   1608,	   1567,	   1185	   cm-­‐1.	   HRMS	  
(ESI)	  calcd	  for	  C20H15N3NaO6S	  [M+Na]+	  448.0574	  m/z	  found	  448.0571	  m/z.	  
	  
12.17	  Procedure	  for	  triazole	  formation	  170:	  
3-­‐Chloro-­‐6-­‐(2,4-­‐diisopropoxy-­‐phenyl)-­‐pyridazine	   (26)	   or	   1-­‐chloro-­‐4-­‐(2,4-­‐diisopropoxy-­‐
phenyl)-­‐phthalazine	   (33)	   (1.63	   mmol)	   were	   dissolved	   in	   n-­‐BuOH	   (12	   mL)	   and	   then	   the	  
corresponding	  benzhydrazide	   (1.79	  mmol)	  was	  added.	  The	  reaction	  mixture	  was	  allowed	  
to	  stir	  140	  °C	  overnight.	  The	  solvent	  was	  evaporated	  off	  under	  reduced	  pressure	  and	  the	  







[1,2,4]triazolo[4,3-­‐b]pyridazine	   (50)	   and	   (RCZ60):	   The	   product	  
was	  purified	  by	  flash	  column	  chromatography	  (2%	  methanol	  in	  
DCM)	   to	   obtain	   a	   yellow	   foam	   (402	   mg,	   0.92	   mmol)	   in	   56%	  
yield.	   1H-­‐NMR	   (CDCl3	   400	   MHz)	   δ	   8.89	   (2H,	   d,	   J	   =	   9.1	   Hz,	  
2xC(NO2)CH),	  8.42	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(NO2)CHCH),	  8.14	  (1H,	  
d,	  J	  =	  9.8	  Hz,	  CNNNCH),	  7.80	  (1H,	  d,	  J	  =	  9.8	  Hz,	  CNCH),	  7.71	  (1H,	  d,	  J	  =	  8.6	  Hz,	  C(CN)CH),	  
6.68	  (1H,	  dd,	  J	  =	  8.7	  Hz,	  2.3	  Hz,	  C(CN)CHCH),	  6.60	  (1H,	  d,	  J	  =	  2.2	  Hz,	  C(OiPr)CHC(OiPr)),	  4.77	  
-­‐	   4.59	   (2H,	   m,	   2xCH3CH),	   1.43	   (6H,	   d,	   J	   =	   6.1	   Hz,	   2xCHCH3),	   1.39	   (6H,	   d,	   J	   =	   6.1	   Hz,	  
2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.7	   (C(OiPr)CHC(OiPr)),	   157.3	   (C(CN)C(OiPr)),	  
154.8	   (CNN),	   148.2	   (C(NO2)),	   146.1	   (CNNN),	   144.9	   (C(CNNN)),	   132.6	   (CNNNCH),	   132.0	  
(C(CN)CH),	   128.0	   (2xC(NO2)CH),	   124.3	   (CNNNCH),	   123.9	   (2xC(NO2)CHCH),	   122.8	   (CNCH),	  
117.0	   (C(CN)),	  107.2	   (C(CN)CHCH),	  102.4	   (C(OiPr)CHC(OiPr)),	  71.0	   (CH3CH),	  70.3	   (CH3CH),	  
22.0	   (4xCHCH3).	   IR	   (neat)	   νmax:	   2346,	   1623,	   1182,	   1011,	   781	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	  




[1,2,4]triazolo[3,4-­‐a]phthalazine	   (52):	   The	   product	  
crystallised	  upon	  cooling	  of	   the	   reaction	  mixture.	  The	  white	  
solid	   thus	   obtained	   was	   collected	   by	   suction	   filtration	   to	  
afford	   a	   white	   powder	   (436	   mg,	   0.90	   mmol)	   in	   80%	   yield.	  
m.p.	  237	  °C.	  1H-­‐NMR	  (CDCl3	  400	  MHz)	  δ	  8.84	  (2H,	  d,	  J	  =	  9.1	  
Hz,	  2xC(NO2)CH),	  8.80	  (1H,	  d,	  J	  =	  7.9	  Hz,	  CNNCCH),	  8.39	  (2H,	  d,	  J	  =	  9.1	  Hz,	  2x(C(NO2)CHCH),	  
7.96	   (1H,	   ddd,	   J	   =	   8.1	   Hz,	   6.6	   Hz,	   1.8	   Hz,	   CNNNCCHCH),	   7.80	   -­‐	   7.68	   (2H,	   m,	   CNCCH,	  
CNCCHCH),	  7.42	  (1H,	  d,	  J	  =	  8.4	  Hz,	  C(CN)CH),	  6.69	  (1H,	  dd,	  J	  =	  8.5	  Hz,	  2.2	  Hz,	  C(CN)CHCH),	  
6.64	   (1H,	  d,	   J	  =	  2.2	  Hz,	  C(OiPr)CHC(OiPr)),	  4.70	   (1H,	  quint.,	   J	  =	  6.0	  Hz,	  CH3CH),	  4.56	   (1H,	  
quint.,	   J	   =	   6.1	   Hz,	   CH3CH),	   1.47	   (6H,	   d,	   J	   =	   6.0	   Hz,	   2xCHCH3),	   1.13	   (6H,	   d,	   J	   =	   6.0	   Hz,	  
2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.0	   (C(OiPr)CHC(OiPr)),	   157.1	   (C(CN)C(OiPr)),	  
156.8	   (CNN),	   148.2	   (C(NO2)),	   147.1	   (CNNN),	   144.5	   (C(CNNN)),	   133.4	   (CNNNCCCH),	   132.8	  
(Ar-­‐CC),	   132.0	   (C(CN)CH),	   130.3	   (Ar-­‐CC),	   129.6	   (Ar-­‐CH),	   128.4	   (2xC(NO2)CH),	   123.8	  
(2xC(NO2)CHCH,	  Ar-­‐CH),	  123.2	   (Ar-­‐CH),	  123.1	   (Ar-­‐CH),	  116.3	   (C(CN)),	  106.3	   (C(CN)CHCH),	  




(CHCH3),	  21.6	  (CHCH3).	  IR	  (neat)	  νmax:	  2356,	  1728,	  1577,	  1189,	  832	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  
for	  C27H25N5NaO4	  [M+Na]+	  506.1875	  m/z	  found	  506.1899	  m/z.	  
	  
6-­‐(2,4-­‐Diisopropoxy-­‐phenyl)-­‐3-­‐(phenyl)-­‐[1,2,4]triazolo[4,3-­‐b]pyridazine	  
(51):	   	   The	  product	  was	  purified	  by	   flash	   column	  chromatography	   (5%	  
methanol	  in	  DCM)	  to	  obtain	  a	  white	  foam	  (172	  mg,	  0.44	  mmol)	  in	  68%	  
yield.	  1H-­‐NMR	  (CDCl3	  500	  MHz)	  δ	  8.60	  (2H,	  d,	  J	  =	  6.5	  Hz,	  2xArCH),	  8.08	  
(1H,	  d,	  J	  =	  10.0	  Hz,	  CNNNCH),	  7.72	  -­‐	  7.69	  (2H,	  m,	  C(CN)CH,	  CNCH),	  7.58	  
-­‐	  7.49	   (3H,	  m,	  3xArCH),	  6.65	   (1H,	  dd,	   J	  =	  9.0	  Hz,	  2.5	  Hz,	  C(CN)CHCH),	  
6.58	  (1H,	  d,	  J	  =	  8.9	  Hz,	  C(OiPr)CHC(OiPr)),	  4.68	  -­‐	  4.62	  (2H,	  m,	  2xCH3CH),	  1.39	  (6H,	  d,	  J	  =	  6.1	  
Hz,	   2xCHCH3),	   1.30	   (6H,	   d,	   J	   =	   6.1	   Hz,	   2xCHCH3).	   13C-­‐NMR	   (CDCl3	   126	   MHz)	   δ	   161.3	  
(C(OiPr)CHC(OiPr)),	   157.2	   (C(CN)C(OiPr)),	   154.0	   (CNN),	   148.0	   (C(CNNN)),	   144.3	   (CNNN),	  
132.0	   (CNNNCH),	   129.8	   (C(CN)CH),	   128.6	   (2xArCH),	   127.7	   (2xArCH),	   126.7	   (CNNNCH),	  
123.4	  (CNCH),	  122.7	  (ArCH),	  117.6	  (C(CN)),	  107.2	  (C(CN)CHCH),	  102.4	  (C(OiPr)CHC(OiPr)),	  
71.0	   (CH3CH),	  70.2	   (CH3CH),	  22.0	   (4xCHCH3).	   IR	   (neat)	  νmax:	  2109,	  1678,	  1428,	  1002,	  879	  
cm-­‐1.	  HRMS	  (ESI)	  calcd	  for	  C23H24N4NaO2	  [M+Na]+	  411.3932	  m/z	  found	  411.3921	  m/z.	  	  
	  
12.18	  Procedure	  for	  isopropyl	  de-­‐protection:	  
The	  desired	  bis	  iso-­‐propoxyl	  derivative	  (0.30	  mmol)	  was	  dissolved	  in	  dry	  DCM	  (10	  mL)	  and	  
anhydrous	  aluminium	  trichloride	  (1.50	  mmol)	  was	  added.	  The	  reaction	  mixture	  was	  stirred	  
at	   room	  temperature	  until	   starting	  material	   consumption	   (2-­‐3	  hours),	  monitored	  by	  TLC.	  
The	   solvent	   was	   evaporated	   off	   under	   reduced	   pressure	   and	   the	   product	   was	   purified	  
through	  flash	  column	  chromatography	  to	  afford	  the	  desired	  compound.	  
	  
4-­‐[3-­‐(4-­‐Nitro-­‐phenyl)-­‐[1,2,4]triazolo[4,3-­‐b]pyridazin-­‐6-­‐yl]-­‐
benzene-­‐1,3-­‐diol	   (RCZ57):	   The	   product	   was	   purified	   by	   flash	  
column	   chromatography	   (2%	   methanol	   in	   DCM)	   to	   obtain	   a	  
yellow	  solid	  (61	  mg,	  0.17	  mmol)	  in	  58%	  yield.	  m.p.	  262	  °C.	  	  1H-­‐
NMR	  (DMSO	  400	  MHz)	  δ	  10.37	  (1H,	  s,	  COH),	  9.99	  (1H,	  s,	  COH),	  
8.77	   (2H,	   d,	   J	   =	   8.6	   Hz,	   2xC(NO2)CH),	   8.49	   (2H,	   d,	   J	   =	   8.6	   Hz,	  
2xC(NO2)CHCH),	  8.43	  (1H,	  d,	  J	  =	  9.7	  Hz,	  CNNNCH),	  7.98	  (1H,	  d,	  J	  =	  9.6	  Hz,	  CNCH),	  7.68	  (1H,	  
d,	  J	  =	  8.5	  Hz,	  C(CN)CH),	  6.61	  -­‐	  6.34	  (2H,	  m,	  C(CN)CHCH,	  C(OH)CHC(OH)).	  13C-­‐NMR	  (DMSO	  




145.7	   (CNNN),	  145.0	   (C(CNNN)),	   132.8	   (CNNNCH),	  132.1	   (C(CN)CH),	  128.3	   (2xC(NO2)CH),	  
124.6	  (CNNNCH),	  124.4	  (2xC(NO2)CHCH),	  123.9	  (CNCH),	  113.0	  (C(CN)),	  108.6	  (C(CN)CHCH),	  
103.4	  (C(OH)CHC(OH)).	  IR	  (neat)	  νmax:	  3454,	  2251,	  1653,	  1025,	  820	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  
for	  C17H11N5NaO4	  [M+Na]+	  372.0723	  m/z	  found	  372.0736	  m/z.	  
	  
4-­‐[3-­‐(4-­‐Nitro-­‐phenyl)-­‐[1,2,4]triazolo[3,4-­‐a]phthalazin-­‐6-­‐yl]-­‐
benzene-­‐1,3-­‐diol	  (RCZ59):	  The	  product	  was	  purified	  by	  flash	  
column	  chromatography	  (2%	  methanol	  in	  DCM)	  to	  obtain	  a	  
yellowish	  solid	  (120	  mg,	  0.30	  mmol)	  in	  62%	  yield.	  m.p.	  287	  
°C.	  	  1H-­‐NMR	  (DMSO	  400	  MHz)	  δ	  9.85	  (1H,	  s,	  COH),	  9.81	  (1H,	  
s,	  COH),	  8.72	  -­‐	  8.63	  (3H,	  m,	  2xC(NO2)CH,	  CNNNCCH),	  8.47	  
(2H,	  d,	  J	  =	  9.1	  Hz,	  2xC(NO2)CHCH),	  8.13	  -­‐	  8.04	  (1H,	  m,	  CNNNCCHCH),	  7.92	  (1H,	  t,	  J	  =	  7.7	  Hz,	  
CNCCHCH),	  7.77	  (1H,	  d,	  J	  =	  7.9	  Hz,	  CNCCH),	  7.30	  (1H,	  d,	  J	  =	  8.3	  Hz,	  C(CN)CH),	  6.53	  (1H,	  d,	  J	  
=	  2.2	  Hz,	  C(OH)CHC(OH)),	  6.48	   (1H,	  dd,	   J	  =	  8.3	  Hz,	  2.3	  Hz,	  C(CN)CHCH).	   13C-­‐NMR	  (DMSO	  
126	   MHz)	   δ	   160.8	   (C(OH)CHC(OH)),	   157.2	   (C(CN)C(OH)),	   157.1	   (CNN),	   148.3	   (C(NO2)),	  
146.9	  (CNNN),	  144.3	  (C(CNNN)),	  134.4	  (CNNNCCCH),	  132.8	  (Ar-­‐CC),	  132.3	  (C(CN)CH),	  131.6	  
(Ar-­‐CC),	   129.9	   (Ar-­‐CH),	   128.7	   (2xC(NO2)CH),	   124.6	   (2xC(NO2)CHCH),	   124.0	   (Ar-­‐CH),	   122.9	  
(Ar-­‐CH),	  122.9	  (Ar-­‐CH),	  112.9	  (C(CN)),	  107.6	  (C(CN)CHCH),	  103.1	  (C(OH)CHC(OH)).	  IR	  (neat)	  
νmax:	   3400,	   2249,	   1658,	   1053,	   821	   cm-­‐1.	   HRMS	   (ESI)	   calcd	   for	   C21H13N5NaO4	   [M+Na]+	  
422.0965m/z	  found	  422.0987	  m/z.	  
	  
4-­‐[3-­‐(Phenyl)-­‐[1,2,4]triazolo[4,3-­‐b]pyridazin-­‐6-­‐yl]-­‐benzene-­‐1,3-­‐diol	  
(RCZ58):	   The	   product	   was	   purified	   by	   flash	   column	   chromatography	  
(2%	  methanol	  in	  DCM)	  to	  obtain	  a	  beige	  foam	  (58	  mg,	  0.19	  mmol)	  in	  
78%	  yield.	  1H-­‐NMR	  (DMSO	  400	  MHz)	  δ	  10.35	  (1H,	  s,	  COH),	  9.96	  (1H,	  s,	  
COH),	  8.44	  -­‐	  8.42	  (2H,	  m,	  2xArCH),	  8.35	  (1H,	  d,	  J	  =	  10.0	  Hz,	  CNNNCH),	  
7.88	  (1H,	  d,	  J	  =	  9.6	  Hz,	  CNCH),	  7.63	  -­‐	  7.55	  (4H,	  m,	  3xArCH,	  C(CN)CH),	  
6.49	  (1H,	  d,	  J	  =	  2.5	  Hz,	  C(OH)CHC(OH)),	  6.47	  (1H,	  dd,	  J	  =	  8.9	  Hz,	  2.5	  Hz,	  C(CN)CHCH).	  13C-­‐
NMR	   (CDCl3	  126	  MHz)	  δ	  161.8	   (C(OH)CHC(OH)),	  159.3	   (C(CN)C(OH)),	  156.1	   (CNN),	  148.3	  
(C(CNNN)),	   144.9	   (CNNN),	   132.2	   (CNNNCH),	   129.0	   (C(CN)CH),	   128.4	   (2xArCH),	   127.5	  
(2xArCH),	  125.9	  (CNNNCH),	  124.4	  (CNCH),	  122.5	  (ArCH),	  116.2	  (C(CN)),	  106.3	  (C(CN)CHCH),	  
100.5	  (C(OH)CHC(OH)).	  IR	  (neat)	  νmax:	  3376,	  2125,	  1652,	  1005,	  705	  cm-­‐1.	  HRMS	  (ESI)	  calcd	  




13	  Biology	  experimental	  part	  
13.1	  Strains,	  plasmids,	  growth	  media	  and	  storage	  
13.1.1	  Growth	  media	  
Luria-­‐Bertani	  (LB)	  growth	  media	  was	  prepared	  in	  deionised	  water	  according	  to	  the	  recipe	  
shown	  in	  Table	  15	  and	  then	  sterilised	  by	  means	  of	  autoclave.	  For	  LB	  solid	  media	  (LB-­‐Agar)	  
1.5%	  agar	  was	  added	  before	  sterilisation.	  For	  6%	  sucrose	  solid	  media	  (LB-­‐Agar-­‐Sucrose)	  for	  
sacBkan	   cassette	  selection,	  6%	  of	   sucrose	  was	  added	   to	   the	   final	  volume	  of	   the	  solution	  
prior	  to	  autoclaving,	  while	  sodium	  chloride	  was	  omitted	  from	  the	  recipe.	  Minimal	  Essential	  
Media	   with	   HEPES	   modification	   (MEM-­‐HEPES)	   was	   purchased	   from	   Sigma-­‐Aldrich®	  
(M7278).	  
	  
Media	   Components	  per	  litre	  
LB	  
10	  g	  tryptone	  
5	  g	  yeast	  extract	  
10	  g	  NaCl	  
LB-­‐Agar	  
10	  g	  tryptone	  
5	  g	  yeast	  exctract	  
10	  g	  NaCl	  
15	  g	  agar	  
Table	  15:	  Media	  recipes.	  






Strains	  used	  and	  generated	  in	  this	  study	  are	  listed	  below	  in	  Table	  16.	  	  
	  
Strain	   Description	  and	  genotype	   Source	  
Escherichia	  coli	   	   	  
TUV	  93-­‐0	   Derivative	  of	  EHEC	  O157:H7	  strain	  EDL933	  Shiga	  toxin	  negative	  (stx)	   190	  
TUV	  93-­‐0	  ΔespD	   Clean	  deletion	  of	  espD	  gene	  
Tom	  
Parker	  
TUV	  93-­‐0	  EspD-­‐HA	  





TUV	  93-­‐0	  producing	  EspD-­‐HA	  where	  the	  region	  between	  amino	  acid	  26	  




TUV	   93-­‐0	   producing	   EspD-­‐HA	   where	   the	   region	   between	   amino	   acid	  




TUV	   93-­‐0	   producing	   EspD-­‐HA	   where	   the	   region	   between	   amino	   acid	  




TUV	   93-­‐0	   producing	   EspD-­‐HA	   where	   the	   region	   between	   amino	   acid	  




DH5-­‐α	   Competent	   cells	   Tetr	   Δ(mcrA)183	   Δ(mcrCB-­‐hsdSMR-­‐mrr)173	  
endA1	   supE44	   thi-­‐1	   recA1	  gyrA96	   relA1	   lac	  Hte	   [F’	  proAB	   laclqZΔM15	  
Tn10	  (Tetr)	  Amy	  Camr]	  
Agilent	  
One	  Shot®	  TOP10	  
Competent	  Cells	  
Chemically	   competent	   cells	   F-­‐	   mcrA	   Δ(mrr-­‐hsdRMS-­‐mcrBC)	  
F80lacZΔM15	   ΔlacX74	   recA1	   araΔ139	   Δ(ara-­‐leu)7697	   galU	   galK	   rpsL	  
(StrR)	  endA1	  nupG	  
Invitrogen	  
NEB	  Competent	  Cells	  
DH5-­‐α	   Competent	   cells	   fhuA2	   Δ(argF-­‐lacZ)U169	   phoA	   glnV44	   Φ80	  
Δ(lacZ)M15	  gyrA96	  recA1	  relA1	  endA1	  thi-­‐1	  hsdR17	  
NEB	  
Table	  16:	  List	  of	  strains	  used	  and	  generated	  in	  this	  study.	  
	  





Plasmids	  used	  and	  generated	  in	  this	  study	  are	  listed	  below	  in	  Table	  17.	  
	  




rpsM:GFP	   Reporter	  for	  rpsM	   Chl	   191	  
tir:GFP	   Reporter	  for	  tir	   Chl	   191	  
LEE1:GFP	   Reporter	  for	  LEE1	   Chl	   191	  
pAJR70	   gfp-­‐containing	  plasmid	   Chl	  
pAJR70	  
ref.	  
pIB307	   Recombinant	  temperature	  sensitive	  plasmid	   Chl	   165,192	  
pIB307-­‐sacBkan	  
Recombinant	   temperature	   sensitive	   plasmid	   bearing	  
sacBkan	  cassette	  
Chl/Kan	   165,192	  
pRZ001	  
pAJR70	   digested	   with	   BamH1/Kpn1,	   tir	   promoter/espD	  






pIB307	   digested	   with	   Sac1/Pst1,	   LEE4-­‐espD-­‐HA	   construct	  






pIB307-­‐LEE4-­‐EspD-­‐HA	  digested	  with	  BamH1,	  sacBkan	  gene	  






pIB307-­‐LEE4-­‐sacBkan	   digested	   with	   BamH1/ApaL1,	   espD-­‐







pIB307-­‐LEE4-­‐sacBkan	   digested	   with	   BamH1/ApaL1,	   espD-­‐







pIB307-­‐LEE4-­‐sacBkan	   digested	   with	   BamH1/ApaL1,	   espD-­‐







pIB307-­‐LEE4-­‐sacBkan	   digested	   with	   BamH1/ApaL1,	   espD-­‐










13.1.4	  Storage	  of	  bacteria	  
Frozen	   bacterial	   stocks	   were	   made	   by	   adding	   glycerol	   to	   a	   final	   volume	   of	   30%	   to	   an	  
overnight	   LB	   culture,	  which	  was	   transferred	   to	   cryo	   tubes	   and	   stored	   at	   -­‐80	   °C	   in	   1	  mL	  
aliquots.	  
	  
13.1.5	  Growth	  of	  bacteria	  
All	   strains	  were	   inoculated	   into	   the	   required	  media	   or	   agar	   plates	  with	   the	   appropriate	  
antibiotics.	  When	  required,	  antibiotics	  were	   included	  at	   the	   following	  concentrations:	  50	  
μg/mL	  kanamycin	  (Kan),	  35	  μg/mL	  chloramphenicol	  (Chl)	  and	  100	  μg/mL	  ampicillin	  (Amp).	  
For	  general	  purposes,	  e.g.	   cloning,	  E.	  coli	  cultures	  were	  propagated	   from	  a	  single	  colony	  
and	  grown	  at	  the	  desired	  temperature	  (28	  °C,	  37	  °C	  or	  42	  °C)	  at	  200	  rpm	  for	  aeration.	  
	  
13.2	  Molecular	  techniques	  
13.2.1	  Preparation	  of	  genomic	  DNA	  
Cells	   were	   pelleted	   from	   1	   mL	   overnight	   LB	   cultures	   and	   genomic	   DNA	   (gDNA)	   was	  
extracted	   using	   the	   ChargeSwitch	   gDNA	   Mini	   Bacteria	   kit	   (Invitrogen,	   UK),	   as	   per	   the	  
manufacturer’s	   instructions.	   DNA	   was	   re-­‐suspended	   in	   200	   μL	   of	   nuclease	   free	   water	  
(Ambion,	  UK)	  and	  stored	  at	  4	  °C.	  
	  
13.2.2	  Oligonucleotide	  primers	  
Oligonucleotide	  primers	  were	  synthesised	  by	   Invitrogen	  and	  used	  to	  amplify	  DNA	  by	  PCR	  
as	  described	  in	  Paragraph	  13.2.3.	  Primers	  were	  dissolved	  in	  nuclease	  free	  water	  to	  a	  10	  μM	  












Primer	  name	   Sequence	  5’	  to	  3’	  
pRZ001	  F	   TTACTTGTACAGCTCGTCCATGCC	  
pRZ001	  R	   GGATCCCGCGATAAAGAAACTTAAT	  
pIB307-­‐LEE4-­‐EspD-­‐HA	  1	  F	   CGGACTGTTGTAACTCAG	  
pIB307-­‐LEE4-­‐EspD-­‐HA	  1	  R/	  
pIB307-­‐LEE4-­‐EspD-­‐HA	  2	  R	  
TGCGACTCCTGCATTAGG	  
pIB307-­‐LEE4-­‐EspD-­‐HA	  2	  F	   CCGTGACCAGTCTTGCTG	  
BamH1	  Span	  F	   CCATCGTTACTTGAGTATTATC	  
BamH1	  Span	  R	   TTCAGCAAATGTCGAATAC	  
espD-­‐HAFrg1	  F	   GTGCGACTAGATTGAGTAATACCAGAAGTACC	  
espD-­‐HAFrg1	  R	   CATTAAATCTCTTAACGAGGTGCACGTTCTGATGTGC	  
espD-­‐HAFrg2	  F	   AATAAAATTCTCTTTAATAAGGGATCCTTAAGCGTAATCTGGAAC	  
espD-­‐HAFrg2	  R	   ACTCAATCTAGTCGCACTGAGGAGGCA	  
espD-­‐HAFrg3	  F	   TGGCCAACCATATAAATCTCGTTAGAGTTTTTCAG	  
espD-­‐HAFrg3	  R	   CATTAAATCTCTTAACGAGGTGCACGTTCTGATGTGC	  
espD-­‐HAFrg4	  F	   AATAAAATTCTCTTTAATAAGGGATCCTTAAGCGTAATCTGG	  
espD-­‐HAFrg4	  R	   GATTTATATGGTTGGCCAGGTCTTTGGT	  
espD-­‐HAFrg5	  F	   TACCAAATTTAAAGACCTGGCCAACAATTTTAC	  
espD-­‐HAFrg5	  R	   CATTAAATCTCTTAACGAGGTGCACGTTCTGATGTGC	  
espD-­‐HAFrg6	  F	   AATAAAATTCTCTTTAATAAGGGATCCTTAAGCGTAATCTG	  
espD-­‐HAFrg6	  R	   CAGGTCTTTAAATTTGGTAATGTTGCTAACAAAATTG	  
espD-­‐HAFrg7	  F	   CATCAGTTGACTCTCACCTAAGCTTTCAC	  
espD-­‐HAFrg7	  R	   CATTAAATCTCTTAACGAGGTGCACGTTCTGATGTGC	  
espD-­‐HAFrg8	  F	   AATAAAATTCTCTTTAATAAGGGATCCTTAAGCGTAATCTG	  
espD-­‐HAFrg8	  R	   GTGAGAGTCAACTGATGTCCGATTCAG	  
Table	  18:	  List	  of	  oligonucleotides	  used	  in	  this	  study.	  
	  
13.2.3	  Polymerase	  chain	  reaction	  (PCR)	  
A	   typical	   PCR	   used	   10	   μL	   of	   GoTaq	  Master	  Mix	   Polymerase	   (Promega,	   UK),	   100	   pM	   of	  
forward	  and	  reverse	  primers	  and	  0.1	  μM	  of	  genomic	  DNA	  in	  a	  final	  volume	  of	  20	  μL.	  The	  







Temperature	  (°C)	   Step	   Time	  (s)	  
95	   Initial	  denaturation	   300	  
95	   Denaturation	   45	  
55	   Annealing	   45	  
72	   Extension	   60	  (/Kb)	  
72	   Final	  extension	   600	  
4	   Final	  hold	   -­‐	  
Table	  19:	  Standard	  PCR	  cycle	  conditions	  (30	  cycles)	  
.	  
13.2.4	  High-­‐fidelity	  polymerase	  chain	  reaction	  (HF-­‐PCR)	  
High-­‐fidelity	  PCR	  (HF-­‐PCR)	  was	  performed	  with	  Q5	  High-­‐Fidelity	  DNA	  Polymerase	  (NEB,	  UK)	  
using	  a	  final	  concentration	  of	  200	  μM	  of	  deoxynucleotides	  (dNTPs)	  mix,	  0.5	  μM	  of	  forward	  
and	  reverse	  primers,	  0.1	  μM	  of	  DNA	  and	  0.02	  U/μL	  of	  Q5	  HiFi	  polymerase	  in	  a	  final	  volume	  
of	  50	  μL	  per	  reaction.	  The	  standard	  HF-­‐PCR	  protocol	  used	  is	  shown	  in	  Table	  19.	  
	  
13.2.5	  Agarose	  gel	  electrophoresis	  
For	  a	  1%	  w/v	  agarose	  gel,	  1	  g	  of	  ultrapure	  agarose	  was	  added	  to	  100	  mL	  of	  1x	  Tris-­‐acetate-­‐
EDTA	  buffer	   (TAE).	   The	  mixture	  was	  heated	   to	  dissolve	   the	   agarose	   and	  allowed	   to	   cool	  
down	   to	   approximately	   50	   °C.	   SYBR	   Safe	   gel	   stain	   (Life	   Technologies,	   UK)	   or	   GelRED	  
(Cambridge	   Biosciences,	  UK)	  were	   added	   at	   1:10’000	   as	   per	  manufacturer’s	   instructions	  
before	  the	  solution	  was	  poured	  into	  a	  gel	  tray	  and	  allowed	  to	  set.	  The	  appropriate	  volume	  
of	  10x	  loading	  buffer	  (Invitrogen,	  UK)	  was	  added	  to	  the	  DNA	  samples	  prior	  to	  loading	  and	  
the	  gel	  was	  then	  run	  at	  100	  V	  for	  40	  minutes.	  1Kb	  Reference	  DNA	  ladder	  was	  purchased	  
from	  NEB,	  UK.	  
For	  a	  1.2%	  w/v	  agarose	  gel,	  1.2	  g	  of	  ultrapure	  agarose	  were	  added	  to	  100	  mL	  of	  1x	  Tris-­‐
acetate-­‐EDTA	  buffer	  (TAE).	  The	  mixture	  was	  heated	  to	  dissolve	  the	  agarose	  and	  allowed	  to	  
cool	  down	  to	  approximately	  50	  °C.	  SYBR	  Safe	  gel	   stain	   (Life	  Technologies,	  UK)	  or	  GelRED	  
(Cambridge	   Biosciences,	  UK)	  were	   added	   at	   1:10’000	   as	   per	  manufacturer’s	   instructions	  
before	  the	  solution	  was	  poured	  into	  a	  gel	  tray	  and	  allowed	  to	  set.	  The	  appropriate	  volume	  
of	  10x	  loading	  buffer	  (Invitrogen,	  UK)	  was	  added	  to	  the	  DNA	  samples	  prior	  to	  loading	  and	  
the	  gel	  was	  then	  run	  at	  100	  V	  for	  70	  minutes.	  100bp	  Reference	  DNA	  ladder	  was	  purchased	  
from	  NEB,	  UK.	  Agarose	  gels	  were	  visualised	  by	  means	  of	  an	  AlphaImager	  trans-­‐illuminator	  





13.2.6	  Restriction	  enzyme	  digestion	  
All	   restriction	   enzyme	   digestions	   were	   performed	   according	   to	   the	   manufacturer’s	  
instructions	  (NEB,	  UK).	  A	  typical	  digestion	  reaction	  consisted	  of	  approximately	  1	  μg	  of	  DNA,	  
the	   corresponding	   amount	   of	   the	   appropriate	   10x	   restriction	   enzyme	   digestion	   buffer	  
solution	   (typically	   2	   μL)	   and	   10	  U	  of	   the	   desired	   restriction	   enzyme	   (typically	   1	   μL).	   The	  
reaction	  was	  made	   up	   to	   the	   desired	   volume	   (usually	   20	   μL)	   using	   nuclease	   free	  water	  
(Ambion,	   UK).	   If	   more	   than	   one	   enzyme	   was	   used,	   the	   compatibility	   of	   the	   enzymes	  
determined	   whether	   the	   reaction	   was	   carried	   out	   simultaneously	   or	   sequentially.	   The	  
reaction	  was	  mixed	  and	  incubated	  at	  37	  °C	  for	  1.5	  hours.	  Digested	  products	  were	  resolved	  
by	  agarose	  gel	  electrophoresis	  to	  visualise	  and	  to	  purify	  the	  DNA	  fragments	  of	  interest.	  
	  
13.2.7	  DNA	  gel	  purification	  
Linearised	   DNA	   products	   generated	   from	   PCR	   or	   restriction	   enzyme	   digestion	   were	  
resolved	   by	   agarose	   gel	   electrophoresis	   (Paragraph	   13.2.5).	   DNA	   bands	   were	   visualised	  
using	  a	  trans-­‐illuminator	  and	  bands	  of	   interest	  were	  excised	  from	  the	  gel	  and	  purified	  by	  
means	  of	  the	  Qiagen	  Gel	  Extraction	  Kit	  as	  per	  the	  manufacturer’s	  instructions.	  The	  purified	  
DNA	   was	   eluted	   with	   20-­‐30	   μL	   of	   nuclease	   free	   water	   (Ambion,	   UK)	   depending	   on	   the	  
concentration	   used	   in	   the	   reaction.	   The	   DNA	   concentration	   was	   calculated	   using	   a	  
NanoDrop	  at	  200	  nm.	  DNA	  fragments	  were	  stored	  at	  4	  °C	  for	  short	  term	  storage	  and	  at	  -­‐20	  
°C	  for	  long	  term	  storage.	  
	  
13.2.8	  Ligation	  reaction	  
Ligation	   reactions	   were	   performed	   as	   per	   the	   manufacturer’s	   instructions	   (NEB,	   UK).	   A	  
standard	  ligation	  reaction	  consisted	  of	  100	  ng	  of	  digested	  plasmid,	  the	  appropriate	  amount	  
of	   DNA	   insert	   molar	   ratio	   (typically	   1:3	   ratio	   plasmid:insert),	   10x	   of	   DNA	   ligase	   buffer	  
(typically	  1μL)	  and	  5	  U	  of	  T4	  DNA	  ligase	  (typically	  1	  μL)	  (NEB,UK).	  The	  reaction	  final	  volume	  
(usually	  10-­‐20	  μL)	  was	  made	  up	  using	  nuclease	  free	  water	  (Ambion,	  UK),	  depending	  on	  the	  
concentrations	  of	  the	  starting	  material.	  The	  reactions	  were	   incubated	  either	  overnight	  at	  
16	  °C	  in	  a	  thermocycler	  or	  for	  1	  hour	  at	  28	  °C	  in	  a	  water	  bath,	  depending	  on	  the	  nature	  of	  





13.2.9	  Plasmid	  assembly	  reaction	  
Plasmid	   assembly	   reaction	   was	   carried	   out	   using	   the	   NEBuilder®	   HiFi	   DNA	   Assembly	  
Cloning	   Kit	   (NEB,	   UK)	   according	   to	   the	   manufacturer’s	   instructions.	   A	   typical	   assembly	  
reaction	  consists	  of	  50	  ng	  of	  the	  digested	  plasmid,	  the	  appropriate	  molar	  ratio	  of	  purified	  
DNA	   fragments	   (1:2	   plasmid:fragments	   molar	   ratio	   for	   fragments	   >	   of	   200	   bp	   or	   1:5	  
plasmid:fragments	  molar	  ratio	  for	  DNA	  fragments	  <	  of	  200	  bp)	  and	  10	  μL	  of	  NEBuilder	  HiFi	  
DNA	  Assembly	  Master	  Mix	  (NEB,	  UK).	  The	  reaction	  final	  volume	  (20	  μL)	  was	  made	  up	  using	  
nuclease	   free	   water	   (Ambion,	   UK).	   The	   reaction	   was	   then	   incubated	   at	   50	   °C	   for	   20	  
minutes	  and	  then	  directly	  used	  in	  an	  electroporation	  transformation	  reaction.	  
	  
13.2.10	  Heat	  shock	  transformation	  
5	  μL	  of	   the	  desired	   ligation	   reaction	  were	  added	   to	  50	  μL	  of	   chemically	   competent	   cells	  
(TOP10	   from	   Invitrogen	   or	   Strataclone	   from	   Agilent)	   and	   incubated	   under	   ice	   for	   30	  
minutes	  to	  allow	  cell	  thawing	  and	  DNA	  attachment	  to	  the	  cell	  surface.	  The	  cells	  were	  then	  
heated	  at	  42	   °C	   in	   a	  water	  bath	   for	  30	   seconds	  and	   immediately	   returned	  under	   ice	   for	  
another	  2	  minutes.	  500	  μL	  of	  SOC	  medium	  or	  LB	  were	  added	  to	  the	  transformed	  bacteria,	  
followed	  by	  a	  2	  hours	   incubation	  at	  37	  °C	  or	  28	  °C	  and	  200	  rpm.	  The	  mixture	  was	  plated	  
out	  onto	  LB	  agar	  plates	  containing	  the	  appropriate	  antibiotics	  and	  incubated	  at	  37	  °C	  or	  28	  
°C,	  depending	  on	  the	  nature	  of	  the	  plasmid.	  
	  
13.2.11	  Production	  of	  electrocompetent	  E.	  coli	  
A	  single	  TUV	  93-­‐0	  colony	  was	  amplified	  in	  5	  mL	  LB	  broth	  (with	  appropriate	  antibiotics	  when	  
needed)	  overnight	  at	  37	   °C	  or	  28	   °C	  and	  200	   rpm.	  500	  μL	  of	   the	  overnight	  culture	  were	  
added	  to	  20	  mL	  of	  pre-­‐warmed	  LB	  broth	  (with	  appropriate	  antibiotics	  when	  needed)	  and	  
incubated	  at	  37	  °C	  or	  28	  °C	  and	  200	  rpm	  until	  an	  OD600	  of	  0.6	  was	  reached	  (typically	  2.5	  
hours).	   Bacteria	   were	   then	   placed	   under	   ice,	   centrifuged	   at	   3’750	   rpm	   and	   4	   °C	   for	   10	  
minutes	  and	  pellets	  were	  re-­‐suspended	  in	  20	  mL	  sterilised	  ice-­‐cold	  10%	  (v/v)	  glycerol.	  This	  
step	   was	   repeated	   three	   times.	   After	   the	   final	   centrifugation	   step,	   the	   pellets	   were	   re-­‐
suspended	  in	  1	  mL	  sterilised	  ice-­‐cold	  10%	  (v/v)	  glycerol	  and	  centrifuged	  again	  at	  6’000	  rpm	  
and	  4	  °C	  for	  2	  minutes.	  This	  step	  was	  repeated	  three	  times.	  After	  the	  final	  centrifugation	  
step,	  the	  pellets	  were	  re-­‐suspended	  in	  100	  μL	  of	  sterilised	  ice-­‐cold	  10%	  (v/v)	  glycerol.	  40	  





13.2.12	  Electroporation	  transformation	  
4	   μL	   of	   ligation	   reaction	   or	   plasmid	   assembly	   reaction	   were	   added	   to	   40	   μL	   of	  
electrocompetent	   E.	   coli	   cells	   which	   were	   transformed	   by	   electroporation	   using	   an	  
electroporator	  (Invitrogen,	  UK)	  at	  2.5	  kV	  and	  a	  capacitance	  of	  25	  μF.	  1	  mL	  of	  SOC	  medium	  
or	  LB	  was	  immediately	  added	  to	  the	  mixture	  and	  incubated	  for	  2	  hours	  at	  37	  °C	  or	  28	  °C	  
and	  200	  rpm	  according	  to	   the	  nature	  of	   the	  transformed	  plasmid.	  The	  mixture	  was	  then	  
plated	  onto	  LB	  agar	  plates	  containing	  the	  appropriate	  antibiotics	  and	  incubated	  at	  37	  °C	  or	  
28	  °C	  overnight.	  For	  plasmid	  assembly	  reactions	  incubation	  was	  prolonged	  for	  48	  hours	  at	  
28	  °C.	  
	  
13.2.13	  Extraction	  of	  plasmid	  DNA	  
A	  single	  bacterial	  colony	  was	  cultured	  in	  5	  mL	  of	  LB	  broth	  overnight	  at	  37	  °C	  or	  28	  °C	  and	  
200	   rpm	   (the	   appropriate	   antibiotics	   was	   added	   when	   needed).	   The	   bacteria	   were	  
centrifuged	   at	   3’750	   rpm	   and	   4	   °C	   for	   10	  minutes.	   The	   plasmid	   was	   purified	   using	   the	  
QIAprep	   Spin	  Miniprep	   Kit	   as	   per	  manufacturer’s	   instructions.	   The	   purified	   plasmid	  was	  
eluted	   in	   25	   μL	   of	   nuclease	   free	   water	   (Ambion,	   UK).	   The	   plasmid	   concentration	   was	  
calculated	  using	  a	  NanoDrop	  at	  200	  nm.	  Purified	  plasmids	  were	  stored	  at	  4	  °C.	  
	  
13.2.14	  Creation	  of	  TUV	  93-­‐0	  EspD-­‐HA	  strain	  by	  allelic	  exchange	  
The	   target	   gene	  espD	  was	   replaced	  with	  an	  espD-­‐HA	   gene	  by	  means	  of	   a	  process	   called	  
allelic	  exchange,	  which	  has	  been	  optimised	  for	  EHEC	  using	  the	  protocol	  by	  Emmerson	  et	  al.	  
165.	   The	   method	   relies	   on	   the	   creation	   of	   a	   temperature	   sensitive	   exchange	   plasmid	  
(pIB307-­‐LEE4-­‐sacBkan)	   encoding	   a	   chloramphenicol	   transferase	   gene	   (cat)	   to	   confer	  
chloramphenicol	   resistance,	   the	   3’	   and	   5’	   homologous	   flanking	   regions	   of	   espD	   and	   a	  
sacBkan	   cassette	   inserted	   between	   such	   homologous	   regions,	   which	   contains	   the	   levan	  
sucrose	  gene	  (sacB),	  toxic	  for	  E.	  coli	  in	  presence	  of	  sucrose,	  and	  the	  kanamycin	  gene	  (kan)	  
to	  confer	  kanamycin	  resistance	  (Fig.	  53).	  The	  plasmid	  was	  then	  transformed	  into	  the	  TUV	  
93-­‐0	  at	  28	  °C	  and	  the	  transformants	  were	  subjected	  to	  periods	  of	  high	  temperatures	  (42	  
°C)	   and	   antibiotic	   selection	   (Chl),	   forcing	   the	   plasmid	   to	   integrate	   into	   the	   chromosome	  




temperatures	   (28	   °C)	   and	   antibiotic	   selection	   (Kan)	   in	   order	   to	   allow	   the	   plasmid	   to	  
replicate	  and	  excise	  from	  the	  chromosome.	  Overnight	  sub-­‐culturing	  of	  the	  bacteria	  in	  LB	  at	  
28	  °C	  promoted	  plasmid	  loss	  and	  successful	  recombinants	  were	  selected	  for	  the	  KanRChlS	  
phenotype,	   generating	   a	   new	   strain	   (TUV	   93-­‐0	   ΔespD-­‐sacBkan)	   encoding	   the	   sacBkan	  
cassette	   instead	   of	   the	   espD	   gene.	   Correct	   cloning	   was	   confirmed	   by	   PCR	   reaction	  
(Paragraph	  13.2.2	  for	  primers	  sequence)	  across	  the	  new	  inserted	  gene.	  
A	   new	   temperature	   sensitive	   exchange	   plasmid	   (pIB307-­‐LEE4-­‐EspD-­‐HA),	   that	   carries	   a	  
chloramphenicol	  transferase	  gene	  (cat),	  the	  3’	  and	  5’	  homologous	  flanking	  regions	  of	  espD	  
and	   an	   espD-­‐HA	   gene	   flanked	   between	   such	   homologous	   regions,	   encoding	   for	   the	  HA-­‐
labelled	  version	  of	   the	  virulence	  protein	  EspD,	  was	   transformed	   into	   the	  new	  strain	  TUV	  
93-­‐0	  ΔespD-­‐sacBkan	  at	  28	  °C	  (Fig.	  54).	  Positive	  colonies	  were	  then	  subjected	  to	  periods	  of	  
high	   temperatures	   (42	   °C)	   and	   antibiotic	   selection	   (Kan),	   forcing	   the	   new	   plasmid	   to	  
integrate	   into	   the	   chromosome	   through	   homologous	   recombination	   in	   the	   area	   of	   the	  
sacBkan	   cassette.	   The	   culture	   was	   then	   incubated	   to	   low	   temperatures	   (28	   °C)	   in	   LB	  
medium,	   allowing	   the	   plasmid	   to	   replicate	   and	   excise	   from	   the	   chromosome.	   The	  
recombinants	  were	  selected	  for	  the	  SucroseR	  phenotype	  (using	  6%	  sucrose	  LB-­‐Agar	  plates)	  
and	   then	   replica	   plated	   onto	   LB-­‐Chl-­‐Agar,	   LB-­‐Kan-­‐Agar	   and	   LB-­‐Agar	   plates.	   Successful	  
colonies	   grew	   only	   onto	   LB-­‐Agar	   plates	   and	   generated	   the	   desired	   TUV	   93-­‐0	   EspD-­‐HA	  
strain,	   which	   produces	   the	   HA-­‐labelled	   version	   of	   the	   virulence	   protein	   EspD.	   Correct	  
cloning	  was	  confirmed	  by	  PCR	  reaction	  (Paragraph	  13.2.2	  for	  primers	  sequence)	  across	  the	  
new	  inserted	  gene.	  Expression	  and	  secretion	  of	  the	  new	  tagged-­‐protein	  were	  analysed	  by	  
α-­‐HA	  Western	  blot.	  
	  
13.2.15	  Creation	  of	  plasmids	  for	  TUV	  93-­‐0	  EspD-­‐HA	  allelic	  exchange	  
Temperature	   sensitive	  exchange	  plasmids	   to	  perform	  allelic	  exchange	  were	  generated	   in	  
our	   lab	   through	   standard	  molecular	   biology	   techniques	   (Fig.	   52).	   The	   synthetic	  espD-­‐HA	  
gene	   flanked	   by	   homologous	   flanking	   regions	   of	   the	   espD	   gene	   was	   synthesised	   by	  
Genescript,	   UK.	   The	   plasmid	   was	   transformed	   in	   TOP-­‐10	   competent	   cells	   (Paragraph	  
13.2.10)	   and	   then	   purified	  with	   the	  QIAprep	   Spin	  Miniprep	   Kit	   (Paragraph	   13.2.13).	   The	  
plasmid	  was	  digested	  with	  both	  Sac1	  and	  Pst1	  restriction	  enzymes	  (Paragraph	  13.2.6)	  and	  
the	  espD-­‐HA	  flanked	  gene	  was	  extracted	  and	  purified	  from	  agarose	  gel	  (Paragraph	  13.2.7).	  




vector	   (pIB307),	   generating	   the	   first	   allelic	   exchange	   plasmid	   pIB307-­‐LEE4-­‐EspD-­‐HA.	   The	  
correct	   cloning	   of	   the	   plasmid	   was	   confirmed	   by	   PCR	   reaction	   (Paragraph	   13.2.2	   for	  
primers	   sequence)	   across	   the	   pIB307	   backbone	   and	   the	   espD-­‐HA	   flanked	   gene	   and	   by	  
enzymatic	  digestion	  of	  the	  PCR	  product	  with	  HindIII.	  
pIB307-­‐LEE4-­‐EspD-­‐HA	   was	   digested	   with	   BamH1	   restriction	   enzyme	   and	   the	   pIB307	  
backbone	  with	  the	  5’	  and	  3’	  homologous	  flanking	  regions	  was	  extracted	  and	  purified	  from	  
agarose	   gel.	   Purified	   sacBkan	   cassette	   was	   cloned	   into	   this	   backbone	   between	   the	  
homologous	   regions	   of	   the	   espD	   gene,	   creating	   the	   second	   allelic	   exchange	   plasmid	  
pIB307-­‐LEE4-­‐sacBkan.	  The	  correct	  cloning	  of	   the	  plasmid	  was	  confirmed	  by	  PCR	  reaction	  
(Paragraph	   13.2.2	   for	   primers	   sequence)	   across	   the	   pIB307	   backbone	   and	   the	   sacBkan	  
flanked	  gene	  and	  by	  enzymatic	  digestion	  of	  the	  PCR	  product	  with	  Nco1.	  
	  
	  13.2.16	  Creation	  of	  truncated-­‐EspD-­‐HA	  strains	  by	  allelic	  exchange	  
Truncated-­‐EspD-­‐HA	  clones	  were	  generated	  following	  the	  second	  step	  (Fig.	  54	  and	  Fig.	  55,	  
Paragraph	   13.2.14)	   of	   the	   allelic	   exchange	   protocol	   using	   the	   appropriate	   temperature	  
sensitive	   exchange	   plasmid	   (pIB307-­‐LEE4-­‐EspD-­‐HAΔ26-­‐81,	   pIB307-­‐LEE4-­‐EspD-­‐HAΔ138-­‐171,	  
pIB307-­‐LEE4-­‐EspD-­‐HAΔ176-­‐251	   or	   pIB307-­‐LEE4-­‐EspD-­‐HAΔ333-­‐356)	   transformed	   into	   the	  
intermediate	  strain	  TUV	  93-­‐0	  ΔespD-­‐sacBkan.	   Successful	   recombinants	  were	  selected	   for	  
the	  SucroseRKanSChlS	  phenotype	  as	  previously	  performed	  and	  confirmed	  by	  PCR	  reaction	  
(Paragraph	   13.2.2	   for	   primers	   sequence)	   across	   the	   new	   inserted	   gene.	   Expression	   and	  
secretion	  of	   the	  new	   tagged/truncated-­‐proteins	  were	   analysed	  by	  α-­‐HA	  Western	  blot.	   A	  
total	   of	   4	   new	   clones	   were	   created	   each	   one	   producing	   a	   different	   truncated-­‐EspD-­‐HA	  






13.2.17	  Creation	  of	  plasmids	  for	  truncated-­‐EspD-­‐HA	  allelic	  exchange	  
The	  4	  temperature	  sensitive	  exchange	  plasmids	  for	  the	  formation	  of	  the	  truncated-­‐EspD-­‐
HA	  clones	  were	  generated	  using	   the	  NEBuilder	  HiFi	  DNA	  Assembly	  Cloning	  Kit	   (NEB,	  UK)	  
(Paragraph	  13.2.9)	  and	  the	  Q5	  High-­‐Fidelity	  DNA	  Polymerase	  (NEB,	  UK)	  (Paragraph	  13.2.4)	  
(Fig.	  55).	  The	  pIB307-­‐LEE4-­‐EspD-­‐HA	  plasmid	  was	  subjected	  to	  multiple	  HiFi	  PCR	  reactions	  
with	   different	   sets	   of	   primers	   (Paragraph	   13.2.2	   for	   primers	   sequence)	   to	   amplify	   8	  
different	   gene	   fragments	   (espD-­‐HAFrgs).	   Fragments	   were	   coupled	   into	   4	   different	   pairs	  
(espD-­‐HAFrg1+espD-­‐HAFrg2,	   espD-­‐HAFrg3+espD-­‐HAFrg4,	   espD-­‐HAFrg5+espD-­‐HAFrg6,	  
espD-­‐HAFrg7+espD-­‐HAFrg8)	  and	  designed	  in	  order	  to	  have	  15-­‐30	  bp	  overlap	  between	  each	  
other	   or	  with	   either	   the	   5’	   and	   3’	   homologous	   flanking	   regions	   of	   the	   gene	  espD.	   Once	  
these	  gene	  fragments	  were	  amplified,	  DNA	  gel	  extraction	  and	  purification	  from	  agarose	  gel	  
was	   performed	   (Paragraph	   13.2.7).	   The	   pIB307-­‐LEE4-­‐sacBkan	   was	   then	   subjected	   to	  
double	   enzymatic	   digestion	  with	  BamH1	   and	  ApaL1	   and	   the	   vector,	   thus	   obtained,	   was	  
used	  as	  main	  backbone	  for	  all	  4	  new	  plasmids.	  Generation	  of	  the	  4	  exchange	  plasmids	  was	  
achieved	   using	   the	   digested	   pIB307	   vector,	   the	   correct	   couple	   of	   espD-­‐HAFrgs	   and	   the	  
Fig.	  52:	  Creation	  of	  temperature	  sensitive	  plasmids	  for	  allelic	  exchange:	  A)	  Synthetic	  pLEE4-­‐EspD-­‐HA	  from	  Genscript	  was	  
subjected	  to	  sequencial	  digestion	  with	  Sac1	  and	  Pst1.	  B)	  The	  purified	  construct	  from	  the	  digestion	  was	  ligated	  into	  the	  
temperature	  sensitive	  backbone	  pIB307.	  C)	  pIB307-­‐LEE4-­‐EspD-­‐HA	  is	  the	  first	  temperature	  sensitive	  exchange	  plasmid	  for	  
the	  allelic	  exchange.	  The	  plasmid	  was	  subsequently	  digested	  with	  the	  restriction	  enzyme	  BamH1	  to	  excise	  the	  espD-­‐HA	  
gene	   from	   the	   backbone.	   D)	   sacBkan	   was	   cloned	   between	   the	   3’	   and	   5’	   homologous	   regions	   of	   the	  BamH1	   digested	  




NEBuilder	  HiFi	  DNA	  Assembly	  reaction	  conditions	  (Paragraph	  13.2.9).	  After	  transformation	  
in	  DH5-­‐α	  competent	  cells,	  the	  plasmids	  were	  purified	  using	  the	  QIAprep	  Spin	  Miniprep	  Kit	  
(Paragraph	   13.2.13).	   Correct	   assembly	   of	   the	   new	   4	   plasmids	   was	   confirmed	   by	   PCR	  
reaction	   (Paragraph	   13.2.2	   for	   primers	   sequence)	   across	   the	   pIB307	   backbone	   and	   the	  
newly	  assembled	  espD-­‐HATr	  flanked	  genes	  (espD-­‐HAΔ26-­‐81,	  espD-­‐HAΔ138-­‐171,	  espD-­‐HAΔ176-­‐251	  
or	   espD-­‐HAΔ333-­‐356)	   and	   by	   enzymatic	   digestion	   of	   the	   PCR	   product	  with	  HincII.	   Plasmids	  
were	   consequently	   transformed	   in	   the	   intermediate	   strain	   TUV	   93-­‐0	   ΔespD-­‐sacBkan	   to	  






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Fig.	   55:	   Creation	   of	   truncated	   EspD-­‐HA	   strains:	   A)	   High	   fidelity	   PCR	   was	   employed	   to	   amplify	   8	   different	  
fragments	  of	  the	  espD-­‐HA	  gene	  (espD-­‐HAFrg1-­‐8).	  B)	  BamH1/ApaL1	  digestion	  provided	  the	  desired	  temperature	  
sensitive	   vector	   to	  use	   as	   a	   backbone	  for	   the	  new	  plasmids.	  C)	  Plasmid	  assembly	  reaction	  was	  performed	  to	  
create	   the	   new	   allelic	   exchange	   plasmids:	   the	   espd-­‐HAFrgs	   were	   coupled	   (1-­‐2,	   3-­‐4,	   5-­‐6	   and	   7-­‐8)	   and	   then	  
cloned	   into	   the	   digested	   vector.	   4	   new	   plasmids	   were	   created,	   namely	   pIB307-­‐LEE4-­‐EspD-­‐HAΔ26-­‐81,	   pIB307-­‐
LEE4-­‐EspD-­‐HAΔ138-­‐171,	  pIB307-­‐LEE4-­‐EspD-­‐HAΔ176-­‐251	  and	  pIB307-­‐LEE4-­‐EspD-­‐HAΔ333-­‐356.	  D)	  The	  new	  plasmids	  were	  
transformed	  into	  the	  allelic	  exchange	  intermediate	  strain	  ΔespD-­‐sacBkan.	  E)	  Allelic	  exchange	  was	  performed	  on	  
the	   new	   strains,	   allowing	   the	   insertion	   of	   the	   desired	   espD-­‐HATr	   gene	   into	   the	   sacBkan	   cassette	   area,	   thus	  
generating	  4	  new	  strains	  producing	  a	   truncated	  HA-­‐labelled	  version	  of	   the	  virulence	  protein	  EspD.	  F)	  Correct	  
insertion	  of	   the	  gene	  was	  assessed	  by	  PCR	  across	   the	  determined	  espD-­‐HATr	  gene	  and	  by	  α-­‐HA	  Western	  blot	  





13.3	  Biochemical	  techniques	  
13.3.1	  SDS-­‐PAGE	  
Secreted	  proteins	  and	  whole	  cell	  lysate	  samples	  were	  analysed	  and	  prepared	  for	  western	  
blotting	  by	  SDS-­‐PAGE	  electrophoresis	  using	  the	  NuPage	  system	  (Invitrogen).	  Samples	  were	  
mixed	  with	  4x	  NuPage	  LDS	  loading	  buffer	  and	  boiled	  at	  95	  °C	  for	  10	  minutes	  before	  loading	  
onto	  a	  NuPage	  4-­‐12%	  Bis-­‐Tris	  pre-­‐cast	  gel	   (Invitrogen).	  Samples	  were	  generally	   loaded	   in	  
10	  μL	  aliquots	  and	  SeeBlue	  plus2	  pre-­‐stained	  protein	  marker	  (Invitrogen)	  was	  employed	  as	  
a	   molecular	   weight	   marker.	   Concentrations	   of	   each	   sample	   were	   estimated	   using	   a	  
NanoDrop	  2000	  to	  assure	  an	  equal	  loading	  of	  the	  proteins.	  SDS-­‐PAGE	  gels	  were	  run	  using	  
NuPage	  MES	  running	  buffer	  (Invitrogen)	  at	  180	  V	  for	  45	  minutes.	  Gels	  were	  then	  stained	  
with	  Coomassie	  Brilliant	  Blue	  stain	  (Table	  20	  for	  recipe)	  for	  1	  hour	  on	  an	  orbital	  shaker	  and	  
destained	   with	   3	   washes	   of	   destain	   solution	   (Table	   21	   for	   recipe)	   for	   2	   hours	   or	   with	  
deionised	  water	  overnight.	   Protein	  bands	   to	  be	  analysed	   for	   identification	  using	   tandem	  
mass-­‐spectrometry	   (MS/MS)	  were	  excised	   from	  the	  gels	  using	  a	  clean	  and	  sterile	   scalpel	  
blade	  and	  placed	   into	   individual	   sterile	  1.5	  mL	  microcentrifuge	   tubes.	  These	  bands	  were	  
prepared	  and	  analysed	  by	  Dr.	  Richard	  Burchmore	   in	  the	  University	  of	  Glasgow	  Polyomics	  
division.	  
	  
Component	   Volume/Amount	  per	  litre	  
ddH2O	   500	  mL	  
Acetic	  Acid	   100	  mL	  
Methanol	   400	  mL	  
Coomassie	  blue	  R250	   0.5	  g	  
Table	  20:	  Coomassie	  Brilliant	  Blue	  stain	  recipe.	  
	  
Component	   Volume/Amount	  per	  litre	  
ddH2O	   500	  mL	  
Acetic	  Acid	   100	  mL	  
Methanol	   400	  mL	  
Table	  21:	  Destain	  solution	  recipe	  
	  
13.3.2	  Western	  blot	  
Proteins	  for	  western	  blot	  were	  transferred	  from	  SDS-­‐PAGE	  gels	  to	  Amersham	  Hybond	  ECL	  




system	  (Invitrogen).	  The	  membrane	  was	  then	  blocked	  with	  5%	  skimmed	  milk	   (Marvel)	   in	  
PBST	  overnight.	  Primary	  antibody	  was	  made	  up	  at	  the	  specified	  concentration	  (Table	  22)	  in	  
PBST	   and	   incubated	   on	   the	   membrane	   for	   1	   hour	   at	   room	   temperature	   on	   an	   orbital	  
shaker.	   The	  membrane	  was	  washed	   three	   times	  with	   PBST	   for	   10	  minutes	   each	   before	  
incubation	   with	   the	   secondary	   horseradish-­‐peroxidase	   (HRP)	   conjugated	   antibody	   for	   1	  
hour	  at	  room	  temperature.	  The	  secondary	  antibody	  concentration	  employed	  was	  usually	  
half	   of	   the	   primary	   antibody	   concentration.	   After	   1	   hour,	   the	  membrane	  was	  washed	   3	  
times	   with	   PBST	   for	   10	   minutes	   each	   and	   then	   developed	   with	   SuperSignal	   West	   Pico	  
Chemiluminescent	  ECL	  Substrate	  (Thermo	  Scientific).	  All	  Western	  blots	  were	  performed	  in	  
triplicates	  coming	  from	  3	  independent	  experiments.	  
	  
Antibody	   Source	   Primary	  Concentration	   Secondary	  Concentration	  
EspD	   Mouse	   1/4’000	   1/8’000	  
Tir	   Mouse	   1/1’000	   1/2’000	  
GroEL	   Rabbit	   1/10’000	   1/25’000	  
HA	   Mouse	   1/2’500	   1/10’000	  
Table	  22:	  Antibodies	  and	  relevant	  concentrations	  used	  in	  this	  study	  
	  
13.3.3	  Pull-­‐down	  assay	  with	  biotinylated	  RCZ12	  and	  RCZ20	  
The	   pull-­‐down	   assay	   was	   performed	   using	   Dynabeads™	   M-­‐280	   Streptavidin	   magnetic	  
beads	  (Invitrogen)	  and	  MagnaRack	  (Invitrogen)	  for	  beads	  separation	  from	  the	  solution.	  E.	  
coli	  O157	  TUV	  93-­‐0	  strain	  was	  cultured	  overnight	  in	  LB	  and	  then	  diluted	  to	  an	  OD600	  ≤	  0.05	  
in	  pre-­‐	  warmed	  MEM-­‐HEPES	  medium.	  Cultures	  were	  grown	  at	  37	  °C	  to	  an	  OD600	  ≥	  0.9.	  The	  
cells	   were	   pelleted,	   washed	   several	   times	   with	   PBS	   and	   concentrated	   in	   PBS	   to	   a	   final	  
volume	  of	  2	  mL.	  The	  suspended	  cells	  were	  lysed	  by	  means	  of	  a	  sonicator	  and	  kept	  under	  
ice.	  The	  magnetic	  beads	  were	  aliquoted	  in	  Eppendorf	  tubes	  and	  washed	  with	  PBS	  using	  a	  
MagnaRack	   (Invitrogen)	   for	   beads	   separation	   from	   the	   solution.	   A	   250	   μM	   solution	   of	  
biotin-­‐RCZ12	  or	  biotin-­‐RCZ20	  in	  PBS:DMSO	  (100:1)	  was	  added	  to	  the	  beads	  and	  incubated	  
shaking	   for	  1	  hour	  at	   room	  temperature.	  The	  biotin-­‐RCZs	  solution	  was	   removed	  and	   the	  
beads	  were	  washed	  three	  times	  with	  PBS.	  500	  μL	  of	  the	  suspended	  cell	  lysate	  solution	  was	  
then	   added	   to	   the	   tubes	   and	   incubated	   shaking	   for	   another	   hour	   at	   room	   temperature.	  
The	  lysate	  solution	  was	  removed	  and	  the	  beads	  were	  washed	  three	  times	  with	  PBS.	  Once	  




boiled	   at	   95	   °C	   for	   10	  minutes	   to	  promote	   specific	   bound	  proteins	  denaturation.	   Equals	  
volumes	   of	   PBS	   washes	   and	   SDS	   samples	   were	   loaded	   onto	   a	   gel,	   the	   proteins	   were	  
separated	   through	   SDS-­‐PAGE	   electrophoresis	   and	   visualised	   by	   Coomassie	   Brilliant	   Blue	  
staining	  (Table	  20	  and	  21	  for	  recipes).	  Specific	  bound	  proteins	  were	  excised	  for	  subsequent	  
in-­‐gel	   digestion	   and	   analysis	   by	   tandem	   mass-­‐spectrometry	   193.	   Proteins	   analysed	   by	  
peptide	  mass	   fingerprinting	  were	  given	  a	  MOWSE	  score	   194	   to	   indicate	   the	  probability	  of	  
the	   identification	   being	   correct.	   We	   set	   a	   threshold	   MOWSE	   value	   of	   100	   or	   greater,	  
ensuring	  a	  significance	  of	  P	  <	  10-­‐8.	  
	  
13.3.4	  Sample	  preparation	  for	  metabolomics	  analysis	  
Preparation	   of	   samples	  was	   adapted	   from	  Creek	   et	   al.	   2011	   195.	   Bacterial	   cultures	  were	  
grown	  to	  an	  OD600	  of	  0.9	  in	  M9	  medium	  (10	  mL).	  2.5	  mL	  of	  the	  bacteria	  solution	  was	  added	  
to	  2.5	  mL	  of	  fresh	  M9	  medium	  and	  the	  appropriate	  compound	  concentration.	  The	  solution	  
was	  incubated	  for	  1	  hour	  at	  room	  temperature.	  10-­‐Bromodecane	  oil	  (100	  μL)	  was	  added	  
to	  1	  mL	  of	  the	  incubated	  solution	  and	  the	  mixture	  was	  then	  centrifuged	  at	  13’000	  rpm	  and	  
4	   °C	   for	   2	   minutes	   to	   separate	   the	   bacteria.	   12.5	   μL	   of	   the	   supernatant	   solution	   were	  
transferred	   into	   a	   sterile	   micro-­‐centrifuge	   tube	   and	   500	   μL	   of	   a	   1:3:1	  
chloroform:methanol:water	   extracting	   solution	  were	   added	   to	   generate	   the	   supernatant	  
sample.	   The	   remnant	   of	   the	   supernatant	   solution	   from	   the	   centrifuged	   solution	   was	  
removed	  and	  200	  μL	  of	  a	  1:3:1	  chloroform:methanol:water	  extracting	  solution	  were	  added	  
to	  create	  the	  bacteria	  sample.	  Every	  biological	  samples	  were	  performed	  in	  triplicates	  from	  
different	   solutions	   and	   all	   the	   samples	  were	   stored	   at	   -­‐80	   °C	   until	  MS	   analysis.	   Dr.	   Karl	  
Burgess	  and	  Dr.	  Stefan	  Weidt	  of	  the	  University	  of	  Glasgow	  Polyomics	  division	  carried	  out	  
the	  metabolomics	  analysis.	  Samples	  were	  analysed	   through	  hydrophilic	   interaction	   liquid	  
chromatography	   (HILIC)	   on	   a	   Dionex	   UltiMate	   3000	   RSLC	   system	   (Thermo	   Fischer	  
Scientific,	  Hemel	  Hempstead,	  UK)	  using	  a	  ZIC-­‐pHILIC	  column	  (Merck	  Sequant).	  	  The	  column	  
was	   maintained	   at	   30	   °C	   and	   samples	   were	   eluted	   with	   a	   linear	   gradient	   (20	   mM	  
ammonium	   carbonate	   in	  water,	   A	   and	   acetonitrile,	   B)	   over	   26	  min	   at	   a	   flow	   rate	   of	   0.3	  
mL/min.	   The	   injection	   volume	  was	   10	   μl	   and	   samples	  were	  maintained	   at	   4	   °C	   prior	   to	  
injection.	  For	   the	  MS	  analysis,	  a	  Thermo	  Orbitrap	  Exactive	   (Thermo	  Fisher	  Scientific)	  was	  




medium	  and	  appropriate	  compound	  concentration	  and	  extraction	   solution	  were	  used	  as	  
controls	  for	  the	  analysis.	  
	  
13.4	  Transcriptome	  analysis	  
Transcriptome	  analysis	  was	  carried	  out	  by	  Dr.	  James	  Connolly	  (University	  of	  Glasgow)	  and	  
a	  brief	  description	  of	  the	  method	  used	  is	  described	  below.	  
	  
13.4.1	  Total	  RNA	  extraction	  and	  mRNA	  enrichment	  
Bacterial	  cells	  were	  cultured	  as	  described	  above	  (Paragraph	  XX)	  before	  being	  mixed	  with	  
two	  volumes	  of	  RNAprotect	  reagent	  (Qiagen,	  Valencia,	  CA,	  USA),	  incubated	  for	  5	  minutes	  
at	  room	  temperature	  and	  harvested	  by	  centrifugation.	  Total	  RNA	  was	  extracted	  using	  an	  
RNeasy	   kit	   (Qiagen)	   according	   to	   the	   manufacturer’s	   specifications.	   Genomic	   DNA	   was	  
removed	   using	   TURBO	   DNase	   (Ambion,	   Carlsbad,	   CA,	   USA).	   Total	   RNA	   samples	   were	  
enriched	   for	  mRNA	   using	   a	  MICROBexpress	  mRNA	   enrichment	   kit	   (Ambion).	   Integrity	   of	  
enriched	  mRNA	  samples	  for	  sequencing	  were	  tested	  using	  an	  Agilent	  Bioanalyzer	  2100	  at	  
the	  University	  of	  Glasgow	  Polyomics	  Facility.	  
	  
13.4.2	  RNA-­‐sequencing	  and	  transcriptome	  analysis	  
cDNA	   synthesis,	   library	   generation	   and	   sequencing	   was	   performed	   at	   the	   Edinburgh	  
Genomics	  facility	  (Illumina	  HiSeq	  2500)	  obtaining	  100	  bp	  single	  end	  reads.	  Three	  biological	  
replicates	  were	  used	  for	  each	  condition	  of	  the	  transcriptome	  analysis.	  Samples	  of	  TUV	  93-­‐0	  
cultured	   in	  MEM-­‐HEPES	  with	   and	  without	  50	  μM	  of	  RCZ20	  were	  used	   to	  extract	  mRNA.	  
Raw	  sequencing	  reads	  were	  assessed	  for	  quality	  using	  FastQC	  (Babraham	  Bioinformatics,	  
Cambridge,	  UK)	  and	  trimmed	  where	  necessary	  using	  CLC	  Genomics	  Workbench	  (CLC	  Bio,	  
Aarhus,	  Denmark).	  Sequence	  reads	  were	  then	  mapped	  to	  the	  EDL933	  reference	  genome	  
(NCBI	   NC_002655.2)	   allowing	   for	   3	  mismatches	   per	   read	   and	   at	   least	   5	   reads	   per	   open	  
reading	   frame	  under	  all	   conditions	   tested.	  To	  determine	  differential	  expression	  between	  
conditions,	   analysis	   was	   performed	   using	   the	   Empirical	   analysis	   of	   DGE	   tool	   in	   CLC	  
Genomics	  Workbench,	  which	   implements	   the	   EdgeR	   Bioconductor	   tool	   196.	   Differentially	  
expressed	   genes	   were	   identified	   by	   positive	   or	   negative	   absolute	   fold	   change	   and	  
considered	   significant	   if	   the	   corrected	   P-­‐value	   was	   ≤	   0.05	   (false-­‐discovery	   rate	   of	   5%).	  




their	  designated	  gene	  ontology	  (GO)	  terms	  obtained	  from	  the	  EMBL-­‐EBI	  QuickGO	  database	  
(https://www.ebi.ac.uk/QuickGO/).	   Bar	   charts	   summarizing	   the	   data	   were	   generated	   in	  
GraphPad	   Prism	   version	   5.0	   (San	   Diego,	   CA,	   USA)	   and	   heat-­‐maps	   of	   gene	   expression	  
patterns	  were	   generated	   in	  Microsoft	   Excel.	   The	   raw	   sequence	   reads	   in	   this	   study	   have	  
been	  deposited	  in	  the	  European	  Nucleotide	  Archive.	  
	  
13.5	  Phenotypic	  characterisation	  techniques	  
13.5.1	  E.	  coli	  O157	  secreted	  protein	  profiling	  
Secreted	   protein	   extraction	   from	   E.	   coli	   O157	   TUV	   93-­‐0	   was	   performed	   as	   previously	  
described	   197.	  Overnight	   cultures	  were	   sub-­‐cultured	   to	  a	   starting	  OD600	  of	   approximately	  
0.05	  into	  50	  or	  25	  mL	  of	  pre-­‐warmed	  MEM-­‐HEPES	  and	  were	  grown	  at	  37	  °C	  and	  200	  rpm	  
until	  OD600	  of	  0.6-­‐0.7.	  Culture	  were	  centrifuged	  at	  3’750	  rpm	  and	  4	  °C	  for	  15	  minutes.	  The	  
cell	  pellet	  was	  separated	  by	  the	  supernatant	  solution,	  re-­‐suspended	  in	  500	  μL	  of	  BugBuster	  
Mix	   (Novagen)	   and	   incubated	   for	   30	   minutes	   at	   room	   temperature.	   The	   sample	   was	  
centrifuged	  at	  13’000	  rpm	  and	  room	  temperature	  for	  5	  minutes	  and	  the	  clear	  solution	  was	  
transferred	  to	  a	  sterilised	  Eppendorf	  tube.	  The	  whole	  cell	  pellet	  was	  stored	  at	  -­‐20	  °C.	  The	  
supernatant	  solution	  was	  carefully	  separated	  from	  the	  centrifuged	  cell	  pellet	  and	  filtered	  
through	   a	   0.2	   μm	   filter	   (Fischer,	   UK).	   A	   6.1	   N	   solution	   of	   trichloroacetic	   acid	   (TCA)	  was	  
added	   to	   a	   final	   concentration	   of	   10%	   v/v	   and	   the	   sample	   was	   mixed	   and	   left	   at	   4	   °C	  
overnight.	  Secreted	  protein	  fractions	  were	  then	  harvested	  by	  centrifugation	  at	  3’750	  rpm	  
and	   4	   °C	   for	   an	   hour.	   The	   supernatant	   solution	  was	   carefully	   removed	   and	   the	   protein	  
pellet	  was	  allowed	  to	  dry	  at	  room	  temperature.	  The	  pellet	  was	  re-­‐suspended	  in	  80-­‐100	  μL	  
of	  Tris-­‐HCl	  (pH=8.0)	  and	  stored	  at	  -­‐20	  °C.	  Both	  whole	  cell	  and	  supernatant	  samples	  were	  
subjected	  to	  SDS-­‐PAGE	  electrophoresis	  for	  western	  blot	  analyses.	  
	  
13.5.2	  GFP	  reporter	  fusion	  assay	  
Population	   based	   gene	   expression	   analysis	  was	   carried	   out	   using	  E.	   coli	   O157	   TUV	   93-­‐0	  
transformed	  with	  different	  GFP-­‐promoter	   transcriptional	   fusion	   constructs	   (Table	  X)	   that	  
have	   been	   described	   elsewhere	   191.	   Overnight	   cultures	   of	   the	   desired	   strain	   were	   sub-­‐
cultured	  to	  an	  initial	  OD600	  of	  approximately	  0.05	  into	  pre-­‐warmed	  MEM-­‐HEPES	  and	  then	  
grown	  at	  37	  °C	  and	  200	  rpm.	  A	  800	  μL	  aliquot	  was	  taken	  hourly	  from	  the	  sample	  and	  the	  




transferred	  to	  a	  black	  flat-­‐bottomed	  96-­‐well	  microtitre	  plate	  for	  GFP	  expression	  analysis	  by	  
a	  FLUOstar	  Optima	  Fluorescence	  Plate	  Reader	  (BMG	  Labtech,	  UK).	  TUV	  93-­‐0	  without	  any	  
GFP-­‐promoter	   plasmid	   was	   used	   as	   a	   negative	   control	   to	   measure	   the	   background	  
fluorescence.	  Data	  are	  presented	  as	  the	  mean	  and	  standard	  deviation	  of	  three	  biological	  
replicates.	  Readings	  for	  fluorescence	  (RFU	  values)	  were	  plotted	  against	  OD600	  values	  using	  
GraphPad	   Prism	   5	   (GraphPad	   Software,	   USA).	   The	   curves	   were	   then	   analysed	   by	   linear	  
regression	  and	  interpolated	  at	  the	  determined	  OD600	  of	  0.6.	  Student’s	  t	  test	  was	  employed	  
for	  statistical	  comparison	  of	  the	  untreated	  samples	  (WT)	  with	  the	  treated	  samples.	  
	  
13.6	  Microscopy	  techniques	  
13.6.1	  Transmission	  electron	  microscopy	  (TEM)	  
Margaret	  Mullin,	  head	  of	  the	  University	  of	  Glasgow	  electron	  microscopy	  service,	  prepared	  
bacterial	   samples	   for	   imaging.	   Bacterial	   samples	   were	   fixed	   on	   ice	   with	   1%	  
paraformaldehyde/PBS	   for	   an	   hour	   and	   washed	   three	   times	   in	   PBS	   for	   5	   minutes	   each	  
time.	  Sample	  suspension	  droplets	   (5	  μl)	  were	  placed	  onto	  Formvar/Carbon	  nickel-­‐coated	  
support	   grids	   which	   had	   been	   pre-­‐treated	   with	   a	   0.1%	   poly-­‐L-­‐lysine	   solution.	   Bacterial	  
suspensions	  were	   left	   to	  settle	   for	  20	  minutes,	   the	  grids	  were	   floated	  sample	  on	  0.05	  M	  
glycine/PBS	   droplets	   for	   5	  minutes	   and	   then	   rinsed	   three	   times	   with	   3%	   BSA/PBS	   for	   5	  
minutes.	   Bacterial	   samples	   were	   placed	   onto	   an	   α-­‐EspA	   (1:100	   dilution)	   for	   an	   hour,	  
washed	   six	   times	   on	   3%	   BSA/PBS	   for	   5	  minutes	   each	   and	   then	   placed	   onto	   droplets	   of	  
secondary	  GAR	  10	  nm	  gold	  for	  an	  hour.	  Samples	  were	  washed	  six	  times	  in	  3%	  BSA/PBS	  for	  
5	  minutes	  each,	  rinsed	  with	  PBS	  six	  times	  for	  3	  minutes,	   fixed	  on	  1%	  glutaraldehyde/PBS	  
for	   5	  minutes,	  washed	   six	   times	   in	   distilled	  water	   and	   then	   left	   to	   dry.	   Immuno-­‐stained	  
bacterial	   samples	  were	  viewed	  on	  a	  FEI	  Tecnai	  T20	  TEM	  running	  at	  200	  kV	  and	  dm4/tiff	  
images	  were	  captured	  using	  Gatan	  Digital	  Imaging	  software.	  
	  
13.6.2	  Transmission	  electron	  microscopy	  (TEM)	  for	  membrane	  morphology	  
Bacterial	   suspensions	   were	   washed	   twice	   in	   PBS	   for	   5	   minutes	   each	   before	   an	   initial	  
fixation	  with	   2%	   glutaraldehyde,	   2%	  paraformaldehyde,	   0.1	  M	   sodium	   cacodylate	   buffer	  
for	  an	  hour.	  Samples	  were	  rinsed	  three	  times	  with	  0.1	  M	  sodium	  cacodylate	  buffer	  for	  5	  
minutes	   each	   then	   post	   fixed	   for	   an	   hour	   in	   1%	   osmium	   tetroxide,	   0.1	   M	   sodium	  




water	  for	  10	  minutes	  each	  before	  en	  bloc	  staining	  with	  0.5%	  aqueous	  uranyl	  acetate	  for	  an	  
hour	   (light	   sensitive	   stain,	   samples	   kept	   in	   dark).	   Samples	   were	   given	   two	   washes	   in	  
distilled	   water	   then	   dehydrated	   through	   an	   ethanol	   series	   as	   follows	   30,	   50,	   70,	   90%	  
ethanol	  for	  15	  minutes	  each,	  100%	  ethanol	  for	  5	  minutes	  and	  then	  100%	  dried	  ethanol	  (3	  
A	  molecular	  sieves)	  for	  5	  minutes.	  Samples	  were	  given	  three	  5	  minutes	  rinses	  in	  propylene	  
oxide	   and	   then	   left	   overnight	   in	   a	   1:1	   mixture	   of	   propylene	   oxide:epon	   araldite	   resin.	  
Samples	  were	  given	  three	  changes	  of	  pure	  resin	  throughout	  the	  following	  day	  before	  fresh	  
embedding	   and	   polymerising	   at	   60	   °C	   for	   48	   hours.	   Ultrathin	   50	   nm	   sections	   were	   cut	  
using	  a	  Leica	  EM	  UTC	  Ultratome	  and	  a	  Diatome	  diamond	  knife,	  sections	  were	  collected	  on	  
200	  mesh	  formvar	  copper-­‐coated	  support	  grids	  then	  contrast	  stained	  with	  2%	  methanolic	  
uranyl	  acetate	  stain	  for	  5	  minutes	  followed	  by	  5	  minutes	  in	  Reynolds	  lead	  citrate.	  Bacterial	  
samples	   were	   viewed	   on	   a	   FEI	   Tecnai	   T20	   TEM	   running	   at	   200	   kV	   and	   dm4/tiff	   images	  
captured	  using	  Gatan	  Digital	  Imaging	  software.	  
	  
13.7	  Bioinformatics	  and	  statistical	  analysis	  
13.7.1	  Bioinformatic	  and	  database	  tools	  
Nucleotide	   and	   amino	   acid	   sequences	   were	   obtained	   from	   NCBI	  
(http://www.ncbi.nlm.nih.gov)	  and	  Colibase	  198.	  Alignments	  were	  performed	  using	  Clustal	  
Omega	   (http://www.ebi.ac.uk/Tools/msa/clustalo/)	   and	   cloning	   strategies	  were	   designed	  
using	  MacVector.	  
	  
13.7.2	  Statistical	  analysis	  
Statistical	   analysis	   for	   comparison	   of	   two	   samples	   was	   carried	   out	   using	   a	   Student’s	  
unpaired	   t-­‐test	   in	   GraphPad	   Prism	   unless	   otherwise	   stated.	   Error	   bars	   were	   calculated	  
using	   the	   standard	   error	   from	   the	  mean.	   RNA-­‐seq	   analysis	  was	   performed	  by	  Dr.	   James	  
Connolly	  using	  CLC	  Genomics	  Workbench	  (CLC	  Bio).	  Significance	  levels	  are	  depicted	  in	  the	  
figures	  as	  *,	  **	  or	  ***	  denoting	  P	  ≤	  0.05,	  P	  ≤	  0.01	  and	  P	  ≤	  0.001	  respectively.	  
	  
